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Abstract  
Lung cancer is the most common cause of death from cancer worldwide, estimated to 
be responsible for nearly one in five (1.59 million deaths, 19.4% of the total). Lung 
cancer is acknowledged as a complex and heterogeneous disease, not only at the 
biochemical level (genes, proteins, metabolites) but also at the tissue, organism, and 
population level. In the past decade, with the advancements in high-throughput 
profiling technologies, a huge amount of work has been done to derive biomarkers to 
supplement clinical diagnosis. The levels of a variety of different biomarkers, such as 
proteins and metabolites, in biological fluid or tissue/cells could potentially detect 
cancer at an early stage, determine cancer subtype, or monitor the sensitivity/resistance 
to cancer treatment. 
The research in this thesis aims to discover new biomarkers, using proteomic 
techniques, with the potential to supplement current clinical criteria for the 
management of lung cancer patients. Label-free mass spectrometry of bronchoalveolar 
lavage fluid (BALF), blood (serum), tissue and cell lines was performed to identify 
candidate biomarkers and perturbed cellular pathways. Validation of significant results 
was performed using immunological methods and biochemical assays. 
These studies have yielded valuable information that has unravelled several key 
molecular events of lung cancer tumorigenesis, including proteomic signature of lung 
cancer in BALF, tissue and blood. BALF analysis identified a promising signature 
distinguish between adenocarcinoma of the lung and squamous cell carcinoma of the 
lung. Many proteins found to be significant changed in abundance in BALF also 
displayed similar trends in tissue specimens. Tumour heterogeneity was also evident 
when examining tumour specimens, reinforcing the need for panels of biomarkers and 
multiple sampling. At strong metabolic pattern was also evident during proteomics 
 
 
xl 
based investigations of clinical material, a result that was confirmed using 
metabolomics platforms to screen patient samples. Drug resistant protein patterns were 
also identified using label-free mass spectrometry on cell lines models demonstrating 
resistance to Apitolisib (GDC-0980), a dual phosphatidylinositol-3-kinase and 
mammalian target of rapamycin kinase inhibitor. Early in vitro data on resistant 
mechanisms associated with new lung cancer treatments is crucial to allow resistance 
to be detected in patients and to understand and potentially target resistant pathways.  
The molecular analysis of a variety of biospecimens has allowed the discovery of 
relevant candidate biomarkers and consequently the identification of novel proteins 
that may have a role in the development of lung cancer and establishment of drug 
resistance. There is a need for incorporating findings from multiple discovery 
platforms and multiple sample types into a lung cancer specific data framework that 
can improve our level of understanding of the disease process.
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1 
1. Introduction 
1.1.  Lung cancer  
Cancer is one of the feared life-threatening diseases, and its global incidence has 
increased concomitantly with the increase in population size (Chen et al., 2016, Saika 
and Sobue, 2013, Vollmer et al., 1985). Cancer does not discriminate poor from rich 
people, and the disease prevalence is directly proportional to the mean age of the 
population. Lung cancers are solid tumours that are difficult to cure. Nearly 50% of 
people with lung cancer die within the first 12 months after diagnosis, and only 15-
18% of them survive for 5 years if they receive proper treatment (Zappa and Mousa, 
2016).  
1.2. Prevalence of lung cancer  
The cancer statistics centre of the American Cancer Society reported that lung cancer 
came in the second place after breast cancer in the estimated future prevalence of the 
disease in women (Siegel et al., 2017). In 2017, the estimated new cases of lung cancer 
in both sexes was 222,500 and of breast cancer 255,180. The presence of breast cancer 
at the top of the list likely reflects the efforts of the health authorities and civil societies 
to familiarize women with the disease at schools, colleges and other locations and to 
the availability of free mammogram examinations. From another perspective, lung 
cancer is at the top of the list of estimated deaths, causing 155,870 deaths compared to 
41,070 deaths from breast cancer, which came in fourth place (Siegel et al., 2017). 
This too reflects the importance of early diagnosis in the outcome of cancer treatment. 
In Ireland, only 20% of lung cancers are diagnosed at stage I, while 35-40% are 
diagnosed at the metastatic stage (stage IV). Interestingly, between 1994 and 2014, the 
incidence of lung cancer among women in Ireland increased from 28 to 42 per 100,000 
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per year, with an annual increase in the rate of 2.3%. In contrast, in men it decreased 
from 70 to 52 per 100,000 per year, which represents a decline rate of 0.8% annually. 
Concomitantly, the number of deaths has also increased in women by 0.4% but in men 
it declined by 1.8%. This discrepancy might reflect the increase among Irish women 
(compared to men) in the number of smokers and exposure to other predisposing 
factors such as alcohol consumption and passive smoking. The survival rate among 
lung cancer patients in general has improved in Ireland, where it doubled from 9% 
(1994-1998) to 17.9% (2009-2013). In Ireland, during 2012-2014 about 85% of lung 
cancer cases were diagnosed by histopathology; treatment involved surgery in 20% of 
cases, chemotherapy in 33%, and radiotherapy in 36% (Irish Cancer Registry). In 
China, analysis of data taken from 72 national cancer registries in 2015 showed an 
estimate of 4,292,000 new cancer cases and 2,814,000 deaths from lung cancer, which 
was the leading cause of death among cancer patients (Chen et al., 2016). 
 In Libya, among 3307 cancer cases recorded in the eastern region cancer registry 
between 2003 and the end of 2005, lung carcinoma accounted for 18.9% of the cases 
in men but none among women (Bodalal et al., 2014, El Mistiri et al., 2007, El Mistiri 
et al., 2015). The survival rate among all the registered cancer cases was 19.8% in men 
and 28.2% in women (El Mistiri et al., 2007). According to the Western Libya cancer 
registry, lung cancer accounts for 15.6% of cancers, while no case among women was 
documented (Alhdiri et al., 2017, Taha Beyased1, 2017, TAHA BEYASED1 and 
NUREDDIN ASHAMMAKHI, 2017, TAHA BEYASED, 2017). In Libya, smoking 
is uncommon and socially unacceptable among women, this might interpret the low 
rate of lung cancer incidence among women compared to men and other types of 
cancer.  
 
 
 
1.3. Risk factors 
The best-known illness related to the modern lifestyle is depression resulting from 
increased daily exposure to noise from our industrial environment. Depression 
contributes partially to the incidence of cancer. The results of 25 independent studies 
including a total of 1,469,179 participants and 89,716 cancer cases showed a 
significant association of depression with lung and liver cancer incidence but no 
significant correlation with breast, prostate, colorectal or colon cancers (Jia et al., 
2017). Depression is associated with reduced natural killer cells activity (Irwin and 
Miller, 2007), possibly due to increased cortisol levels among depressed people 
(Katuri et al., 2016). In industrial countries, the environment is a major contributor 
to the incidence of lung cancer (Cuadras et al., 2016) (Figure 1).  
                    
Figure 1: The major environmental causes of lung cancer (Cuadras et al., 2016) 
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Cigarettes smoking is a major cause of lung cancer, with 10-15% of smokers 
developing the disease at a late stage of life, and it accounts for almost 86% of all 
lung cancer cases, including passive smoking (Mattson et al., 1987). The effect of 
cigarette smoking as a factor predisposing to lung cancer is higher among individuals 
who started smoking as teenagers.  Among never smokers (NS), passive smoking is 
less dangerous than active smoking, but it can still increase the susceptibility to lung 
cancer by 25% in comparison to NS who are not exposed to passive smoking. On the 
other hand, regular consumption of cigarettes and heavy exposure of NS to tobacco 
smoke contribute towards increasing the risk of lung cancer by almost 50% (Wang 
et al., 2015). 
Smoking is responsible for almost 50% of squamous cell carcinomas (SqCC) and 
20% of adenocarcinoma among smokers; the opposite percentages were seen in lung 
cancer patients who never smoked. Kirsten rat sarcoma 2 viral oncogen (K-Ras) gene 
mutation is rarely seen in patients who never smoked, but it is very common among 
smokers; the opposite is true for epidermal growth factor receptor (EGFR) gene 
amplification, which is common in patients who never smoked (Helland and 
Brustugun, 2009). Exposure to asbestos cement materials also contributes to the 
increased susceptibility to lung cancer in individuals with past lung-related diseases 
or genetic susceptibility to pleural mesothelioma and lung cancer (Oddone et al., 
2014). Exposure to radiation is also a risk factor for lung cancer; radiation increases 
the rate of gene mutations in normal tissues and facilitates transition of pre-cancer 
tissues to malignancy (Li et al., 2017).   
Genetic susceptibility to lung cancer differs from one individual to another. 
Oncogenes are involved in the activation of cell growth and division, whereas tumour 
suppressor genes suppress these processes (Bello and Rey, 1995). The correct 
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balance between oncogenes and tumour suppressor genes as well as the existence of 
a healthy DNA repair system are the most important cornerstones in protection 
against cancer. The gene repair machinery’s ability to repair acquired mutations also 
plays an important role in susceptibility (Spitz et al., 2003) and/or protection against 
the disease (Valdiglesias et al., 2011). Genetic polymorphism, e.g. in epidermal 
growth factor receptors (EGFRs) can contribute to increased susceptibility to lung 
cancer and failure of treatment using tyrosine kinase inhibitors (TKI), such genetic 
polymorphism can be utilized in the prediction of tumour resistance to TKI (Wang 
et al., 2017b). DNA-repair gene polymorphism (Yu et al., 2008) can enhance and 
facilitate the production of bulky DNA adducts (conjugates between large reactive 
electrophiles and DNA) by environmental agents and is associated with increased 
risk of lung cancer (Munnia et al., 2017). Inheritance of the susceptibility to cancer 
differs between people. Death of one family member from lung cancer or current 
hospitalisation for treatment of lung cancer also represents a risk factor contributing 
to increased susceptibility of other family members to developing lung cancer; the 
risk is increased by daily exposure to different predisposing agents (Mattson et al., 
1987).  
1.4. Classification of lung cancer    
Most lung cancers are incidentally detected in x-rays or CT-scans done for other 
reasons such as trauma or lung tuberculosis (TB) screening of some job seekers 
(Lana et al., 2014). Two main cornerstones in diagnosis of lung cancer are important 
for proper selection of treatment and precise prediction of treatment outcome. The 
first cornerstone is to correctly determine the histological type of the tumour (Gibbs 
and Thunnissen, 2001, Shimosato, 2002). The second is to stage it correctly (Heelan, 
2004). 
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Histopathological diagnosis of lung cancer relies on cell morphology and the 
nucleus-to-cytoplasm size ratio (N/C ratio) (Su Lim et al., 2015) to distinguish small 
cell lung cancer (SCLC) from non-small lung cancer (NSCLC) by light microscopy 
of tissue biopsy (Gibbs and Thunnissen, 2001). Reactivity (level of expression) to at 
least one neuroendocrine immune-histochemical (IHC) marker helps to differentiate 
SCLC from NSCLC and also neuroendocrine from non-neuroendocrine non-small 
cell carcinomas (Feng et al., 2016). Information on the patient’s lifestyle and smoking 
habits might aid in distinguishing between SqCC and adenocarcinoma (Okamoto et 
al., 2014). The concern was always about the lack of microscopic characterization 
reproducibility between the different sections of same biopsies as only 30% of lung 
carcinomas originate from a single cell and the rest are  histologically heterogeneous 
(Junker, 2000). Incorrect histological typing or staging, late diagnosis, and complex 
heterogeneity of the intra-tumour microenvironment are the top factors responsible 
for treatment failure (Hirsch et al., 2002). Better molecular characterisation of lung 
carcinomas would considerably improve patient outcome by enhancing diagnosis 
precision and treatment selection. This is part of the scope of this study. 
Histologically, lung cancer is classified into two main categories: SCLC and NSCLC 
(Neal et al., 2014). Based on their cell type origin, primary lung tumours (Figure 2) 
are classified into two types: (1) neuroendocrine (NETs) carcinoma, which includes 
SCLC, large cell neuroendocrine carcinoma (LCNEC) and both typical and atypical 
forms of lung carcinoids; (2) non-neuroendocrine lung carcinomas, including SqCC 
and adenocarcinomas (Rekhtman, 2010).   
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1.4.1. Neuroendocrine lung tumours (NETs) 
Neuroendocrine lung tumours account for 25% of lung cancers and are graded as low 
grade typical carcinoid (TC), intermediate grade atypical carcinoid (AC), or high 
grade carcinomas, including LCNEC and SCLC (Travis et al., 2010).  
1.4.1.1. Small cell lung cancer (SCLC) 
This type of lung cancer is usually seen near the bronchi and is mostly caused by 
chronic tobacco smoking (Figure 2). SCLC is the most commonly diagnosed lung 
neuroendocrine tumour, representing 20% of lung cancers and 95% of lung NETs. 
Only 5% of all small-cell tumours are diagnosed outside the lungs (bladder, uterus, 
cervix and oesophagus). Therefore, most metastatic small-cell cancers of the bones 
originate from primary tumours in the lung (Powell, 1988). Most patients diagnosed 
with SCLC have nodal metastasis in the lung hilar region. Late stages of lung SCLC 
commonly metastasise to the bone marrow, bones or liver (Bos et al., 2009), and in 
50-80% of patients with SCLC spread to the brain (Samson et al., 2007).  
SCLC tumour biopsies, based on their levels of neuroendocrine markers expression, 
react strongly to neural cell adhesion molecule (NCAM/CD5/6) mAbs (highly 
expressed)  (Hiroshima et al., 2006), weakly reactive to synaptophysin and 
chromogranin (Hiroshima et al., 2006), very weakly reactive to cytokeratins (CKs) 
such as CK-AE1 and AE3 mAbs (expressed at very low amounts) (Cerilli et al., 
2001). SCLC is also strongly reactive (highly expressed) (90% of SCLC) to thyroid 
transcription factor 1 (TTF1), which is expressed in the brain and lungs in addition 
to the thyroid glands, and is considered as a very specific marker for primary lung 
small cell carcinoma (SCLC) but not extra-pulmonary metastasis (Ordóñez, 2000).  
In general, SCLC is a very aggressive cancer that spreads rapidly and has a bad 
prognosis. Only 5% of SCLC patients survive for 5 years from the date of diagnosis 
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(Rekhtman, 2010). SCLC is sensitive to radiotherapy, cisplatin, etoposide, and 
combination regimens (Samson et al., 2007). SCLC can be pure (70%) or mixed 
(30%) with NSCLC (adenocarcinoma, SqCC, large cell carcinoma or carcinoids) 
(Vollmer et al., 1985). Limited SCLC is treated with cisplatin + etoposide + 
radiotherapy, whereas extensive SCLC is treated only with chemotherapy (Byers and 
Rudin, 2015). 
1.4.1.2. Large-cell neuroendocrine lung cancer (LCNEC) 
Large-cell neuroendocrine lung cancer (LCNEC) is very rare (Figure 2). This 
carcinoma grows rapidly, has a poor prognosis (Filosso et al., 2017) and accounts for 
3% of all lung neuroendocrine tumours (Rekhtman, 2010). LCNEC is considered to 
be less progressive than SCLCs, with a 5-year survival rate of 50% (Iyoda et al., 
2007).  
LCNEC is staged according to the staging guidelines of the American Joint 
Committee on Cancer (tumour, node, and metastasis; TNM) (Battafarano et al., 
2005). The same criteria are applied to NSCLC, but LCNEC can be distinguished 
from NSCLC by its reactivity (high expression) to at least one neuroendocrine 
marker (e.g., Synaptophysin, CD56 or chromogranin A) and thyroid transcription 
factor (TTF1) (Wiatrowska et al., 2001, Travis et al., 2010, Travis et al., 2015b). It 
is also distinguished from SCLC by the large nucleus, abundant cytoplasm, and high 
nucleus-to-cytoplasm ratio (Hiroshima et al., 2006). TTF1 is also expressed  
Figure 2 shows the main histological types of lung cancer, how they look like under the 
light microscop (top panel), the rate of their incidence among lung cancer (LC) 
(second panel) and male and female incidence ratio (third panel). The figure also 
shows the correlation between smoking and the incidence of each type of lung cancer 
(4th and 5th panels) and the overall level of each lung cancer type aggression (6th  
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panel), their early metastability (7th panel) and the outcome of surgical resection (8th 
panel). 
                 
Figure 2: The main histological types of lung cancer. LC: lung cancer, SR: surgical 
resectability (Modified from respiratory system diseases, lung cancer, PPT by Ya. 
Bodnar and Frank H. Netter’s illustrations). 
 
in neuroendocrine tumours outside the lungs, as in the male genitourinary tract, so it 
cannot be used to assess secondary tumours (Alijo Serrano et al., 2007). LCNEC is 
a good candidate for surgical treatment with adjuvant cisplatin-etoposide 
chemotherapy combined with radiotherapy (Prelaj et al., 2017). 
1.4.1.3. Lung carcinoid tumours 
Carcinoid tumours account for 20% of all well-differentiated neuroendocrine 
tumours in humans. Lung carcinoid tumours account for only 2.2% of all 
neuroendocrine lung tumours and are of two types: typical carcinoids (TC), which 
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account for 2% of lung NETs, and atypical carcinoids (ACs), the rarest lung 
carcinoid tumour, which accounts for only 0.2% of lung NETs (Rekhtman, 2010). 
Starting from the 7th edition of the International Association for the study of  lung 
cancer (IASLC) staging committee, lung carcinoid tumours are to be staged 
according to the criteria used for staging NSCLC (Travis et al., 2008). In 
histopathological examination, carcinoids are distinguished from SCLC by their 
strong reactivity (high expression) to synaptophysin & chromogranin and weak 
reactivity to CD5/6 markers (expressed at low levels). About 50 ± 25% 
(Mean/STDV) of SCLCs exhibit negative or very weak reactivity to synaptophysin 
and chromogranin (expressed at very low levels) but strong reactivity to CD5/6 
(highly expressed) (Hiroshima et al., 2006, Marchevsky and Wick, 2015). The 
opposite is true for reactivity to TTF1 (highly expressed), with 90% of SCLCs 
strongly reacting to the marker made it specific for SCLC (Ordóñez, 2000). Non-
metastasized carcinoids are cured by surgery whereas metastatic carcinoids require 
post-surgical chemotherapy and radiotherapy (Hilal, 2017).  
1.4.2. Non-neuroendocrine non-small cell lung tumours  
1.4.2.1. Lung adenocarcinoma  
Lung adenocarcinoma, the most common lung cancer in individuals who have never 
smoked, accounts for 40% of lung cancers and usually arises from the alveoli (Figure 
2). The well-differentiated adenocarcinomas have papillary and acinar growth 
patterns, whereas the poorly differentiated ones might exist as solid cribriform 
clusters that can be distinguished from LCNEC only by their reactivity to 
neuroendocrine markers (Jiang et al., 1998, Rekhtman, 2010). Besides positive 
mucin staining, adenocarcinoma reacts positively in IHC with TTF-1, Napsin A, and 
CK7 markers (Kerr et al., 2014). Up to 20% of NSCLC have reactivity to one or 
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more neuroendocrine IHC markers, which is common for adenocarcinoma but not 
for SqCC (Rekhtman et al., 2011), though SqCC has NSCLC morphology (i.e., no 
neuroendocrine morphological changes) (Berendsen et al., 1989, Iyoda et al., 2001). 
In contrast, some NSCLC resemble LCNEC morphologically but their reactivity to 
neuroendocrine markers is very difficult to confirm by IHC (González-Aragoneses 
et al., 2007).  
1.4.2.2. Lung squamous cell carcinoma (SqCC) 
Lung SqCC tumours (Figure 2) grow slowly, arise mainly in the large airways, and 
are strongly associated with chronic tobacco smoking (Kenfield et al., 2008). Lung 
SqCC is characterised, like any other NSCLC, by its high nucleus to cytoplasm ratio 
(N/C ratio) (Su Lim et al., 2015) and is diagnosed immunohistochemically by its 
expression of P63, P40, 4A4 and high molecular weight cytokeratins (CK5/6) or 
34βE12, but not TTF1 (Rekhtman, 2010, Bini et al., 2008, Kerr et al., 2014).  
In 2011, Rekhtman et al. tested 315 resected tumours, including adenocarcinomas 
(n=200) and SqCC (n=115), for their reactivity to the IHC markers commonly used 
to differentiate adeno from SqCC: TTF-1, P63, cytokeratin 5/6 and 34βE12. The only 
specific marker clustering lung adenocarcinoma from SqCC was TTF-1, and none of 
the SqCC specimens showed reactivity to it even in diffuse tumours. 
Adenocarcinomas were widely heterogeneous in responding to SqCC-specific 
markers. 38 Out of the 315 NSCLC tissue samples were morphologically 
unclassifiable small biopsies/cytology specimens. Analysis of the whole tissue 
sections showed that squamous cell carcinomas had a highly consistent IHC profile 
(negativity to TTF-1 and p63/CK5/6 AND 34βE12 with small variation). In contrast, 
adenocarcinoma specimens showed significant IHC heterogeneity for squamous 
carcinoma markers where; 32% of them showed reactivity to P63, 18% to CK-5/6, 
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82% to 34βE12, and 89% to TTF-1 (Rekhtman et al., 2011). A panel of TTF-1/P63 
and CK5/6 markers eliminates any overlap between AD and SqCC.  
Before deciding on the treatment of a patient with SqCC, samples should be analysed 
immunohistochemically for DNA mutations by in situ hybridization (ISH) or DNA-
based technologies. Treatment-naive adenocarcinomas with activating EGRF 
mutations respond effectively to the first generation tyrosine kinase inhibitors 
(Gefitinib, erlotinib, afatinib) rather than to chemotherapy (Kerr et al., 2014). ALK 
rearrangement is very common in lung adenocarcinomas, very rare in SqCC and also 
seen in adenosquamous mixed lung carcinomas. Adenocarcinomas with ALK 
rearrangement respond well to crizotinib (Chaft et al., 2012). The second European 
Society for Medical Oncology (ESMO) consensus conference on lung cancer 
recommends that before starting treatment, the tumour should be screened for human 
epidermal growth factor receptor 2 (HER2) amplification, BRAF mutations, and 
rearrangement of serine/threonine kinases ROS1 and RET (Cardarella and Johnson, 
2013, Marchetti et al., 2013).   
Good laboratory practice for diagnosis of lung cancer relies on the examination of 
the entire tumour mass (Teng, 2005). Not all of lung tumours are intended for 
surgical resection, therefore, obtaining the right histopathological diagnosis using 
small tissue biopsies remains a high bar. However, ESMO recommends 
classification of specimens with no definitive morphological evidence of squamous 
or glandular differentiation as well as heterogeneous adenocarcinomas as NSCLC- 
non otherwise specified (NSCLC-NOS) (Thomas et al., 1993, Chuang et al., 1984, 
Edwards et al., 2000).  
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1.5. Lung cancer metastasis 
The exchange of gases and nutrients at the cellular level between arterioles and 
venules occurs via the interstitial fluid, which is formed by secretion of plasma from 
the fine arterioles into the extracellular space, followed by its reabsorption through 
capillary venules. The plasma secreted into the interstitial space carries waste 
products coming from vital organs such as the lungs, liver, colon, and kidneys (Liao 
and von der Weid, 2015), and possibly infectious materials, including bacteria and 
viruses. About 90% of the interstitial fluid is reabsorbed and the rest enters the 
lymphatic vessels, where it is called the lymph. The lymph also helps in restoration 
of proteins and absorption of fats from the interstitial space back into the blood 
circulation.  
The lymph also serves as a continuous sample of the interstitial space that is reported 
to the immune system. It contains micro-organisms (MOs), antigen presenting cells 
and B-cells (Jewell et al., 2014) that are moved towards local lymph nodes through 
the afferent lymphatic vessels drainage (Blum and Pabst, 2006), to the sub-capsular 
sinus, towards the cortical sinus, and then further to the medullary sinuses. The 
immunological response in the lymph nodes is initiated by antigen presenting cells 
(dendritic cells) capturing the microbial antigens or cancer-specific antigens 
(recognised by altered post-translational modification signatures, e.g., an altered 
human glycan signature) (Summerfield and McCullough, 2009). Dendritic cells 
present captured antigen(s) in association with MHC-II complex to naive T- cells to 
start adaptive immunological responses. Dendritic cells also present the antigen in 
the context of MHC-II to B-lymphocytes, triggering their differentiation into 
antibody-producing plasma cells (Wykes and MacPherson, 2000). The antibodies 
facilitate micro-organisms (MOs) opsonization and clearance through the 
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reticuloendothelial system (bone marrow, spleen and liver) (Randolph et al., 2005). 
Activation of B-lymphocytes is also involved in the maturation of T-lymphocytes to 
generate natural killers (NK) and the memory cells (Waithman and Mintern, 2012). 
The lymph leaves the medullary sinuses of the lymph nodes in one direction through 
the efferent lymphatic vessels, which form larger lymphatic vessels as they proceed 
away from the lymph nodes towards the subclavian veins on the sides of the neck 
(Liao and von der Weid, 2015). 
Metastasis of cancer cells involves morphological changes. Endothelial-
mesenchymal transition (EMT) facilitates their penetration into and out of blood 
vessels (Castañón et al., 2017), enabling tumour cells to leave the primary tumour, 
enter the blood stream, or invade local lymph nodes. Cells that migrate through the 
blood circulation attach to the blood vessels and infiltrate into new organs by virtue 
of organ-specific genes (Bos et al., 2009). Cancer cells extravasate into the bone 
marrow relatively easily through the fenestrated endothelium lining the sinusoid 
capillaries. Extravasation into the pulmonary parenchyma requires the expression of 
certain genes that mediate vasodilatation and increase blood vessel permeability, 
e.g., Cyclooxygenase-2  (Bos et al., 2009). Lung cancer cells grow at the primary 
tumour, spread into the mediastinal lymph nodes, and migrate via the blood to other 
organs, such as the liver (Wakabayashi et al., 2017). Detection of lymphatic 
metastasis is important for treatment decisions, prognosis and outcome. Several 
methods are available for mapping the thoracic lymphatic node drainage of the 
tumour and for sampling the sentinel node from the regional lymph nodes drainage 
(Karaman and Detmar, 2014).  
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1.6. TNM staging  
Cancer staging facilitates the exchange of information between clinicians about their 
cancer patients in order to choose the optimal treatment protocol for each patient. 
The staging and grading of cancer is also helpful in prognosis and prediction of 
treatment outcome (Telloni, 2017). The TNM staging system provides a descriptive 
clinical assessment of the tumour. Staging of SCLC is different from that of NSCLC 
(Kodama, 1997). SCLC is staged by the American Veterans Administration System 
(AVAS) as limited when the tumour nodules remain in one lung lobe and extensive 
when they spread to the other lung and other parts of the body. The TNM staging 
system still  needs to be adopted towards using for staging of SCLC, as well as 
towards decision of surgical candidates of SCLC (Chen, 2016). In the TNM staging 
system of NSCLC, tumour nodules that are still growing locally are referred to as (T) 
and the size of each nodule is recorded. Involvement of lymph nodes is symbolized 
as (N), and the number and sizes of lymph nodes involved is recorded. Due to the 
continuously increasing knowledge of cancer brought about by the  use of genomic 
and proteomic profiling of tumours by second generation sequencing (SGS) and 
mass spectrometry, this staging protocol is updated annually (Telloni, 2017).  TNM 
staging describes the size and location of the tumours and the existence of metastasis 
(Donnem et al., 2015). Two methods are used for TNM staging of lung cancer. 
Clinical staging, which is less accurate, is based on physical examination, imaging 
(chest x-ray, ultra-sound, CT-scan, MRI or PET-scan) and laboratory tests. 
Histopathologic or pathological staging is more accurate but is very invasive and not 
tolerated by patients because of the need for surgery.  
In TNM staging of lung cancer, patients undergo a series of investigations that can 
include ultrasonography, computed axial tomography (CT) and magnetic resonance 
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imaging (MRI). Ultrasound is considered the best method for detecting lymph nodes 
and metastasis. It is low cost, non-invasive, reproducible, and suitable for follow-up. 
However, CT-scan is considered superior by almost all clinicians dealing with head 
and neck lymph node pathology. The addition of contrast media, digital 
reconstruction, temporal and spatial high resolution images and fine-cut images has 
made CT-scan effective and efficient for lung cancer staging (Table 1).  
Magnetic resonance imaging (MRI) is convenient and effective for assessing the 
anatomical structure of soft tissues in head and neck cancer (Gujam et al., 2014). The 
International Association for the Study of Lung Cancer (IASLC) has proposed 
revisions based on the evaluation of outcomes in an extensive worldwide database 
(Tanoue and Detterbeck, 2009).  The seventh TNM staging edition (Table 1) issued 
by the IASLC remained in use in the CT-scan Olympic software until January 2017. 
The only change made on the TNM staging  system in the seventh edition is that the 
N category depends on the number of zones involved (Figures 3 & 4), and the M 
extends to distinguish oligo metastatic from extra thoracic spread (Edge and 
Compton, 2010, Chassagnon et al., 2017). 
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                   Table 1: The 7th edition of IASLC TNM staging system (Chassagnon et al.,   2017)  
 
 
 
 
 
 
 
 
 
 
 
                      
 
 
 
 
 
Where; N: number of lymph node involved, M: number of metastatic lesions outside 
lung, T: number of tumour nodules. Stage 1A: one primary tumour nodule and no 
lymph node involved. Stage IB: no lymph node involved and another lung nodule 
might exist. Stage IIA: one or two primary tumour nodules and one lymph node is 
involved. Stage IIB: three lung primary nodules or two nodules and one lymph node 
is involved. Stage IIIA: upto four primary nodules plus one or two lymph nodes are 
involved. Stage IIIB: upto four primary tumour nodules and three lymph nodes are 
involved. Stages from IA to IIIB: no outside lung spread of the tumour (M0). Stage 
IV: indicates outside lung spread of the tumour (minimum of M1) regardless of the 
number of the primary tumour nodules and the lymph nodes involved (usually >3).  
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Figure 3: A systematic reference of the thoracic lymph nodes used in Olympus CT 
scan lymph node mapping for TNM staging. Modified from the American Joint 
Committee on Cancer (AJCC) 7th Edition TNM staging posters provided by the 
American Cancer Society (Edge and Compton, 2010). 
 
 
 
The purpose of improving the TNM staging system is to help select the right 
candidates for radiotherapy or surgery. A combination of positron emission 
tomography (PET-scan) using 18F-FDG as a tumour tracer and computed 
tomography scan helps to reduce the number of CT-scan based TNM-staging 
candidates who queue for radiotherapy (RT) by approximately 34% (Abramyuk et 
al., 2012).  
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Figure 4: Olympus CT scan lymph node mapping for TNM staging (Abramyuk et al., 
2012). aA: Ascending aorta, Az: Azygos vein, dA: descending aorta, ESO: 
esophagus, LCA: left carotid artery, LiV: left innominate vein, left pulmonary artery, 
LSCA: left subclavian vein, LSPV: left superior pulmonary vein, PT: pulmonary 
trunk, RBCV: right bronchocephalic vein, RCA: right carotid artery, superior vena 
cava, TRA: trachea. 
 
1.7. Lung cancer grading  
Grading of cancer is a descriptive microscopic examination of cancer biopsies 
reflecting how likely the lung cancer would spread rapidly, and it has important 
prognostic value (Carriaga and Henson, 1995). A successful histopathology report 
relies on collection of a representative tumour tissue biopsy that will not compromise 
the treatment decision. In 1988, Ehrhart described the basic techniques of biopsy 
acquisition and handling as well as surgical margin resection (Ehrhart, 1998). 
Basically, cancer is graded as well-differentiated (cells are organised as in normal 
tissue) or poorly differentiated (cells are not organised as in normal tissue). 
Depending on the percentage of abnormal cells, cancer grading is usually rated as 
follows: 
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Gx (undetermined grade): cells are very difficult to distinguish from normal  tissues;  
G1 (low grade): well-differentiated; 
G2: (intermediate grade) moderately differentiated; 
G3: (high grade) cells appear different from normal tissue control or poorly  
differentiated; 
G4: (high grade): undifferentiated tumour cells, in which the cells of the tumour 
tissue biopsies appear totally different.  
In Gx and G1, tumour growth is very slow. In grades 3 and 4, the organisation of the 
cells is heterogeneous and not unique. The tumour’s ability to grow and metastasise 
aggressively is maximal in grade 4 (Powers et al., 1995, Carriaga and Henson, 1995).    
1.8. Lung cancer screening of high risk groups 
1.8.1. Low-dose computed tomography  
The screening examination that is most recommended for lung cancer is low-dose 
computed tomography (often called low-dose CT scan or LDCT). During this test, 
an X-ray machine scans the body with low doses of x-ray radiation to make 
exceptionally detailed images of the lungs. As a benefit, low-dose computed 
tomography uses less ionising radiation than a standard CT scan. The benefit of 
screening is that it can detect disease early before the first symptoms appear, when it 
is most treatable. A screening test is not considered completely effective until it 
manages to reduce the number of deaths caused by the given disease. Screening by 
low-dose CT-scan was found to reduce lung cancer-specific mortality by 20% in high 
risk groups (Chiles, 2014). Detailed protocols demonstrating practical and technical 
issues to be considered have been reviewed in  (Marshall et al., 2013). 
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1.8.2. Sputum cytology 
Microscopic examination of sputum (mucus) can detect the presence of abnormal 
cells such as cancerous cells (Thunnissen, 2003, Ammanagi et al., 2012). Sputum 
may be collected by asking the patient to cough up mucus or breath in saltwater mist 
and then cough; it can also be collected during bronchoscopy (Su et al., 2015). 
However, sputum cytology is not currently used to screen people who are particularly 
at risk of lung cancer, such as heavy smokers.  
1.8.3. Bronchoscopy  
There is standard white light video bronchoscopy (WLB) and auto-fluorescence 
bronchoscopy. A thin tube, named a bronchoscope, is used to thoroughly examine 
the lungs and to take a sample of lung tissue to test for the presence of abnormal 
cells. The bronchoscope is inserted into the mouth or nose and passed down the 
trachea and into the lungs (Van't Westeinde and van Klaveren, 2011). Bronchoscopy 
could be indicated when a chest X-ray shows evidence of an infection, a collapsed 
lung, or a potentially cancerous tumour. Bronchoscopy is very effective for detecting 
lung cancer before it reaches an advanced stage, which reduces the risk of mortality. 
Also, bronchoscopy is generally safe and has minimal risk. However, in very rare 
cases, some patients may experience bleeding, infection, or trouble breathing after 
the procedure (Stahl et al., 2015, Chhajed et al., 2003). 
1.8.4. Chest x-ray 
Chest X-rays can also detect lung cancer, but by then the tumour is often too far 
advanced for treatment to be effective. Chest X-rays usually cannot detect small, 
potentially curable lung tumours. Also, many things seen on a chest X-ray turn out 
to be harmless or benign problems (van Beek et al., 2015). Lung cancer appears as a 
white-grey mass on a chest X-ray, but a lung mass cannot give a definitive diagnosis 
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because on X-rays it is often impossible to differentiate between lung cancer and 
other pulmonary diseases such as lung abscesses. 
1.8.5. Thoracoscopy or Thoracotomy 
Thoracoscopy/thoracotomy is also currently used to diagnose lung cancer. Usually 
under anaesthesia, a small incision is made in the chest and a tube resembling a 
bronchoscope is passed through it. The physician can examine the lining of the lungs, 
the chest wall, the mediastinum and the pericardium, and collect samples. Like 
bronchoscopy, this procedure is relatively risk free (Petersen et al., 2012, Onaitis et 
al., 2006). However, some people experience a sore throat, bleeding, infection, 
pneumonia or a partial or complete collapse of the lung (Kaiser and Bavaria, 1993). 
Thoracoscopy is very effective for diagnosing lung cancer at a much earlier stage 
than a chest X-ray. 
1.9. Tumour protein markers  
After proteins are translated, they frequently undergo various modifications, such as 
acetylation, methylation and phosphorylation. These post-translational modifications 
regulate the production, function, and half-life of proteins, as well as their 
immunological makeup. The regulation of protein production and function inside 
cells is governed by their response to extracellular stimuli, such as growth hormones 
and inflammatory mediators. Proteins are produced in amounts that are suitable for 
coping with the routine cellular processes, but they are upregulated or downregulated 
in certain normal and abnormal conditions. In some circumstances, the changes in 
protein expression and modifications are controllable and reversible. For example, 
in inflammation, cells return to their normal state when the causative stimulus 
disappears. But in cancer, the changes are beyond the control capability of the cells. 
In principle, any detectable increase in a protein’s abundance or in its 
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posttranslational modifications in cancer might serve as a biomarker of the disease. 
But in practice, after more than 50 years of research on cancer biomarkers, early 
correct diagnosis and correct choice of treatment sometimes seem very difficult to 
achieve, despite the advances in imaging technologies, biomarker discovery, and 
instrumentation. These difficulties are rooted in the complexity of cancer, the 
dynamic changes in tumour cell populations within the tumour environment, and the 
existence of heterogeneity. Treatment failure, development of drug resistance, and 
relapse of the disease remain major challenges. Moreover, detection of cancer before 
it can be visualised by imaging systems has to rely on molecular biomarkers used for 
screening for lung cancer in people who are at risk, such as chronic smokers or in 
occupational medicine services.  
Cancer biomarkers, also called tumour markers, can be general or specific. If the 
affected organ produces a specific protein, the tumour marker will be unique and 
specific, e.g. prostate specific antigen (PSA) in prostate cancer. Other tumour 
markers are associated with several malignancies, such as CA-19-9 glycoprotein 
antigen in carcinoma of lung, stomach and pancreas (Steinberg, 1990). The 
disadvantage of using tumour markers in diagnosis is that they are not consistently 
elevated in all patients (Hara et al., 2008). The clinical utility of these markers is 
restricted to monitoring patients with lung cancer (Figure 5) in order to minimise 
exposure to the low dose x-rays and radionuclides used for monitoring treatment 
outcome. Table 2 lists some protein biomarkers used for diagnosis, prognosis and 
staging of lung cancer.  
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1.9.1. History of clinically used tumour markers  
The first cancer biomarker, carcinoembryonic antigen (CEA), was reported in 1965 
(GOLD and FREEDMAN, 1965). After further research, the same group argued in 
1967 that CEA is specific to cancers of the gastrointestinal tract (Thomson et al., 
1969), but later, CEA was demonstrated to be elevated in different cancers, including 
lung, breast, and genitourinary tract tumours (Reynoso G, 1972).  
The clinical utility of biomarkers relies on the use of cut-off values that distinguish 
benign from cancerous or diseased tissues. The initial established cut-off value of 
CEA was 2.5 ng/ml (Reynoso G, 1972), but later it was found that 10-17% of normal 
people have plasma values > 2.5 ng/ml (Vincent and Chu, 1973, Concannon et al., 
1973). From the beginning of the 1970s, stress was placed on the need for 
distinguishing early from late stages of cancer in terms of their complexity. CEA was 
reported to be > 2.5 ng/ml in patients with bronchial carcinomas (Reynoso G, 1972). 
But this finding was not consistent because about 22% of patients with advanced 
metastatic lung cancer were reported to have CEA levels within normal values (< 2 
ng/ml) (Meeker et al., 1973). In 1974, Joseph et al.  reported that the CEA cut-off 
value for bronchogenic carcinoma was < 5 ng/ml, and consequently concluded that 
CEA is not a good diagnostic or prognostic biomarker for bronchogenic cancers 
(Concannon et al., 1974). CEA failed to discriminate between bronchial carcinoma 
and chronic bronchitis (Pauwels and Van der Straeten, 1975).  
Progastrin-releasing peptide (ProGRP) can diagnose SCLC with a sensitivity of 76% 
(Korse et al., 2015). Combining Pro-GRP with CEA increases the sensitivity to 91%. 
Squamous cell carcinoma antigen (SCCA) is used to differentiate between 
adenocarcinoma and SqCC. SCCA combined with CEA can differentiate between 
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adenocarcinoma and the very rare adenosquamous lung carcinoma (ASC) (Jin et al., 
2017b). The value of combining biomarkers was also shown by combining CYFRA 
19 with neuron-specific antigen (NSE) and CEA (Lequaglie et al., 1995) in diagnosis 
of lung adenocarcinoma. Another example of using biomarkers panels is the 
combination of CEA as a general tumour marker, SCCA as a marker specific for 
SqCC, NSE as a marker for AD tumour in addition to the small cell lung carcinoma 
specific biomarker Progastrine-releasing peptide (ProGRP). This panel was accurate 
in predicting the presence of lung cancer and distinguishing small from non-small 
lung cancers (Molina et al., 2016). When this panel was evaluated in the diagnosis 
of lung nodules, it identified eight out of twelve lung cancers among patients 
negatively diagnosed by CT-scanning (Yang et al., 2015). 
Tissue polypeptide antigen (TPA) is not sensitive for diagnosis of SCLC, but its 
sensitivity increases when it is combined with lactate dehydrogenase. One advantage 
of integrating lung tumour markers with other diagnostic tools for monitoring 
treatment (Table 2, Figure 5) is to reduce exposure to radiation and stressful 
diagnostic procedures (Holdenrieder et al., 2016).  
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Table 2: Biomarkers commonly used in diagnosis of lung cancers 
               
DD: Differential diagnosis. P/S: Prognosis/Staging. T(M/S): Treatment 
(Monitoring/ Surveillance). AD: Adenocarcinoma. NSCLC: Non-small cell lung 
cancer. SCLC: small cell lung cancer. NET: neuroendocrine tumour. CEA: 
carcinoemberionic antigen. HE4: Human epididymis protein 4. CA-(#): Cancer 
carbohydrate antigen. CYFRA 21-1: Cytokeratin 19 fragment. NSE: Neuron-
specific enolase. ProGRP: Progastrin- releasing peptide. SCCA: Squamous cell 
carcinoma antigen. Modified from (Holdenrieder et al., 2016).   
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Figure 5: Integration of tumour markers with other diagnostic modalities. Modified 
from (Holdenrieder et al., 2016). DDx: Differential diagnosis. TM: Tumour marker. 
IHC: Immunohistochemistry. NSCLC: Non-small cell lung cancer. EGFR: 
Epidermal growth factor receptor. PCR: Polymerase chain reaction. NGS: Next 
generation sequencing. TKI: Tyrosine kinase inhibitor. CYFRA 21-1: Soluble 
fragment of cytokeratine 19 (fragment 21-1) detected in serum. CEA: 
carcinoemberionic antigen. SCCA: Squamous cell carcinoma antigen. ProGRP: 
Progastrin- releasing peptide. NSE: Neuron- specific enolase. TM: Tumour marker. 
C2369T: Cytosine at nucleotide number 2369 in EGFR gene changed to thymine 
(point mutation) and the encoded amino acid changed to methionine instead of 
threonine (T790M) in the EGRF peptide. T2573G: In EGFR gene, nucleotide 
thymine changed to guanine ( the number denote its location in the EGFR gene. The 
encoded amino acid changed from leucine to arginine. A: nodule discovery, B1: 
biomarker panel assessed in blood (serum/plasma), B2: taking biopsy from the 
nodule using fine needle aspiration (FNA) for IHC typing (C1) and mutational 
analysis using microchips and hybridization to known mutations (C2), E: treatment 
decision beased on the type of cancer (C1-1) and the mutated gene involved (C2-1). 
In advanced cases, further investigation might include global mutational screening 
using NGS and further mutation confirmation by PCR and direct sequencing. Before 
start of treatment, elevated biomarker(s) (B1-1) used to monitor the treatment 
efficiency [tumour is good responding to the treatment (B1-1A) and treatment failure 
after some time due to tumour heterogeneity or development of resistance to 
treatment (B1-1B). In treatment failure, again CT-scan (G1) is required and liguid 
biopsies are collected for further mutational analysis (G2) to decide another 
treatment combination (H).         
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1.9.2. Biomarkers for discriminating between SqCC and AD 
The previous differential diagnosis of NSCLC vs. SCLC for treatment decisions has 
been superseded by a need for a more precise classification. SqCC is a malignant 
epithelial tumour showing keratinisation and/or intercellular bridges. Keratinisation 
can be in the form of pearl formation or single cell. In poorly differentiated tumours, 
these features can be difficult to define. AD is diagnosed histologically by the 
formation of glandular spaces, papillary structures, surface alveolar growth, and/or 
intracytoplasmic mucin in the tumour. While biomarkers that differentiate SqCC 
from AD have been reported, additional markers would help enhance diagnostic 
accuracy (Agackiran et al., 2012, Li et al., 2014, Patnaik et al., 2015, Zhan et al., 
2015). In 2015, the World Health Organisation (WHO) published its classification 
of lung tumours (Scagliotti et al., 2009). IHC markers such as p40 and TTF-1 are 
recommended for definitive histological diagnosis of SCC and AD when diagnosis 
based solely on morphological features is inconclusive. Recent developments in 
targeted therapies, such as pemetrexed and bevacizumab, require precise typing of 
NSCLCs, since these drugs are inappropriate for SqCC due to the increased risk of 
hemoptysis (Reck et al., 2009, Sandler et al., 2006, Travis et al., 2015a, Hellmann et 
al., 2013). Most candidate biomarkers discussed in the literature in terms of their 
sensitivity in discriminating between SqCC and AD are tissue-based proteins, but a 
biofluid-based biomarker would be a major advantage because only a small amount 
of tissue is available for testing, and rebiopsying is difficult and sometimes 
impossible.       
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1.10. Biofluids, breath and tissues as sources of biomarkers 
1.10.1. Blood 
Blood is a biological fluid that supplies the tissues with nutrients and oxygen, and 
this delivery is controlled by the blood circulation and blood pressure (Klabunde, 
2012). Erythrocytes are responsible for gas exchange between the pulmonary alveoli 
and the circulation collateral capillaries, and also between the capillaries and body 
tissues. The circulation also plays a major role in defending the body against invasion 
by pathogenic micro-organisms, supplying the affected organ with white blood cells, 
the major immune cells defending against pathogens.  
All cellular biological waste is pooled in the blood, so blood is used in routine 
laboratory investigations and in measurement of tumour markers. Waste products are 
transported by the blood to the liver to increase their water solubility before they are 
eliminated through the kidneys, so urine is also used for routine laboratory 
investigations. Carbon dioxide is either delivered into the lung (so exhaled breath is 
used for diagnosis of some pulmonary as well as systemic diseases) or converted into 
bicarbonate to neutralize acids formed from cellular metabolism.   
From the diagnostic point of view, blood is a liquid tissue consisting of a complex 
and dynamic mixture of biomolecules reflecting the overall normal or 
pathophysiological state of the body.  The levels of these molecules, especially those 
used in diagnosis of diseases other than kidney diseases, depend mainly on the 
performance of two organs, the kidneys (Bellomo and Ronco, 2005, Karim et al., 
2002, LAVENDER, 1946, MILNE, 1955) and lungs (Brambilla et al., 2003, 
McFadden, 1970, Nattie, 1990). In renal failure, the clinical utility of tumour 
biomarkers is completely lost (Nomura et al., 1998, Trojan et al., 2013) mainly 
because dehydration leads to haemoconcentration (Aranda et al., 2017). Insufficient 
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fluid intake is also responsible for the variability of biomarkers’ levels in blood. 
Dilution due to overhydration or dialysis might also affect the clinical utility of 
biomarkers in terms of multiple reaction monitoring (MRM). Heart diseases also 
affect the consistency of biomarkers due to the effect of oedema. The choice of 
candidate volunteers for discovery and validation of biomarkers, especially in 
cancers, should fulfil certain criteria to minimize the presence of outliers and the loss 
of statistical significance. This also should be considered in the assessment of their 
clinical utility in terms of excluding false positive results arising from food, disease 
(Cioppa, 2017) and drug interaction (Forman and Young, 1976). 
1.10.2. Exhaled breath condensate 
Exhaled breath is a good source of biomarkers that can reflect various 
pathophysiological conditions of the respiratory system, including asthma, lung 
carcinoma and chronic obstructive airway disease (Montuschi and Barnes, 2002). 
The exhaled breath can be investigated as a vapour (Dallinga et al., 2014) or as a 
liquid condensate (Konstantinidi et al., 2015). The latter is optimal for proteomic 
analysis, which requires liquid samples, but though using exhaled breath condensate 
(EBC) is not invasive, many challenging issues limit its routine (Md, 2017). The 
major issues include its limited protein content (< 1µg/ml), its limited content of 
biomarkers, and the lack of reference values (Montuschi, 2007, Hayes et al., 2016). 
EBC should be obtained without exhausting the patient, and the patient should be 
asked to breathe normally. Following good standard protocols for EBC collection 
increases its clinical utility as a monitoring biomarker, also called multiple reaction 
monitoring (MRM). In 2005, the first guidelines for the collection and preservation 
of breath condensate were published jointly by the American Thoracic Society and 
the European Respiratory Society. The guidelines suggest collection of breath 
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condensate for no longer than 10 minutes to avoid patient exhaustion (Horváth et al., 
2005). The guidelines also detail other considerations for collecting breath 
condensate, especially for MRM. These considerations include consumed food, 
smoking before collection, and room temperature. Body temperature also plays a role 
in the consistency of breath condensate samples because hyperthermia leads to 
hyperventilation as a consequence of the decrease in alveolar carbon dioxide pressure 
(hypocapnia) (Tsuji et al., 2016). This lowers the water content of exhaled breath and 
thus its ability to carry relatively large molecules and even intact cells. Label-free 
mass spectroscopy has maximised the number of detected volatile and non-volatile 
biomarkers in the breath condensate (Hayes et al., 2016).  
The first relatively quantitative proteomic profiling of breath condensate of healthy 
people was done by Muccilli et al. in 2015, who successful identified 165 proteins 
using label-free mass spectroscopy, 113 of which had not been identified in breath 
condensate previously (Muccilli et al., 2015). Most breath condensate proteins were 
cytokeratins, up to 20% were the inflammatory cytokines, interleukines, TNF-α, and 
angiogenic factors such as vascular endothelial growth factor (VEGF). In NSCLC, 
Cystatin-A, which is responsible for the induction of TNF-α and  interleukins 
(Magister and Kos, 2013, Kopitar-Jerala, 2006), accounted for up to 2% of the breath 
condensate proteome (Muccilli et al., 2015, Magister and Kos, 2013). Other proteins 
identified by mass spectroscopy in breath condensate from NSCLC patients included 
actin, desmoplakin and other mediators of pre-inflammation and pre-fibrosis. The 
vasoconstrictor endothelin-1 was one of the active peptides found to be increased in 
non-small cell carcinoma (Carpagnano et al., 2004). Survivin, cyclooxygenase II 
[COX II], and matrix metallo-proteinase 9 (MMP-9) were also elevated in the breath 
condensate from a patient with NSCLC (Carpagnano et al., 2010). The clinical utility 
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of breath condensate in diagnosis and monitoring of lung cancer would be 
conditioned with the development of an economical analytical method that can detect 
biomarkers at the concentrations present in breath condensate. 
1.10.3. BALF 
Bronchoalveolar lavage (BALF) is collected routinely from both paediatric and 
elderly patients (Brajer-Luftmann et al., 2016, Ramsey et al., 2017) for diagnosis of 
different lung diseases (Meyer et al., 2012), especially infiltrative lung diseases to 
detect opportunistic infections in immunocompromised patients (Brownback and 
Simpson, 2013). BALF is collected in the surgical theatre by bronchoscopy. 
Bronchoscopes are either rigid metal or flexible fibre-optic. Bronchoscopy is 
performed for investigation and surgical purposes and requires anaesthesia. The use 
of conscious sedation with fast, short acting anaesthetics such as ketamines is the 
standard technique for simple bronchoscopic procedures, but general anaesthesia is 
mandatory for long bronchoscopic surgery (Chadha et al., 2015).  
The similarity between the inflammatory cells profile (associated with lung diseases 
including carcinomas) harvested in the lavage (eg: decreased T lymphocytes in lung 
carcinomas, increased polymorphonuclear leucocytes in asbestosis and cystic 
fibrosis or degraded alveolar macrophages in proteinosis) and their clinical 
laboratory manifestation in these diseases  gave rise to the assumption that BALF 
can reflect the overall status of the lungs (Gee and Fick, 1980). BALF has been used 
for decades in clinical proteomics research, and with the emergence of non-invasive 
label-free mass spectrometry and polymerase chain reaction (PCR)-based 
techniques, the composition of lung lavage has become better characterized and the 
proteomic signatures of various lung diseases has become superior to single or 
combinations of diagnostic protein biomarkers (Plymoth et al., 2003).   
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In healthy people, proteins such as albumin, transferrin and α1- antitrypsin are seen 
in BALF, but inflammatory mediators and increased cell count are absent (Obertacke 
et al., 1987). The earliest study on normal references for cytological and proteomic 
values for BAL fluid was conducted in 1974 (Reynolds and Newball, 1974). The 
clearance capacity of the lung is increased in the presence of lower respiratory tract 
infection (Ramsey et al., 2017). 
BAL fluid can be helpful in isolating resistant microbial pathogens infecting the 
lungs for selection of the right antimicrobial agent (Dancewicz et al., 2009). 
Detection of inflammatory mediators in BAL fluid has great value in the assessment 
of lung allograft rejection in children (Wong et al., 2015, Benden et al., 2007). BAL 
fluid is also used in monitoring the progression of diseases like in paediatric 
pulmonary alveolar proteinosis, which is characterised by reduction in alveolar gas 
exchange due to  accumulation of excess surfactants in the alveoli (Badiozaman et 
al., 2013).  
Because BALF is close to tumour tissues, it has an advantage over blood because  of 
the simplicity of its constitution and the absence of the “background” from 97% of 
the blood proteome. In 2015, the simplicity of the BALF proteome led to successful 
differentiation of lung adenocarcinoma from other lung carcinomas and non-
malignant diseases (Almatroodi et al., 2015). BAL fluid has also been used for 
metabolic profiling of lung cancer, which showed that glutamate and glycerol 
metabolic pathways are altered in BALF from lung cancer patients compared to 
normal controls (Callejón-Leblic et al., 2016). Incorporation of gene microarrays 
chip discs might give more diagnostic details of lung diseases using bronchoalveolar 
lavage (Meyer, 2007). 
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However, BALF remains unsuitable for routine clinical and research use due to the 
collection technique and other factors (Singletary et al., 2008). Therefore, efforts 
continue to establish a standard protocol for BALF collection to enhance its 
diagnostic value (Singletary et al., 2008). The European Respiratory Society has 
established general guidelines for measurements and standardisation of normal 
human BALF (Crystal et al., 1986). 
1.10.4. FFPE tissue 
The standard protocol for tissue sample processing in hospitals worldwide includes 
fixation by formalin and moulding in paraffin. The tissues become highly stable and 
can be stored for a long time even at room temperature without deterioration. 
Proteomic analysis of formalin-fixed paraffin-embedded (FFPE) tissue would enable 
retrospective discovery of biomarkers in a huge archive of well-characterised clinical 
tissue samples. However, the proteins in FFPE tissues cannot be used in proteomic 
investigations with many state of the art methods because the proteins are cross-
linked by formaldehyde (Dowling, 2018).  
Nevertheless, the advantage of proteomic biomarkers discovery in FFPE tissue over 
fresh or frozen tissues is the availability of a good source of samples and the ease of 
handling and storage. Fresh or frozen tissues are often difficult to obtain in large 
numbers and relatively difficult to store in a stable form. Hence, FFPE tissues 
represent a potentially attractive sample pool for retrospective discovery of protein 
biomarkers. Immunohistochemistry (IHC) is the golden method for obtaining 
detailed proteomic information in hospitals.  Unfortunately, IHC has low sensitivity 
and is not quantifiable (Hood et al., 2005). 
The advantages of the mechanistic information on disease progression and 
manifestation offered by proximal biofluid-derived biomarkers is much appreciated. 
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Unfortunately, because tissue sample collection is invasive, pathologic diagnosis 
relies on a small amount of tissue. For decades, FFPE tissue remained the basic 
foundation for pathological diagnosis of diseases, mainly by IHC and in situ 
hybridization (ISH) to examine the expression of specific proteins or transcripts 
(Henke et al., 2006). Until recently, the ability to analyse FFPE tissues by mass 
spectrometry (MS) has been essentially non-existent (Hood et al., 2006, Zordan, 
2011).   
FFPE-based tissue samples have been thought unsuitable for proteomic analysis 
other than by IHC because of the extensive covalent cross-linking between the 
protein peptides and formaldehyde. The improved methods for extracting proteins 
from FFPE tissues enables their identification and quantification by tandem mass 
spectrometry (Scicchitano et al., 2009). Targeted proteomics based on enrichment of 
disease-specific proteins from high-quality tissue specimens provides great 
opportunities for discovery and validation of new diagnostic and prognostic 
biological markers in all phases of clinical trials. FFPE tissue collections, along with 
their relevant clinical information, are invaluable for retrospective discovery of 
protein biomarkers and performing various translational studies on malignant 
diseases (Guo et al., 2007, Kokkat et al., 2013). 
1.11. Non-malignant lung diseases  
Lung mucosal cells, due to their high surface area in contact with the surrounding 
environment, are exposed to all types of allergines, micro-organisms ( eg.viruses and 
bacteria) and to the weather stress (cold and heat). The differences in response to 
allergens between individuals leads to a broad range of lung diseases (such as 
bronchitis, asthma, …etc). The presence of auto-immune diseases such as sarcoidosis 
or genetic diseases such as cystic fibrosis would affect the overall content of lung 
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lavage. Therefore, when screening for lung cancer biomarkers using bronchoalveolar 
lavage, such conditions should be considered in the control samples and results 
should be interpreted along with the patients’ clinical information.      
1.11.1.  Sarcoidosis  
Sarcoidosis is an autoimmune, granulomatous, inflammatory lung disease of 
unknown aetiology. The disease is characterised by increased production of 
inflammatory cytokines due to accumulation of CD4+ T-lymphocytes in the affected 
lung tissues (Dubrey et al., 2016). The successful use of Rituximab targetting B-
lymphocytes cells-surfaces CD20 receptors in treatment of sarcoidosis might 
demonstrate their role in the pathogenesis of the disease (Dubrey et al., 2016, Cinetto 
et al., 2015). Sarcoidosis can affect any organ, but the lungs and thoracic lymph 
nodes account for 90-95% of the cases (Baughman et al., 2001). Like any other 
autoimmune disease, treatment of sarcoidosis relies on stabilizing the condition and 
preventing progression. Stabilizing inflammatory cells and preventing them from 
further production of inflammatory mediators involves the use of corticosteroids, 
which can be used locally (inhaled) or systemically in the exacerbated forms of the 
disease (Schutt et al., 2010). The disease is usually asymptomatic, and the main 
complaint of patients with symptomatic disease is repetitive coughing due the 
dryness caused by lung tissue necrosis in the main airways as a consequence of 
increased inflammatory mediators, of which tumour necrosis factor (TNF-α) is the 
most important. Therefore, interfering with the effect of TNF-α would help in 
preventing further deterioration of lung tissues. Golimumab, Ustekinumab and 
Rituximab are monoclonal antibodies used as cytokine modulators to interfere with 
the effect of TNF-α and stabilizing the disease (Bargagli et al., 2011, Judson et al., 
2014, Cinetto et al., 2015, Sweiss et al., 2014).   
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1.11.2. Asthma  
Asthma is an inflammatory disease manifested in reversible obstruction of 
pulmonary airways. The disease affects 300,000,000 individuals worldwide with an 
approximate mortality of 250,000 patients annually (Bousquet et al., 2007). Studies 
on BALF and tissue specimens from asthma patients revealed that Th2 CD+4 T 
lymphocytes play a master role in predisposing to asthma (Robinson et al., 1992). 
Th2 lymphocytes are responsible for the release of cytokines and interleukins and 
activation of mast cells. This is associated with massive release of histamine, the 
main broncho-constrictive autacoid, and subsequent recruitment of other leucocytes, 
e.g. eosinophils, neutrophils and monocytes, the latter of which differentiate into 
macrophages (Xie and He, 2005, Khan et al., 1985, Holgate, 2008). Local 
inflammation in asthma leads to activation of repair mechanisms and remodelling of 
airway walls involving vascular, epithelial and mesenchymal morphological changes 
(Holgate, 2008). Eosinophils release a specific transforming growth factor 
(eosinophils-derived TGF-β), cytokines, and cationic proteins (Kariyawasam and 
Robinson, 2007). Besides interacting with mast cells, these factors contribute to 
increased angiogenesis and activation of epithelial-to-mesenchymal transition and 
the overall pathological modelling of airway walls, including fibrosis (Aceves and 
Broide, 2008, Wilson and Wynn, 2009). Inflammation-induced injury of the lung 
epithelium leads to a local increase in epidermal growth factor (EGFR) receptors that 
favours the epithelial cells repair process (Puddicombe et al., 2000). When epithelial 
cells enter the repair phase, they produce profibrotic mediators, including TGF-β, 
endothelin and fibroblast growth factor (FGF). These mediators modulate the release 
of glycoproteins, proteoglycan, collagen (types I, II, V), tenascin, and fibronectin 
from myofibroblasts, leading to airway thickening (Holgate et al., 2000, Brewster et 
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al., 1990). Such biomolecules might be confusing when found elevated in lung 
cancer. Therefore, these biomarkers and of course others should be excluded when 
seeking biomarkers for diagnosis of cancer.   
1.11.3. Chronic bronchitis  
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of 
chronic bronchitis. COPD is an obstructive lung disease caused by chronic heavy 
smoking or chronic exposure to silica dust (silicosis). The disease is associated with 
goblet cell hyperplasia and overproduction of mucins, leading to small airways 
obstruction, epithelium remodelling, and a large decrease in alveolar compliance. 
The overall clinical manifestation of COPD is a large decline in pulmonary function 
and increased susceptibility to infection leading to chronic bronchitis. The latter is 
characterized by shortness of breath, wheezing, mild fever and central cyanosis due 
to inadequate alveolar CO2/O2 exchange  (Kim and Criner, 2013).   
Emphysema is another cause of chronic bronchitis similar to COPD, characterised 
by increased residual volume, the volume remaining in the lung after complete 
exhalation at rest). Emphysema is different from COPD in that the predisposing 
factor is alteration of the balance between pleural and alveolar pressure, which 
coordinates and facilitates smooth dynamic compression of pulmonary airways and 
maintenance of PaO2 and PaCO2 close to normal values (Robins, 1983). 
Pneumoconiosis, also known as black lungs, is an occupational diseases caused by 
inhalation of inert inorganic dust, which can be seen in x-rays but causes no damage 
to the lungs, or by inhalation of coal dust and fibrogenic materials such as asbestos 
and crystalline silica dusts (Cullinan and Reid, 2013). Lung cancer and pulmonary 
hypertension are associated with pneumoconiosis (Rosenman and Zhu, 1995). 
Intoxication with silica and coal dust results in secretion of lipases and proteases and 
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consequently activation of oxygen radical production by phagocytes in the lung 
epithelial and alveolar cells. Consequently, monocytes are recruited and differentiate 
into macrophages, leading to release of proinflammatory cytokines and reactive 
oxygen species (ROS), which cause lung scarring (Castranova and Vallyathan, 
2000).  
1.11.4. Acute bronchitis  
Acute bronchitis is an inflammation of the trachea and main bronchi without 
evidence of pneumonia caused by viral infection or other predisposing factors 
(Kinkade and Long, 2016). Strong coughing (with mucus) is the main symptome, 
but shortness of breath, wheezing, mild fever and chest tightness might occur (Wark, 
2015, Knutson and Braun, 2002).   
1.11.5. Pneumonia   
Pneumonia is infection of one or both lungs caused by bacteria, fungi, viruses or 
mycoplasma (Kashyap and Sarkar, 2010). The air sacs and alveoli become full of 
pus and inflammatory exudates, leading to fever due to pyrogens from the 
microorganism, night sweating, confusion, cough with slimy products, breathing 
troubles, and pain (Hoare and Lim, 2006). Pneumonia can be serious in people over 
the age of 65 years (Wawruch et al., 2004) if not treated properly and can be very 
dangerous if the patient is affected by diabetes (Kornum et al., 2007), COPD (Festic 
and Scanlon, 2015), congestive heart failure (Nimdet and Techakehakij, 2017), or is 
immunocompromised (e.g. organ transplant) (Sanders et al., 2006) or taking 
chemotherapy (De Weerdt et al., 2017) . 
1.11.6. Tuberculosis 
Tuberculosis a disease caused by Mycobacterium tuberculosis and affects the lungs 
because they are the first gate of infection. Only 5-10% of people infected with M. 
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tuberculosis develop symptoms at any stage of their life, and the condition resolves 
spontaneously in most cases (LoBue et al., 2010). Symptoms include haemoptysis, 
weight loss, anorexia, fever, malaise, terminal cachexia and breathlessness 
(Campbell and Bah-Sow, 2006). The risk of developing serious clinical systemic 
manifestations is expected only in children and immunocompromised or HIV 
patients (Harries and Dye, 2006). The diagnosis of latent tuberculosis is made either 
by the tubercullin skin test or by the interferon gamma reslease assay, whereas 
pulmonary tuberculosis is diagnosed by sputum smear microscopy for acid fast 
bacilli (Pai, 2013), chest radiography, sputum culture, and PCR confirmation of the 
presence of the bacterium DNA (LoBue et al., 2010).  
1.11.7. Cystic fibrosis  
Cystic fibrosis is a life-limiting autosomal recessive disorder affecting mainly people 
of European descent and others to a minor extent (Cutting, 2015). The main two 
organs affected are the lungs and the pancreas; other organs include intestines, sweat 
glands, biliary duct, and male reproductive tract (Cutting, 2015). Genetically, cystic 
fibrosis is attributed to F508del in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene (Rommens et al., 1989). CFTR functions as a cyclic AMP-
dependent chloride ion channel (Moskowitz et al., 2008, Kartner et al., 1991). The 
disease is characterised by viscous secretions of the pulmonary airway and pancreatic 
duct leading to obstruction, inflammation and damage to both organs. Loss of 
pancreatic exocrine would lead to poor growth and malnutrition in children if not 
therapeutically replaced. Therefore, screening of neonates for immunoreactive 
trypsinogen and CFTR alleles has become the gold standard for early detection of 
and intervention in cystic fibrosis (Moskowitz et al., 2008).  
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1.11.8. Pulmonary oedema 
The filtered plasma fluid and solutes that across the endothelium of the lung 
capillaries gathers in the interstitial spaces and then moved to the lymphatic vessels 
by means of pressure gradient. The amount of filtered plasma depends on the 
capillaries’ vascular pressure (hydrostatic pressure) and the protein colloid pressure 
(Staub, 1974). Accumulation of fluid in the interstitial spaces (oedema) occurs when 
the filtration rate exceeds the lymphatic drainage clearance. Lung oedema might be 
cardiogenic (secondary oedema), in which the pulmonary capillary pressure is 
elevated due to left-side congestive heart failure (LCHF), or non-cardiogenic 
(primary) oedema resulting from increased endothelial permeability caused by 
inflammation (Murray, 2011, Guntupalli, 1984). The symptoms include 
paroxysmal nocturnal dyspnea, anxiety and diaphoresis. Cardiogenic oedema can be 
treated by diuretics, vasodilators and cardiotonic drugs such as digoxin. Pulmonary 
oedema is treated by treating the underlying condition (Guntupalli, 1984).  
1.11.9. Acute respiratory distress syndrome (ARDS) 
ARDS is a pathophysiological condition of alveolar accumulation of fluids due to 
increased protein content in the pulmonary oedema. ARDS causes severe symptoms, 
including severe hypoxemia and central cyanosis due to impaired CO2 elimination 
(Matthay and Zemans, 2011). Pneumonia and gastro-oesophageal reflex diseases are 
the main disorders involved in the development of ARDS (Matthay et al., 2012).   
1.11.10. Benign lung nodules  
Among the rare benign lung nodules are papilloma nodules (squamous, glandular or 
mixed), which are single or multi-focal tumours found more commonly in the lower 
than in the upper respiratory tract (Popper et al., 1992).  These benign tumours might 
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lead to complete airway obstruction and consequently to pneumonia (Soldatski et al., 
2005).  
Sclerosing haemangioma (pneumocytoma) is another benign lung neoplasm 3-5 cm 
in size originating from an epithelial type II pneumocyte. Haemangiomas are of two 
morphological types: cuboidal epithelial cells positive for thyroid transcription factor 
(TTF-1), epithelial membrane antigen (EMA) and cytokeratin, and round stromal 
cells characterised by a weakly acidic cytoplasm, and Round stromal cells of 
haemangioma type are positive for TTF-1 and epithelial membrane antigen (EMA), 
and negative for cytokeratin (Devouassoux-Shisheboran et al., 2000).  
Alveolar adenoma is a rare, multi-cystic, peripheral lung neoplasm that is 
immunohistochemically positive for cytokeratin, TTF-1, and surfactant protein B&C 
(Burke et al., 1999). Type II pneumocyte papilloma is also a small (1.5 cm) 
peripheral neoplasm of type II pneumocyte that is positive for TTF-1 (Noguchi et al., 
1986). Salivary gland type tumours are very rare benign tumours developing in the 
central lung and are of two types: mucous gland adenoma and pleomorphic 
adenomas (Moran et al., 1994). Mucinous cystadenoma is a rare cystic epithelial lung 
neoplasm that proliferates slowly and is positive for TTF-1 and cytokeratin 7 (Rossi 
et al., 2004). Pulmonary hamartoma is also a peripheral, non-neoplastic, 
mesenchymal, lung tissue growth; < 10% of pulmonary hamartomas are endotracheal 
(Gjevre et al., 1996, Hansen et al., 1992). A detailed descriptive review of the rare 
lung tumours and benign nodules has been published by Borczuk, et al. in 2008 
(Table 3). 
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1.12. Lung cancer treatment 
Limited-stage, small-cell lung cancer is treated with chemotherapy and radiation 
therapy or a combination of more than cytotoxic drugs for those who cannot receive 
radiation therapy. These approaches might be preceded by surgical resection of the 
tumour (Brock et al., 2005, Takenaka et al., 2015). Radiation to the brain is done for 
successfully treated patients (Marr and Ganti, 2016). In the treatment of extensive 
metastatic stage SCLC, radiation therapy might be extended to involve the common 
sites of metastasis, such as bones and the spine (Davies et al., 2004, Jeremic et al., 
2017).  Treatment of NSCLC relies on the stage at which the tumour is discovered. 
If the tumour is localised to the lung and is discovered at a very early stage (called 
occult tumour), surgical resection remains the gold standard treatment (Weigel and 
Martini, 2000). 
Treatment of NSCLC tumours at stage 0 (carcinoma in situ) might involve wedge or 
segmental surgical resection, near-bronchus photodynamic radiotherapy, 
cryosurgery, and laser surgery (Griffin et al., 2006, Corti et al., 2007). Selection of 
the treatment protocol relies on the patient’s overall general health. In stage I 
NSCLC, surgical resection might include wedge, segmental, sleeve or lobectomy. 
Stereotactic body radiation (STBR) therapy is recommended for patients who cannot 
undergo surgery. Still in clinical trial is a combination therapy after surgery 
consisting of chemotherapy and radiotherapy or chemoprevention and photodynamic 
therapy (PDT) (Zaric et al., 2013, Corti et al., 2007).   
In addition to the previously mentioned surgical resection types intended for stage I 
NSCLC, surgical resection for stage II lung cancer might involve the whole lung or 
one or more lobes (pneumonectomy). Sometimes, surgical resection is either 
preceded or followed by chemotherapy and radiation, and vice versa (Zaric et al., 
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2013). External radiation is still recommended for those who cannot tolerate surgery 
(Low et al., 2007).   
Surgical treatment of stage IIIA NSCLC is preceded or followed by chemotherapy 
and/or radiotherapy (Logan et al., 1997, Cicenas et al., 2009). Recommended for 
non-surgical treatment of stage IIIA NSCLC is a combination of chemotherapy and 
radiotherapy sequentially or in parallel in addition to external radiation therapy, 
internal radiation therapy or laser surgery as a palliative treatment (Zhu and Tsao, 
2014).   
Stage IIIB is usually associated with pain and cardiopulmonary complications. At 
this stage, chemotherapy is mandatory, and followed by radiation therapy. Laser 
therapy, external or internal radiation therapy is usually done as a palliative therapy 
to relieve symptoms.  
Surgery is not used to treat stage IV NSCLC (Sculier, 2013). At this stage, treatment 
is limited to chemotherapy to prevent cancer progression. Targeted therapy, 
including monoclonal antibodies (suffixed mab) or small molecules (suffixed tinib) 
is highly recommended by the World Health Organisation. Table 4 summarizes some 
of the targeted mAbs and small molecules approved by the US Food and Drug 
Administration (FDA) and recommended for treatment of NSCLC in combination 
with chemotherapy. For example, the FDA has granted approval for Necitumumab 
as a first line treatment of SqCC. This mAb, in combination with the pyrimidine 
analogue gemcitabine, binds and antagonises the EGFR receptor. Similar approval 
has been given for the chemotherapeutic agent cisplatin, which binds DNA and 
interferes with DNA repair (Fala, 2016, Fuertes et al., 2003). To improve the quality 
of life, palliative therapy (such as external and/or internal radiation) and laser therapy 
is also used routinely.   
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The WHO has provided recommendations for the treatment of lung cancer detailing 
standard operating procedures for all oncology hospitals worldwide. The expected 
treatment outcome depends on the stage at which the cancer is detected, the 
histopathological state, the age of the patient, the presence of other diseases, and the 
overall health of the patient.  
 
Table 3: Benign lower respiratory tract nodules (Borczuk, 2008) 
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    Table 4: FDA-approved targeted therapy for NSCLC 
                 
M.T.: molecular target, TKI: tyrosine kinase inhibitor, M.O.A: Mechanism of 
action, VEGF: vascular endothelial growth factor, EGFR: epidermal growth 
factor receptor, VGFR: vascular growth factor receptor, ALK: anaplastic 
lymphoma kinase, ROS1: receptor kinase similar to ALK, PD: programmed 
death ligand-1, S small molecule inhibitor, M monoclonal antibody. 
 
1.13. Label-free proteomics 
The principal enabling technology of proteomic discovery is mass spectrometry, 
which accurately identifies and quantifies proteins and provides information on their 
structures and modification sites. In parallel, liquid chromatography (LC) has 
become very efficient and reproducible in separating proteins and peptides in 
complex samples. Technology platforms incorporating mass spectrometry for 
proteomic biomarker discovery include the following: (i) pattern-based methods that 
produce mass spectrometry-derived protein patterns by surface-enhanced laser 
desorption-ionization (SELDI), (ii) matrix-assisted laser desorption–ionization 
(MALDI), and (iii) electrospray and identity-based methods that yield lists of 
sequence-identified peptides from LC-MS/MS analysis of proteolytically digested 
proteins (Rifai et al., 2006). Accurate protein quantitation using differential labelling 
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technologies, such as iTRAQ (isobaric tag for relative and absolute quantitation) and 
SILAC (stable isotope labelling with amino acids in cell culture) are ideal for 
determining relative changes in protein expression in sets of samples and can lead to 
the discovery of potential biomarkers (Bouchal et al., 2009, Sun et al., 2008). 
Label-free quantitative mass spectrometry overcomes some of the limitations of 
label-based proteomics. Interest has increased in label-free strategies that can be 
applied to a wide variety of biological samples for biomarker discovery. Label-free 
quantitation has the advantage of being independent of the experimental design and 
allowing comparison of many samples under different conditions. Typically, 
hundreds of proteins can be simultaneously identified and their expression levels 
quantified in each sample. Thus, the effects of treatment or manipulation can be 
analysed across time series and underlying mechanistic pathways identified.  It is 
also possible to dig deeper in the proteome by applying a variety of separation 
strategies, such as immunodepletion and nanoparticle enrichment (Morrissey et al., 
2013, Yokomizo et al., 2011). 
1.14. Validation approaches (ELISA, IHC, MRM) 
There is general agreement that panels of biomarkers or biosignatures are more 
sensitive and specific than single markers. The use of large panels of biomarkers 
overcomes the problems caused by the substantial heterogeneity among cancers and 
is less likely to yield unreliable results. But developing assays for validation of 
biomarkers associated with disease or treatment response is difficult. The assays can 
be in the form of enzyme-linked immunosorbent assays (ELISA), 
immunohistochemistry (IHC), or mass spectrometry, each of which has its 
advantages and disadvantages. 
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Typically, studies include hundreds of patient specimens that are screened using 
sensitive immunotechniques such as radioimmunoassay (RIA) or ELISA for 
biofluids, and IHC for tumour biopsies (Zingone et al., 2014, Santra et al., 2011). 
Quantitative MS analysis using multiple reaction monitoring (MRM) is a convincing 
alternative to ELISA and IHC (Kitteringham et al., 2009). MRM uses multiple stages 
of mass spectrometry to quantitate proteins in a complex mixture with high 
sensitivity and specificity. Precise selection of a targeted chromatographically 
separated peptide in the first quadrupole and a specific fragment ion mass in the third 
quadrupole results in a high degree of specificity. Absolute quantitation is achieved 
by adding isotopically-Labelled internal standards. Specific antibodies with the 
required affinity and specificity for the targets may not be available to screen for the 
proteins of interest using ELISA and IHC, so MRM has become increasingly 
attractive for detecting proteomic components in a complex mixture. 
1.15. Cell culture models of drug resistance  
In 1951, the HeLa (Henrietta Lacks) cell line became the first cancer cell line to be 
successfully propagated in cell culture. The original cells were taken from a cervical 
cancer. Nowadays, more than 400 lung cancer cell lines (small and non-small cell) 
are well-characterised and in use (Gazdar et al., 2010b). The main reason for using 
lung cancer cell lines to study the molecular basis of lung cancer is that they resemble 
the tumour tissue from which they were isolated and contain all the driving mutations, 
including deletions, insertions and translocations, and the associated changes in post-
translation modifications found in the tumour tissues (Gazdar et al., 2010a). However, 
the optimal benefit from using such lung cancer cell lines as a lung malignant tumour 
representative cells is shortened due to their genomic vulnerability (instability), lack 
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of differentiation, and absence of vascular stroma responsible for formation of 
neovascularisation and microvascular extravasation in cancer (Bremnes et al., 2011). 
In drug resistance studies, proteomic-based comparative analysis of proteins from 
cell line lysates provides information on the proteins expressed differently in the 
original cell line. More specifically, certain protein subsets, such as mitochondrial, 
exosomal, membrane or nuclear proteins, can be enriched and studied. Moreover, 
proteins secreted in the culture media can be quantified and 
compared. The establishment of chemotherapy-resistant cancer cell lines is widely 
used for investigating the mechanisms of cytotoxicity and resistance to 
chemotherapeutic agents. Biedler and Riehm were among the earliest researchers 
(1970) to describe the development of drug resistance in cancer at the cell culture 
level. Their in vitro studies demonstrated cellular resistance to Actinomycin D 
in Chinese hamster cells (Gazdar et al., 2010b). 
Drug-resistant cell lines are often established by training the cells at low 
concentrations of the drug. The cells are given time to recover from the drug and 
then the training continues at a higher dose (called pulsed treatment strategy) to 
mimic the chemotherapy cycles often used for cancer patients. When the cells 
become resistant to the drug, they are maintained constantly in its presence. The 
mimicking of drug-resistance, the main cancer patients’ suffering issues during 
chemotherapy, in cell lines display up to ten-fold dose tolerance “resistance” 
compared to their parental cell line has a great clinical significance (McDermott et 
al., 2014).  
Despite the large number of anti-neoplastic drugs, including the new targeted 
therapies, treatment failure due to acquired or intrinsic drug resistance remains 
problematic. Avoiding or overcoming drug resistance requires elucidation of its 
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mechanisms. Therapeutic targets to overcome cancer drug resistance may also serve 
as biomarkers (theragnostics) (Reungwetwattana and Dy, 2013, Lee et al., 
2016). GDC-0980 is a class I PI3K/m-TOR dual inhibitor shown to have a promising 
therapeutic advantages in treatment of advanced solid tumours. The only 
disadvantage of using GDC-0980 in treatment of cancer is that it still can be tolerated 
by tumour tissue (resistance) (Dolly et al., 2016). H1975 lung adenocarcinoma cell 
line is a good example for the acquired form of resistance to GDC-0980 small 
molecule targetting PI3K/m-TOR pathways (Moore et al., 2017). A549 lung 
adenocarcinoma cells has an intrinsic ability to tolerate doses higher than other cell 
lines which is most likely attributed to the inactive mTOR pathway (Heavey et al., 
2016). 
1.16. Metabolomics 
Metabolomics is the study of chemical processes involving metabolites, the small-
molecule intermediates and products of metabolism. Living systems endeavour to 
maintain metabolic homeostasis and biological balance, and when an organism’s 
systems are perturbed by disease, metabolic profiles often change. This makes 
metabolites exceptional candidates as cancer biomarkers and particularly useful for 
understanding pathophysiology. Metabolomics specifically addresses the activities 
of small molecules (< 10 kDa) produced by active cells during their life cycles. The 
most frequently used technologies in metabolomics are nuclear magnetic resonance 
(NMR) spectroscopy and MS. The most popular analytical methods in MS are gas 
chromatography-mass spectrometry (GC-MS), LC-MS, and capillary 
electrophoresis coupled to mass spectrometry (CE-MS). These methods make it 
possible to comprehensively perform high throughput discovery metabolomics. The 
complementarity of these techniques enables in-depth metabolome analysis. 
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Discovery metabolomics studies the increase and/or decrease of abundant 
metabolites and the effect of their fluctuations on metabolic pathways. Typically, 
discovery-phase metabolomics is performed to identify biomarkers to improve early 
diagnosis, identify resistance signatures, and assist in monitoring the disease during 
treatment. Recent improvements in metabolomics technologies have increased their 
power in biomarker discovery and validation, as demonstrated by the mounting 
number of metabolomics-based publications (Deidda     M, 2015). Metabolites 
represent the downstream expression of the genome, transcriptome, and proteome in 
normal physiology and in pathophysiology. Indeed, by their complementarity, 
proteomics and metabolomics enable a more detailed overview of an organism’s 
phenotype.  
Cancer metabolism differs from normal metabolism. In the 1950s, Otto Warburg 
showed that cancer cells rely on anaerobic metabolism for energy, even under normal 
homeostatic oxygen levels. Features of cancer metabolism such as in central carbon 
metabolism, glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation 
are core considerations in the quest for accurate biomarkers, and one of the main 
reasons why metabolomics is one of the most rapidly developing disciplines in 
research, including on lung cancer (Guo et al., 2012). 
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1.17. Aim of the project  
1- To identify candidate biomarkers using proteomic analysis of  BALF from lung  
cancer patients and subsequent validation/verification of selected proteins in 
blood specimens and to identify candidate protein biomarkers that distinguish 
between adenocarcinoma (AD) and squamous cell carcinoma (Sq) of the lung 
when investigating bronchoalveolar lavage fluid (BALF) from lung cancer 
patients using label-free mass spectrometry.  
2- To evaluate tumour specimens from lung cancer patients compared to matched 
control tissue and identify heterogeneity associated with abnormal protein 
expression associated with different areas of the tumour tissue.  
3- Analyse a number of selected proteins from the tumour tissue work by using 
immunohistochemistry of tissue microarrays from lung cancer patients and 
identification of protein expression patterns between different types of lung 
cancer and associated stage/grade.  
4- To use Metabolon diagnostics discovery platform to evaluate metabolites 
that may function as lung cancer biomarkers and subsequently validate the 
most interesting metabolites in a larger cohort of serum samples using ELISAs 
and biochemical assays.   
5- To investigate the development of resistance to Apitolisib (GDC-0980), a dual 
phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase 
inhibitor, in A549 and H1975 lung adenocarcinoma cell line models using mass 
spectrometry, and how the abundance levels of cell cycle specific proteins are 
perturbed in the resistant phenotype.   
6- Label-free mass spectrometry and western blot analysis of mitochondrial 
associated proteins using cell line models of Apitolisib (GDC-0980) resistance.   
 
 
 
 
 
 
 
 
Chapter 2 
 
 
 
Materials and methods 
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2. Materials and methods 
2.1. BALF samples 
Bronchoalveolar lavage fluid (BALF) specimens (Table 5) were obtained from the 
Department of Respiratory Medicine, Beaumont hospital, Dublin 9, Ireland. 
Specimens containing haemolytic and/or fresh blood were excluded. Cells and cell 
debris was removed by centrifugation at 4000 x g for 15 min at 4°C.  The supernatants 
were concentrated using 5-kDa Amlpicon filters (Sigma; cat. #Z648019) by 
centrifugation at 30 g for 45 min at 4°C. ReadyPrep™ 2-D clean-up kit (Bio-Rad; 
cat. #163-2130) was then used to clean up the concentrated BALF: 200 µl of the 
BALF was combined with 300 µl of precipitating agent 1 in a 1.5-ml micro-
centrifuge tube, vortexed, and incubated on ice for 15 min. 300 µl of precipitating 
agent 2 was then added ,vortexed and centrifuged at 20,800 g for 30 min. The BALF 
protein pellets was suspended in 8 M urea buffer containing 0.1% ProteaseMax™ 
from (Promega; cat. #TB373) in 50-mM NH4HCO3. Total protein amount was 
estimated using the protein assay reagent from Bio-Rad (Bradford, 1976).  
 
2.1.1. BALF protein content 
In the Bradford reagent (Bradford, 1976) microassay protocol (Sigma-Life Science, 
lot #SLBH7472V), bovine serum albumin (BSA) was used as standard. Five µl of 
sample was combined with 295 µl of Bradford reagent in a Nunc microplate, mixed 
thoroughly, and incubated for 5 min in the dark. The plate was read at 595 nm in a 
Synergy HT BioTEK reader using KC4 kineticalc software version #3.3/Re #10. 
Samples concentration was calculated using the linear equation obtained from 
plotting BSA serial concentrations versus corresponding optical density (OD). 
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Table 5: Patient lavage samples biodata    
 
BALF: bronchoalveolar lavage, AD, adenocarcinoma, SqCC, squamous cell 
carcinoma, M, male, F, female, STD: standard deviation. 
 
 
2.1.2. Sample preparation for label-free mass spectroscopy 
BALF protein samples equivalent to 20 µg were reduced with 0.1 M dithiothreitol 
(DTT) (Sigma; CAS No. 3483-12-3) in 50 mM ammonium bicarbonate (Sigma- 
CAS No. 213-911-5) for 30 min at 37ºC. Samples were then alkylated with 0.2 M 
iodocetamide (IAA) (CAS No. 144-48-9) in 50 mM NH4HCO3 for 20 min at room 
temperature in the dark. Samples were then mixed with 50 mM NH4HCO3 in a 4:1 
ratio (v/v) and subjected to two digestion steps. The first digestion was performed 
using Lys-C for 4 h at 37°C.  The second was done using 1 µl of 1 U/µl trypsin 
(Sequencing grade modified trypsin; Promega ref. V5111) per 20 µg sample protein 
overnight for 15 h at 37°C with shaking at 6 g (Thermomixer Confort; Eppendorf 
AG, Hamburg, No. 5355 39149). The digestion was stopped using sample buffer 
(20% acetonitrile (ACN) (Fluka; CAS No. 75-05-8) containing 2% triflouroacetic 
acid (TFA) (Sigma-Aldrich; Product code 101398066) and 78% double distilled 
water) in a 3:1 sample to buffer ratio. Samples were then vortexed, incubated for 30 
min on ice, and de-salted using C18 spin columns (Thermo-Scientific, UK) 
according to the manufacturer’s protocol.  
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2.1.3. Sample desalting using C18 spin column at 1500 x g for 1 min 
The desalting resin was activated in C18 spin columns by centrifuging through it 200 
µL of 50% methanol and equilibrated twice with 200 µL of equilibration solution 
(0.5% TFA in 5% ACN) followed by centrifugation. Samples were then loaded and 
centrifuged and the flow-through was loaded and centrifuged again. Samples after 
then washed three times with 400 µL of the equilibration solution by centrifugation. 
All centrifugations were at 1500 x g for 1 min. Sample proteins were eluted using 40 
µL of 70% ACN containing 0.1 TFA, dried in the vacuum evaporator,  dissolved in 
25 µL of buffer A containing 0.1% TFA, and centrifuged at 20,800 g for 20 min. The 
top 20 µL was transferred into MS vials. 
 
2.1.4. Label-free MS/MS protocol 
Digested protein samples were analysed using a Q-Exactive mass spectrometer 
coupled to a Dionex RSLCnano (Thermo Scientific, Waltham, MA, USA). Peptide 
separation was performed using a Biobasic C18 Picofrit column (ThermoFisher 
Scientific, Hemel Hempstead, UK) of 100 mm length and 75 mm ID. Solvent A 
consisted of 2% (v/v) ACN and 0.1 % (v/v) formic acid (FA) in LC–MS grade water. 
Solvent B consisted of 80% (v/v) ACN and 0.08% (v/v) FA in LC–MS grade water. 
The solvents were used in a 2–40% gradient for 65 min at a flow rate of 250 µl/min.  
A full MS scan at 140,000 resolution and a range of 300–1700 m/z was followed by 
an MS/MS scan at 17,500 resolution and a range of 200–2000 m/z, selecting the 15 
most intense ions prior to MS/MS (Top15 method) (Manzanares-Miralles et al., 
2016). 
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2.1.5. Label-free MS/MS data processing 
Raw data generated from LC-MS/MS analysis was processed using Progenesis label-
free LC-MS software version 3.1 (Newcastle upon Tyne, UK). The retention times 
of all runs were aligned to a reference sample run yielded most peptide ions, and 
peak intensities were then normalized accordingly (Dowling et al., 2014). Three filter 
parameters were applied on the MS/MS data files before they were exported to 
Proteome Discoverer 1.4 software (Thermo-Scientific) for protein identification, 
including peptides ANOVA between the compared groups (p <0.05), peaks charge 
ranges from +1 to +5, and > 1 isotope per peptide. The PepXML generic file 
generated from all exported MS/MS spectra was used for peptide identification using 
Proteome Discoverer 1.4 against Sequest HT (SEQUEST HT algorithm, licence 
Thermo Scientific, registered trademark University of Washington, USA). 
UniProtKB-SwissProt database (taxonomy: Homo sapiens) was used to search the 
exported data. The following search parameters were set for protein identification: 
(i) peptide and MS/MS masses were set to 10 ppm and 0.02 Da, respectively; (ii) not 
more than two missed cleavages permitted; (iii) carbamidomethylation and 
methionine oxidation were set as fixed and variable modifications, respectively. Data 
were then imported back into Progenesis software for further analysis and only 
peptides with XCorr. Scores > 1.9 (+1), > 2.2 (+2) > 3.75 (+3) and of high confidence 
were selected. To ensure proper identification of cellular proteins, the criteria applied 
included p < 0.05 between tested groups, fold change ≥ 2 and proteins with ≥ 2 
peptides matched (Murphy et al., 2015).  
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2.1.6. ELISA biomarkers validation 
2.1.6.1. Plasma samples  
A total of 72 plasma samples from lung cancer patients, patients with benign lung 
disease (Sarcoidosis) and healthy indiviuals were used for initial validation of the 
candidate biomarkers (Table 6). Fasting blood samples were collected in EDTA-
containing tubes, mixed by inversion, centrifuged at 1800 g for 20 min. The separated 
plasma was stored in Eppendorf tubes at -80ºC (Chariot et al., 1994). 
 
   Table 6: Plasma samples biodata 
            
NSCLC: non-small cell lung cancer, AD: adenocarcinoma, SqCC: squamous cell 
carcinoma, M: male, F: female. 
 
  
2.1.6.2. BALF candidate biomarkers   
Table 7 provides information about the R&D DuoSet®Sandwitch ELISA kits used 
in the BALF candidate biomarkers validation in plasma.  
2.1.6.3. ELISA assay procedure  
Two 96-well plates (R&D Systems, Catalog #DY990) were coated overnight with 
100 µl of the capture antibody at room temperature (Tables 7, 8).  The plates were 
then washed 3 times with wash buffer containing 0.05% Tween-20®  in PBS, pH 7.2-
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7.4 (R&D Systems, Catalog #WA126). Plates were blocked for 2 h with PBS pH 
7.2-7.4 containing 1% BSA and filtered (0.2 µm; R&D System Catalog #DY995). 
 This step was followed by washing three times and the residual liquid after the last 
wash was removed by flicking the plates against a clean paper towel. plasma samples 
or standards in reagent diluent were added (100 µL per well), and the plates were 
covered with an adhesive strip and incubated for 2 h at room temperature. The plates 
were washed 3 times and the remaining liquid was removed as mentioned above. 100 
µL of biotinylated detection antibody diluted in reagent diluent was added to each 
well, and the plate was covered and incubated for 2 h at room temperature. 100 µL 
of the working dilution of Streptavidin-HRP was then added to each well and 
incubated for 20 min at room temperature in the dark, followed by 3 washes. 100 µL 
of substrate solution was added to each well and incubated for 20 min at room 
temperature. The reaction was stopped by adding 50 µL of stop solution containing 
2 N H2SO4 (R&D Systems, Catalog #DY994). The well contents were mixed 
thoroughly by gently moving the plates in circles. OD was measured at 570 nm and 
corrected for 450 nm. For the antibodies dilutions used in the assays, refer to table 8. 
2.1.6.4. Calculations of samples concentrations 
The natural logarithms (Ln) of the corrected OD values was plotted against the 
corresponding concentrations, and the derived linear equation was used to calculate 
the Ln(s) of sample concentrations. The sample concentrations were calculated from 
their Ln values. 
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2.1.6.5. Statistical analysis  
Wilcoxon-Mann-Whitney test (Marx, 2016) was used for calculation of the 
significance between the compared groups. In biomedical sciences, this test is 
preferred over the parametric and non-parametric methods to calculate more accurate 
p values between two populations using permutation (Ludbrook J., 1998).    
 
Table 7: ELISA kits used for BALF validation. 
   
All antibodies were reconstituted in 0.5 ml reagent diluent (137 mM NaCl, 2.7 
mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, PH 7.2-7.4, 0.2 µm filtered)(R&D 
System cat. #DY995).  
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Table 8: ELISA antibodies working concentrations and standard concentrations 
            
* Eight two-fold serial dilutions starting from the recommended highest 
standard concentration, Ab: antibody. 
 
2.2. Metabolomics analysis 
2.2.1. Serum samples preparation 
Fasting blood samples were collected from lung cancer patients and normal controls 
in anticoagulant-free sterile tubes and left to coagulate for 30 min at room 
temperature. The serum was collected after centrifuged at 1800 g for 20 min 
(Kocijancic et al., 2014) and transferred into clean sterile Eppendorf tubes and frozen 
at -80ºC. 250 µl of serum samples were shipped on dry ice (Chariot et al., 1994) to 
Metabolon Inc., NC, USA.  
At Metabolon Inc., the serum samples were centrifuged at 20,800 g, the obtained 
supernatants were divided into four equal aliquots and dried overnight in nitrogen 
vacuum drier at medium speed without heat. Dried samples were subjected to three 
independent analyses, two of which were for acidic and basic amino acids using 
UHPLC/MS optimized and the third for GC/MS.  
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2.2.2. UHPLC/MS protocol 
One dried specimen was reconstituted in 50 µl of 0.1% formic acid (acidic injection) 
and  another in 50 µl of 6.5 mM NH4HCO3 pH 8.0 (basic injection). Samples were 
run on Waters Acquity UHPLC coupled to an LTQ mass spectrometer equipped with 
an electrospray ionization source. Two independent UHPLC/MS injections were 
performed: acidic and basic for monitoring positive and negative ions, respectively.  
2.2.3. GC/MS protocol 
The third dried specimen was reconstituted in a mixture (1:1 v/v) of N,O-bis-tri-
methyl-silyl-trifluoroacetamide (TFA) and a solvent containing [1(acetonitrile): 
1(dichloromethane): 1(cyclohexane)] and [5% trimethylamine] at a ratio of 4:1 and 
heated at 60ºC for 1 h.  All solvents used in sample reconstitution were also used as 
an internal control to monitor instrument performance. The GC/MS data were 
analysed using Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole MS. 
2.2.4. Data processing  
The MS/MS2 data were analysed against the Metabolon’s reference standard library. 
The library contains information about the retention time/index, mass to charge ratio 
(m/z), and the MS/MS spectra of 1500 standards used in making the library. The 
library also contains the associated adducts, multi-meres and in-source fragments of 
the standards. These multi-parameters were used to identify the detected metabolites. 
All quantifications and identifications were subjected to quality control (QC) to 
verify the quality of peak integration and identification. 
2.2.5. Metabolomics’ biomarkers validation 
2.2.5.1. Serum sample handling 
Fasting blood samples were collected in anticoagulant-free vacutainer tubes and 
allowed to clot for 30 min and centrifuged at 1800 g for 15 min. The serum was 
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collected (Kocijancic et al., 2014), aliquoted,  and frozen in cryovials at -80ºC until 
use (Chariot et al., 1994).   
2.2.5.2. Pyruvate 
The colorimetric method described in the Enzychrom™ pyruvate assay kit (Cat 
#EPYR-100) was used (Hansen JL and EF, 1978). 10 µl of sample or standard per 
well was mixed with 90 µl of enzyme mix working cocktail [94 µl enzyme mix 
(pyruvate oxidase and hydrogen peroxide) and 1µl of dye reagent] in a 96-well plate 
and incubated at room temperature for 30 min. OD was read at 570 nm (550-585 
nm). A standard serial dilution ranging from zero (water as a blank) to 500 µM was 
used to construct the standard curve. Sample concentration was calculated using the 
following equation:  
𝐏𝐲𝐫𝐮𝐯𝐚𝐭𝐞	𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧	(µ𝐌) = 𝐒𝐚𝐦𝐩𝐥𝐞	𝐎𝐃 − 𝐛𝐥𝐚𝐧𝐤	𝐎𝐃𝐒𝐥𝐨𝐩  
Samples with OD higher than the OD of 500 µM were diluted in assay buffer, 
measured again and the calculated values were multiplied by the dilution factor. 
2.2.5.3. Free fatty acids (FFAs) 
The colorimetric method described in the Enzychrom™ free fatty acid assay kit (Cat 
#EFFA-100) was used (Seo et al., 2011, Lu et al., 2013). 10 µl of sample or standard 
was mixed with 90 µl working reagent containing (1 µl Enzyme A, 1 µl Enzyme B, 
1 µl co-substrate, 1 µl dye reagent and 90 µl assay buffer) in a 96-well plate, 
incubated at room temperature for 30 min, and OD was read at 570 nm (550-585 
nm). Free fatty acid concentrations were calculated from the following equation:  
𝐒𝐚𝐦𝐩𝐥𝐞	𝐅𝐅𝐀𝐬	𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧	(µ𝐌) = 	𝐒𝐚𝐦𝐩𝐥𝐞	𝐎𝐃 − 𝐛𝐥𝐚𝐧𝐤	𝐎𝐃𝐒𝐥𝐨𝐩  
Samples with OD higher than the OD of 1000 µM were diluted in assay buffer, 
measured again and the calculated values were multiplied by the dilution factor. 
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2.2.5.4. Ketone bodies  
The colorimetric method described by Siegel, et al. (1977) for the EnzyChrom™ 
ketone assay kit (EKBD-100) was used for quantitative assay of ketone bodies.  
2.2.5.4.1. Acetoacetic acid (AcAc) 
195 µl of assay reagent containing (195 µl AcAc buffer, 8 µl reconstituted AcAc 
reagent and 0.5 µl 3-hydroxybutyrate dehydrogenase enzyme) was added per well 
and combined with 5 µl of serum sample, water or standard. Sample blank assay 
reagent contained no enzyme. Samples were run in duplicates, one using the assay 
reagent and the other with blank reagent. The reaction mixture was incubated at room 
temperature for 5 min and the OD of NADH was measured at 340 nm (Hansen and 
Freier, 1978). The AcAc concentration was calculated from the following formula:  
𝐀𝐜𝐀𝐜	𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧	(𝐦𝐌) = 	 𝐎𝐃	𝐬𝐚𝐦𝐩𝐥𝐞 − 𝐎𝐃	𝐛𝐥𝐚𝐧𝐤𝐎𝐃	𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝 − 𝐎𝐃	𝐰𝐚𝐭𝐞𝐫 	𝐱	𝟖															 
8: samples dilution factor. 
 
2.2.5.4.2.  3 β-hydroxybutyric acid (BOHB) 
 
In each well, 195 µl of assay reagent containing (195 µl of AcAc buffer, 8 µl of 
reconstituted BOHB reagent and 0.5 µl of 3-hydroxybutyrate dehydrogenase 
enzyme) was added to 5 µl serum sample, water or standard. Sample blank assay 
reagent contained no enzyme. Samples were run in duplicates, one using the assay 
reagent and the other with the blank reagent. The reaction mixture was incubated at 
room temperature for 15 min and the OD of NADH was measured at 340 nm (Hansen 
and Freier, 1978). The BOHB concentration was calculated from the following 
formula:  
𝐁𝐎𝐇	𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧	(𝐦𝐌) = 	 𝐎𝐃	𝐬𝐚𝐦𝐩𝐥𝐞 − 𝐎𝐃	𝐛𝐥𝐚𝐧𝐤𝐎𝐃	𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝 − 𝐎𝐃	𝐰𝐚𝐭𝐞𝐫 	𝐱	𝟖												 
8: samples dilution factor. 
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2.2.5.5. Glutamate  
Glutamate Colorimetric Assay Kit (Bio vision® Catalogue #K629-100) was used 
according to the manufacturer’s recommendations (Koçdor et al., 2003). 100 µl of 
reaction mixture containing [90 µl of glutamate assay buffer (part No. K629-100-1), 
2 µl glutamate enzyme mix (part No. K629-100-2) and 8 µl glutamate developer 
(part No. K629-100-3)] was added to each well containing 50 µl of standard or serum 
sample (diluted 5 times in assay buffer). Sample background was performed by 
adding 100 µl of reaction mixture containing 2 µl of water instead of glutamate 
enzyme mix. The plate was mixed well, incubated at 37ºC for 30 min, and the OD  
was measured at 450 nm in a microplate reader. Samples OD values were corrected 
by subtracting the blank values, and the linear equation obtained from the standard 
curve was used to calculate glutamate concentrations in the samples. The obtained 
values were multiplied by the dilution factor as following:  
 𝐆𝐥𝐮𝐭𝐚𝐦𝐚𝐭𝐞	(𝐦𝐌) = 𝐒𝐚𝐒𝐯   
 
Sa: sample amount calculated fro the standard curve Y= a x (-/+)b (Y = sample OD, 
x = sample concentration, a: slop (given), b: intercept (given) and Sr: sample volume 
added to the well. The obtained values were multiplied by sample dilution factor.  
 
 
2.2.5.6. Acetyl co-A 
Human acetyl co-A sandwich ELISA kit (Wuhan Fine Biological Technology Co. 
Ltd.; cat. #EH0606) was used to estimate the levels of acetyl Co-A in serum control 
and lung cancer patients’ samples. The kit uses 96-well plates pre-coated with anti 
acetyl co-A capture antibodies, biotinylated anti acetyl co-A detection antibody, 
HRP-streptavidin and TMB as substrate for the peroxidase, which turns blue 
corresponding to the amount of glutamate in the sample. The reaction was terminated 
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by adding 1M H2SO4 and the resultant yellow colour was measured at OD 340 nm. 
The acetyl co-A levels were then calculated from the standard curve equation.  
2.2.5.7. Statistical analysis 
Wilcoxon-Mann-Whitney test (Marx et al., 2016) was used to calculate the 
significance of change among the compared samples. In biomedical sciences, it is 
preferred over the parametric and non-parametric methods to calculate more accurate 
p values for comparison of two populations using permutation (Ludbrook J., 1998).  
2.3. Formaldehyde-fixed paraffin-embedded tissue (FFPE) samples  
2.3.1. Tissue sample collection 
Four formaldehyde-fixed, paraffin-embedded tumour tissue samples (Table 9) were 
obtained from Saint James’ Hospital, Department of Thoracic Oncology, Dublin. 
The tumour mass together with normal surrounding lung tissue was harvested, 
immediately cut into four quadrant pieces, fixed in formaldehyde, and sent to the 
pathology laboratory for typing and grading. Three of the quadrants were moulded 
in a paraffin cube, cut with a microtome into 2-mm sections, and kept at 4°C. 
 
    Table 9: FFPE tissue samples biodata     
 
   D.O.B: date of birth, TNM: tumour, lymph nodes. x/y: denote patient codes.  
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2.3.2. Protein extraction and digestion for LC-MS/MS 
Protein extraction from samples for mass spectroscopy was performed using 
FASP™-Protein Digestion Kit (Expendeon part #: 44255) (Ostasiewicz et al., 2010, 
Wiśniewski et al., 2009). The procedure involves removal of the paraffin wax using 
two xylene–ethanol steps. Samples were first treated with 0.5 ml of xylene regardless 
of their weights, incubated at room temperature for 5 min with periodic gentle 
vortexing. This step was done twice and the solvent at the end of each step was 
discarded. The samples were then treated twice with 0.5 ml of absolute ethanol and 
the solvent was removed after each treatment. The tissue samples were then nitrogen 
vacuum-dried and the weight of each dried tissue sample was recorded (Table 10).  
Samples were then homogenized in 300 µl of UPX universal protein extraction 
buffer for 5 min using a dounce homogenizer, and then incubated in a thermomixer 
at 105°C for 30 min with agitation at 6 g. After cooling to room temperature, they 
were centrifuged for 15 min at 20,800 g to remove cell debris. The tissue lysates 
were mixed with urea buffer (prepared in Tris-hydrochloride) and the lysate volume 
was normalised for tissue weight used (Table 10). The lysate was applied onto a spin 
filter (provided), centrifuged at 20,800 g for 20 min, and washed twice with 200 µl 
of urea. Centrifugation was under the same conditions, and all flow-through was 
discarded.  
2.3.3. Protein digestion   
Heat-denatured samples were alkylated by adding 100 µl of 1X iodoacetamide in 
urea buffer (IAA) to the spin columns and incubating them for 20 min in the dark at 
room temperature. Afterwards, the spin filters were centrifuged at 20,800 g for 10 
min and washed with 100 µl of urea sample solution. To prepare protein samples for 
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trypsin digestion, the spin filters were treated twice with 50 mM NH4HCO3 and 
centrifuged at 20,800 g for 10 min. 
 Finally, the protein was digested with 75 µl of trypsin in 50 mM NH4HCO3  (1 U 
trypsin/20 µg protein). Spin filters were mixed for 1 min, wrapped with paraffin film, 
and incubated overnight at 37ºC.  They were then transferred to new collection tubes, 
centrifuged at 20,800 g for 10 min and centrifuged using 50 µl of 0.5 M NaCl to 
release the bound peptides from the spin filter. The digestion was stopped with 50 
mM NH4HCO3 (3:1 v/v sample to buffer ratio). Finally, the spin filters were 
centrifuged at 20,800 g for 5 min and the top 50 µl was transferred into MS vials. 
2.3.4. LC-MS/MS protocol 
Samples were run in triplicates. The Q-EXACTIVE settings were set as mentioned 
in section (2.1.5). Twelve raw data files were obtained per patient. Nine files 
represent the proteome of three different areas within the tumour, and the other three 
file represent the proteome of the surrounding normal tissue (table 10). 
2.3.5. Processing mass spectroscopy raw files 
In a separate experiment, Mass spectroscopy raw files uploaded individually into 
MaxQuant software. The protein-group text file was then uploaded into the Perseus 
software then the principal component analysis (PCA) and heat-map clustering of 
the proteomic signature of the tumour parts and the normal tissues were generated. 
The results were exported to an Excel file and the log2x values were converted back 
into numbers using the online calculator at http://www.endmemo.com/algebra/log2.php.  
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Protein abundance fold-change was then calculated using the following equations: 
 
Up-regulated proteins =    𝑵𝒖𝒎𝒃𝒆𝒓	𝒄𝒐𝒓𝒓𝒆𝒔𝒑𝒐𝒏𝒅𝒊𝒏𝒈	𝒕𝒐	𝑸𝒙𝑵𝒖𝒎𝒃𝒆𝒓	𝒄𝒐𝒓𝒓𝒆𝒔𝒑𝒐𝒏𝒅𝒆𝒏𝒕	𝒕𝒐	𝑵𝒄 
Q: quadrant, x: (1, 2, 3), Nc: normal control  
 
Down-regulated proteins = 𝑵𝒖𝒎𝒃𝒆𝒓	𝒄𝒐𝒓𝒓𝒆𝒔𝒑𝒐𝒏𝒅𝒆𝒏𝒕	Y𝒐	𝒕𝒉𝒆	𝑵𝒄𝑵𝒖𝒎𝒃𝒆𝒓	𝒄𝒐𝒓𝒓𝒆𝒔𝒑𝒐𝒏𝒅𝒆𝒏𝒕	𝒕𝒐	𝒕𝒉𝒆	𝑸𝒙 
 
                                                       Q: quadrant, x: (1, 2, 3), Nc: normal control 
 
Where; Qx: any quadrant, Nc: normal tissue control.  
 
Table 10: FFPE tissue sample preparation for mass spectroscopy 
      
Sample ID (x/y): x denote patient code and y denote microtome cut number code, 
 *: normal lung tissues. 
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The lists of significantly upregulated and downregulated proteins per tumour 
quadrant were further analysed using the online Venn diagram bioinformatics and 
systems biology too available at  http://bioinformatics.psb.ugent.be/webtools/Venn/.  
The upregulated and downregulated proteins shared in all three quadrants were 
listed. The shared upregulated and downregulated proteins in all quadrants and in all 
patients were filtered and listed. Further bioinformatics analysis was performed to 
find a common area for proper biomarkers discovery and validation.  
2.3.6. Tissue microarrays validation of heterogeneity  
Four candidate protein biomarkers (Talin-1, lactate dehydrogenase-A, pyruvate 
dehydrogenase and fatty acid synthase) were selected based on their high abundance 
among all tumour tissues and based on their know role in cancer. Antibodies dilutions 
were: Talin-1(C45F1) rabbit mAb #4021 diluted 1:50, lactate dehydrogenase-A 
(C4B5) rabbit mAb #3582 diluted 1:400, pyruvate dehydrogenase (C54G1) rabbit 
mAb #3205 diluted 1:100 and fatty acid synthase (C20G5) rabbit mAb #3180 diluted 
1:50 as recommended. Two NSCLC Tissue micro arrays (TMAs) slides (serial 
numbers LC10013at and LC819t) were used for experimental optimization. Two 
LC10011a NSCLC (TMAs) containing lung adenocarcinoma (AD), lung squamous 
cell carcinoma (SqCC), as well as normal lung tissues (appendices 43 & 44) were 
used to validate Talin-1 and lactate dehydrogenase-A (LDHA) expression 
heterogeneity. Two LC819 TMAs containing lung adenocarcinoma and squamous 
cell carcinoma but not normal tissue cores were used for detection of pyruvate 
dehydrogenase (PDH) and fatty acid synthase (FASN) expression heterogeneity. 
2.3.6.1. Immunohistochemistry protocol 
The TMAs tissue sections were processed in a Dako autostainer at the National 
Institute of Cellular Biotechnology (NICB) in Dublin City University, Dublin. 
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Antigen was retrieved using Dako citrate buffer (pH 6) (Agilent Dako products code 
#S2031, part #S203130-2) for 20 min. The incubation time was 30 min for the 
primary antibodies. Counterstaining was done with haematoxylin. Dehydration of 
tissue sections was performed by reversing the rehydration steps, starting with 95% 
ethanol, then 100% ethanol, and finally xylene. All incubations were done twice for 
10 min each. The tissue sections were then covered with a coverslip using mounting 
medium.  
2.3.6.2. Intensity scoring of tissue cores  
Colour intensity was assessed under a 20x optical lens for adenocarcinoma (AD), 
squamous carcinoma (SqCC) and normal tissue (N) cores. Staining intensity was 
scaled as 0 (negative), 1 (weak), 2 (good) or 3 (very strong). The number of cores 
per score per tissue type (AD, SqCC, N) per antibody was tabulated and a 
representative core per score per antibody per core tissue type is represented in the 
results chapter. The score of TMA cores per candidate protein is tabulated as 
appendices 43, 44 and 45.          
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2.4. Drug resistance- based biomarkers heterogeneity 
2.4.1. Cell culture  
GDC-0980 sensitive parent (P) and resistant H1975 (R) lung adenocarcinoma cells 
(NCI-H1975, ATCC® CRL-5908™) were cultured in T75 cell culture flasks with tilted 
neck and vented caps in Roswell Park Memorial Institute medium (RPMI-1640 
medium, Sigma R5886 Lot: RNBF1079) supplemented with 10% foetal bovine 
serum (FBS Sigma, F7524, Lot: BCBR 1178V) and 1% penicillin-streptomycin-
glutamine (Gibco™ Cat No: 10378-016).  
The media for the resistant cells was conditioned with 1 µM GDC-0980 (R+) or 
GDC-0980 free media (R-). Cells were harvested at 80% confluence, washed twice 
with 5 ml sterile 1x PBS, detached by adding 2 ml of trypsin (1X trypsin/EDTA, 
product No. 59430C, Sigma Aldrich) per T75 flask for 3-5 min at 37°C.  For every 
ml trypsin added, 3 ml of RPMI was added to deactivate the enzyme. The cell 
suspensions were then collected in 15-ml falcon tubes, labelled, and centrifuged for 
3 min at 10 g at 15ºC. The supernatants were discarded and the cell pellets were re-
suspended in lysis buffer for mass spectrometry and western blot validation, frozen 
at -20ºC for mitochondrial enrichment, or re-suspended in sterile RPMI for further 
cells passaging or seeding for confocal microscopy, cell cycle profiling by Cytell®, 
seahorse basic metabolic measurement; or cytotoxicity study.  
2.4.2. Cell lysis  
Harvested cell pellets were re-suspended in 8 M urea PTMscan lysis buffer 
(PTMscan® lysis buffer, Cell Signalling Technology, Inc.), sonicated using 
Bandelin Sonopuls sonicator for three cycles each of 30 seconds at power setting of 
50%, centrifuged at 20,800 g for 20 min at 4°C, and protein content in the supernatant 
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was measured using Bradford assay reagent (Pierce Detergent Compatible Bradford 
Assay Kit cat. #23246S) (Bradford, 1976). 
2.4.3. Mitochondrial enrichment 
GDC-0980 sensitive parent (P) and resistant (R) H1975 cells were cultured as 
mentioned in section 2.4.1. The mitochondrial isolation kit (cat. #ab110171) was 
purchased from Cell Signalling Technology. To enhance the mechanical disruption 
of the cell membrane, the cell pellets were frozen at -20ºC overnight and thawed at 
room temperature. Cells were then suspended in 1 ml of cell lysis buffer (Buffer A, 
provided) and incubated for 30 min on ice. The cell suspension was then vortexed 
and transferred into a 2-ml Dounce homogenizer precooled at -20°C, and the cells 
were lysed by mechanical rupture through 30 strokes using pestle B (provided). To 
remove the relatively large debris, the cell lysate was centrifuged at 5400 g for 10 
min at 4°C. The supernatant was then transferred into a new 2-ml centrifuge tube and 
the pellet was re-suspended in 1 ml of buffer A and given 30 more strokes in the pre-
cooled Dounce homogenizer. The two supernatants were combined and centrifuged 
at 20,800 g at 4°C for 20 min. The pellet (orange) was re-suspended in 500 µl of 
buffer C containing protease inhibitor (provided) and kept at -80°C until protein 
quantitation. 
2.4.4. Samples protein quantification 
The Bradford Reagent Micro assay protocol (Sigma-Life Science, Lot 
#SLBH7472V) and micro plate reader (Synergy HT BioTEK and KC4 kineticalc 
software version #3.3/Re #10) at 595 nm were used to measure the protein content 
of supernatants. The lysate was divided into aliquots equivalent to 20 µg total protein 
and kept at -20°C until used for mass spectrometry analysis, western blot validation 
or other assays.  
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2.4.5. Label-free mass spectroscopy  
2.4.5.1. Protein sample preparation for label-free LC-MS/MS 
Samples equivalent to 20 µg of total protein (GDC-0980 parent vs. resistant (R+, R-
) H1975 cells) in triplicates were reduced with 1µl of 10 mM dithiothreitol (DTT; 
CAS No. 3483-12-3) in water for 30 min at 37°C and then alkylated with 1 µl of 50 
mM iodoacetamide (IAA; CAS No. 144-48-9) prepared in 50 mM ammonium 
bicarbonate in the dark at room temperature. Next, samples were mixed with 50 mM 
ammonium bicarbonate (CAS No. 213-911-5) buffer in a 3:1 buffer to sample ratio. 
Then, protein samples were digested with 1.5 µl of trypsin (sequencing grade 
modified trypsin; Promega ref. V5111) at a concentration of 1µg/µl at 37°C with 
shaking at 6 g overnight (minimum of 15 hours). The reaction was stopped using 
sample buffer containing a combination of 2 ml acetonitrile (Fluka, CAS No. 75-05-
8) supplemented with 200 µl of triflouroacetic acid (Sigma-Aldrich, prod. code 
101398066) and 7.8 ml of double distilled H2O), in a 3:1 sample to buffer ratio. The 
samples were vortexed, put on ice for 30 min, and de-salted using C18 spin columns 
(Thermo Pierce C18 spin columns) according to the manufacturer’s protocol. The 
desalted samples were dried in nitrogen vacuum drier at a low drying rate without 
heat. Finally, the precipitate was dissolved in 25 µl of buffer A containing 0.1% TFA 
and centrifuged at 20,800 g for 20 min, and the top 20 µl of supernatant was 
transferred into a MS vial. 
2.4.5.2. LC-MS/MS  
Samples in triplicates were introduced in Q-EXACTIVE with the same settings 
described in section 2.1.4. The raw files were processed as mentioned in section 
2.1.5. The significant (p-value ≤ 0.05) proteins found up or downregulated in GDC-
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0980 resistant H1975 lung adenocarcinoma cells either cultured in (R+) or without 
(R-) the drug compared to the parent cells were listed in tables for further validation. 
 
2.4.6. Western blot 
Samples equivalent to 20 µg protein were used in triplicate to compare GDC-0980 
sensitive parent and resistant H1975 cells cultured in RPMI medium conditioned as 
described in section 2.4.1. Low protein content samples were treated with 5 volumes 
of acetone chilled at -80°C, vortexed, and incubated overnight at -20°C. The acetone-
treated samples were centrifuged at 20,800 g at 4°C for 30 min and the pellet was 
suspended in a volume of water equivalent to 25% of the original sample volume (4x 
concentrate). The protein content was measured again to calculate the volume 
equivalent to 20 µg protein.  
2.4.6.1. SDS gel separation of cells lysate-proteome 
Samples in triplicate were reduced with 5 µl of 4x sample loading buffer (Table 11) 
for 5 min on a thermo-mixer (Thermo-Fisher Scientific) at 1.5 g. Next, samples were 
cooled on ice for 2 min before being loaded on a SDS polyacrylamide gel. Proteins 
were resolved in 12% pre-casted SDS gels (GE healthcare Amersham™ ECL gels 
12%, Lot No. 28-9898-05) at 140 V for 65 min in a horizontal electrophoresis unit 
(Amersham™ ECL Gel Box horizontal electrophoresis unit) using 1x 
electrophoresis running buffer containing 25 mM Tris-base, 192 mM glycine and 
0.1% SDS (Table 12). Color-coded pre-stained protein marker (Cell-Signalling 
Technology, cat. #14208) (Figure 6) was used to confirm the protein molecular sizes. 
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                           Table 11: Composition of 4x Laemmli sample loading buffer  
Chemical name Quantity 
1M Tris-HCl pH 6.8 2 ml 
Sodium dodecyl sulphate (SDS)   0.8 g 
β-mercaptoethanol 4 ml 
10% Bromophonol blue 10 µl 
Glycerol 4 ml 
 
 
 
                           Table 12: Composition of SDS-PAGE running buffer 
10X running buffer recipe         Quantity 
Glycine            144 g 
Tris base           30.2 g 
SDS              10 g 
Double distilled H2O          Up to 1 L 
 
 
 
     Figure 6: Color-coded pre-stained protein marker. 
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2. 4.6.2. Nitrocellulose membrane protein electro-transfer and antibody 
incubation 
The resolved proteins were electro-transferred onto nitrocellulose membrane (0.22 
µm pore diameter) using One-Step transfer buffer (Thermo Scientific, product No. 
84731) and Pierce G2 fast blotter (Thermo-Fisher Scientific) at 25 V for 5 to 10 min, 
depending on the molecular weight of the protein. The transfer cassette consists of 
(bottom to top) seven layers of absorbent papers soaked in transfer buffer, followed 
by a nitrocellulose membrane, then by the SDS gel containing the resolved proteins 
(with the marker to the left), then on top seven more layers of soaked absorbent 
paper.  
The membrane was then blocked in 5% non-fat skimmed milk (Marvel skimmed 
milk powder, Premier Food Group Ltd., UK) prepared in 1x PBS containing 0.01% 
Tween-20® for 2 h with medium shaking. The membrane was then washed twice 
with 1xX PBS/0.1 Tween-20 and incubated with the primary antibody (monoclonal) 
overnight at 4°C on a medium speed shaker (Table 13). Then, the nitrocellulose 
membrane was washed twice with 1x PBS/0.1 Tween-20 and incubated with the 
secondary antibody, anti-mouse IgG HRP-linked antibody (Cell Signalling cat. No. 
7076) or anti-rabbit IgG HRP-linked antibody (Cell Signalling cat. No. 7074) for 2 
h. The membrane was again washed twice and kept in 1x PBS/0.1 Tween-20 washing 
buffer until developed.  
2.4.6.3. Incubation of nitrocellulose membrane with HRP  
The nitrocellulose membrane was incubated with 5 ml of 1:1 volume ratio of reagents 
A and B (ECL western blotting substrate, Pierce Thermo-Scientific, prod. #32106) 
for 2-3 min, and the chemiluminescent signal corresponding to the amount of the 
protein in the sample was captured using G-Box (G:Box Chemi-XT4 GENESys). 
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Images were obtained and saved as tiff files with a black background and white signal 
(the default G-Box settings) for further Image-J software quantitative analysis. 
2.4.6.4. ECL signal measurement   
 
Image-J software (version K 1.45) was used to measure the chemiluminescent signal 
in the tiff images taken by G-Box. Rectangles of the same size were drawn around 
the captured ECL signals and the image J corresponding numbers were compared 
using Prism software.  
2.4.6.5. Chemiluminescent signal analysis 
Image J measured values correspondent to the intensities of the bands obtained by 
western blot (in triplicates), the values were then divided by their correspondent 
loading control values and expressed as ratio, and the p values from comparing the 
protein abundance of the resistant cells (treated, R+ or non-treated, R-) to the parent 
cells were calculated using non-parametric two-way ANOVA with GraphPad 
Prism7.  
2.4.6.6. Western blot loading control 
Beta actin, alpha tubulin and glyceride-3-phosphate dehydrogenase enzyme 
(GAPDH ) which used routinely as a loading control were all elevated in the resistant 
cells compared to the parent cells, so the first step was to find a loading control for 
the comparision of GDC-0980 treated (R+) and non-treated (R-) with the parent (P) 
H1975 cells. HDAC I was the best  (reproducible) for comparing R- and P and PCNA 
was reproducible for comparing R+ and P (figure 7). These two loading controls 
were then used for all western blots to confirm equal amount of samples (20µg 
protein) and to exclude any samples loss during samples loading into the gel wells.  
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Figure 7: western blot loading control for treated (R+) and non-treated GDC-
0980 resistant cells compared to their matching parent cells (P). 
 
 
Table 13: Mitochondrial membrane marker antibody sampler kit (Cat.# 8674T) 
 
HSP: heat shock protein, SDHA:P succinate dehydrogenase A, VDAC: voltage-
dependent anionic channel, PDH: pyruvate dehydrogenase, PHB1: prohibitin B1 
isoform, COX IV: cytochrome c oxidase 6, SOD: superoxide dismutase. IgG: 
immunoglobulin G, HRP: horseradish peroxidase, Ab: antibody. mAb: mono-clonal 
antibody, pAb: polyclonal antibodies, BSA: bovine serum albumin. Antibodies were 
diluted at 1:1000 in 5% w/v BSA containing 0.1% Tween-20 in 1xPBS. Inclubation 
time was overnight in all primary antibodies and two hours for the secondary 
antibodies.**Rabbit mAb, ***Mouse mAb, Ω Secondary antibody, m: mAb, p: pAb. 
*Marvel skimmed milk powder (Premier Food Group Ltd., UK). 
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2.4.7. TMRE mitochondrial membrane potential assay kit (cat. #ab113852). 
Cells were cultured as in section 2.4.1 and harvested in 1 ml PBS. To distinguish live 
from dead cells, the cells in 0.4% trypan blue sterile-filtered solution (cat. #T8154, 
CAS #72-57-1, Sigma-Aldrich® -now Merck) were counted under light microscopy 
using a X20 lens and hemocytometer slide . Cell suspension volumes equivalent to 
approximately 150,000 cells were transferred into five 1.5-ml Eppendorf tubes and 
the volume was made up to 200 µl sterile media conditioned as mentioned above.  
Cells were then treated as follows:  
Tube 1: Only cells; 
Tube 2: Negative control containing 50 µM carbonyl cyanide p- trifluoromethoxy 
phenylhydrazone (FCCP); 
Tube 3: Containing 200 nM TMRE (tetramethylrhodamine, ethyl ester); 
Tube 4: TMRE pre-treated with FCCP; 
Tube 5: Stained with Mito tracker as described in its protocol). 
In tube 4, cells were pre-treated with FCCP for 20 min at 37°C, and all treatments 
were incubated for 30 min at 37°C. Cells were then washed twice with 1x PBS and 
analysed in BD Accuri™ C6 Plus flow cytometer using side scatter content (SCC) 
at FL2 channel. The population obtained was gated into four quadrants to correlate 
cell cycle phase with mitochondrial membrane activity (Hikita et al., 2015, Fujiwara 
et al., 2015).    
2.4.8. Basic metabolic phenotyping 
This experiment was conducted in Saint James’ Hospital, Department of Surgery at 
the Institute of Molecular Medicine. Seahorse XF24 extracellular Flux AnalyZer and 
Seahorse XF24 FluxPak mini kit (Part #100867-100) were used in this experiment. 
 
 
81 
2.4.8.1. Optimisation of seeding density for seahorse analysis  
Based on the growth curve, three seeding densities were used to select the optimal 
seeding density for producing a good Seahorse XF24 Analyzer signal (Diagrams 1 
& 3). The average of six measurements of the oxygen consumption rate (OCR) and 
the extracellular acidification rate (ECAR) per treatment were taken.  
Diagrams 2 & 3 depict the experimental setup. The experiment was performed once 
a week for three consecutive weeks, and the average measurements of three plates 
per tested cells was taken: parent sensitive, resistant (drug free, R-) and resistant (plus 
drug, R+). 
 
Diagram 1: Optimisation of H1975 cells seeding density for seahorse analysis 
 
        
 
P (Parent: GDC-0980 sensitive cells), R- (GDC-0980-resistant cells grown and 
assayed in GDC-0980 free RPMI/assay medium), R+ (GDC-0980-resistant cells 
grown and assayed in RPMI/assay medium containing 1 µM DC-0980), numbers in 
bold are the used cells density. 
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Diagram2: Seahorse experiment design 
           
P (Parent: GDC-0980 sensitive cells), R- (GDC-0980-resistant cells grown and 
assayed in GDC-0980 free RPMI/assay medium), R+ (GDC-0980-resistant cells 
grown and assayed in RPMI/assay medium containing 1 µM DC-0980), * see plate 
map (diagram 3). 
 
 
 
   Diagram 3: Plate mapping for seahorse OCR and ECAR measurement 
           
Where: M-(GDC-0980-free assay medium), M+ (Assay medium + 1 µM GDC-0980 
final concentration), P (Parent: GDC-0980 sensitive cells), R- (GDC-0980-
resistant cells grown and assayed in GDC-0980 free RPMI/assay medium), R+ 
(GDC-0980-resistant cells grown and assayed in RPMI/assay medium containing 
1 µM DC-0980), OCR: oxygen consumption rate, ECAR: extracellular 
acidification rate. 
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2.4.8.2. Basic metabolism measurement protocol  
GDC-0980 sensitive (P) and resistant H1975 (R) lung adenocarcinoma cells were 
cultured in RPMI medium containing 10% BSA and 1% streptomycin in T75 flasks. 
The medium for growing the resistant cells was conditioned by supplementation with 
a final concentration of 1µM GDC-0980 (R+) or GDC-0980 free media (R-). To 
select the optimal seeding density for H1975 cells, a growth curve was constructed 
using five T25 flasks for each of the three conditions. OD at 600 nm was read on five 
consecutive days and plotted against time. Sensitive (P), resistant treated (R+) or 
resistant non-treated (R-) cells were seeded at densities of 40,000, 60,000 and 80,000 
cells/well, respectively, in 24-well cell culture plates (Seahorse Bioscience V7-PS, 
TC-treated, Part #100777-004, Lot: 26516) in 250 µl per well and allowed to adhere 
overnight.  
The XF24 sensor cartridge was hydrated in 1 ml of Seahorse XF Calibrant per well 
(Seahorse bioscience, Lot No. 089, Part No. 100840-000) overnight at 37°C in a 
CO2-free incubator.  
The next day, wells were washed three times with the assay medium (XF assay 
medium, modified DMEM, CAT No. 102352-000, part No.102365-100, Lot 
08816010) supplemented with 10 mM glucose (G8270 Sigma, CAS No. 50-99-7) 
and 10 mM sodium pyruvate (P2256 Sigma-Aldrich, CAS No. 113-24-6) final 
concentration. 150 µl of the RPMI medium was removed and 1 ml of assay medium 
was added, then 900 µl was removed and 300 µl of assay medium was added to get 
a final volume of 500 µl. Cells were incubated for 40 min at 37°C in a CO2-free 
incubator. In the last 20 min of incubation, the XF24 sensor cartridge was introduced 
into the Seahorse XF24 Analyzer after removing the lid and the utility plate. After 
calibration, the cartridges were placed on the tested plate and introduced into the 
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Seahorse XF24 Analyzer. Cells were stained with 0.5% crystal violet solution at 
room temperature for 20 min, washed three times with water, and incubated with 50 
µl of 0.1% Triton-X100 with shaking at 37°C for 2 h. OD was read at 595 nm, and 
the results from the Seahorse XF24 Analyzer were normalized by dividing their 
values by the corresponding crystal violet measurement. The normalized OCR and 
ECAR values were compared using GraphPrism® 7.0. The XF24 report generator 
template from Agilent was used to explain the metabolic phenotyping differences.  
 
2.4.9. H1975 mitochondrial distribution pattern (Lackner, 2013) 
MitoTracker® Red CMXRos (Cell Signalling®, Cat #9082s) was used to examine 
the pattern of mitochondrial distribution in the cytoplasm. Cells were seeded in a 
Lab-Tek II® chamber slide with cover (RS glass slide sterile/8 well, cat. #154534, 
lot #081315-8-1). The MitoTrackerÒ Red CMXRos vial contains 50 µg of 
lyophilized stain reconstituted in 94.1 µl high quality DMSO to make 1 mM 
MitoTrackerÒ stock solution. Each experiment condition (H1975 GDC-0980 parent 
cells, H1975 GDC-0980 resistant cells without drug (R-) and H1975 GDC-0980 
resistant cells with drug (R+) were seeded on separate slides, and the stain was 
diluted directly into the medium at four different final concentrations: 100, 200, 350, 
and 400 nM, and then incubated for 45 min at 37°C under 5% CO2.  
The cells were then fixed using ice-cold methanol for 15 min at -20°C and then rinsed 
with PBS for 5 min three times. Finally, the slide chamber was removed, the slide 
cover was carefully placed on top of the slide aided by mounting medium ( Sigma-
Aldrichâ -now Merck -cat. #M1289-10ML). The slide cover edges were sealed with 
nail polish, and the slides were examined by confocal microscopy. 
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2.4.10. Cell cycle of GDC-0980 parent and resistant H1975 and A549 cells  
GDC-0980 sensitive parent and resistant H1975 and A549 lung adenocarcinoma 
cells were cultured in RPMI and F12 medium, respectively as detailed in section 
2.4.1. Cells were seeded in Nunc™ MicroWell™ 96-well microplates in six 
replicates per treatment condition (parent P, resistant with drug R+ and resistant 
without drug R-) and each cell line was tested in separate plate on the same day. Cells 
were allowed to adhere for 24 h in medium conditioned as described in section 2.4.1 
and then washed with 300 µl 1x PBS twice and fixed in pre-warmed (37°C) 4% 
formaldehyde (Image-iT™ Fixative Solution; 4% formaldehyde, methanol free, Cat 
#FB002) containing 0.3% Triton-X100 (ThermoFisher Scientific, Triton™ X-100 
Surfact-Amp™ Detergent Solution, cat. #28313) (pre-warmed at 37°C) for 15 min 
at 37°C. Next, cells were washed twice with 1x PBS, incubated with DAPI 
(Invitrogen™-DAPI, cat. #D3571) (5µg/ ml final concentration) for 15 min at room 
temperature (Kapuscinski, 1995), and then kept in 1x PBS after two washes. Cell 
cycle was read in a Cytell® Cell Imaging System (GE Healthcare Life Sciences) at 
the Institute of Molecular Medicine, Saint James’ Hospital, Trinity College Dublin.  
2.4.11. Western blot validation of cell cycle  
GDC-0980 sensitive parent and resistant H1975 lung adenocarcinoma treated (R+) 
or untreated (R-) as described in section 2.4.1 were harvested at 85% confluence and 
lysed in 8 M urea buffer as described in section 2.4.2. Protein content was measured 
using Bradford protein quantitation reagent (Pierce Detergent Compatible Bradford 
Assay Kit Cat#. 23246S) (Bradford, 1976) (section 2.4.4.). Sample volumes 
equivalent to 20 µg of total protein were used to compare GDC-0980 sensitive parent 
and resistant cells grown with or without the drug. The protocol detailed in section 
2.4.6 was used to assess cell cycle cyclins (Table 14). 
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Table 14: Cyclin Antibody Sampler Kit (cat. #9869) 
 
BSA: bovine serum albumin, antibodies were diluted at 1:1000 in 5% w/v BSA 
(rabbit-Abs) or 1:200 in 5% w/v skimmed milk (mouse-Abs) containing 0.1% Tween-
20/PBS. *Marvel skimmed milk powder (Manufacturer: Premier Food Group Ltd, 
UK), **Rabbit IgG mAb, Ω secondary antibody, IgG mAb, ***Mouse IgG mAb, Ω 
secondary antibodies, HRP: horseradish peroxidase, IgG: immunoglobulin G. mAb: 
monoclonal antibody, pAb: polyclonal antibodies. Inclubation time was overnight in 
all primary antibodies and two hours for the secondary antibodies.   
  
 
2.4.12. Histone acetylation of GDC-0980 parent and resistant H1975 and A549 
cells  
GDC-0980 sensitive parent and resistant H1975 lung adenocarcinoma, treated (R+) 
and untreated (R-) (section 2.4.1) were harvested at 85% confluence and lysed in 8 
M urea buffer as mentioned in section 2.4.2. Protein content was measured using 
Bradford protein quantitation reagent (Pierce Detergent Compatible Bradford Assay 
Kit cat. #23246S) (Bradford, 1976). Sample volumes equivalent to 20 µg of total 
protein were used to compare GDC-0980 sensitive parent and resistant cells grown 
with or without the drug. The protocol described in section 2.4.6 was used to assess 
differences in acetylation level among the cell populations. Table 15 shows the list 
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of the primary antibodies used. Anti-rabbit IgG, HRP-linked antibody 
(CellSignalling®, cat. #7074) and HRP-linked anti-mouse IgG (CellSignalling®, cat. 
#7076) were used as secondary antibodies when applicable (1:1000 and 1:2000 
dilutions, respectively). 
 
2.4.13. Histone co-localization in H1975 
GDC-0980 sensitive parent and resistant H1975 lung adenocarcinoma, treated (R+) 
and untreated (R-) ( section 2.4.1) were seeded in a Lab-Tek II® chamber slide with 
cover (RS Glass slide sterile/8 well cat. #154534, lot #081315-8-1) and allowed to 
adhere overnight. Then, they were washed twice with 1x PBS, fixed in 4% 
formaldehyde (Image-iT™ Fixative Solution (4% formaldehyde, methanol free), cat. 
#FB002) containing 0.3% Triton-X100 (pre-warmed at 37°C), for 15 min at 37°C. 
The fixed cells were permealised by adding 100 µl of 0.3% Triton X-100 (Thermo-
Fisher Scientific, Triton™ X-100 Surface-Amp™ Detergent Solution, cat. #28313) 
prepared in 1x PBS and washed once with 1x PBS for 5 min. The slides were blocked 
with 100 µl of 5% goat serum (Normal goat serum, cat. #5425, Cell Signalling 
Technology®) prepared in 1x PBS containing 0.3% Triton™ X-100 per well for 60 
min at room temperature. The blocking buffer was aspirated, the cells were washed 
twice with 1x PBS for 5 min, and incubated overnight at 4°C with 100 µl anti histone 
H3 primary antibody (Histone H3 (D1H2) XP® Rabbit mAb cat. #4499) diluted 
1:500 in antibody dilution buffer containing 1% BSA (Cell Signalling Technology®, 
cat. #9998) in 1x PBS containing 0.3% Triton™ X-100. 
Next, the cells were washed twice with 1x PBS for 5 min and incubated in the dark 
for 2 h with the secondary antibody (anti-rabbit IgG (H+L), F(ab)2 fragment (Alexa 
Fluor 488 conjugate), cat. #4412) diluted 1:400 in antibody dilution buffer at room 
temperature. The cells were washed with 1x PBS and stained with DAPI at a 
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concentration of 5µg/ml. Finally, the slide chamber was removed, the slide cover 
was carefully placed on top of the slide using one drop of mounting medium (Sigma-
Aldrich®, now Merck, cat. #M1289-10ML), sealed with nail polish, and examined 
by confocal microscopy.  
2.4.14. Western blot validation of lysine acetyl-transferases and histone 
deacetylases 
GDC-0980 sensitive parent and resistant H1975 lung adenocarcinoma treated (R+) 
and untreated (R-) cells (section 2.4.1) were harvested at 85% confluence and lysed 
in 8 M urea buffer as mentioned in section 2.4.2. Protein content was measured using 
Bradford protein quantitation reagent (Pierce Detergent Compatible Bradford Assay 
Kit Cat#. 23246S) (Bradford, 1976). Samples volumes equivalent to 20 µg of total 
protein were used to compare GDC-0980 sensitive parent and resistant cells grown 
with or without the drug. The western blot protocol described in section 2.4.6 was 
used to assess differences in the levels of lysine acetyl-transferases (Cell Signalling®, 
cat. #9928) and histone deacetylases (Cell Signalling®, cat. #8686) among the cell 
populations. Table 16 lists the primary antibodies used.  HRP-linked anti-rabbit IgG 
(Cell Signalling®, cat. #7074) and HRP-linked anti-mouse IgG (Cell Signalling®, cat. 
#7076) were used as secondary antibodies when applicable in 1:1000 and 1:2000 
dilution, respectively. 
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Table 15:  Acetyl-Histone Antibody Sampler Kit (cat. #9927) 
               
BSA: bovine serum albumin, Lys: lysine, mAb: monoclonal antibody, pAb: 
polyclonal antibodies. Antibodies were diluted at 1:1000 in 5% w/v BSA 
containing 0.1% Tween-20 in 1xPBS. Inclubation was overnight in all 
primary antibodies and two hours for the secondary antibodies.**Rabbit, Ω 
Secondary antibody.  
  
 
 
2.4.15. Functional validation of HDAC role in GDC-0980 resistance  
SAHA (Vorinostat) (Sigma-Aldrich, CAS. #149647-78-9) was used as a broadly 
acting HDAC inhibitor (Robey et al., 2011). A BrdU cell proliferation colorimetric 
ELISA kit (Cell-Signalling Technology®, cat. #6813) was used to construct the dose–
response curve for SAHA. GDC-0980 sensitive parent and resistant H1975 lung 
adenocarcinoma cells were cultured in RPMI medium conditioned as detailed in 
section 2.4.1. Cells were harvested at 70% confluence and seeded in Nunc™ 
MicroWell™ 96-well microplates in six replicates. The cells for each treatment 
(parent P, resistant with drug R+ and resistant without drug R-) were seeded in 
separate plates and allowed to adhere overnight.  
A GDC-0980 dose-response curve was constructed by treating the cells with a 
gradient concentration starting from 10 nM to 35 µM and the percentage inhibition 
of growth was plotted against the log of GDC-0980 concentration.  
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A dose-response curve was also constructed for SAHA using a concentration 
gradient range from 1-20 µM in H1975 lung adenocarcinoma cells with or without 
incubation with GDC-0980 to show the effect of HDAC phosphorylation on the 
activity of SAHA. 
 
 
Table 16: Lysine Acetyl Transferase, deacetylase Antibody Sampler Kits  
 
HDAC: histone deacetylase, numbers denote enzyme isoforms, PCAF: 
P300/CBP associated factor, CBP: CREB binding protein, CREB: cAMP 
response element binding protein, GCN5L2: general control of amino acid 
synthesis, IgG: immunoglobulin G, mAb: monoclonal antibody, pAb: polyclonal 
antibodies, BSA: bovine serum albumin. Antibodies were diluted at 1:1000 in 
5% w/v BSA (rabbit-Abs) or skimmed milk (mouse-Abs) containing 0.1% Tween-
20/1xPBS. Inclubation was overnight in all cases. *Marvel skimmed milk 
powder (Manufacturer: Premier Food Group Ltd, UK), **Rabbit, ***Mouse, Ω 
secondary antibodies, and π (phosphorylation site: Ser246 and Ser259 in HDAC 
4, 5, respectively.  
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2.4.15.1. BrdU Cell Proliferation ELISA Assay protocol  
BrdU Cell Proliferation colorimetric ELISA Kit (Cell-Signalling Technology®, cat. 
#6813) was used to study the cytotoxicity of vorinostat (SAHA) to GDC-0980 
sensitive and resistant H1975 adenocarcinoma cells cultured either with or without 
GDC-0980 incubation. After incubating the cells overnight with SAHA in six 
replicates per concentration, they were labelled with 1x BrdU labelling reagent (final 
concentration) for 4 h. They were next washed 3x with 300 µl of 1x washing buffer 
and fixed/denatured in 200 µl 1x ready to use fixation buffer for 30 min at room 
temperature. The cells were washed 3x with 300 µl of 1x wash buffer and incubated 
for 2 h with 100 µl of 1x anti-BrdU detection mouse monoclonal antibody at room 
temperature. 100 µl of 1x HRP-conjugated anti-mouse secondary antibody was 
added per well followed by incubation at room temperature for 30 min. After 3 
washes, they were left to dry at room temperature. The cells were then incubated 
with 100 µl of TMB substrate (part #7004) for 30 min at room temperature. Once the 
blue colour developed, the reaction was stopped by adding 100 µl stop solution (1 N 
HCl, part #7002) and the absorbance was read at 450 nm within 10 min. All 
measurements were uploaded into Prism 7.0 software and the log-dose response as 
percentage inhibition of growth was obtained. 
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2.4.16. Western blot validation of cell survival, apoptosis and evasion 
biomarkers 
GDC-0980 sensitive parent and resistant H1975 lung adenocarcinoma cells, treated 
or untreated as mentioned in section 2.4.1, were harvested at 85% confluence and 
lysed in 8 M urea buffer as mentioned in section 2.4.2. Protein content was measured 
using Bradford protein quantitation reagent (Pierce Detergent Compatible Bradford 
Assay Kit Cat#. 23246S) (Bradford, 1976). Sample volumes equivalent to 20 µg of 
total protein were used to compare GDC-0980 sensitive parent and resistant cells 
grown with or without the drug. The western blot protocol mentioned in section 2.4.6 
was used to evaluate the expression of the proteins involved in cell survival and 
evasion of apoptosis in the different cells under the specified conditions. Tables 17, 
18 and 19 list all the antibodies used.  
 
                Table 17: NF-Kb family member antibody sampler kit (cat. #4766) 
 
Antibodies were diluted at 1:1000 in 5% w/v BSA containing 0.1% Tween-20 in 
1xPBS. Inclubation was overnight in all cases.**Rabbit mAb, Ω Secondary antibody, 
π P50 active, Ω P52 active.  
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Table 18: 14-3-3 Family Antibody Sampler Kit (cat. #9769). 
               
 
 Antibodies were diluted at 1:1000 in 5% w/v BSA containing 0.1% Tween-20 
in 1xPBS.  Inclubation was overnight in all cases.**Rabbit mAb, Ω Secondary 
antibody. 
 
 
  Table 19: Miscellaneous antibodies. 
                  
Antibodies were diluted at 1:1000 in 5% w/v BSA containing 0.1% Tween-20 in 
1xPBS. Inclubation was overnight in all cases.**Rabbit mAb, Ω Secondary 
antibody. 
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3. Bronchoalveolar lavage discovery work 
3.1. Introduction  
Bronchoalveolar lavage collection is collected in the surgical theatre by 
bronchoscopy. Bronchoscopes are either rigid or fibre-optic flexible bronchoscopes. 
Bronchoscopy is used for investigation and surgery and requires anaesthesia.  
For simple bronchoscopic procedures, conscious sedation using fast, short acting 
anaesthetics such as ketamines is the standard, but general anaesthesia is mandatory 
for long surgical procedures (Chadha et al., 2015). The similarity between lung cells 
obtained  by biopsies and those harvested in BALF gave rise to the assumption that 
BALF can reflect the overall lungs status (Gee and Fick, 1980). However, collection 
of BALF is unsuitable as a routine clinical or research sampling procedure 
(Singletary et al., 2008). Therefore, efforts continue to establish a protocol for BALF 
collection to enhance its diagnostic value (Singletary et al., 2008). The European 
Respiratory Society has tried to establish general guidelines for the 
measurement and standardization for human normal BALF (Crystal et al., 
1986). Like blood, BALF is near the tumour tissue, but it is superior in that it does 
not contain an abundance of proteins, for example albumin, that can mask 
others, especially when using mass spectrometry for comparing clinical lavage 
samples for biomarkers discovery.  
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3.2. Experimental design 
The study aimed to find biomarkers for diagnosis and differentiation of lung 
adenocarcinoma and squamous cell carcinoma. Institutional ethical approval was 
granted from the Beaumont Hospital, Ethics Committee (REC reference: 10/61). 
BALF and blood samples were collected from patients whom were undergoing 
diagnostic bronchoscopy in Beaumont Hospital, Dublin, Ireland. 
NSCLC samples represented all stages of the disease.  BALF control 
samples  collected from healty individuals (7 male and 5 female) and sarcoid patients 
(4 male, 0 female) were compared with BALF samples from patients with NSCLC 
lung carcinomas (AD: 10 male, 3 female  and SqCC: 8 male, 5 female) using label-
free mass spectrometry. All TNM stages were included; [AD: 3 male, 3 female (stage 
I/II) and 7 male, 0 female (stage III/IV)] and [SqCC 4 male, 4 female (stage I/II) and 
4 male, 1 female (stage III/IV)]. Age matching samples was also applied in this 
experiment (table 5). Candidate biomarkers were selected based on their high 
abundance and knowledge of their involvement in the pathogenicity of lung 
cancer, and validated in small number of samples using Enzyme-Linked 
immunosorbent assay (ELISA). The promising candidate biomarkers (Cystatine C, 
Lipocalin II, Heat shock protein 70 and Tissue Inhibitor of Metallo-Proteinases 
(TIMP-1) were then validated in a large size of NSCLC plasma samples (figure 11).   
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3.3. Results 
3.3.1. The cut-off value for lung adeno and squamous carcinomas proteome 
signature. 
Figure 8 shows the selection of the fold change cut-off value for the LC-MS/MS 
analysis comparing lung adenocarcinoma and squamous cell carcinoma lung lavages 
with the control lavages (healthy individuals and sarcoid) for determining which 
signature that can help differentiate between the two types of lung carcinoma studied 
in this discovery experiment. A 1.2-fold up or down change was set as the acceptable 
lowest fold change to differentiate between the two lung carcinomas. The columns 
represent the number of proteins additionally excluded after applying 1.2 fold change 
as a cut-off value. This figure helps to decide which method is appropriate for 
validating such changes in expression. 
                        
Figure 8: The number of proteins excluded per fold change cut-off value for 
upregulation (A) or down-regulation (B) in lung squamous cell carcinoma, and 
upregulation (C) or down-regulation (D) in adenocarcinoma.   
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3.3.2. Comparison of lung adenocarcinoma lavage proteome to the control 
lavage 
3.3.2.1. Proteins significantly elevated in AD lavage compared to control.   
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
control (healty individuals and sarcoid) and lung adenocarcinoma (table 5). Using a 
1.2-fold change as cut-off, 479 proteins were found significantly elevated in lung 
adenocarcinoma broncho-alveolar lavage compared to the control samples 
(Appendix 1); the top 30 are listed in table 20.  
Table 20: Top 30 significantly elevated proteins in AD compared to the controls 
 
AD: lung adenocarcinoma, P/C: number of peptides, P/C*: number of specific 
peptides, FC: maximum fold change, control: healthy individuals and sarcoid, 16 
Ig removed. 
Accession P/C P/C* Score p-value FC (1.2)  Description
P62269 1 1 2 2.E-07 30.1 40S ribosomal protein S18 
P07108 6 6 29 6.E-07 4.9 Acyl-CoA-binding protein 
P84077 3 3 12 3.E-06 2.8 ADP-ribosylation factor 1 
P01009 27 27 206 9.E-07 5.9 Alpha-1-antitrypsin 
P35609 9 9 28 3.E-07 3.1 Alpha-actinin-4 
P07355 9 9 41 4.E-08 3.4 Annexin A2 
P20073 1 1 3 1.E-06 7.7 Annexin A7 
P03973 10 10 63 5.E-08 7.6 Antileukoproteinase 
P61769 3 3 17 1.E-07 7.2 Beta-2-microglobulin 
P31939 1 1 2 5.E-08 241.8 Bifunctional purine biosynthesis protein 
P62158 6 6 42 9.E-10 9.6 Calmodulin 
P13987 3 3 19 2.E-07 11.3 CD59 glycoprotein 
P08962 1 1 2 1.E-08 25.7 CD63 antigen 
P21926 1 1 4 8.E-07 12.3 CD9 antigen 
Q13387 1 1 5 2.E-10 10.3 C-Jun-amino-terminal kinase-interacting P2 
P35606 1 1 3 2.E-08 5.5 Coatomer subunit beta' 
P06681 1 1 3 7.E-15 300.3 Complement C2 
Q9UGM3 20 20 101 2.E-07 10.9 Deleted in malignant brain tumors 1 
P81605 2 2 13 2.E-07 3.6 Dermcidin 
P63096 3 3 8 3.E-10 7.3 Guanine NT-binding protein G(i) subunit α1 
Q14103 3 3 12 2.E-06 3.7 Heterogeneous nuclear ribonucleoprotein 
P01591 7 7 32 7.E-07 3.9 Immunoglobulin J chain 
B9A064 8 8 44 8.E-08 2.5 Ig lambda-like polypeptide 5 
P13646 6 6 27 3.E-06 2.8 Keratin, type I cytoskeletal 13 
P00338 6 6 24 1.E-07 3.5 L-lactate dehydrogenase A chain 
P07195 8 8 28 3.E-07 5 L-lactate dehydrogenase B chain 
Q02817 1 1 2 1.E-08 13.4 Mucin-2 
P05204 1 1 2 1.E-06 10 Non-histone chromosomal protein HMG17 
P15531 3 3 12 3.E-06 4.1 Nucleoside diphosphate kinase A 
P62942 1 1 4 2.E-09 192.8 Peptidyl-prolyl cis-trans isomerase FKBP1A 
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3.3.2.2. Proteins significantly lowered in AD lavage compared to control.   
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
control (healty individuals and sarcoid) and lung adenocarcinoma (table 5). Using 
a 1.2-fold change cut-off, 145 proteins were found significantly lowered in lung 
adenocarcinoma broncho-alveolar lavage compared to the control samples 
(Appendix 2); the top 30 are listed in table 21.     
 
Table 21: Top 30 significantly lowered proteins in AD compared to the controls 
 
AD: lung adenocarcinoma carcinoma, P/C: number of peptides, P/C*: number of 
specific peptides, FC: maximum fold change, control: healthy individuals and 
sarcoid, *glutamic acid, ** family member. 
Accession P/C P/C* Score p-value FC (1.2)  Description
Q13200 1 1 3 5.E-04 4.2 26S proteasome non-ATPase regulatory sub 2 
P46108 1 1 2 3.E-07 9.3 Adapter molecule crk 
Q01518 4 4 17 3.E-05 2.6 Adenylyl cyclase-associated protein 1 
P08758 9 9 56 2.E-04 3.4 Annexin A5 
P07339 8 8 43 3.E-04 2 Cathepsin D 
Q8TD46 1 1 3 4.E-05 3.6 Cell surface glycoprotein CD200 receptor 1 
P0C0L5 1 1 5 3.E-04 2.3 Complement C4-B 
Q9ULV4 1 1 5 5.E-07 4.3 Coronin-1C 
P15090 2 2 16 8.E-04 3.7 Fatty acid-binding protein, adipocyte 
O75369 3 3 8 1.E-05 2.2 Filamin-B 
P09467 2 2 14 4.E-04 6.1 Fructose-1,6-bisphosphatase 1 
P13284 2 2 12 6.E-05 4.6 Ɣ-INF-inducible lysosomal thiol reductase 
P17900 1 1 4 1.E-05 9.8 Ganglioside GM2 activator 
P00390 6 6 31 9.E-04 2.2 Glutathione reductase, mitochondrial 
P02042 4 4 33 5.E-04 4.1 Hemoglobin subunit delta 
Q16576 1 1 4 9.E-05 38.2 Histone-binding protein RBBP7 
Q4G0P3 1 1 3 2.E-04 88.3 Hydrocephalus-inducing protein homolog 
O15397 1 1 2 2.E-07 6.9 Importin-8 
Q9Y547 1 1 6 8.E-06 3.6 Intraflagellar transport protein 25 homolog 
P05787 7 7 31 9.E-07 3 Keratin, type II cytoskeletal 8 
P22079 9 9 44 3.E-04 2.1 Lactoperoxidase 
Q9UKX2 1 1 2 2.E-09 4.4 Myosin-2 
Q9Y3Q0 1 1 3 9.E-06 90.4 N-acetylated-alpha-linked acidic dipeptidase 2 
P22894 1 1 5 2.E-11 44.4 Neutrophil collagenase 
A8MRT5 1 1 3 7.E-06 20.3 Nuclear pore complex-interacting protein B5** 
P13796 16 15 74 7.E-04 2.2 Plastin-2 
O60888 1 1 8 6.E-05 3.3 Protein CutA 
P06703 3 2 17 5.E-04 2.5 Protein S100-A6 
Q96FV2 1 1 3 8.E-04 4.9 Secernin-2 
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3.3.3. Comparison of lung squamous carcinoma lavage proteome to the control 
lavage 
3.3.3.1. Proteins significantly elevated in SqCC lavage compared to control.   
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
control (healty individuals and sarcoid) and lung Squamous cell carcinoma (table 5). 
Using a 1.2-fold change as cut-off, 419 proteins were found significantly elevated in 
lung squamous cell carcinoma broncho-alveolar lavage compared to the control 
samples (Appendix 3); the top 30 are listed in table 22.  
 
Table 22: Top 30 significantly elevated proteins in SqCC compared to the controls 
 
SqCC: squamous cell carcinoma, P/C: number of peptides, P/C*: number of specific 
peptides, FC: maximum fold change, control: healthy individuals and sarcoid, ** 
interacting protein. 
 
Accession P/C P/C* Score p-value FC (1.2)  Description
P07108 2 2 7 9.E-06 4.5 Acyl-CoA-binding protein 
P19652 4 4 35 2.E-12 8.2 Alpha-1-acid glycoprotein 2 
P01009 31 31 273 3.E-08 4 Alpha-1-antitrypsin 
P04745 27 27 243 6.E-05 18 Alpha-amylase 1 
P08133 1 1 4 9.E-06 3.6 Annexin A6 
P01008 8 8 40 2.E-05 2.8 Antithrombin-III 
P17213 1 1 3 3.E-08 27 Bactericidal permeability-IP**
P02749 9 9 45 2.E-05 3.4 Beta-2-glycoprotein 1 
P27797 6 6 20 4.E-05 3.1 Calreticulin 
O43852 1 1 3 4.E-05 238.3 Calumenin 
P00450 25 25 169 6.E-05 2.7 Ceruloplasmin 
P09871 2 2 7 2.E-06 7.7 Complement C1s subcomponent 
P01031 6 6 20 4.E-05 6.9 Complement C5 
P08603 12 12 64 1.E-05 4 Complement factor H 
P08185 4 4 12 1.E-06 2.9 Corticosteroid-binding globulin 
P02671 5 5 21 8.E-07 4.8 Fibrinogen alpha chain 
P00738 10 9 62 3.E-05 4.7 Haptoglobin 
P00739 8 8 38 3.E-06 8.7 Haptoglobin-related protein 
P62805 6 6 17 9.E-06 3.6 Histone H4 
P01860 7 7 39 5.E-05 4.1 Ig gamma-3 chain C region 
P01765 1 1 8 6.E-05 8.3 Ig heavy chain V-III region TIL 
Q8WWA0 1 1 5 2.E-05 23.7 Intelectin-1 
P13646 13 13 81 1.E-05 31.2 Keratin, type I cytoskeletal 13 
P19013 11 11 59 5.E-05 29.2 Keratin, type II cytoskeletal 4 
P13647 8 7 39 2.E-06 4 Keratin, type II cytoskeletal 5 
P01042 4 4 15 1.E-06 4.2 Kininogen-1 
P02750 4 4 39 5.E-07 4.8 Leucine-rich alpha-2-glycoprotein 
P00338 7 7 31 2.E-05 4.3 L-lactate dehydrogenase A chain 
E9PGF7 1 1 7 9.E-06 7.6 Mucin-5AC 
P35579 12 11 53 3.E-06 5 Myosin-9 
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3.3.3.2. Proteins significantly lowered in SqCC lavage compared to the control. 
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
control (healty individuals and sarcoid) and lung Squamous cell carcinoma (table 5). 
Using a 1.2-fold change as cut-off, 183 proteins were found significantly lowered in 
lung squamous cell carcinoma broncho-alveolar lavage compared to the control 
samples (Appendix 4); the top 30 are listed in table 23. 
 
Table 23: Top 30 significantly lowered proteins in SqCC compared to the controls 
 
SqCC: squamous cell carcinoma, P/C: number of peptides, P/C*: number of specific 
peptides, FC: maximum fold change, control:healthy individuals and sarcoid, RP*: 
regulating protein, P1: prorein 1, CS: catalytic subunit. 
Accession P/C P/C* Score p-value FC (1.2)  Description
P62195 1 1 2 5.00E-04 24.8 26S protease regulatory subunit 8 
P25325 1 1 4 6.00E-04 1.9 3-mercaptopyruvate sulfurtransferase 
Q12979 1 1 3 5.00E-06 5.9 Active breakpoint cluster region-RP* 
P14550 3 3 15 3.00E-05 2.9 Alcohol dehydrogenase [NADP(+)] 
P08758 9 9 55 4.00E-04 3.8 Annexin A5 
P63010 1 1 3 4.00E-04 2.7 AP-2 complex subunit beta 
P16050 4 4 18 2.00E-04 2.4 Arachidonate 15-lipoxygenase 
Q68DU8 1 1 3 8.00E-06 31.1 BTB/POZ domain-O
Q8TD46 1 1 3 2.00E-06 6.1 Cell surface glycoprotein CD200 R1 
P50238 1 1 4 2.00E-08 223.9 Cysteine-rich protein 1 
Q12926 1 1 3 7.00E-10 12.5 ELAV-like protein 2 
Q15056 1 1 4 2.00E-04 51.6 Eukaryotic translation initiation factor 4H 
P15090 2 2 15 2.00E-04 6.2 Fatty acid-binding protein, adipocyte 
P09467 7 7 29 3.00E-04 5.3 Fructose-1,6-bisphosphatase 1 
P48506 1 1 3 4.00E-04 2.9 Glutamate--cysteine ligase CS 
P07203 1 1 3 2.00E-04 12.1 Glutathione peroxidase 1 
P49773 2 2 15 4.00E-04 2.9 Histidine triad nucleotide-binding P1  
P01714 1 1 7 3.00E-06 3.6 Ig lambda chain V-III region SH 
O14654 1 1 3 7.00E-10 13.5 Insulin receptor substrate 4 
O43240 1 1 3 5.00E-05 4.6 Kallikrein-10 
P05787 5 5 21 2.00E-05 2.2 Keratin, type II cytoskeletal 8 
O95573 1 1 3 5.00E-04 2.1 Long-chain-fatty-acid--CoA ligase 3 
O14745 1 1 4 3.00E-04 2.7 Na(+)/H(+) exchange regulatory cofactor 
O96009 1 1 5 5.00E-04 2.4 Napsin-A 
P22894 3 3 19 4.00E-05 6.6 Neutrophil collagenase 
Q02818 2 2 5 5.00E-06 4.4 Nucleobindin-1 
P30041 2 2 9 5.00E-04 1.7 Peroxiredoxin-6 
P68402 1 1 2 7.00E-04 7.9 Platelet-AF acetylhydrolase IB subunit-β 
P25788 1 1 4 5.00E-04 2.7 Proteasome subunit alpha type-3 
P14618 2 2 10 2.00E-04 4.3 Pyruvate kinase PKM 
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3.3.3.3. Proteins were found elevated in AD and SqCC lavage compared to the 
control. 
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
SqCC and AD using control lavage (healty individuals and sarcoid) as a reference 
(table 5). One hundred and ninety-two proteins were found significantly elevated in 
both adenocarcinoma and squamous cell carcinoma compared to the control lavage; 
the top 30 are listed in table 24 (full list is in appendix 5).  
 
Table 24:  Top 30 significantly elevated proteins in both AD and SqCC compared to 
controls 
 
PC: peptide count, PC*: specific peptide count, AD: adenocarcinoma, SqCC: 
squamous carcinoma, S: confidence score, control:healthy individuals and sarcoid. 
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3.3.3.4. Proteins were found lowered in AD and SqCC lavage compared to the 
control.  
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
SqCC and AD using control lavage (healty individuals and sarcoid) as a reference 
(table 5). Fifty-three proteins were found significantly lowered in adenocarcinoma 
and squamous cell carcinoma compared to the control lavage (Appendix 6); the top 
30 are listed in table 25.  
Table 25: Top 30 significantly lowered proteins in both AD and SqCC compared to 
control 
 
PC: peptide count, PC*: specific peptide count, AD: adenocarcinoma, SQ: 
squamous carcinoma, S: confidence score, control: healthy individuals and sarcoid, 
*: translation initiation factor, DNT: deoxynucleotide, Hase: hydrolase, P*: protein. 
Accession PC PC* S AD ↓ PC PC* S SqCC ↓ Description
O43598 2 2 8 2 2 2 8 2 2'-DNT-5'-phosphateN-Hase1 
P25325 1 1 3 2 1 1 4 1.9 3-mercaptopyruvate sulfurtransferase 
P10155 1 1 4 1.6 1 1 4 2.2 60 kDa SS-A/Ro ribonucleoprotein 
Q12979 1 1 3 2.1 1 1 3 5.9 Active breakpoint cluster region
P08758 9 9 56 3.4 9 9 55 3.8 Annexin A5 
P27824 1 1 3 2.2 1 1 4 2 Calnexin 
P07339 8 8 43 2 7 7 28 1.8 Cathepsin D 
Q8TD46 1 1 3 3.6 1 1 3 6.1 Cell surface glycoprotein CD200R1 
Q9ULV4 1 1 5 4.3 1 1 5 4.9 Coronin-1C 
Q13409 1 1 3 1.9 1 1 4 1.4 Cytoplasmic dynein 1 intermediate 2 
Q96KP4 9 9 36 1.9 2 2 8 1.6 Cytosolic non-specific dipeptidase 
Q16555 1 1 5 1.9 1 1 5 2.9 Dihydropyrimidinase-related P*2 
Q9NY33 3 3 13 2.3 2 2 9 1.5 Dipeptidyl peptidase 3 
Q12926 1 1 3 2 1 1 3 12.5 ELAV-like protein 2 
Q13347 1 1 3 4.5 1 1 3 1.3 Eukaryotic TIF3* subunit I 
P15090 2 2 16 3.7 2 2 15 6.2 Fatty acid-binding protein, adipocyte 
P02792 4 4 17 5.8 2 2 9 2.8 Ferritin light chain 
P09467 2 2 14 6.1 7 7 29 5.3 Fructose-1,6-bisphosphatase 1 
P09382 1 1 5 4.7 1 1 5 3.5 Galectin-1  
P13284 2 2 12 4.6 1 1 5 2.3 Ɣ-INF -inducible lysosomal reductase 
P35754 1 1 3 4.7 2 2 9 2.2 Glutaredoxin-1 
P48637 2 2 6 1.5 1 1 5 1.6 Glutathione synthetase 
P21695 1 1 3 18.6 1 1 3 9 GAPDH [NAD(+)], cytoplasmic 
P61978 2 2 9 1.7 1 1 4 2.1 Heterogeneous NRP K 
P49773 2 2 19 2.3 2 2 15 2.9 Histidine triad nucleotide-binding P*1 
Q16576 1 1 4 38.2 1 1 4 21.1 Histone-binding protein RBBP7 
Q9Y547 1 1 6 3.6 1 1 6 2.1 Intraflagellar transport protein 25 
P05787 7 7 31 3 5 5 21 2.2 Keratin, type II cytoskeletal 8 
Q14894 1 1 5 2.5 2 2 12 2.8 Ketimine reductase mu-crystallin 
P40121 3 3 21 2.7 4 4 24 2.8 Macrophage-capping protein 
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3.3.4. Classification of proteins found changed in AD and SqCC compared to 
control. 
Figure 9, Panther biological processes analysis of the proteins that were found 
elevated or lowered in both AD and SqCC lung lavage by label-free mass 
spectrometry comparative analysis compared to the control (healthy individuals and 
sarcoid) lavage.  
 
Figure 9: PANTHER GO-Slim Biological Process Analysis of proteins found 
lowered or elevated in adenocarcinoma (AD) and squamous cell carcinoma (SqCC) 
lavages compared to the control (C): healthy individuals and sarcoid patients 
lavages, numbers indicate the number of genes involved per process. 
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3.3.5. Proteome signature differentiating between lung AD and SqCC. 
3.3.5.1. Proteins elevated in SqCC but lowered in AD compared to the control.  
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
SqCC and AD using control lavage (healty individuals and sarcoid) as a reference 
(table 5). A total of 23 proteins were found significantly elevated in the lavage 
collected from squamous cell carcinoma patients compared to the control lavage. In 
contrast, using the same lavage control samples, these proteins were found lowered 
in lung adenocarcinoma lavage (Table 26). 
 
Table 26: Proteins significantly elevated in SqCC but lowered in AD compared to 
the control 
 
SqCC: squamous cell carcinoma, AD: adenocarcinoma, P/C: number of peptides, 
P/C*: number of specific peptides, FC: maximum fold change, S: score P1*: protein 
1. Numbers in bold are fold changes were found elevated in SqCC and lowered in 
AD compared to control lavages (healthy individuals and sarcoid patients). 
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3.3.5.2.  Proteins elevated in AD but lowered in SqCC compared to the control.  
Label-free mass spectrometry comparative analysis of bronchoalveolar lavage from 
SqCC and AD using control lavage (healty individuals and sarcoid) as a reference 
(table 5). There were 58 proteins were found significantly elevated in lung 
adenocarcinoma lavage (AD) compared to the control lavage  (healthy individuals 
and sarcoid patients) (Table 27). Interestingly, these proteins were significantly 
lowered in the lavage collected from lung squamous cell carcinoma (SqCC)  relative 
to the same control lavage samples.   
  
Table 27: Proteins significantly elevated in AD but lowered in SqCC compared to the 
control 
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AD: lung adenocarcinoma, SqCC: lung squamous cell carcinoma, AC: accession 
number, PC: peptide count, PC*: specific peptide count, S: confidence score, TNS*: 
tissue non-specific, TIF*: translation initiation factor, CS: catalytic subunit, P*: 
protein, BP*: binding protein. Numbers in bold are fold changes were found 
elevated in AD and lowered in SqCC lavages compared to the control lavages  
(healthy individuals and sarcoid patients). 
 
 
 
 
 
 
 
 
 
Accession PC PC* S AD↑ PC PC*  S SqCC↓     Description       Table 27 continued          
P18065 3 3 13 2.8 2 2 8 1.9 Insulin-like growth factor-binding P*2 
P05362 1 1 3 6.7 1 1 2 18.3 Intercellular adhesion molecule 1 
O43240 2 2 7 1.6 1 1 3 4.6 Kallikrein-10 
Q8WXI7 21 20 74 3.9 1 1 4 1.3 Mucin-16 
P02144 2 2 7 4 1 1 3 2.1 Myoglobin 
O14745 4 4 22 2.3 1 1 4 2.7 Na/H (exchange regulatory cofactor) 
Q02818 5 5 15 3.3 2 2 5 4.4 Nucleobindin-1 
P80303 11 11 50 2.1 2 2 6 2.6 Nucleobindin-2 
P19338 1 1 2 6.1 1 1 4 1.9 Nucleolin 
Q06830 7 7 36 2.3 8 8 47 2.7 Peroxiredoxin-1 
P30041 4 4 11 4.1 2 2 9 1.7 Peroxiredoxin-6 
P30086 5 5 24 2.1 3 3 11 2.2 Phosphatidylethanolamine BP*1 
O43490 9 9 32 2.4 3 3 9 1.3 Prominin-1 
Q14914 1 1 5 6 1 1 5 2.1 Prostaglandin reductase 1 
P14618 9 9 55 1.8 2 2 10 4.3 Pyruvate kinase 
Q5TD94 1 1 3 7.3 1 1 6 1.2 Radial spoke head protein 4A 
P34096 2 2 9 2.7 1 1 3 1.6 Ribonuclease 4 
P07998 2 2 16 4.6 1 1 4 1.4 Ribonuclease pancreatic 
Q9Y265 1 1 3 3 1 1 4 3.2 RuvB-like 1 
Q9NR45 3 3 12 2.4 1 1 5 2.7 Sialic acid synthase 
P49368 1 1 4 2.3 1 1 3 1.1 T-complex protein 1 subunit gamma 
P67936 1 1 4 3.7 1 1 3 1.5 Tropomyosin alpha-4 chain 
Q9H4B7 5 5 18 2.9 4 4 11 2.3 Tubulin beta-1 chain 
Q13509 2 2 7 2.5 1 1 3 1.9 Tubulin beta-3 chain 
Q9BW30 5 5 28 2.1 1 1 5 2.6 Tubulin polymerization-promoting P*3 
O75347 1 1 11 3.9 2 2 8 1.3 Tubulin-specific chaperone A 
P22314 2 2 9 2.1 3 3 16 3.3 Ubiquitin-like modifier-activating E1 
P08670 6 6 21 2.8 1 1 4 1.5 Vimentin 
P12955 1 1 3 1.7 1 1 3 6.2 Xaa-Pro dipeptidase 
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3.3.6. Classification of proteins that could differentiate beween lung AD and 
lung SqCC 
Proteins detected by label-free mass spectrometry and found to differentiate lung 
adenocarcinoma from lung squamous cell carcinoma in bronchoalveolar lavage were 
subjected to Panther biological processes analysis (Figure 10). The most prominent 
types were proteins involved in metabolic and cellular processes. 
 
         
Figure 10: PANTHER GO-Slim Biological Process of unique proteins that were 
found elevated/lowered in adenocarcinoma (AD) and have opposite profile in 
squamous cell carcinoma (SqCC) lavages compared to the control: healthy 
individuals and sarcoid patients lavages, numbers indicate the number of genes 
involved per process. 
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3.3.7. ELISA verification  
3.3.7.1. Candidate proteins for ELISA validation 
Table 28 shows the proteins belong to the families of lipocalins, heat shock proteins 
and cysteine protease inhibitors identified by label-free mass spectrometry as 
significantly elevated in NSCLC (AD and SqCC) lavages compared to the control 
lavage collected from healthy individuals and sarcoid patients (table 5). To validate 
the label-free mass spectrometry comparative analysis; Cystatin C, HSP 70, TIMP-
1 and Lipocalin-2 were selected for the ELISA verification based on their increased 
abundance in NSCLC lavage compared to the control group lavage used in this study 
(table 28), and also based on their known role in the pathogenicity of lung cancer. 
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Table 28: Protein families detected elevated by label-free mass spectrometry in 
lavage from AD and SqCC patients compared to control (healthy individuals and 
sarcoid) in this research discovery work and selected for verification by ELISA.  
 
AD: lung adenocarcinoma, SqCC: lung squamous cell carcinoma, *: member 
of Lipocalins, ER-HSP: endoplasmic reticulum heat shock protein, Cystatin A, 
B, C, D, S, SA and SN are cystatin isoforms, apolipoproteins A, B, C and D are 
apolipoprotein isoforms, lipocalin (#s): isoforms.  
 
 
 
Accession AD SqCC Description
P01033 2 2.2  TIMP-1
P02763 2.8 4 Alpha-1-acid glycoprotein 1* 
P19652 3.1 8.2 Alpha-1-acid glycoprotein 2* 
P02647 0 3.9 Apolipoprotein A-I*
P02652 112.4 7.3 Apolipoprotein A-II* 
P06727 3.6 5.1 Apolipoprotein A-IV* 
P04114 0 25.4 Apolipoprotein B-100* 
P02654 0 7.2 Apolipoprotein C-I* 
P05090 9.7 0 Apolipoprotein D* 
P02649 4.4 0 Apolipoprotein E* 
P01040 0 5.9 Cystatin-A 
P04080 1.8 0 Cystatin-B 
P01034 2 4.5 Cystatin-C 
P28325 13.7 4.8 Cystatin-D 
P01036 0 3.4 Cystatin-S 
P09228 1.6 2.6 Cystatin-SA 
P01037 5 3.4 Cystatin-SN 
Q01469 2.4 3.7 Fatty acid-binding protein 
P11142 1.6 2.2 Heat shock cognate 71 kDa protein 
P61604 0 7.2 heat shock protein 10 kDa , mitochondrial 
Q92598 0 5 Heat shock protein 105 kDa 
P34931 1.9 0 Heat shock protein 70 kDa protein 1-like 
P04792 0 7 Heat shock protein beta-1 
P54652 2 0 Heat shock-related 70 kDa protein 2 
P31025 4.4 9.9 Lipocalin-1*
Q6UWW0 6.4 0 Lipocalin-15*
Q14568 0 2.1 Putative heat shock protein HSP 90-α A2 
Q58FF8 3.6 0 Putative heat shock protein HSP 90-beta 2 
Q58FF7 2.2 0 Putative heat shock protein HSP 90-beta-3 
P27797 3.1 3 Calreticulin, (ER-HSP)
Fold change 
(compared to control)
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3.3.7.2. ELISA verification results 
Figure 11 shows Box and Wiskers plot representing the levels of four proteins 
selected for verification of mass spectrometry results in plasma cohert samples 
(n=72) collected from healthy controls and patients with lung adenocarcinoma and 
squamous cell carcinomas by ELISA . Heat shock proteins were elevated in 
squamous cell carcinoma compared to control (healthy individuals) and to patients 
with lung adenocarcinoma (A). The level of cystatin C was significantly elevated in 
both adeno and squamous lung carcinomas compared to the control samples (B). The 
level of lipocalin-1 was elevated in both adeno and squamous lung carcinomas 
compared to the control samples (C). The level of tissue inhibitor of 
metalloproteinase (TIMP-1) was also significantly elevated in both types of lung 
carcinoma (D).  
      
Figure 11: ELISA verification. Box-and-Whisker plots of the levels of (A) HSP70, 
(B) Cystatin-C, (C) Lipocalin-2, and (D) TIMP-1 in control (healthy and sarcoid) 
n= 26, AD (n=23) and SqCC (n= 23) plasma samples. Box-and-Whisker plots 
represent data with boxes ranging from the 25th to the 75th percentile of the 
observed distribution of values. The bold line of the boxes represents the median of 
plasma levels of HSP70, Cystatin-C, Lipocalin-2 and TIMP-1. Whiskers span the 
minimum to maximum observed values. Statistical significance was tested by 
Kruskal-Wallis one-way ANOVA using SPSS 15.0 for Windows. (*p ≤ 0.05: 
significant; **p ≤ 0.01: very significant).  
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3.3.8. Metabolism in non-small cell lung cancer 
In the Label-free mass spectrometry experiment that comparing bronchoalveolar 
lavage from SqCC and AD using control lavage (healty individuals and sarcoid) 
(table 5). Among the lowered Fifty three  proteins in both AD and SqCC, Fiftheen 
out of them were enzymes (Table 29) and also 33 were enzymes out of the 192 
proteins that were found significantly elevated in both AD and SqCC were enzymes 
(Table 30).  
Table 29:  Enzymes found by LC-MS/MS to be decreased in both lung AD and 
SqCC  
 
 
PC: peptide count, PC*: specific peptide count, AD: lung adenocarcinoma, SqCC: 
lung squamous carcinoma, S: confidence score, DNT: deoxynucleotide, Hase: 
hydrolase, P*: protein.GT**: glutamyltransferase, INF: interferon. Numbers in bold 
are fold changes were found downregulated in both AD and SqCC. 
 
 
 
 
 
 
 
 
 
 
 
Accession PC PC* S AD ↓ PC PC* S SqCC ↓  Description                
O43598 2 2 8 2 2 2 8 2 2'-DNT- 5'-phosphate N-Hase 1 
P25325 1 1 3 2 1 1 4 1.9 3-mercaptopyruvate sulfurtransferase 
Q96KP4 9 9 36 1.9 2 2 8 1.6 Cytosolic non-specific dipeptidase 
Q16555 1 1 5 1.9 1 1 5 2.9 Dihydropyrimidinase-related P*2 
Q9NY33 3 3 13 2.3 2 2 9 1.5 Dipeptidyl peptidase 3 
P09467 2 2 14 6.1 7 7 29 5.3 Fructose-1,6-bisphosphatase 1 
P13284 2 2 12 4.6 1 1 5 2.3 ɣ-INF-inducible lysosomal reductase 
P48637 2 2 6 1.5 1 1 5 1.6 Glutathione synthetase 
P21695 1 1 3 18.6 1 1 3 9 Glycerol-3-PDH [NAD(+)]
Q14894 1 1 5 2.5 2 2 12 2.8 Ketimine reductase mu-crystallin 
P22894 1 1 5 44.4 3 3 19 6.6 Neutrophil collagenase 
P21980 5 5 27 2 5 5 33 1.9 Protein-glutamine ɣ-GT** 2 
P19971 4 4 20 2.6 4 4 13 2.7 Thymidine phosphorylase 
O14773 2 2 9 3 2 2 6 4.1 Tripeptidyl-peptidase 1 
P23381 3 3 9 1.8 1 1 5 3 Tryptophan--tRNA ligase, cytoplasmic 
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Table 30: Enzymes found by LC-MS/MS to be elevated in both AD and SqCC of 
lungs   
 
PC: peptide count, PC*: specific peptide count, AD: lung adenocarcinoma, SqCC: 
lung squamous carcinoma. Numbers in bold are fold changes were found upregulated 
in both AD and SqCC. 
 
 
 
 
 
 
Accession PC PC* S AD ↑ PC PC* S SqCC ↑ Description
P07327 5 5 15 8.2 1 1 4 2.7 Alcohol dehydrogenase 1A 
P00326 3 2 13 3.7 2 2 11 11.7 Alcohol dehydrogenase 1C 
P04745 30 30 287 4.6 27 27 243 18 Alpha-amylase 1 
P03973 10 10 63 7.6 3 3 15 5.6 Antileukoproteinase 
P00966 1 1 3 1.6 2 2 9 2.6 Argininosuccinate synthase 
O00571 1 1 2 3.2 1 1 3 8.3 ATP-dependent RNA helicase 
P00915 4 4 25 4 3 3 25 4.8 Carbonic anhydrase 1 
P00918 3 3 10 2 1 1 3 3.8 Carbonic anhydrase 2 
P23280 4 4 14 2.1 6 6 31 7.9 Carbonic anhydrase 6 
P49327 2 2 8 9.5 3 3 10 3.3 Fatty acid synthase 
Q92820 1 1 3 2 1 1 3 3.1 Gamma-glutamyl hydrolase 
O60547 2 2 6 7.4 1 1 2 32.3 GDP-mannose 4,6 dehydratase 
P06744 14 14 68 1.8 11 11 69 3.7 Glucose-6-phosphate isomerase 
P04406 12 12 61 2.1 6 6 43 2.4 GAPDH 
P11216 2 2 6 16.3 1 1 4 10 Glycogen phosphorylase, brain 
Q6B0I6 1 1 3 2.3 1 1 3 2.8 Lysine-specific demethylase 4D 
P40925 7 7 29 1.6 1 1 3 7.5 Malate dehydrogenase
P14780 9 9 35 2.4 7 7 36 4 Matrix metalloproteinase-9 
P01033 6 6 29 2 2 2 11 2.2 Metalloproteinase inhibitor 1 
P05164 21 19 76 1.7 21 21 100 2.9 Myeloperoxidase 
P80188 15 15 76 1.8 5 5 25 2.2 Lipocalin 2 
P43490 2 2 8 3.2 4 4 19 3.2 Nicotinamide P-RTase 
P62937 5 5 31 2.1 2 2 6 2.3 Peptidyl-prolyl cis-trans A 
P00558 14 14 63 1.9 2 2 8 2.3 Phosphoglycerate kinase 1 
P05155 11 11 55 2.7 2 2 11 2.3 Plasma protease C1 inhibitor 
P07237 10 10 35 4 4 4 20 3.6 Protein disulfide-isomerase 
Q08188 1 1 3 10 8 8 53 8.4 glutamine ᵧ-glutamyltransferase E 
P00491 1 1 2 2.3 3 3 9 3.6 Purine nucleoside phosphorylase 
O60361 1 1 3 1.6 2 2 6 4 nucleoside diphosphate kinase 
Q9H477 1 1 2 1.8 1 1 2 2.2 Ribokinase 
O00584 2 2 6 4.8 1 1 4 4.4 Ribonuclease T2 
P27169 1 1 4 6 1 1 3 10.2 Serum paraoxonase/arylesterase 1 
Q00796 2 2 6 3.5 1 1 3 1.3 Sorbitol dehydrogenase 
P37837 5 5 22 3.1 2 2 6 5.1 Transaldolase 
P60174 12 12 60 1.7 5 5 31 2.1 Triosephosphate isomerase 
P29144 1 1 2 5.6 1 1 3 3.4 Tripeptidyl-peptidase 2 
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3.4. Discussion   
To build up a pool of classifier biomarkers to assist in the diagnosis of lung cancer, 
and mainly of poorly differentiated lung adenocarcinoma, cut-off values were 
carefully chosen while avoiding the exclusion of too many proteins (Figure 8). The 
chosen cut-off value permits validation of candidate biomarkers with the sensitivity 
of available methodologies. The cancer proteome is very dynamic. The abundance 
of proteins responsible for the cell cycle, growth, proliferation and survival change 
upon demand. In general, overexpression of oncogenes and dysregulation of tumour 
suppressor genes is expected in cancer, as well as changes in the metabolic signature 
and increased rates of energy substrate utilisation. Also expected is increased 
abundance of building units, such as histones, DNA, enzymes, and cytoskeletal 
proteins, and increased mitochondrial activity.  
In this part of the study, BALF from normal controls and patients diagnosed with 
lung AD or SqCC was analysed by LC-MS/MS. The aim was to obtain a proteomic 
signature that differentiates between the two main types of NSCLC, adenocarcinoma 
and squamous cell carcinoma, which represent 38.5% and 20% of all lung cancers, 
respectively (Herbst et al., 2008). The validation of the signature on tissue samples 
from patients with lung adenocarcinoma is reported in chapter IV.  
A 1.2-fold change in protein expression was considered an acceptable threshold for 
deriving a lung cancer proteome signature (Figure 8). The proteins found to be 
significantly upregulated in adenocarcinoma compared to the control samples  are 
listed in Appendix 1. After exclusion of all immunoglobulin classes, the top 30 
significantly upregulated proteins were listed (Table 20). A list of the top 30 proteins 
significantly downregulated in adenocarcinoma was derived in the same way (Table 
21; full list in Appendix 2). The same approach was taken to identify the top 30 
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proteins significantly up or down regulated in squamous cell carcinoma (Tables 22 
and 23; full list Appendixes 3 and 4). These full lists can serve as reference data for 
future validation of biomarkers. Proteins that were elevated in both adeno and 
squamous carcinomas compared to the control samples were also identified 
(Appendix 5), and from there the top 30 upregulated proteins were identified (Table 
24). Proteins down regulated in both carcinomas are listed in appendix 6, and the top 
significantly down regulated proteins are in table 25.  
Interestingly, 58 proteins were found elevated in AD but lowered in SqCC, while 24 
proteins were elevated in SqCC but down regulated in AD (Tables 26, 27). The 
validation of these proteins on formaldehyde-fixed, and -embedded lung 
adenocarcinoma specimens is described in chapter V. PANTER GO-Slim Biological 
Process analysis of the proteins found that notable protein categories with increased 
expression levels in AD and SqCC compared to the controls included proteins 
involved in the cellular response to stimuli or in cellular biogenesis, biological 
regulatory proteins, and those involved in metabolic and cellular processes (Figure 
9). Figure 10 also represents invaluable data, where the classification of each lung 
carcinoma (AD/SqCC) is presented. At the cellular metabolism level, 16 enzymes 
were in low abundance and 36 enzymes were elevated in both AD and SqCC (Tables 
29, 30). This provided motivation for undertaking a separate metabolic study  
focused on the key enzymes controlling the switching between anaerobic and aerobic 
utilisation of glucose (reported in chapter IV).  
The main focus of this research was to identify a panel of protein biomarkers 
differentially expressed in adenocarcinoma and squamous cell carcinoma and to 
verifiy some of them in plasma samples from matched types of lung cancer. Among 
the elevated proteins differentiating between adenocarcinoma and squamous cell 
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carcinoma of the lung were folate receptor alpha (FRA), which was increased 13.9-
fold in AD compared to SqCC (3.8 fold). Previous work has shown that 
immunohistochemical analysis of FRA expression can distinguish lung AD from 
SqCC (O'Shannessy et al., 2012, Nunez et al., 2012).  
Folate receptor A (FRA) was proposed as a prognostic marker in lung AD, in which 
its overexpression was correlated with increased survival (Wood, 2012). Coronin 1A 
too was elevated in lung AD compared to SqCC. Coronin 1A plays multiple 
functions: in addition to its actin-related function, it plays a role in the heterotrimeric 
assembly of proteins and is involved in the calcium-calcineurin signalling axis. Its 
absence was found to be associated with severe forms of immunodeficiency in 
humans (Moshous and de Villartay, 2014). On the other hand, it is overexpressed in 
many cancers, including breast cancer (Kim et al., 2009), renal cell carcinoma (Atrih 
et al., 2014) and bladder carcinoma (D'Costa et al., 2016).  
Another protein that was found elevated in lavage of AD patients and could 
distinguish AD from SqCC is Cofilin-1, an intracellular actin-modulating protein that 
binds and depolimerises filamentous F-actin and inhibits the polymerisation of G-
actin monomers (Simhadri et al., 2017). Elevation of Cofilin 1 has also been observed 
in prostate cancer (Lu et al., 2015) and pancreatic ductal adenocarcinoma (PDAC) 
(Satoh et al., 2017), and in NSCLC, in which it has a suppressive effect on growth 
and invasion (Tsai et al., 2015). Cofilin-1 was also found correlated with cisplatin 
resistance in lung adenocarcinoma (Becker et al., 2014). Notably, Cofilin-1 was 
associated with diminished overall survival rates in NSCLC (Castro et al., 2010).  
In our study, Calpastatin was found to be overexpressed in lung AD but not in 
squamous cell carcinoma. Calpastatin is an endogenous cysteine protease inhibitor 
involved in tumorigenesis, migration and invasion. Targeting Calpastatin was found 
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to be a promising cancer therapy (Leloup and Wells, 2011). Calpastatin is also 
downregulated in many cancers, including gastric cancer (Liu et al., 2017) and 
ovarian cancer (Salehin et al., 2011). In our study, Calcyphosin, a calcium-binding 
protein belonging to the calmodulin family, was found overexpressed in AD but 
down regulated in SqCC. Calcyphosin has been reported to be overexpressed in lung 
cancer (Pastor et al., 2013), ovarian adenocarcinoma (Partheen et al., 2006) and 
endometrial carcinoma (Li et al., 2010b). Clusterin, also called Apolipoprotein J 
(ApoJ), is a secreted protein found in most human fluids (Trougakos and Gonos, 
2002). In our label-free LC-MS/MS discovery work, Clusterin  was elevated in the 
lavage from lung adenocarcinoma patients compared to normal control lavage, but 
not in lavage from squamous cell carcinoma patients. Similarly, Clusterin was 
reported to be upregulated in adenocarcinoma and downregulated in squamous cell 
carcinoma (Jin et al., 2017a), validating our finding. Clincally, Clusterin 
overexpression was found to be directly correlated with patient survival in non-small 
cell lung cancer  (Albert et al., 2007) (Panico et al., 2013).  
In our study, Cystatin C, MIF, lipocalin-2, TIMP-1, periostin, Cathepsin V, PGRP, 
VEGF, HSP70 and Clusterin were selected as candidate biomarkers for plasma 
validation. Only TIMP-1, Cystatin C, HSP70 and lipocalin-2 showed promising 
results in the initial validation phase and were further validated using a large number 
of samples (Figure 11). 
Cystatins are of three types: type I (also called steffins A and B), type II (Cystatin C, 
E, M and F) and type III (also called kininogens with multi-functional domains), 
which play a role in counteracting tumour associated proteases (Henskens et al., 
1996). Cystatin overexpression was observed in many malignancies,, including lung 
cancer, and was associated with tumour metastasis and aggressiveness (Ohara et al., 
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2012, Werle et al., 2006). Cystatin C is a cysteine protease inhibitor found to be 
overexpressed at the protein and mRNA levels in oesophageal cancer (Zeng et al., 
2011) and in human glioma cell lines (Konduri et al., 2002). On the other hand, 
Cystatin C was found down regulated in stomach neoplasm (Zeng et al., 2010) and 
colorectal cancer (Zore et al., 2001).  
However, in our study, cystatins C, D, SA and SN were significantly overexpressed 
in a heterogeneous expression pattern in both adeno and squamous lung carcinomas 
(table 28). Cystatins D and SN were detected at higher levels in lung lavage of lung 
adenocarcinoma than in lung squamous carcinoma patients compared to the control 
lavage from normal individuals; the fold change was 13.7 and 5 in adenocarcinoma 
compared to 4.8 and 3.4 in squamous cell carcinoma, respectively. In contrast, 
cystatins C and SA were found more overexpressed in lung squamous cell carcinoma 
than in lung adenocarcinoma; fold changes were 4.5 and 2.6 compared to 2 and 1.6 
respectively. Cystatin C, selected for ELISA validation on plasma samples (Table 
28), was significantly elevated (p ≤ 0.01) in both adeno and squamous cell carcinoma 
patients’ plasma compared to normal individuals (Figure 11-B).  
Cystatin A and cystatin S were significantly overexpressed (5.9 and 3.4 fold 
increases, respectively) only in squamous cell carcinoma, but they were undetectable 
in adenocarcinoma (Table 28). Cystatin B was significantly overexpressed only in 
lung adenocarcinoma lavage (1.8 folds) and was not among the differentially 
expressed proteins in lung squamous cell carcinoma (Table 28). This could have been 
due to technical issues rather than to the tissue itself.  
Tissue inhibitor of metalloproteinase (TIMPs) is a family of four proteins encoded 
by the TIMP gene, with splice variants designated as TIMP-1, 2, 3 and 4. Only 
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TIMP-1 and 2 can inhibit all extracellular matrix metallopeptidases (MMPs) (Gomez 
et al., 1997). TIMPs are known to induce cell proliferation (Ando et al., 2017), 
interact with Bcl2, and inhibit P53-mediated apoptosis in lung adenocarcinoma 
(Nalluri et al., 2015). TIMP-1 elevation was found associated with poor prognosis in 
triple-negative breast cancer (Cheng et al., 2016) and laryngeal squamous cell 
carcinoma (Ma et al., 2014). TIMP-1 overexpression was found correlated with 
advanced NSCLC, and so it has a prognostic value (Thomas et al., 2000).  
Overexpression of TIMP-1 in NSCLC could predict disease recurrence (Gouyer et 
al., 2005). In this study, TIMP-1 was found elevated in the lavage collected from 
lung AD and SqCC patients compared to normal control lavage.  
The increase was 2- and 2.2-fold in adeno and squamous cell carcinomas, 
respectively (Table 28). TIMP-1 was selected among the differentially expressed 
proteins for verification in plasma samples (Table 28) by ELISA: plasma levels of 
TIMP-1 were significantly elevated (p ≤ 0.01) in both carcinomas compared to the 
control group (Figure 11-D).     
Lipocalins are a group of small extracellular proteins that perform a wide variety of 
biological functions (figure 12). All lipocalins can bind hydrophobic molecules, 
macromolecules, lipids, steroid hormones, and secondary metabolites such as 
vitamins and co-factors, and they have a cell surface binding receptor (Schiefner and 
Skerra, 2015). Most lipocalins have in common three highly conserved sequence 
motifs called kernel, and a few, called outliers lipocalins, share only one conserved 
sequence motif.  
Kernel lipocalins include; Retinol-binding protein (RBP) [RBP 1,2,5,7 are cellular 
proteins and 4 was detected in plasma], Purpurin (RURP), Cellular retinoic acid-
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binding proteins 1&2 (CRABP1&2), α2u-Globulin (A2U), Major urinary protein 
(MUP), Bilin-binding protein (BBP), α-Crustacyanin, Pregnancy protein 14 (PP14), 
β-Lactoglobulin (Blg), α1-Microglobulin (A1M), Complement component 8 gamma 
(C8ᵞ), Apoliloprotein D (ApoD), Apoliloprotein M (ApoM), fatty acid binding 
proteins, Lazarillo (LAZ), Prostaglandin D synthase (PGDS), Quiescence-specific 
protein (QSP), neutrophil lipocalin (NGAL, LCN2) and choroid plexus protein (Du 
et al., 2015). Outlier lipocalins include; Odorant-binding protein 2A and 2B 
(OBP2A/2B), von Ebner’s-gland protein (VEGP), α1-Acid glycoprotein (AGP), 
Probasin and Aphrodisin (Flower, 1996). 
The role of lipocalines in cancer is modulated through their activation of peroxisome 
proliferator-activated receptor (PPAR) and retinoic acid receptor (RAR)-retinoid X 
nuclear receptor (RXR) (figure 12) (Mourey et al., 1994, Poirier et al., 1997). In the 
current discovery experiment, the mass spectrometry detected a significant increase 
in some of the above mentioned lipocalins, where the α1-Acid glycoprotein was 
elevated by 2.8 fold in the adenocarcinoma lavage and 4.0 fold in the lavage of lung 
squamous cell carcinoma compared to the normal control lavage (table 28), 
Apolipoprotein D was also elevated in lung adenocarcinoma lavage with a fold 
increase of  9.7. Other apolipoproteins were elevated in adenocarcinoma include 
Apolipoprotein A-II, A-IV and E with fold increase of 112.4, 3.6, 4.4 respectively. 
Fatty acid-binding protein (FABP) was also found 2.4 and 3.7 fold increased in 
adenocarcinoma and squamous carcinomas compared to the normal control. The 
level of apolipoproteins A-IV was also detected elevated in lung SqCC lavage with 
fold change of 5.1. Apolipoproteins include apolipoprotein A-I, II, B-100 and C-I 
were also found elevated in SqCC their fold change was 3.9, 7.3, 25.4, 7.2, 
respectively (table 28). Among Lipocalins, neutrophil lipocalin-2 (NGAL) was 
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selected for ELISA verification on plasma samples (table 5) and was found to be 
significantly (p ≤ 0.05) elevated in both AD and SqCC lavage (figure 11-C). 
 
 
 
Shown in figure 12, the downstream signalling of lipocalin receptor [modified from 
(Bratt, 2000)]. [+] indicates the protein the protein that were found in our study  to 
be significantly elevated in both AD and SqCC. 
               
Figure 12: Extracellular lipocalin receptor-mediated intracellular signalling. 
Faint arrows represent inhibition, EGF: epidermal growthfactor, PKC: protein 
kinase C, PMA: phorbol myrisate acetate, NGAL: neurophile gelatinase-
associated lipocalins, FABP: fatty acid binding protein, RBP: retinol binding 
protein, HFA: hydroxy fatty acids, CREP: c-AMP response element protein, c-
AMP: cyclic adenosine triphosphate, arrows through FABP or CRBP indicate 
carrier protein is involved, (+): activation, (+P): phosphorylate and activate, [+]: 
was found significantly elevated using mass spectrometry in our study. 
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Heat shock proteins (HSPs), also called chaperons as they function to protect 
proteins, during their peptides assembly in the cytoplasm as well as assembly of 
complex proteins working together, from the physical damage of the stressful 
cytoplasmic environment such as pH and temperature. Heat shock proteins also play 
role in cell cycle progression, cell survival and also involved in the proper antigen 
presentation in antigen presenting cells (macrophages and dendritic cells) (Li and 
Srivastava, 2004). Heat shock proteins are classified according to their molecular 
weight and some have specific cell compartment localization such as mitochondrial 
heat shock proteins including HSP10 which play a role in tolerance of ischemia 
(Hartman et al., 1992), HSP60 which found overexpressed in sever cell damage and 
function to induce innate immunity through toll-like receptor activation (Ohashi et 
al., 2000), mitochondrial HSP70 which play a major role in importing proteins to the 
mitochondria (Liu et al., 2003). Other HSPs are cytosolic which include HSP27, 
HSP110, HSP70, HSP90α/β. The later was found involved in cell cycle control and 
its inhibition was found to promote cell cycle arrest at G2/M phase (Pastorek et al., 
2016).  Endoplasmic reticulum heat shock proteins (HSP47) function to maintain 
proper protein folding and sorting in the cytoplasm (Tasab et al., 2000). Table 28 
summarizes heat shock proteins found significantly elevated in the lavage fluid of 
both lung AD and SqCC by mass spectrometry analysis conducted in this current 
research work. The endoplasmic reticulum HSP (Calreticulin) was the only 
significantly overexpressed HSP with a fold change of 3.0 in both carcinomas. 
HSP70 was known to be overexpressed in most type of cancers (Murphy, 2013), its 
downregulation was found to induce P53 mediated cell death in several lung cancer 
cell lines (Frese et al., 2003). Heat shock protein 70 downregulation by Ibuprofen 
was found to sensitize cisplatin-resistant tumours (Endo et al., 2014). In non-small 
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cell lung cancer, HSP70 was found significantly elevated in 49 patient serum samples 
while no significant change was observed on the level of HSP90 compared to normal 
control samples (Zhong et al., 2003). The verification results conducted in this 
research work revealed a significant elevation of HSP70 in the plasma from lung 
squamous cell carcinoma patients while no change among lung adenocarcinoma 
patients was detected (figure 11-A) despite its significant elevation  by the LC-
MS/MS.  
Finally, the next paragraph was the closing message that translate the philosophy of 
this sophisticated research work published in BBA clinical. “The utility of mass 
spectrometry-based quantitative proteomics as an additional piece of information to 
facilitate clinicians in the classifications of tumours is a significant area in 
development, as more treatments are specifically aimed at squamous and non-
squamous cell carcinoma. Also, a better understanding of the NSCLC histological 
subtypes may provide valuable insight in support of developing targeted therapeutics 
that are specific for precisely classified lung tumours. Several new targeted therapies 
have been recently approved for non-squamous NSCLC that inhibit Vascular 
Endothelial Growth Factor (VEGF), Epidermal Growth Factor Receptor (EGFR), 
Anaplastic Lymphoma Kinase (ALK), and Reactive Oxygen Species (ROS-1) 
(Bansal et al., 2016). As more driver mutations are discovered and therapeutic 
compounds developed to target these abnormal pathways, precise diagnosis of lung 
cancer and its subtypes will be crucial (Caparica et al., 2016). Protein expression and 
signalling in either BALF or plasma may have clinical relevance in the future through 
its ability to precisely differentiate subtypes and facilitate lung cancer diagnosis”. 
However, The discussion of this currently presented data will be extended to the next 
chapter focusing on biomarkers that play a role in cancer metabolism, and also would 
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be used as a reference for further comparison discovery phase done on foraldehyde-
fixed paraffine-embeded (FFPE) lung adenocarcinoma tumour tissue (chapter V).  
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4. Metabolic biomarkers discovery work    
4.1 Introduction 
To cope with the exceptional increase in energy demand, cancer cells use all the 
available energy substrates other than the aerobic catabolism of glucose (Devic, 
2016, Keibler et al., 2016). Glucose utilisation in cancer is restricted to the lactic acid 
cycle (Devic, 2016) for two reasons: the increased 
demand for the production of nitrogen bases via the phosphate pentose pathway 
(Jiang et al., 2014), and the lack of sufficient angiogenesis to supply the tumour 
environment with enough oxygen required to convert the produced pyruvate to 
acetyl Co-A, the starting substrate of citric acid cycle (Cairns et al., 2011a, Cairns et 
al., 2011b). Only two molecules of ATP are produced per glucose molecule, but 
the rate of ATP production is 100 times higher compared to the 
full aerobic oxidation of glucose in mitochondria (Devic, 2016). By promoting 
metabolic adaptation or transformation, Cancer cells can survive in environment that 
kill normal cells (Cairns et al., 2011a). 
Metabolic transformation involves the use of substrates that can be converted into 
acetyl co-A to compensate for the incomplete utilisation of glucose. Fatty acids, 
glutamate and urea are the most common energy substrates used by cancer cells 
(Callejón-Leblic et al., 2016). Interestingly, the incidence of cancer among people 
with type I diabetes mellitus is very low and vice versa in people consuming 
excessive amounts of carbohydrates (Devic, 2016). Therefore, interesting targets 
of biomarker discovery and targeted therapy include enzymes controlling the 
production of acetyl co-A and utilising all possible substrates, as well as those 
controlling its metabolism, became targets in biomarker discovery and targeted 
therapy. Sheng, et al. have published a good review of inhibitors targeting glucose, 
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glutamine and free fatty acid metabolism in cancer (Sheng et al., 2009).  In the 
context of the proteome signature that distinguishes lung adenocarcinoma from 
squamous cell carcinomas and previous work on lung lavage (Callejón-Leblic et al., 
2016, Almatroodi et al., 2015), one of the objectives of this study was to carry out 
biomarkers discovery on metabolomics. 
4.2. Experimental design  
Serum samples were collected from patients with lung cancer, including both small 
and non-small lung carcinomas. Control samples were collected from healthy 
individuals and from patients with non-cancer inflammatory and autoimmune 
diseases. Samples in quadriplicates  were shipped to Metabolon Inc. (N.C., USA) for 
analysis. Two aliquots were analysed for basic and acidic peptides by UHPLC-
MS/MS and one for analysed for relatively small-molecule metabolites GC/MS and 
the 4th aliquots was kept as a reference .  A second set of serum 
samples was collected and tested for ketone bodies, including acetoacetic 
acid and 3-hydroxybutyrate ketone bodies. The serum samples were also tested for 
the levels of pyruvate, acetyl co-A, fatty acids, and glutamate. To avoid 
misinterpretation of false positive and false negative levels of 
the candidate biomarkers, non-cancerous common respiratory system inflammatory 
were included.   
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4.3.  Results  
4.3.1. Elevated serum metabolites levels detected by LC/MS and GC/MS 
analysis in NSCLC compared to control  
Seventeen metabolites were significantly elevated in sera of patients with lung 
squamous and adenocarcinomas compared to the normal control (Table 31).  
 
 
Table 31: Metabolites significantly up-regulated in sera of lung cancer 
patients and controls 
Compound Detection 
method 
AD vs C SqCC vs C 
   Serine       
GC/MS 
1.35 1.7 
  Aspartate       2.42 2.94 
Ornithine     4.33 3.29 
Glutamate    
LC/MS + 
3.17 3.53 
Phenylalanine     1.57 1.64 
Tyrosine       1.52 1.53 
Kynurenine      1.19 1.44 
Tryptophan      1.19 1.04 
C-glycosyltryptophan     1.23 1.74 
Lsoleucine     1.69 1.84 
Leucine      1.6 1.8 
Valine      1.18 1.26 
Methionine     1.09 1.39 
Proline     1.36 1.2 
Citrulline     1.82 1.74 
5-oxoproline     2.1 1.98 
3-methyl-2-oxovalerate    LC/MS – 1.52 1.44 
AD: adenocarcinoma, SqCC: squamous cell carcinoma, C: control, +: 
positive, – : negative 
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4.3.2. Lowered serum metabolites levels detected by LC/MS and GC/MS 
analysis in NSCLC compared to control  
Table 32 lists the significantly downregulated metabolites in sera compared to 
normal controls (see also appendix 7). 
 
Table 32: Metabolites found downregulated in sera of lung cancer patients 
compared to the control normal individuals 
 
Numbers in bold indicate p≤0.05 ɸ: LC/MS positive, ɵ: GC/MS, Δ: LC/MS 
negative, D: lowered. 
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4.3.3. Serum levels of some acetyl co-A precursors  
Serum levels of pyruvate and acetyl Co-A were significantly higher in patients with 
lung adenocarcinoma or squamous cell carcinoma (n= 96) than in controls (n= 55) 
(Mann Whitney test, p< 0.0001 and 0.01, respectively). In contrast, the levels of free 
fatty acids and acetoacetate were significantly lower in the cancer patients (p= 0.001 
and 0.0004, respectively). However, there was no significant difference between the 
two groups in 3-hydroxybutyrate (p= 0.7) (figure 13).  
 
               
Figure 13: Serum levels of various metabolites in the patients with NSCLC and 
controls. 
 
 
 
 
 
 
Pyruvate Acetyl coA Free fatty acids
Acetoacetate b-hydroxy butyrate
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4.3.4. Serum glutamate levels  
Shown in figure 14, box and wiskers blot analysis of  Glutamate levels in lung non-
small cell carcinoma: Lung adenocarcinoma serum samples (n=49) [A], Lung 
squamous cell carcinoma (n=43) [B] compared to the normal control group serum 
samples (n=79).  The result revealed a decreased levels of glutamate in both lung 
carcinomas compared to normal control with p value of <0.0001 and 0.001 in 
adenocarcinoma and squamous cell carcinoma, respectively. 
 
                 
Figure 14: Glutamate levels in non-small cell lung cancer compared to control 
group, AD: lung adenocarcinoma, SqCC: squamous cell carcinoma, uM: micro 
molar. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
132 
4.4. Discussion   
There is insufficient metabolites-based research on cancer, making it difficult to 
relate any findings to specific types of lung cancer. Therefore, the data obtained in 
this study will be presented as it is, and the main molecules connecting different 
processes of energy production will be used as markers to judge the increased 
utilization of certain energy substrates. Our findings (summarized in figure 15) will 
be discussed in parallel with the lavage work reported in chapter III.  
The increased uptake and utilization of glucose in cancer is accompanied by 
increased lactate production and activation of gluconeogenesis via the Cori cycle in 
the liver (Hsu and Sabatini, 2008, Lunt and Vander Heiden, 2011). Lactate was 
significantly elevated (p= 0.02) in lung AD with a 1.45-fold change, but no change 
was detected in lung SqCC. In this research work, Serum pyruvate found 
significantly (p= 3.5E-09) elevated in NSCLC serum samples compared to the 
normal controls (figure 13). Pyruvate connects glycolysis, the citric acid cycle, the 
Cori cycle (gluconeogenesis) and amino acids (as a source of acetyl Co-A). 
Therefore, this discussion will focus on pyruvate as a central molecule (Figure 15). 
Pyruvate kinase M1 and 2 (PKM 1/2) , catalysis the conversion of 
phosphoenolpyruvate (PEP) to pyruvate in the last step of glycolysis (Mazurek, 
2011), and play a crucial role in the tumerigenesis and invasion of cancer via lactate 
accumulation (Eigenbrodt et al., 1992). PKM2 was detected elevated in the plasma 
and tumour tissues from NSCLC and colorectal cancer by ELISA and IHC, and such 
overexpression was found not to correlate with the tumour grade and stage 
(Kobierzycki et al., 2014, Schneider et al., 2002). Pyruvate kinase M2 was found 
elevated in many other cancers including stomach, oesophagus and breast cancer 
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(Kobierzycki et al., 2014). In this research work, PKM was detected significantly 
elevated in lung AD (4.E-02) and lowered in SqCC (p= 2.E-04) patients’  lavages 
compared to the normal control lavage with fold change of 1.8 and 4.2, respectively 
(appendix 1, 4).  
 
 
Figure 15:Acetyl Co-A as a central metabolite intermediate for amino acids and fatty 
acids. Red: significant by colourimetry, ELISA, LC-MS/MS or GC. 
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In this research work, the levels of pyruvate was also assessed in NSCLC serum 
samples (n=92) compared to normal control samples (n=79). The results showed a 
significant (p< 0.0001) increase in the levels of pyruvate in NSCLC in compare to 
control samples (figure 13). LC-MS/MS analysis of lavage samples revealed a 
significant increase in the level of lactate dehydrogenase A in lung AD (fold increase 
of 3.5, p= 1.E-07) and SqCC (fold increase 4.3, p = 2.E-05) (Tables 20, 22). 
It is unlikely that single biomarkers can be found for specific tumour types. The 
overall metabolic profile would rely on the availability of energy substrates. The 
overall metabolic signature of NSCLC is that pyruvate production exceeds its 
conversion to lactate. Lactate dehydrogenase B, which catalyses the conversion of 
lactate back to pyruvate, was significantly elevated (p= 3.E-07) in lung AD lavage 
(Table 20) but was not detected in SqCC. This might be a regulatory negative feed-
back mechanism indicating that lactate is produced more in lung AD than in SqCC. 
The elevations in glucose levels in lung AD and SqCC (1.2 and 1.2 fold changes) 
were not significant (p= 0.2). Cancer cells need an alternative source of energy that 
can enter the citric acid cycle without harming the cells, which might explain the 
large loss of fat and muscle mass in cancer patients (cachexia). 
Cachexia is the leading cause of death in 20% of cancer deaths worldwide. It results 
from degradation of body muscles and fat (Tisdale, 2009). Decreased levels of 
ketone bodies is the main clinical finding of cachexia (Shukla et al., 2014). In the 
current study, serum levels of free fatty acids and acetoacetic acid were significantly 
lower in NSCLC patients than in normal controls (p= 0.002 and 0.0001, respectively) 
(Figures 13). But no significant change was seen in 3-hydroxy butyric acid with 
overall decreased pattern (Figure 13). Overall, there was greater fat degradation in 
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lung SqCC than in AD, as indicated by the significant increase in the levels of free, 
medium and long chain (branched/unbranched) fatty acids. 
Muscles contain 98% of total body carnitine, 75% of which comes from dietary 
intake and 25% is endogenously synthesized from lysine and methionine (Sayed-
Ahmed, 2010, Engel and Rebouche, 1984). Carnitine supplementation ameliorates 
the fatigue induced by cisplatin chemotherapy (Graziano et al., 2002). Here, 
significant carnitine metabolism was detected in lung SqCC but not in AD (Appendix 
8). This finding indicates increased dependence of tumour tissues on fats as an 
alternative energy source.  
Amino acids uptake and utilization with concomitant overexpression of their 
transporters was demonstrated in many cancers (Bhutia et al., 2015). Cross-talk 
between ketone bodies and the urea cycle enables provision of another good source 
of non-essential amino acids in cancer by transamination of acetoacetate into amino 
acids such as aspartate. GC/MS analysis showed that serum aspartate was 
significantly elevated in AD and SqCC with fold changes of of 2.42 (p= 0.01) and 
2.9 (p= 0.05) compared to control samples (Table 31). Indeed, amino acid 
deprivation is being adopted in parallel to chemotherapy as a standard cancer 
treatment (Fung and Chan, 2017). Moreover, elevation of serum histidine, aspartate, 
phenylalanine, serine and alanine has been observed in NSCLC (Klupczynska et al., 
2016).  In our study, serine and aspartate were significantly elevated (GC/MS) in AD 
and SqCC, as well as phenylalanine (LC/MS), with fold changes ranging from 1.35 
to 2.9 [Table 31]. Their fold change in respective order were (1.35, 1.7), (2.4, 2.9), 
(1.57, 1.64) in AD and SqCC compared to control samples. The only difference 
between the finding of Klupczynska et al. and ours is that citrulline was decreased in 
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Klupczynska’s polish patients but elevated in our Irish patients, with fold changes of 
1.8 and 1.7 in AD and SqCC, respectively (Table 31).  
In the lavage discovery work, protein-glutamine ɣ-glutamyltransferase 2 
(transglutaminase 2) was significantly elevated in both AD (p= 5.E-05) and SqCC 
(p= 2.E-05), with fold changes of 10.0 and 8.4, respectively. Transglutaminase 2 has 
a role in cancer progression, metastasis and resistance to chemotherapy (Shao et al., 
2009, Begg et al., 2006). Glutathione synthetase, the enzyme involved in glutathione 
synthesis plays a role in detoxification of xenobiotic compounds and in tumour 
growth and resistance to chemotherapy in many cancers, including breast, colon and 
lung cancer (Balendiran et al., 2004). In the lavage work, glutathione synthetase was 
decreased 1.5 fold (p= 3.0E-02) in AD and 1.6 fold (p= 3.0E-02) in SqCC lavage 
compared to the normal control (Appendixes 2, 4). 
Glutamine synthetase (GS) catalyses the conversion of glutamate to glutamine 
(Adeva et al., 2012). Increased glutamine and asparagnine catabolism mediated by 
glutamate dehydrogenase is characterestic of the tumour microenvironment (Spinelli 
et al., 2017). Glutamate dehydrogenase activity is accompanied by accumulation of 
urea (Adeva et al., 2012), which is recycled in the liver via the urea cycle (Kappler 
et al., 2017). In our work, no significant change in the level of glutamine was 
observed by LC-MS/MS, either in lung AD or in SqCC carcinoma (Appendix 7), 
whereas glutamate was elevated 3.17 fold in AD and 3.53 fold in SqCC compared to 
control (Appendix 7). 
Also serum glutamate was assessed in non-small cell lung cancer (squamous and 
adenocarcinomas) (Figure 14). Unexpectedly, glutamate was significantly decreased 
in both AD (n = 49) and SqCC (n = 43) compared to normal control (n = 79). This 
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reflects increased consumption of glutamate in AD and SqCC. Glutamate is elevated 
in many cancers, including lung cancer with neurologic symptoms (Michalak et al., 
2016), stomach cancer, colon cancer (Okada et al., 1993) and breast cancer with 
decreased levels of glutamine (Budczies et al., 2015). These reports support our mass 
spectrometry findings but conflict with the results of our serum colourimetric assay 
used to validate our discovery work. Factors other than the samples per se might be 
responsible for this discrepancy. For instance, chemotherapy induces metabolic 
repregramming, including diminished glutamate synthesis in tumour tissues, which 
will directly affect serum or plasma levels. In any case, the increased consumption 
of ketone bodies, fatty acids, glutamate and aspartate reflects the ability of NSCLC 
cells to consume substrates other than glucose. Despite the long list of significantly 
elevated fat metabolities in lung SqCC compared to AD in our study (Appendix 8), 
it is still too early to speak about metabolic signatures for tumour subtypes. 
Nevertheless, our findings serve as a reference for future reproducibility of such 
metabolic signature found to cluster lung squamous cell carcinoma from lung 
adenocarcinoma. 
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5. Tumour heterogeneity 
5.1. Introduction 
Tumour heterogeneity originates from the high mutability of cancer cells and the 
accumulation  of mutations in the tumour cell populations at the very early 
stages (Andor et al., 2016).  This intra-tumour heterogeneity can be due to both 
genetic factors and diversity of post translational modifications (McGranahan and 
Swanton, 2017). Dominant sub-clonal cancer cells populations that 
are resistant to treatment are common in cancer. These cell populations 
become dominant when the drug sensitive populations are eliminated and became 
responsible for tumour relapse, drug resistance and the overall treatment outcome 
(McGranahan and Swanton, 2017, Greaves, 2015). The mosaic nature of 
cancer makes it very difficult to find stable biomarkers or panels of markers that 
have good clinical utility in diagnosis and monitoring of patients under 
treatment. Over the last three decades, no single protein biomarker of lung 
cancer has been identified and validated sufficiently for clinical use (Hoang, 2017). 
Due to the lack of standardisation in sample collection and due to sample 
vulnerability before  and during staining, immunohistochemistry-based diagnosis of 
lung cancer suffers from staining inconsistency and irreproducibility (Zhu et al., 
2006). This research work aimed to show the heterogeneity in four adenocarcinoma 
tumour samples with known TNM staging and to validate the list of proteins found 
significant in the  broncheoalveolar lavage from lung adenocarcinoma patients. The 
purpose was to cluster a group of proteins specifically related to the tumour but not 
to background abnormalities in the surrounding tissues.  
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5.2. Experimental design 
The inconsistency of the sensitivity and specificity of biomarkers for samples of 
different  groups is attributed mainly to heterogeneity of tumour tissues. Four 
tumour specimens were collected from lung adenocarcinoma patients, along with 
normal lung tissue. Each tumour  specimen was randomly divided into four 
quadrants, three of which were analysed by MS and 
their protein abundance compared to normal lung tissue from the same patient. 
Principal component analysis was performed to illustrate the existence of 
heterogeneity of protein abundance. Heat maps were also used to cluster the protein 
abundance in different parts of the tumour and to visualise the shared and highly 
abundant proteins. Venn diagrams were used to identify groups of shared proteins in 
all parts of the tumour samples and intersect them with the list came off the lavage 
work in chapter 3.    
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5.3. Results  
5.3.1. Principal component analysis 
Principal component analysis (PCA) was done on four lung adenocarcinoma 
specimens (Figure 16). Based on their proteomic signature [both up and down 
regulated proteins and how much changed are they (Fold change)?] obtained from 
the comparative label-free mass spectrometric analysis of the compared biopsies 
(control vs trisects), PCA clustered normal tissues from malignant ones in the first 
component of the analysis, while second component examined the difference in 
abundance in the protein signature among the tumour parts.  
Patient #1. The proteomic signature of (Q3) clustered to have some normal tissues’ 
protein abundance profile as it lying to the right of the component 1, at the same time 
seem different from the other two parts of the tumour (Q1, Q2). 
Patient #2. All tumour parts were differentiated from the normal control tissue. The 
three different parts of the tumour (Q1, Q2 and Q3) showed a wide range of 
differences in protein abundance. Q3 seems to share some protein signatures with 
Q1 and Q2, whereas Q1 and Q2 exhibit the highest degree of heterogeneity in their 
protein signature.  
Patient #3. This patient exhibited the same heterogeneity characteristics as patient 
#2.  
Patient #4. The only difference from patient #3 was that Q2 and Q3 were very close 
to each other, while Q1 showed a very different protein abundance profile.     
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Figure 16: Principal component analysis (PCA) separating tumour from 
normal control tissue (component 1) and heterogeneity within the tumour 
quadrants (component 2), the pecentages represent the variance between 
the two compared groups.  
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5.3.2. Heat map analysis 
Figure 17 shows the heat map analysis of the total proteomes signature (up and down 
regulated proteins detected by mass spectrometry) of three different parts of tumour 
specimens from four lung adenocarcinoma patients compared to their matched 
normal lung tissues  . The Q1(repeats), Q2(repeats) and Q3(repeats) represent 
technical repeats of the same sample. The first branch clusters normal from 
cancerous tissues. The second branch clusters tumour parts based on their abundance.  
 
 
           
 
Figure 17: Heat map comparison of total proteomes (up and down regulated 
proteins) of tumour specimens. N: normal lung tissue, Q: tumour tissue 
quadrants.  
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5.3.3. Analysis of shared elevated protein levels in all tumour tissue parts per 
patient 
Figure 18 represents the proteins found significantly elevated by mass spectrometry 
in different parts of the tumour mass dissected from each patient. In Patient #4; all 
parts of the tumour share only 5 proteins while tumours from patients; 1,2 and 3 share 
56, 52 and 88 proteins in their tumour parts, respectively. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
Figure 18: Venn diagrams showing shared up-regulated proteins compared to 
normal control tissue from the same patient in the three different parts (Q1, Q2, Q3) 
of the same tumour specimen per patient. The protein abundance fold-change cut-off 
value was set to ≥ 1.2. 
 
Patient 1 Patient 2
Patient 3 Patient 4
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5.3.3.1. Patient #1 analysis  
Table 33 shows the top 30 proteins detected significantly elevated by label-free mass 
spectrometry in all parts of the tumour specimen (3 quadrants) for patient #1 
compared to the matched normal control tissue. The full list is in appendix 12.  
 
Table 33: Top 30 proteins of 488 proteins found significantly elevated in all parts 
of the tumour tissue of patient #1  
 
Q: tumour tissue quadrant, C: normal lung control tissue. 
 
 
Accession Q1/C Q2/C Q3/C Protein name
B4DT77 1.3 1.4 1.3 Annexin
B9A064 4.1 6.1 5.4 Immunoglobulin lambda-like polypeptide 5 
H3BS10 2.7 1.5 5.5 Beta-hexosaminidase 
M0R0F0 1.8 2.7 1.7 40S ribosomal protein S5 
O75083 1.2 1.8 1.6 WD repeat-containing protein 1 
P00338 1.5 1.4 2.6 L-lactate dehydrogenase A chain 
P02794 3.2 1.6 3.8 Ferritin heavy chain 
P05091 3 1.6 2.4 Aldehyde dehydrogenase, mitochondrial 
P05783 4.4 3.4 4.4 Keratin, type I cytoskeletal 18 
P06744 1.7 2.5 3.4 Glucose-6-phosphate isomerase 
P07099 1.5 2.3 3 Epoxide hydrolase 1 
P07195 1.4 1.5 1.9 L-lactate dehydrogenase B chain 
P07339 1.4 1.8 2.2 Cathepsin D 
P08238 1.9 3.2 1.8 Heat shock protein HSP 90-beta 
P0DOY2 1.5 2.3 1.6 Immunoglobulin lambda constant 2 
P10599 1.4 1.5 1.4 Thioredoxin 
P10809 4.2 1.8 2.3 60 kDa heat shock protein, mitochondrial 
P11021 1.8 18.9 1.8 78 kDa glucose-regulated protein 
P11142 1.9 2.1 1.7 Heat shock cognate 71 kDa protein 
P14618 1.7 2.1 2.1 Pyruvate kinase PKM 
P15559 16.5 2 21.8 NAD(P)H dehydrogenase [quinone] 1 
P16152 2.9 2.1 5.9 Carbonyl reductase [NADPH] 1 
P21397 2.9 2.1 2.5 Amine oxidase [flavin-containing] A 
P21796 1.9 1.3 1.2 Voltage-dependent anion-selective channel protein 1 
P22314 1.6 10.1 1.8 Ubiquitin-like modifier-activating enzyme 1 
P23396 1.9 1.5 1.6 40S ribosomal protein S3 
P25788 1.7 1.9 1.6 Proteasome subunit alpha type-3 
P27695 1.5 2.3 1.6 DNA-(apurinic or apyrimidinic site) lyase
P28066 2 2.1 1.9 Proteasome subunit alpha type-5 
P28838 1.3 4.7 2.4 Cytosol aminopeptidase 
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5.3.3.2. Patient #2 analysis 
Table 34 shows the top 30 proteins detected significantly elevated by label-free mass 
spectrometry in all parts of the tumour tissue specimen (3 quadrants) for patient 
coded #2 compared to the matched normal control tissue. The full list put in appendix 
20. 
 
Table 34: Top 30 proteins of 352 proteins found significantly elevated in all parts 
of the tumour of patient #2  
 
Q: tumour tissue quadrant, C: normal lung control tissue. 
 
Accession Q1/C Q2/C Q3/C Description
E7EMM4 4.8 1.9 1.6 Acid ceramidase
I3L397 1.8 1.3 1.3 Eukaryotic translation initiation factor 5A 
O43707 3.5 2.2 3 Alpha-actinin-4 
P00352 8 1.5 1.6 Retinal dehydrogenase 1 
P02452 8.6 5.2 6.3 Collagen alpha-1
P02545 3.4 2.7 2.6 Prelamin-A/C [Cleaved into: Lamin-A/C 
P02743 2.5 1.4 2.3 Serum amyloid P-component 
P05387 2.1 1.7 1.4 60S acidic ribosomal protein P2 
P07339 2.7 2.2 1.6 Cathepsin D 
P07355 2.1 1.7 1.6 Annexin A2 
P07384 2.5 1.5 1.5 Calpain-1 catalytic subunit 
P08123 4.7 3.8 2.9 Collagen alpha-2
P08758 2.4 2 1.6 Annexin A5 
P09211 4.4 1.6 1.7 Glutathione S-transferase P 
P12109 2.7 2.6 2.3 Collagen alpha-1
P12110 18.3 15.2 11.9 Collagen alpha-2
P12111 2.6 1.9 1.8 Collagen alpha-3
P12429 4.1 3.6 1.5 Annexin A3 
P14550 1.9 1.4 1.6 Alcohol dehydrogenase [NADP
P21291 3.5 1.8 3 Cysteine and glycine-rich protein 1 
P21333 5.7 5.1 4.3 Filamin-A 
P21810 3.9 1.6 1.8 Biglycan 
P21980 1.8 1.5 2.3 Protein-glutamine gamma-glutamyltransferase 2 
P23284 1.5 1.3 1.7 Peptidyl-prolyl cis-trans isomerase B 
P27348 3.9 1.7 4.1 14-3-3 protein theta 
P30044 8.6 1.7 1.6 Peroxiredoxin-5, mitochondrial 
P30048 3.2 1.7 1.5 Thioredoxin-dependent peroxide reductase, Mito 
P30086 4 1.7 1.5 Phosphatidylethanolamine-binding protein 1 
P35579 2.4 3.5 3.2 Myosin-9 
P36578 1.7 1.2 1.3 60S ribosomal protein L4 
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5.3.3.3. Patient #3 analysis 
Table 35 shows the top 30 proteins detected significantly elevated by mass 
spectrometry in all parts (3 quadrants) of the tumour specimen from patient #3 
compared to the match normal control tissue. The full list is in appendix 28. 
 
Table 35: Top 30 proteins of 396 proteins found significantly elevated in all parts 
of the tumour specimen from patient #3  
 
Q: tumour tissue quadrant, C: normal lung control tissue. 
 
 
 
Accession Q1/C Q2/C Q3/C Protein names
E7EN65 2.7 3.6 4.1 Elastin
O14773 3.2 3.7 2.8 Tripeptidyl-peptidase 1 
O43399 2.2 2.3 1.9 Tumor protein D54 
O43707 1.4 1.3 1.4 Alpha-actinin-4 
P00338 1.6 5.3 3.9 L-lactate dehydrogenase A chain 
P00352 3.2 1.8 1.7 Retinal dehydrogenase 1 
P00558 1.3 1.5 1.7 Phosphoglycerate kinase 1 
P00568 2.4 1.7 2 Adenylate kinase isoenzyme 1 
P02743 3.2 2.3 3.7 Serum amyloid P-component 
P02751 1.3 1.3 1.3 Fibronectin 
P02792 3.2 8 4.9 Ferritin light chain 
P04004 1.8 1.9 2.3 Vitronectin 
P04406 1.6 1.7 1.9 Glyceraldehyde-3-phosphate dehydrogenase 
P04899 1.3 1.3 1.3 Guanine nucleotide-binding protein G
P06744 1.2 2.1 2.1 Glucose-6-phosphate isomerase 
P06748 1.4 2.3 1.6 Nucleophosmin 
P07195 1.6 2.8 2.3 L-lactate dehydrogenase B chain 
P07384 2.1 2.3 2.3 Calpain-1 catalytic subunit 
P07900 1.4 1.4 1.4 Heat shock protein HSP 90-alpha 
P08133 1.7 1.3 1.5 Annexin A6 
P08238 1.9 2 2.1 Heat shock protein HSP 90-beta 
P08758 2.8 2.7 2.5 Annexin A5 
P09211 1.5 2.5 1.8 Glutathione S-transferase P 
P09972 1.2 1.4 2 Fructose-bisphosphate aldolase C 
P12109 2 1.2 1.2 Collagen alpha-1
P12110 3 1.4 1.7 Collagen alpha-2
P12814 4 3.6 3.6 Alpha-actinin-1 
P12956 3 3 3.9 X-ray repair cross-complementing protein 6 
P13639 2.2 3.5 3.7 Elongation factor 2 
P13797 1.4 1.5 1.6 Plastin-3 
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5.3.3.4. Patient #4 analysis 
Table 36 shows the proteins detected significantly elevated by mass spectrometry 
in all parts of the tumour specimen (3 quadrants) from patient #4 compared to the 
match normal control tissue. The full list is in appendix 36. 
 
 
Table 36: Top 5 proteins of 99 proteins found significantly elevated in all parts of 
the tumour tissue of patient #4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accession Q1/C Q2/C Q3/C Protein name
E7EMM4 1.4 1.8 2.1 Acid ceramidase
F8W7C6 1.3 1.7 1.2 60S ribosomal protein L10
P04229 1.3 1.2 1.5 HLA class II histocompatibility antigen, DRB1-1 beta chain 
P21964 1.3 1.4 1.9 Catechol O-methyltransferase 
P45880 1.3 1.3 1.3 Voltage-dependent anion-selective channel protein 2 
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5.3.4. Analysis of proteins diminished in all tumour tissue samples per patient  
Figure 19 represents the significantly diminished proteins detected by mass 
spectrometry in different parts of the dissected tumour for each patient. In patient #4, 
the three parts of the tumour share only 12 proteins while 60, 38 and 97 proteins were 
significantly lowered and shared in all parts within same tumour in patient 2,3 and 4 
respectively. 
 
 
 
 
Figure 19: Venn diagrams showing the shared proteins diminished in the 
three parts (Q1, Q2, Q3) of the same tumour specimen in each patient. The 
cut-off value for protein abundance fold change was set to ≥ 1.2. 
 
 
 
Patient 1 Patient 2
Patient 3 Patient 4
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5.3.4.1. Patient #1 analysis 
Table 37 shows the top 30 proteins detected significantly lowered  by mass 
spectrometry in all parts (3 quadrants) of the FFPE specimen for tumour tissue from 
patient #1 compared to the match normal control tissue. The full list is in appendix 
16. 
Table 37: Proteins significantly lowered in all parts of the tumour tissue of patient 
#1  
 
 Q: tumour tissue quadrant, C: normal lung control tissue. 
 
 
 
Accession C/Q1 C/Q2 C/Q3 Protein name
J3QL05 2.6 1.4 1.6 Serine/arginine-rich-splicing factor 2 
K7EK07 2 2 1.5 Histone H3 
O43707 2.1 2.6 1.3 Alpha-actinin-4 
O95865 2.8 4.3 2.4 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 
O95994 2.6 1.4 1.5 Anterior gradient protein 2 homolog 
P00915 1.4 3.6 2.1 Carbonic anhydrase 1 
P00918 1.4 3.4 2.7 Carbonic anhydrase 2 
P01009 3.8 6.3 2.9 Alpha-1-antitrypsin 
P01024 1.6 2.1 1.4 Complement C3 
P02452 18.8 21.5 4.4 Collagen alpha-1
P02545 1.7 1.7 1.8 Prelamin-A/C [Cleaved into: Lamin-A/C 
P02647 2.5 3.1 2.2 Apolipoprotein A-I 
P02743 1.5 3.1 2.3 Serum amyloid P-component 
P02787 2.5 4 1.4 Serotransferrin 
P04004 3.4 3.7 2.4 Vitronectin 
P04083 1.2 1.7 2.5 Annexin A1 
P05109 3 8.6 2 Protein S100-A8 
P05164 4.4 8.2 4.4 Myeloperoxidase 
P06702 3.5 7.8 2.9 Protein S100-A9 
P07355 1.7 2.9 1.9 Annexin A2 
P08123 6.4 10.7 3.5 Collagen alpha-2
P08133 2 2.4 1.8 Annexin A6 
P08311 4.1 7.8 4.9 Cathepsin G 
P08670 1.3 2.4 1.8 Vimentin
P08758 3.1 3.9 1.5 Annexin A5 
P09382 1.6 2 1.4 Galectin-1 
P09525 2.1 2 1.8 Annexin A4 
P12109 6.6 22.6 5.1 Collagen alpha-1
P12110 11.9 54.1 9.9 Collagen alpha-2
P12277 1.4 4.8 3.4 Creatine kinase B-type 
 
 
151 
5.3.4.2. Patient #2 analysis 
Table 38 shows the proteins detected significantly lowered by mass spectrometry in 
all parts (3 quadrants) of the FFPE specimen for patient #2 compared to the match 
normal control tissue (Appendix 24). 
Table 38: Proteins significantly lower in all parts of the tumour tissue of patient #2  
 
Accession C/Q1 C/Q2 C/Q3 Discription
B9A064 15.5 5 4.3 Immunoglobulin lambda-like polypeptide 5 
C9JA05 3 5.3 2.5 Immunoglobulin J chain 
P00450 13.6 3.2 2.5 Ceruloplasmin 
P00915 1.8 1.7 1.9 Carbonic anhydrase 1 
P01008 8.4 3.5 2.6 Antithrombin-III 
P01009 12.8 2.8 2.5 Alpha-1-antitrypsin 
P01011 5.3 3.2 2.7 Alpha-1-antichymotrypsin 
P01023 3.1 1.8 2.8 Alpha-2-macroglobulin 
P01024 2.7 1.6 2.1 Complement C3 
P01834 7.5 1.5 2.2 Immunoglobulin kappa constant 
P01876 9.1 3.8 2.8 Immunoglobulin heavy constant alpha 1 
P01903 1.3 2.6 2.4 HLA class II histocompatibility antigen, DR α- chain 
P02042 1.6 2.6 1.8 Hemoglobin subunit delta 
P02647 4.2 1.6 1.3 Apolipoprotein A-I 
P02649 24.6 3.8 1.6 Apolipoprotein E 
P02730 3.4 4.8 5.5 Band 3 anion transport protein 
P02763 9.6 1.3 2.5 Alpha-1-acid glycoprotein 1 
P02766 8 3.1 2.6 Transthyretin 
P02774 12.5 1.9 2.8 Vitamin D-binding protein 
P02787 8 1.7 2.2 Serotransferrin 
P02792 5 3.8 1.2 Ferritin light chain 
P04040 1.9 4.2 2.3 Catalase 
P04196 8.2 1.6 2.5 Histidine-rich glycoprotein 
P04217 14.9 4.2 3.6 Alpha-1B-glycoprotein 
P05155 6.6 1.8 2.5 Plasma protease C1 inhibitor 
P06727 7.1 5.6 2.1 Apolipoprotein A-IV 
P0C0L4 4.3 2.8 1.7 Complement C4-A 
P13760 1.2 2 1.4 HLA class II histocompatibility antigen, DRB1-4 β- 
P19652 10.3 1.5 2.1 Alpha-1-acid glycoprotein 2 
P19827 2.3 3.9 2.8 Inter-alpha-trypsin inhibitor heavy chain H1 
P25311 2 3.3 2.3 Zinc-alpha-2-glycoprotein 
P32119 1.7 3.2 2 Peroxiredoxin-2 
P51884 1.5 2.1 1.2 Lumican 
P68871 2.6 2.1 2 Hemoglobin subunit beta 
P69905 2.6 2 1.7 Hemoglobin subunit alpha 
P98088 3.6 1.7 7.6 Mucin-5AC 
Q14624 12.7 4.6 2.9 Inter-alpha-trypsin inhibitor heavy chain H4 
Q5T985 2.7 1.5 1.2 Inter-alpha-trypsin inhibitor heavy chain H2
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5.3.4.3. Patient #3 analysis 
Table 39 shows the top 30 proteins detected significantly low by mass spectrometry 
in all parts (3 quadrants) of the FFPE specimen for tumour specimen from patient #3 
compared to the match normal control tissue (Appendix 32). 
Table 39: Proteins significantly low in all parts of the tumour specimen from 
patient #3  
 
Q: tumour tissue quadrant, C: normal lung control tissue. 
 
 
Accession C/Q1 C/Q2 C/Q3 Protein name
B4E2V5 2 2.4 1.8 cDNA FLJ52062
E7ES10 1.6 1.6 1.2 Calpastatin 
E7EVA0 3.3 1.6 1.7 Microtubule-associated protein
F8W1A4 1.4 1.8 1.5 Adenylate kinase 2, mitochondrial 
G3V4C1 1.4 1.4 1.2 Heterogeneous nuclear ribonucleoproteins C1/C2
H7BYY1 1.9 1.8 1.3 Tropomyosin 1 
J3QS39 2.5 2.4 2.8 Polyubiquitin-B 
M0R0F0 1.9 1.8 2.5 40S ribosomal protein S5 
O75368 1.8 2.1 2.6 SH3 domain-binding glutamic acid-rich-like protein
O96009 2.2 1.9 2.2 Napsin-A 
P00167 3.7 6 3.9 Cytochrome b5 
P00367 1.4 1.4 1.3 Glutamate dehydrogenase 1, mitochondrial 
P00915 1.9 2.9 2 Carbonic anhydrase 1 
P01009 1.5 1.3 2.7 Alpha-1-antitrypsin 
P01903 1.3 1.6 1.7 HLA class II histocompatibility antigen, DR alpha chain 
P01920 2.2 1.3 1.5 HLA class II histocompatibility antigen, DQ beta 1 
P02042 2.1 2.4 1.7 Hemoglobin subunit delta 
P02671 1.3 1.4 1.5 Fibrinogen alpha chain 
P02675 1.5 2 1.8 Fibrinogen beta chain 
P02730 1.9 3.3 2.9 Band 3 anion transport protein 
P04040 3.8 4.4 3.6 Catalase 
P04632 1.5 1.6 1.5 Calpain small subunit 1 
P05091 2.2 3.1 1.8 Aldehyde dehydrogenase, mitochondrial 
P05109 2.1 1.7 2.1 Protein S100-A8 
P05164 1.3 1.5 1.3 Myeloperoxidase 
P07305 2.8 1.9 2.2 Histone H1.0 
P08572 1.5 2.3 2 Collagen alpha-2
P09960 1.3 1.4 1.3 Leukotriene A-4 hydrolase 
P0DP23 1.8 1.5 1.5 Calmodulin-1
P10301 1.8 2 1.6 Ras-related protein R-Ras 
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5.3.4.4. Patient #4 analysis 
Table 40 shows the proteins detected by mass spectrometry to have the lowest 
abundance in three quadrants of the FFPE specimen for tumour specimen from 
patient #4 compared to the matched normal control tissue (Appendix 40). 
 
Table 40: proteins significantly low in all parts of the tumour tissue of patient 4  
 
 
 
5.3.5. Formaldehyde-fixed paraffin-embedded tumour tissue versus lavage fluid 
analysis    
Table 41: Summary of FFPE specimens heterogeneity and availability in BALF 
 
 x/y: Significant/Total detected proteins with fold change cut-off value of 1.2. [-]: 
low and [+]: high in the lavage from NSCLC compared to the control lavage used.   
Accession C/Q1 C/Q2 C/Q3 Protein names
C9JEU5 1.6 3.4 3.5 Fibrinogen gamma chain
P01024 1.4 1.8 1.4 Complement C3 
P01871 1.5 2 1.4 Immunoglobulin heavy constant mu 
P02671 1.4 3.4 3.2 Fibrinogen alpha chain
P02675 1.5 5 6.5 Fibrinogen beta chain 
P05783 1.3 1.3 1.2 Keratin, type I cytoskeletal 18 
P06396 1.3 1.7 1.2 Gelsolin 
P0C0L4 1.4 2.1 1.5 Complement C4-A 
P51659 1.2 1.5 1.4 Peroxisomal multifunctional enzyme type 2 
Q01082 1.4 1.2 2.3 Spectrin beta chain, non-erythrocytic 1 
Q08380 1.7 1.2 2.1 Galectin-3-binding protein 
Q9Y394 1.4 1.3 1.4 Dehydrogenase/reductase SDR member 7 
Shared BALF [+] BALF [-]
Q1 Q2 Q3
x/y x/y x/y
Patient 1 164/178 141/171 183/206 56 22 7
Patient 2 136/147 89/97 136/145 52 15 6
Patient 3 118/132 147/163 136/146 88 33 11
Patient 4 80/88 92/100 128/141 5 0 1
Q1 Q2 Q3
x/y x/y x/y
Patient 1 98/115 98/119 99/110 60 25 3
Patient 2 88/91 104/109 50/63 38 4 22
Patient 3 163/178 139/143 140/157 97 11 17
Patient 4 78/84 208/220 112/116 12 3 4
Elevated
Lowered
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5.3.5.1. Proteins with opposite patterns in lavage fluid compared to the FFPE 
biopsies 
5.3.5.1.1. Proteins elevated in tumour tissue but in low abundance in lavage 
Table 42 lists of proteins detected by mass spectrometry significantly 
heterogeneously overexpressed in all parts of the tumour in each patient sample 
compared to the matched control normal lung tissue and were down regulated in the 
lavage biomarker discovery done on matched tumour types. 
 
Table 42: Proteins elevated in tumour tissues but lowerd in lavage. 
              
BALF: bronchoalveolar lavage, Q: tumour tissue quadrant, C: normal lung control 
tissue. *: found shared in two patients, numbers in bold represent the decreased fold 
change in non-small cell lung cancer lavages compared to normal lavage control. 
(Q1/C, Q2/C and Q3/C) represent the fold change increase in different parts of 
adenocarcinoma tissue specimen compared to their matched normal lung tissue.   
 
 
Accession BALF Q1/C Q2/C Q3/C Protein name Patient 
P31946 1.9 2.9 3.5 1.8 14-3-3 protein beta/alpha 1
P63104 2.4 1.8 1.6 1.8 14-3-3 protein zeta/delta 1
P14550 1.2 1.9 1.4 1.6 Alcohol dehydrogenase [NADP] 1
P08758*  3.4 2.4/2.8 2/2.7 1.6 Annexin A5 2, 3
P40199  1.9 6.9 8.9 6.8 Carcinoembryonic Ag-related cell adhesion molecule 6 3
P07339* 2.0 1.4/2.7 1.8/2.2 2.2/1.6 Cathepsin D 1, 2
P13639 1.2 2.2 3.5 3.7 Elongation factor 2 3
P02792  5.8 3.2 8 4.9 Ferritin light chain 3
P08238 1.2 1.9 2 2.1 Heat shock protein HSP 90-beta 3
P61978  1.7 1.5 1.3 1.2 Heterogeneous nuclear ribonucleoprotein K 1
Q00839 1.5 2.3 1.6 2.4 Heterogeneous nuclear ribonucleoprotein U 1
P04229 17 1.3 1.2 1.5 HLA class II histocompatibility antigen, DRB1-1 β chain 4
P05783 2.6 4.4 3.4 4.4 Keratin, type I cytoskeletal 18 1
P35579* 1.7 2.4/2 3.5/1.7 3.2/1.5 Myosin-9 2, 3
Q99497  1.3 3.4 1.3 1.3 Protein DJ-1 2
P21980*  2.0 1.8/1.7 1.5/1.7 2.3/1.9 Protein-glutamine gamma-glutamyltransferase 2 2, 3
P61026  5.3 1.5 1.3 1.9 Ras-related protein Rab-10 3
Q9Y490  3.5 2.3 1.6 2.4 Talin-1 2
P78371  2.0 1.2 4.5 1.5 T-complex protein 1 subunit beta 1
P19971  2.6 1.2 1.8 1.3 Thymidine phosphorylase 3
P37802 3.4 1.5 2.4 2.1 Transgelin-2 1
O14773  3.0 3.2 3.7 2.8 Tripeptidyl-peptidase 1 3
P68363  2.6 2 2 2.6 Tubulin alpha-1B chain 3
O43399  3.6 2.2 2.3 1.9 Tumor protein D54 3
 
 
155 
 
 
Figure 20: String analysis (GO:0070062 extracellular exosomes) of 
heterogeneously overexpressed proteins found shared in at least all parts of 
one FFPE tissue sample and low in the lung lavage from adenocarcinoma. 
Nodes in red represent the proteins that’s excreated via exosomes and can 
be seen in body fluids. 
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5.3.5.1.2. Proteins lowered in tumour tissue but at high concentration in lavage 
 
Table 43 shows the significant proteins found heterogeneously downregulated by 
label-free mass spectrometry in all parts of the tumour in all patient specimens 
compared to the matched normal lung tissue but were elevated in the lavage 
discovery done on matched tumour type (appendix 43). 
 
Table 43: down-regulated proteins in tumour tissues found elevated in lavage.  
            
*: found shared in two patients, numbers represent the fold change in non-small 
cell lung cancer compared to normal control. 
 
Accession BALF C/Q1 C/Q2 C/Q3 Protein name Patient #
P02671* 5.2 1.4/1.3 3.4/1.4 3.2/1.5 Fibrinogen alpha chain 3,4
P01024* 1.8 2.7/1.4 1.6/1.8 2.1/1.4 Complement C3 2,4
P0C0L4* 4 4.3/1.4 2.8/2.1 1.7/1.5 Complement C4-A 2,4
P01009* 6 12.8/1.5 2.8/1.3 2.5/2.7 Alpha-1-antitrypsin 2,3
P02730* 228 3.4/1.9 4.8/3.3 5.5/2.9 Band 3 anion transport protein 2,3
P00915* 4 1.8/1.9 1.7/2.9 1.9/2 Carbonic anhydrase 1 2,3
Q08380 1.1 1.7 1.2 2.1 Galectin-3-binding protein 4
P01871 4.2 1.5 2 1.4 Immunoglobulin heavy constant mu 4
P27348  4.0 2.2 1.3 1.6 14-3-3 protein theta 3
P61247  4.5 2.3 1.5 1.6 40S ribosomal protein S3a 3
P27797  3.1 2.4 1.5 2.1 Calreticulin 3
P23528  3.2 1.5 1.6 2 Cofilin-1 3
P17661  1.2 1.4 2.4 1.5 Desmin 3
Q01469  2.4 1.7 2.8 3.3 Fatty acid-binding protein, epidermal 3
P02675  1.7 1.5 2 1.8 Fibrinogen beta chain 3
P51858  2.9 2 1.6 2 Hepatoma-derived growth factor 3
P51991  3.6 1.9 1.3 1.4 Heterogeneous nuclear ribonucleoprotein A3 3
P09960  11.5 1.3 1.4 1.3 Leukotriene A-4 hydrolase 3
P05164  1.7 1.3 1.5 1.3 Myeloperoxidase 3
P05109  2.2 2.1 1.7 2.1 Protein S100-A8 3
P02763 2.8 9.6 1.3 2.5 Alpha-1-acid glycoprotein 1 2
P19652 3.1 10.3 1.5 2.1 Alpha-1-acid glycoprotein 2 2
P01011 3 5.3 3.2 2.7 Alpha-1-antichymotrypsin 2
P04217 1.3 14.9 4.2 3.6 Alpha-1B-glycoprotein 2
P01023 1.5 3.1 1.8 2.8 Alpha-2-macroglobulin 2
P01008 2 8.4 3.5 2.6 Antithrombin-III 2
P02647 1.5 4.2 1.6 1.3 Apolipoprotein A-I 2
P06727 3.6 7.1 5.6 2.1 Apolipoprotein A-IV 2
P02649 4.4 24.6 3.8 1.6 Apolipoprotein E 2
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Figure 21: String analysis (GO:0070062 extracellular exosomes) of 
heterogeneously down regulated proteins found shared in all parts of at least one 
tissue sample and elevated in the lung lavage from adenocarcinoma. Nodes in red 
represent proteins that are excreted via exosomes and can be seen in body fluids. 
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5.3.5.2. Proteins exhibiting the same pattern in lavage and FFPE biopsies 
5.3.5.2.1. Proteins overexpressed in tumour tissue and elevated in lavage  
 
Table 44 shows the significant proteins found heterogeneously overexpressed by 
label-free mass spectrometry in all parts of the tumour in all patient specimens 
compared to the matched normal lung tissue and also were elevated in the lavage 
discovery done on matched tumour type (appendix 41). 
Table 44: Top 30 proteins found elevated in one or more tumour quadrants and in 
the lavage 
 
BALF: bronchalveolar lavage fluid, Q/C: value of the protein fold change in the 
tumour tissue compared to the control. Q1, Q2, Q3: three parts of tumour biopsy.  
 
 
 
 
 
Accession BALF Q1/C Q2/C Q3/C Protein name Patient #
P62277 1.4 1.7/5.3 1.5/4.8 1.5/5.2 40S ribosomal protein S13 2&3
O43707 3.1 3.5/1.4 2.2/1.3 3/1.4 Alpha-actinin-4 2&3
P07384 3.1 2.5/2.1 1.5/2.3 1.5/2.3 Calpain-1 catalytic subunit 2&3
P60842 3.6 1.9/2 1.3/2.5 2.3/2.4 Eukaryotic initiation factor 4A-I 2&3
P23284 3.6 1.5/1.2 1.3/1.8 1.7/1.6 Peptidyl-prolyl cis-trans isomerase B 2&3
Q06323 2.2 1.5/2.2 1.3/2.2 1.2/2.1 Proteasome activator complex subunit 1 2&3
P02743 6.8 2.5/3.2 1.4/2.3 2.3/3.7 Serum amyloid P-component 2&3
P00338 3.5 1.5/1.6 1.4/5.3 2.6/3.9 L-lactate dehydrogenase A chain 1&3
P07195 5 1.4/1.6 1.5/2.8 1.9/2.3 L-lactate dehydrogenase B chain 1&3
P62937 2.1 1.5/1.2 1.9/1.7 1.8/1.5 Peptidyl-prolyl cis-trans isomerase A 1&3
P14618 1.8 1.7/1.9 2.1/3.4 2.1/3.1 Pyruvate kinase PKM 1&3
P37837 3.1 2/1.4 1.8/2.4 4.8/1.9 Transaldolase 1&3
P22314 2.1 1.6/1.3 10.1/1.8 1.8/1.8 Ubiquitin-like modifier-activating enzyme 1 1&3
P62906 6.1 1.5 2.1 1.9 60S ribosomal protein L10a 3
P61158 3 2 2.6 2.4 Actin-related protein 3 3
P00568 4.2 2.4 1.7 2 Adenylate kinase isoenzyme 1 3
P08133 3.9 1.7 1.3 1.5 Annexin A6 3
Q14204 13.3 2.4 1.3 1.5 Cytoplasmic dynein 1 heavy chain 1 3
P49327 9.5 2 2.5 2.5 Fatty acid synthase 3
P04406 2.1 1.6 1.7 1.9 GAPDH 3
P04899 15 1.3 1.3 1.3 Guanine nucleotide-binding protein G 3
Q12905 7 2.9 4.5 5.1 Interleukin enhancer-binding factor 2 3
P14174 2 8.6 10.6 7 Macrophage migration inhibitory factor 3
P35580 4 3.2 1.5 1.3 Myosin-10 3
Q9UJ70 2.5 1.4 1.4 1.5 N-acetyl-D-glucosamine kinase 3
P19338 6.1 1.7 1.3 1.6 Nucleolin 3
Q06830 2.3 1.5 1.8 1.6 Peroxiredoxin-1 3
P00558 1.9 1.3 1.5 1.7 Phosphoglycerate kinase 1 3
P49368 2.3 1.5 1.4 2.6 T-complex protein 1 subunit gamma 3
P04004 2.8 1.8 1.9 2.3 Vitronectin 3
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Figure 22: String analysis (GO:0070062 extracellular exosomes) of proteins 
heterogeneously overexpressed in both FFPE and lung lavage from adenocarcinoma 
compared to normal controls. Red ndes represent the proteins that are excreted via 
exosomes and can be seen in body fluids. 
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5.3.5.2.2. Proteins down regulated in tumour tissue and at low level in lavage 
Table 45 shows the significant proteins found heterogeneously down regulated by 
label-free mass spectrometry in all parts of the tumour in all patient specimens 
compared to the matched normal lung tissue and also in the lavage discovery done 
on matched tumour type (appendix 42). 
Table 45: Top 30 proteins found down regulated in one or more quadrants and in 
the lavage 
 
BALF: bronchalveolar lavage fluid, Q/C: value of the protein fold change in the 
tumour tissue compared to the control. Q1, Q2, Q3: three parts of tumour biopsy.  
 
 
Accession BALF C/Q1 C/Q2 C/Q3 Protein name Patient  #
P04040 1.6 1.9/3.8 4.2/4.4 2.3/3.6 Catalase 2, 3
P02042 4.1 1.6/2.1 2.6/2.4 1.8/1.7 Hemoglobin subunit delta 2, 3
P18206  3.6 4.8/1.4 8.4/1.6 3.7/1.5 Vinculin 1, 3
P31946 1.9 3.3 1.7 2.4 14-3-3 protein beta/alpha 3
P62258 1.7 2.4 2.3 2.6 14-3-3 protein epsilon 3
P40121 2.7 2.3 1.7 2.4 Macrophage-capping protein 3
O75368 2.1 1.8 2.1 2.6 SH3 domain-binding glutamic acid-rich protein 3
P37802 3.4 2.4 1.2 1.3 Transgelin-2 3
P67936 2.9 1.7 2 1.5 Tropomyosin alpha-4 chain 3
P23381 1.8 2.2 1.6 1.9 Tryptophan--tRNA ligase, cytoplasmic 3
P02792 5.8 5 3.8 1.2 Ferritin light chain 2
P04196 1.4 8.2 1.6 2.5 Histidine-rich glycoprotein 2
P01009 5.9 3.8 6.3 2.9 Alpha-1-antitrypsin 1
P07355 3.4 1.7 2.9 1.9 Annexin A2 1
P09525 2 2.1 2 1.8 Annexin A4 1
P08133 3.9 2 2.4 1.8 Annexin A6 1
O95994 4.4 2.6 1.4 1.5 Anterior gradient protein 2 homolog 1
Q13938 1.6 4.5 4.2 5.1 Calcyphosin 1
P00915 4 1.4 3.6 2.1 Carbonic anhydrase 1 1
P00918 2 1.4 3.4 2.7 Carbonic anhydrase 2 1
P08311 2.3 4.1 7.8 4.9 Cathepsin G 1
P01024 1.8 1.6 2.1 1.4 Complement C3 1
P21333 4.4 2 3.8 2.3 Filamin-A 1
P68871 7.5 1.4 2.7 1.8 Hemoglobin subunit beta 1
Q6FI13  3.5 2.7 2.9 1.8 Histone H2A type 2-A 1
P62805 5 2 1.9 1.6 Histone H4 1
P61626 4.4 2.8 5.5 4.9 Lysozyme C 1
P05164 1.7 4.4 8.2 4.4 Myeloperoxidase 1
P35579 1.7 4.5 4.9 2 Myosin-9 1
P13796  2.2 1.2 2.1 1.2 Plastin-2 1
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Figure 23: String analysis (GO:0070062 extracellular exosomes) of heterogeneously 
down regulated proteins that were shared in all parts of at least one tissue sample 
and in the lung lavage from adenocarcinoma. Nodes in red represent the proteins 
that are excreted via exosomes and can be seen in body fluids. 
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5.3.6. Tissue microarray validation 
Table 46: Tissue microarray (TMAs) scoring 
 
 LT: lung tissue, AD: adenocarcinoma, Sqcc: squamous cell carcinoma, LDHA: 
lactate dehydrogenase A, PDH: pyruvate dehydrogenase, FASN: fatty acid synthase, 
x/y: number of positive cores/total cores. 
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5.3.6.1. Lactate dehydrogenase A 
Figure 24 shows immunohistochemistry reactivity of TMA cores from normal lung 
tissue (A), lung adenocarcinoma (B) and lung squamous cell carcinomas (C) to 
lactate dehydrogenase A. 0: no staining, 1: weakly stained, 2: good staining, 3: strong 
staining. The clinical information of the lung adenocarcinoma cores is B0 (IIIA, 
grade 2, T3N1M0), B1: (IIIA, grade 2-3, T2N1M0), B2 (IIB, grade 2, T3N0M0) and 
B3:( IIIA, grade 2, T3N1M0). The clinical information of the lung squamous cell 
carcinoma cores is C0: (IA, T1N0M0), C1: (IIB, grade 2, T2N2M0), C2: (IIIA grade 
2, T2N2M0) and C3: (IIIA, grade 2, T2N2M0). The full scoring results are in 
appendix 44. Normal lung tissue expression of LDHA was very low compared to the 
malignant tissues;  score were restricited to 1 and no cores scored 2 or 3. 
 
Figure 24: Immunohistochemical staining of FFPE-based TMA for lactate 
dehydrogenase A (brown) in normal lung tissues (A), lung adenocarcinoma (B) and 
lung squamous cell carcinoma (C). 0, 1, 2, 3 represent reactivity scoring (colour 
intensity). Maximum normal lung tissue score was 1. 0/17: none of the normal cores 
(17 cores) scored as 2 or 3 for their reactivity to LDHA.   
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5.3.6.2. Pyruvate dehydrogenase 
Figure 25 shows immunohistochemical reactivity of TMA cores from lung 
adenocarcinoma (A) and lung squamous cell carcinoma (B) to pyruvate 
dehydrogenase. 0: no staining, 1: weakly stained, 2: good staining, 3: strong staining. 
The clinical information for the lung adenocarcinoma cores is A0 (of stage II, grade 
3,T2N1M0), A1: (IIB, grade 3, T2N1M0), A2 (IIB, grade 1, T2N1M0), and A3: 
(IIIA grade 2, T2N2M0). The clinical information for lung squamous cell carcinoma 
cores is B0: (IIIA, grade 0, T2N2M0), B1: (IIIA, grade 1, T2N2M0), B2: (IIIA, grade 
1, T2N2M0) annd B3: (IIIA, grade 3, T2N2M0). The full scoring results are listed 
in appendix 45. 
             
Figure 25: Immunohistochemical staining of FFPE-based TMA for pyruvate 
dehydrogenase (brown) in lung adenocarcinoma (A) and lung squamous cell 
carcinoma (B). 0, 1, 2, 3 represent reactivity scoring (colour intensity). FFPE: 
formaldehyde-fixed and paraffin-embedded. 
5.3.6.3. Fatty acid synthase 
Fatty acid synthase showed no IHC reactivity in both normal and malignant lung 
tissue.  
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5.3.6.4. Talin -1 
Figure 26 shows immunohistochemical reactivity of TMA cores from normal lung 
tissue (A), lung adenocarcinoma (B) and lung squamous cell carcinomas (C) to talin-
1. 0: no staining, 1: weakly stained, 2: good staining, 3: strong staining. The clinical 
information for the lung adenocarcinoma cores is B0: (IIIA, grade 2, T2N2M0), B1: 
(IIB, grade 2-3, T2N1M0), B2 (IIIA, grade x, T2N2M0), B3:( IIIA, grade 2, 
T3N1M0). The clinical information for the lung squamous cell carcinoma cores are 
C0: (IIIA, grade 2, T2N2M0), C1: (IIB, grade 2, T2N1M0), C2: (IIB grade 2, 
T3N0M0) and C3: (IIIA, grade 2, T2N2M0). The full scoring results are in appendix 
46.  
 
Figure 26: Immunohistochemical staining of FFPE-based TMA for Talin-1 (brown) 
in normal lung tissues (A), lung adenocarcinoma (B) and lung squamous cell 
carcinoma (C). 0, 1, 2, 3 represent reactivity scoring (colour intensity). FFPE: 
formaldehyde-fixed and paraffin-embedded. 
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5.4. Discussion 
In hospital histopathology laboratories, tissue specimens from lung cancer patients 
are preserved by fixation in formaldehyde, moulded in paraffin (FFPE), and sliced 
by a microtome for microscopic and immune-histochemical examination to confirm 
malignancy and determine the correct tumour type. FFPE specimens along with their 
pathology reports and clinical information are good sources for biomarker discovery 
(Paulo et al., 2012). The hundreds of thousands of FFPE specimens archived 
worldwide enable proteomic profiling of enough numbers of each lung cancer 
subtypes, which is advantageous compared to using fresh or frozen tissues samples 
collected for specific research (Werner et al., 2000).  The use of FFPE specimens 
allows high through-put validation of biomarkers as in making tissue microarrays 
(TMAs) for IHC validation of biomarkers (Casadonte and Caprioli, 2011). Despite 
the excellent preservation obtained by crosslinking proteins via methylene bridges 
formed by interaction of basic protein residues, and DNA with formaldehyde, this 
crosslinking interferes with trypsin digestion and identification of proteins, leading 
to loss of experimental reproduciblility (Azimzadeh et al., 2010). 
Here, FFPE tissue specimens were used to study tumour heterogeneity among four 
lung AD specimens by LC-MS/MS. The second aim was to compare the proteome 
signature of the FFPE lung adenocarcinoma tumour specimens with the proteome of 
the lung lavage of the same lung cancer type in order to focus on proteins that exist 
in both sample type that represent the tumour rather than the background. So, this 
discussion will cover only the proteins detected in both discovery experiments. 
LC-MS/MS analysis of the first FFPE specimen (patient #1) revealed 56 proteins 
heterogeneously elevated in all parts of tumour specimen compared to their matched 
normal lung tissue (Table 33, figure 18). Twenty-two out of these proteins were 
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found elevated also in the lavage of matched AD compared to lavage from normal 
individuals. Seven of the 56 proteins listed showed the opposite profile (low) to the 
lavage (Table 42) and the rest of 27 proteins did not detected by LC-MS/MS in the 
lavage fluid (Appendix 12). 
In contrast, 60 proteins were heterogeneously down regulated in all parts of the 
tumour tissue of patient #1 compared to the normal tissue from same patient (Table 
37, Figure 19), 25 of which were also lowered in the lavages of AD patients 
compared to the normal. Only three out of the 60 proteins did not match the lavage 
findings and thirty-three of the 60 proteins were not on the lavage list (Table 43, 
Appendix 16).  
In patient #2, 52 proteins were found heterogeneously overexpressed in lung 
adenocarcinoma tissues compared to matched normal lung tissues (Table 34, figure 
18), Fifteen out of them were matching the lavage work while Six exhibit an opposite 
profile in the lavage experiment of adenocarcinoma patients (Table 42), the rest were 
not on the lavage list (Appendix 20).  
In patient #2, 34 proteins were heterogeneously down regulated in all parts of the 
tumour tissue compared to the matched control normal lung tissue (Table 38, Figure 
19). Only four of them matched the lavage analysis of the same lung tumour type 
(AD). Twenty-two proteins exhibited the opposite pattern in the lavage (Table 43) 
and the other eight were not detected in the lavage by LC-MS/MS (Appendix 24). 
In patient #3, analysis of the lung adenocarcinoma specimen revealed that 88 proteins 
were heterogeneously elevated in the different parts of the tumour tissue (Table 35, 
Figure 18). Thirty-three of these proteins matched the lavage analysis, 11 of which 
exhibit showed the opposite pattern (Table 42) and 44 were not detected in the lavage 
(Appendix 28). On the other hand, 97 proteins were down regulated in all parts the 
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tumour specimen (Table 39, Figure 19), only 11 were matched the lavage work, 17 
exhibited a profile that was opposite to that in the lavage done on the matched tumour 
type (Table 43), and 69 were not detected in the lavage (Appendix 32).  
Comparison of the different parts of the adenocarcinoma specimen from patient #4 
showed that only five proteins were elevated in all parts of the analysed tumour 
tissue, and none of them were detected in the lavage (Table 36, Figure 18), while one 
protein showed the opposite profile in the lavage (i.e., lowered) (Appendix 36). 
In contrast, 12 proteins were down regulated in all tumour tissue parts of patient #4 
(Table 40, Figure 19), only 3 of them matched the lavage discovery work of the same 
lung tumour type, and 4 exhibited the opposite profile from that in the lavage, where 
it was elevated (Appendix 40). 
Principal component analysis (PCA) (Figure 16) and heatmap analysis (Figure 17) 
of all the differentially expressed proteins were used to show the overall 
heterogeneity among tumour tissues of the four FFPE lung adenocarcinoma samples 
used in this study. The greatest variance in proteomic signature between normal and 
malignant tissues (component 1) was seen in patient #2, where it reached 46%. The 
variance in the other tumour tissue biopsies compared to the normal tissues was 39% 
in patient #1, 35% in patient #4 and 29.7% in patient #3. The greatest variance in the 
proteomic signature among tumour parts tissues (tumour heterogeneity) was seen in 
patients #1 and #3, where it scored 23.5% and 22.7%, respectively. The variance 
between the proteomic expression signatures in the tumour tissues of patients 2 and 
4 was 16.7%. Heatmap analysis was used to visualise the shared groups of proteins 
and to cluster biopsies based on the abundance of the proteins. Such mosaic colour 
intensity would interpret the inconsistency of protein biomarkers between different 
analysed cohort samples (Figure 17).  
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Table 41 summerises the total number of significantly changed proteins detected by 
mass spectrometry per part of the tumour compared to the number of total proteins, 
using 1.2 fold change as a cut-off value. It also mentions the number of proteins 
detected in the two discovery experiments (FFPE tissues and BALF), and which of 
them had same expression profile in the two setups and which had the opposite 
profile. Tables 42 and 43 list the proteins that had a protein abundance profile in 
FFPE opposite to that in lavage. Tables 44 and 45 show the proteins that were 
elevated in FFPE and BALF as well as reduced in both specimens. For biomarker 
discovery, a better understanding of biomarkers and the factors affecting their levels, 
it is preferable to compare mass spectrometry data obtained from different types of 
body fluids and tissues and to cluster those that match and those that do not.  
Here, most mass spectrometry results showed fluctuation in the protein levels even 
among different parts of the same tumour biopsy. To demonstrate this heterogeneity 
of protein expression, four candidate proteins fulfilling the criteria for a 
biomarker panel were selected. Lactate dehydrogenase, pyruvate dehydrogenase, 
fatty acid synthase and talin-1 are excretable (GO: 0070062, Figures 20-23), exist in 
lung lavage, have a role in lung cancer, and are heterogeneously expressed in the 
FFPE tumour tissue compared to the matched normal control lung tissues.  
In cancer cells, even in the presence of oxygen, pyruvate is converted into lactate 
(Devic, 2016) by lactate dehydrogenase, which exists as isoforms A and B (Feron, 
2009). Isoform A has more affinity for pyruvate than lactate and is involved mainly 
in the conversion of pyruvate to lactate using NADH as a hydrogen ion donor 
(enzyme cofactor). This hydrogen is converted back by lactate dehydrogenase 
isoform B via hydrogen ion acceptor NAD (Valvona et al., 2016, Doherty and 
Cleveland, 2013). Lactate is toxic to the cells, but in cancer the increased production 
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of lactate is accompanied by increased expression of the facilitated proton-linked 
monocarboxylate transporters (MCTs) or symporters to shuttle lactate between 
cancer cells and the circulation, thus maintaining cell acidity (Halestrap, 2012). 
Targeting both lactate dehydrogenase A and MCTs is among the therapies based on 
the metabolism of cancer cells and are in clinical trial (Doherty and Cleveland, 2013). 
Lactate dehydrogenase A is overexpressed in many types of cancer, including gatric 
cancer (Sun et al., 2014), pancreatic cancer (Rong et al., 2013) and colorectal cancer 
(Li et al., 2016) and could be useful as a prognostic marker in these cancers.  
In this research work, lactate dehydrogenase isoform A (LDHA) was significantly 
and heterogeneously elevated in two lung adenocarcinoma samples (n:4) analysed 
three times in different part of the tumour (refer to section 2.3.1) by LC-MS/MS. The 
fold changes in the two specimens were 1.8±0.6 and 3.6 ± 1.86 (mean ± SD) (Table 
44). LDHA was also detected in one quadrant of sample #4 (fold change 1.4), but it 
was not detected significantly in the third tumour sample. In contrast, the lavage 
discovery work showed a significant elevation of LDHA in both adeno and 
squamous carcinomas, with a fold change of 3.5 and 4.3, respectively (Appendix 1 
& 3). In the same FFPE specimens mentioned above, lactate dehydrogenase isoform 
B (LDHB) showed the same pattern as isoform A, with fold changes of 1.6 ± 0.6 and 
2.2 ± 0.6, respectively (Table 44). LDHB was also found significantly elevated in 
one part of the third tumour tissue sample, with a fold change of 1.6 but it was not 
detected in the fourth sample.  LDHB was not detected in the lavage from SqCC but 
was 4.9-fold increased in lung AD lavage compared to normal control (Appendix 1). 
Therefore, lactate dehydrogenase A was chosen to confirm heterogeneous expression 
in lung SqCC and AD tissue microarrays (TMAs).  
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The IHC results obtained from lung FFPE-based tissue microarrays containing 
normal, AD and SqCC tissue cores revealed the following results (Table 46). In 
normal lung tissue (n= 47), 47.1% of the tissue cores showed no reactivity to LDHA 
(score 0) and the other 52.9% only weak reactivity (score 1) (Figure 24). On the other 
hand, in lung adenocarcinoma tissue cores (n = 28),  only 7.1% of the tissue cores 
exhibited no reactivity (score 0), 28% stained weakly (grade 1), 50% stained well 
(grade 2) and 14.2% had strong reactivity to LDHA (score 3) (Figure 24). SqCC 
showed an expression pattern smlilar to that of AD: 8% of the cores were negative, 
20.8% scored 1, 39.5% scored 2, and 31.5% scored 3 (Figure 24). However, these 
findings indicate that LDHA is overexpressed in both types of non-small cell lung 
canecr (AD & SqCC) and no correlation was found between the expression of LDHA 
and the grade or stage of the cancer. Therefore, inhibition of LDHA was thought to 
have a good therapeutic value in non-small lung caner (Xie et al., 2014).   
Transportation of pyruvate across the inner mitochondrial membrane is facilitated by 
carriers called mitochondrial pyruvate carriers (MPC) which is controlled by the 
demand/satiety principle (McCommis and Finck, 2015). For pyruvate to participate 
in the citric acid cycle, it has to be converted into acetyl Co-A by a reaction involving 
a decarboxylation reaction catalysed by pyruvate dehydrogenase complex (PDHC) 
(Holness and Sugden). Pyruvate dehydrogenase (PDH), as the main enzyme of this 
multi-enzyme complex, is positively regulated by cellular calcium influx, increased 
cellular ADP concentration, and accumulation of its substrate, pyruvate (Spriet and 
Heigenhauser, 2002). Pyruvate dehydrogenase is inhibited when it is phosphorylated 
by pyruvate dehydrogenase kinase (PDK), which is activated by increased ratio of 
NADH/NAD, and increased levels of acetyl Co-A and reactive oxygen species 
(ROS) (Hurd et al., 2012). PDK is inhibited by accumulation of pyruvate and 
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decreased NADH/NAD ratio (Holness and Sugden, 2003). The PDH/PDK pathway 
was found suppressed in approximately 75% (n = 101) of non-small lung cancer, and 
only very aggressive tumours were noticed to maintain high levels of PDH 
(Koukourakis et al., 2005).  
It has been shown that the level of PDH in gastric cancer is indirectly correlated to 
tumour progression. Therefore, its overexpression could be a good prognostic marker 
in cancer dissected patients (Sun et al., 2015). In prostate cancer, the expression of 
PDH was positive and heterogeneous by immunohistochemistry in 84% of the 
samples (n = 88), and the study revealed strong expression of the enzyme in the 
primary tumour tissue but its expression was weaker in tumours with lymph node 
metastasis (Zhong et al., 2017). However, PDH was not detected by LC-MS/MS in 
the four FFPE lung adenocarcinoma specimen examined in our work. The study 
described in chapter 3 did not reveal any PDH in lavage from both adeno and 
squamous cell carcinoma. Absence of PDH from the tissue and lavage in addition to 
the findings of Koukourakis et al. (2005) that correlated the expression of PDH to 
cancer progression in NSCLC make PDH a candidate for TMA heterogeneity 
validation (Koukourakis et al., 2005).  
Immunohistochemistry examination of PDH expression in FFPE-based tissue 
microarrays consisting of 39 SqCC and 39 AD tissue cores showed that the 
expression of pyruvate dehydrogenase was very high (score 3) in both AD (23%) 
and SqCC (30.7%). While 51% of AD cores exhibited good reactivity (score 2) to 
PDH antibody, only 23% of SqCC matched this score. More SqCC cores (35.9%) 
had a weak reactivity compared to only 15.3% in adenocarcinoma. These findings 
indicate that PDH is more overexpressed in AD (74%) compared to SqCC (53.7%), 
with a heterogeneous pattern (Table 46, Figure 25).  
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Increased rate of lipogenesis in cancer is favoured mainly by increased PI3K/AKT 
pathway signalling. This is well documented and has been reviewed in detail in 2006 
(Swinnen et al., 2006). Fatty acid synthase (FASN) is a multfuctional dimer enzyme, 
and each monomer consists of all the catalytic subunits needed for the synthesis of 
palmitate from condensation of acetyl co-A and malonyl CoA. These catalytic 
subunits are thio-esterase, acyl carrier protein, beta-ketoacyl reductase, enoyl 
reductase, beta-hydroxyacyl dehydratase, acetyl/malonyl transacylase and beta-
ketoacyl synthase. Palmitate synthesis and fatty acid synthase overexpression was 
found correlated with tumour progression, metastasis and resistance to chemotherapy 
(Ventura et al., 2015). Fatty acid synthase activity was found by 
immunohistochemistry to be strongly expressed in 42 non-small cell lung cancer 
patients (Cerne et al., 2010). In the current study, fatty acid synthase was 
significantly elevated with a heterogenous expression pattern in FFPE tumour 
tissues, where it was significantly elevated in all parts of one tumour specimen (n = 
4) with a fold change of 2.33 ± 0.28 (mean ± SD) and was increased 9.5-fold in the 
lavage collected from the same type of tumour compared to the normal individuals 
(Table 44). Fatty acid synthase was also detected significantly elevated in lung 
squamous cell carcinoma lavage compared to normal lavage (fold change 3.3). 
Unfortunately,  FASN was not detected in all lung tissue cores (n = 150) in the TMA 
in this research work, though the antibody stained the positive control cores (repeated 
twice).  
Anoikis is a form of programmed cell death activated by inappropriate cell-matrix 
interaction. When cancer cells detach from other cells, focal adhesion proteins that 
mediate interaction of actin with integrins including vimentin, paxillin and talin, are 
recruited. Talin-1 is the first protein that interacts with the cytoplasmic moiety of 
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integrin, leading to activation of the integrin signalling pathway; this favours cancer 
cell survival and proliferation, thus avoiding anoikis (Desiniotis and Kyprianou, 
2011). Immunohistochemical analysis revealed that Talin-1 was overexpressed in 
prostate cancer (n = 199) compared to normal (n = 7) and bengin hyperplasia (n = 
75), and its overexpression was correlated with lymph node metastasis and advanced 
stages of the disease (Xu et al., 2016). Talin-1 was also found elevated in 
hepatocellular carcinoma serum samples and TMAs and was associated with cancer 
progression and poor prognosis (Chen et al., 2017, Youns et al., 2013).  
Here, LC-MS/MS analysis showed that Tallin-1 was significantly elevated in one 
FFPE lung adenocarcinoma specimen (n = 4) with a fold change of 2.1 ± 0.4 (mean 
± SD).  Talin-1 was not detected in the other three samples. Interestingly, Tallin-1 
was significantly low in the lavage from lung adenocarcinoma patients compared to 
normal controls (fold change 3.5). On the other hand, mass spectrometry did not 
detect Talin-1 in the lavage from squamous cell carcinomas. Therefore, Talin-1 was 
selected for tissue microarrays validation, and the results revealed no significant 
differences between normal and malignant tumour cores. The percentage of lung 
tissue cores that had negative reactivity (score 0) to Talin-1 was 27.7% (n = 18) in 
normal tissues, 17% (n = 46) in SqCC, and 3.3% (n = 30) in AD. The percentage of 
cores exhibiting weak reactivity (score 1) was 50% (n = 18) in normal control, 56.5% 
(n = 46) in SqCC, and 50% (n = 30) in AD. The percentage of tissue cores exhibiting 
good reactivity to Talin-1 (score 2) was 11% in normal tissue cores, 23.9% in SqCC 
cores, and 40% in AD cores. Strong activity (score 3) was seen in 11% of normal 
tissue cores, 2% in SqCC cores, and 6.6% in AD cores. In summary, both normal 
and malignant lung tissues exhibited heterogeneous expression of Talin-1, and core 
reactivity was higher in lung AD than in SqCC and normal tissue cores. The tumour 
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stage and grade did not correlate with protein expression level (Table 46, Figure 26). 
These findings support the heterogeneous expression pattern of proteins in tumour 
tissue.    
The disadvantages of using protein biomarkers in clinical diagnosis of cancer have 
been demonstrated (Hara et al., 2008). The clinical use of protein biomarkers is 
currently restricted to multiple reaction monitoring (MRM) of treatment in order to 
minimize patient exposure to the low-dose x-rays in CT-scans or to radionuclides in 
PET-scans (Table 2, Figure 5) (Crutchfield et al., 2016, Holdenrieder et al., 2016). 
Our study demonstrates the difficulty of using protein biomarkers in the diagnosis of 
cancer, at least for lung cancer. Our results also apply a big precaution in using 
biomarkers for MRM principle because based on the TMA analysis the expression 
of proteins might not correlate to the stage and grade of the cancer. However, it is 
very important to study protein biomarker expression patterns for specific tumour 
types at different stages and grades, and to monitor the expression of proteins 
correlated with tumour type, as many proteins are affected by the expression of 
others.  
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6. Cell cycle biomarkers in cancer 
6.1. Introduction 
The high rate of cancer cell proliferation requires increased rates of transcription and 
translation of the genes responsible for cell survival, growth and proliferation, as 
well as more rapid production of the building blocks required for making new 
cells. In the nucleus, about one meter of negatively charged double-stranded 
DNA is zipped and packaged around positively charged histone proteins in structures 
called nucleosomes (Mariño-Ramírez et al., 2005). Histone-acetyl transferase family 
members HATs (PCAF, GCN5L2 and CBP/P300) and their counteracting partner, 
the histone-deacetylases (HDACs) including HDACs 1, 2, 3, 4, 5 and 13, are the 
main proteins controlling the dynamicity of histone-DNA zip-unzip states and 
transcription (Hassig and Schreiber, 1997). Histone acetylation/deacetylation 
dynamics is tightly connected with cell cycle progression, CREB-binding protein 
(CBP) is activated by phosphorylation of cyclin E/CDK2 (Ait-Si-Ali et al., 1998). 
Once transcription factors are activated and localized in the nucleus, they bring with 
them HAT as part of the transcription complex, acetyl groups (negatively charged) 
added to the histone lysine residues facilitate release of DNA and facilitate access of 
the transcription factors to their promotors (Marmorstein and Roth, 2001).  The 
cell cycle is controlled by cyclin-dependent kinases, activation of which involves 
binding to cell-cycle specific cyclins (As, Bs, Ds, Es, Hs), which unmask the ATP-
binding domains, leading to phosphorylation and activation of CDKs by CDK-
activating kinase (CAK) (Lolli and Johnson, 2005). In cancer, acceleration of the cell 
cycle requires availability of excess activated (phosphorylated) CDKs. Increased 
phosphorylation rates in cancer due to gene amplification or gain of function of 
protein kinases result in specific and non-specific downstream signalling that 
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leads to activation of  many transcription factors and increased abundance 
of different proteins (Mariño-Ramírez et al., 2005, Gruber et al., 2017). 
The NFKB transcription factor plays a role in inflammation, cell survival and 
proliferation. Phosphorylation of the inhibitory protein (IKK) that binds and 
sequesters NFKB in the cytoplasm (Whiteside et al., 1997) leads to release of NFKB 
and its proteasomal degradation, dimerization and translocation of its active forms to 
the nucleus (Liou and Baltimore, 1993). Increased proteasomal processing and 
degradation of NFKB in cancer leads to elevation of its active products (P50 and P52) 
and Rel-A, C-Rel, Rel B proteins, leading to alteration of cell functions. Cancer cells 
also need to evade apoptosis (programmed cell death) and counteract the effect of 
tumour suppressor genes. 14-3-3 protein has several tissue-specific 
isoforms that bind and regulate the proteins involved in cell cycle, apoptosis, and the 
net function of these adapter proteins is to stop cell proliferation and favour P53-
mediated cell death. Release of cytochrome c from mitochondria is needed to 
activate the caspase cascade, which is crucial to promote apoptosis via the main P53 
pathway. Abundance and activation of BAX, also called Bcl-2 associated X large 
protein, favours the release of cytochrome c (Finucane et al., 1999) On the other 
hand, BCL-XL inhibits the release of cytochrome c and enhances cell proliferation 
(Janumyan et al., 2003). Cancer results from imbalance between oncogenes and 
tumour suppressor genes (TSG). The products of these genes and the post-translation 
modifications that regulate their function are somehow manipulated so 
that oncogenic genes predominate over TSG. Proteins regulating the 
cell cycle are valuable in the diagnosis of cancer because they are required to favour 
the rate of cell division. AKT/PB is the main operator of the downstream activation 
of the cell cycle, cell proliferation rate and cell survival in cancer; upstream 
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inhibition of this AKT/PB decreases the rate of cell proliferation (Wanzel et al., 
2005). GDC-0980 is a small molecule that inhibits both phosphatidylinocytol-3-
kinase (PI3K) and mammalian target of rapamycin (m-TOR). This inhibitor directly 
affects the progression of the cell cycle through downstream regulation (Kandel et 
al., 2002). Many cell cycle controlling proteins, such as P21, are down 
regulated in non-small cell lung cancer. Downregulation of P21 is indirectly 
proportional to patient survival in lung cancer (Esposito et al., 2004). 
This chapter describes in detail the development of resistance to GDC-0980 in A549 
and mainly in H1975 lung adenocarcinoma and how it affects the abundance of cell 
cycle derived biomarkers. The effect of the inhibitor on the expression of such 
markers in the resistant cells studied, and extrapolation of biomarkers that can 
indicate development of tumour resistance to a drug are also stressed.     
6.2. Experimental design 
Building on the work described in chapters 3-5, biomarker discovery focused on 
proteins controlling the cell cycle and energy provision. The variability 
in the abundance of these proteins shown in chapter four is attributable to the 
complex crosstalk between the signalling pathways controlling the expression 
of these proteins. The pathways are affected by the use of drugs which directly or 
indirectly affect their function, so this would have a direct impact on the expression 
of downstream transcription of such proteins. In this chapter, the cell cycle profile 
of two lung adenocarcinoma cell lines (H1975 and A549) was read using Cytell® 
cell imaging system. The development of cellular resistance to GDC-0980 
PI3K/AKT dual inhibitor was studied in sensitive and resistant cells. To avoid false 
negative or false positive findings due to the drug itself, the cell cycle of the resistant 
cells was studied in (R+) and out (R-) of the drug. This was followed by detailed 
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western blot  scanning of the proteins controlling cell cycle progression, including 
P53, P21, PCNA, cyclins, HDACs/HATs, NFKB and indirect regulatory adaptor 
proteins belonging to the 14-3-3 family. KEGG pathway analysis was performed on 
the mass spectrometry significantly up and down regulated proteins as categorized 
by KEGG to have a role in cell cycle control.  
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6.3. Results 
6.3.1. H1975 growth curve. 
Figure 27 shows the high proliferation rate of the non-treated (R-) GDC-0980 
resistant H1975 cells (B) compared with the sensitive cells (A). Shown also is a 
profound collapse of the proliferation rate when the GDC-0980 resistant H1975 cells 
were grown in medium containing 1 µM GDC-0980 (C). 
 
 
                                                                  Time (Hours) 
 
Figure 27: Growth curves of GDC-0980 sensitive P (A), resistant non-treated (B) 
and resistant  treated R+ cells (C). The five OD points (Y- axis) represent consecutive 
five-day measurements of proliferation rate and the X- axis represents the time 
interval in hours between  measurements. 
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6.3.2. Mass spectrometry analysis of cell cycle control proteins. 
6.3.2.1. List of significantly upregulated proteins in the GDC-0980 resistant 
H1975 compared to drug sensitive cells. 
Tables 47 and 48 list the proteins found significantly elevated by LC-MS/MS in the 
treated resistant H1975 cells (R+) and non-treated cells (R-) compared to the parent 
cells (P).  
 
Table 47: Cell cycle regulatory proteins found by mass spectrometry significantly 
elevated in resistant cells (R+) compared with parent cells  
 
P/C: peptide count, P/C*: specific peptide count, C/S: confidence score, FC: fold 
change. 
 
 
 
 
 
 
 
 
Accession P/C P/C* C/S p. value FC Description
O43684 3 3 22 3.E-04 3 Mitotic checkpoint protein BUB3 
O43929 1 1 5 5.E-04 3.2 Origin recognition complex subunit 4 
P04637 4 4 32 1.E-07 8.2 Cellular tumor antigen p53 
P06493 2 2 14 1.E-08 4.3 Cyclin-dependent kinase 1 
P14635 1 1 3 2.E-02 2 G2/mitotic-specific cyclin-B1 
P25205 2 2 7 6.E-08 7.2 DNA replication licensing factor MCM3 
P33991 11 11 51 1.E-07 4.4 DNA replication licensing factor MCM4 
P33992 4 4 12 1.E-09 7.9 DNA replication licensing factor MCM5 
P33993 11 11 45 5.E-09 7.2 DNA replication licensing factor MCM7 
P49736 6 6 22 9.E-03 1.8 DNA replication licensing factor MCM2 
P49841 1 1 4 8.E-06 4.6 Glycogen synthase kinase-3 beta 
P61812 1 1 5 4.E-03 15.6 Transforming growth factor ß-2 
P62258 2 2 6 1.E-06 1.3 14-3-3 protein epsilon 
P62877 1 1 5 3.E-03 4.5 E3 ubiquitin-protein ligase RBX1 
P78527 50 49 238 8.E-05 3.9 DNA-dependent protein kinase catalytic subunit 
Q13257 1 1 4 9.E-03 3.9 Mitotic spindle assembly checkpoint protein MAD2A
Q13315 2 2 9 5.E-06 10.2 Serine-protein kinase ATM 
Q13547 3 3 9 2.E-07 10.1 Histone deacetylase 1 
Q13616 4 4 14 2.E-05 2.7 Cullin-1 
Q14566 6 6 27 6.E-06 3.5 DNA replication licensing factor MCM6 
Q8N3U4 6 6 25 7.E-03 1.7 Cohesin subunit SA-2 
Q92793 1 1 4 3.E-03 13.4 CREB-binding protein 
Q9UQE7 4 4 15 9.E-09 5.1 Structural maintenance of chromosomes Protein 3
Q9Y6D9 1 1 8 3.E-06 10.9 Mitotic spindle assembly checkpoint protein MAD1
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Table 48: Cell cycle regulating proteins found significantly elevated by mass 
spectrometry in the resistant cells (R-) compared with parent cells (P). 
 
P/C: peptide count, P/C*: specific peptide count, C/S: confidence score, FC: fold 
change. 
 
 
 
6.3.2.2. Significantly downregulated proteins in the GDC-0980 resistant H1975 
compared to drug sensitive cells. 
Table 49 and 50 list the proteins that were found significantly downregulated by LC-
MS/MS in the treated GDC-0980 resistant H1975 cells (R+) and non-treated cells 
(R-) compared to the sensitive parent cells, respectively.  
 
Table 49: Cell cycle regulatory proteins found significantly down regulated by 
mass spectrometry in resistant cells (R+) compared with parent cells (P).  
 
P/C: peptide count, P/C*: specific peptide count, C/S: confidence score, FC: fold 
change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accession P/C P/C* C/S p. value FC Description
P11802 1 1 3 3.E-04 2.8 Cyclin-dependent kinase 4 
P49841 1 1 4 9.E-06 3.6 Glycogen synthase kinase-3 beta 
P61812 1 1 5 2.E-02 4.7 Transforming growth factor beta-2 
P62258 2 2 6 3.E-06 1.6 14-3-3 protein epsilon 
P62877 1 1 5 1.E-02 2.9 E3 ubiquitin-protein ligase RBX1 
P78527 50 49 238 3.E-03 2 DNA-dependent protein kinase catalytic subunit 
Q00534 1 1 5 1.E-04 8.1 Cyclin-dependent kinase 6 
Q13315 2 2 9 3.E-04 3.2 Serine-protein kinase ATM 
Q13547 3 3 9 3.E-04 4.6 Histone deacetylase 1 
Q9UQE7 4 4 15 9.E-04 1.8 Structural maintenance of chromosomes protein 3 
Q9Y6D9 1 1 8 9.E-03 2.8 Mitotic spindle assembly checkpoint protein MAD1 
Accession P/C P/C* C/S p. value FC Description
P12004 1 1 4 9.E-03 1.5 Proliferating cell nuclear antigen 
P61981 1 1 5 8.E-04 1.8 14-3-3 protein gamma 
P63104 4 4 23 2.E-06 1.8 14-3-3 protein zeta/delta 
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Table 50: Cell cycle regulatory proteins found significantly down regulated by 
mass spectrometry in the resistant cells (R-) compared with parent cells (P).  
 
P/C: peptide count, P/C*: specific peptide count, C/S: confidence score, FC: fold 
change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accession P/C P/C* C/S p. value FC Description
P31946 2 1 17 8.E-03 1.5 14-3-3 protein beta/alpha 
P63104 4 4 23 3.E-05 1.6 14-3-3 protein zeta/delta 
Q53H82 3 3 13 4.E-11 19.4 Beta-lactamase-like protein 2 
P06493 2 2 14 9.E-03 1.4 Cyclin-dependent kinase 1 
P49736 6 6 22 5.E-03 2.8 DNA replication licensing factor MCM2 
O60216 2 2 6 3.E-02 1.5 Double-strand-break repair protein rad21 homolog 
P14635 1 1 3 2.E-02 1.8 G2/mitotic-specific cyclin-B1 
Q13416 1 1 3 3.E-04 3.1 Origin recognition complex subunit 2 
O43913 2 2 8 6.E-09 2.2 Origin recognition complex subunit 5
Q14683 3 2 11 2.E-07 2.2 Structural maintenance of chromosomes protein 1A 
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6.3.3. Cell cycle profile  
6.3.3.1. H1975 and A549 cell cycle profile of GDC-0980 parent and resistant 
cells. 
Cyell® Cell Imaging Sysem (GE Healthcare Life Sciences) was used to read the 
cell cycle profile of GDC-0980 sensitive H1975P cells, the cell cycle profile of 
GDC-0980 resistant H1975 cells incubated with GDC-0980 (H1975GR+), and the 
effect of GDC-0980 withdrawal (two weeks in drug-free medium) on the cell cycle 
profile of the GDC-0980 resistant H1975 cells (H1975GR-). The lower three graphs 
show the cell cycle profile of GDC-0980 sensitive A549P cells, the cell cycle profile 
of GDC-0980 resistant A549 cells under GDC-0980 incubation A549R+ and the 
effect of GDC-0980 withdrawal (2 weeks in GDC-0980 free medium) on the cell 
cycle profile of the GDC-0980 resistant A549R- cells (figure 28). 
 
Figure 28: Cell cycle profile of GDC-0980 sensitive parent (P) and resistant (R) 
H1975 cells and A549 adenocarcinoma cells. [-]: resistant cells cultured without 
drug and [+]: resistant cells cultured with GDC-0980 (1 µM for H1975 and 3.34 
µM for A549). 
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6.3.3.2. Effect of GDC-0980 on the cell cycle phases in A549 and H1975 cells 
In the resistant H1975 cells, Cytell® showed a decreased number of cells attending 
G1 phase by 80% (p<0.0001) leading to accumulation of cells in S (p<0.0001) and 
G2/M (p<0.0001) phases in both treated (R+) and non-treated (R-) cells (no reversal 
of GDC-0980 effect up on drug withdrawal for 5 passages, G0/G1 p=0.5, S p=0.19, 
G2/M p=0.27). In contrast, in A549 cells, GDC-0980 caused accumulation of cells 
in G1 phase  and a profound (p<0.0001) decrease of cells attending S (p<0.0001) 
and G2/M (p<0.0001) phases. The effect of GDC-0980 on the cell cycle profile of 
GDC-0980 resistant A549 cells was reversible when the drug was withdrawn from 
the medium for two weeks (p<0.0001 in all cell phases) (figure 29).  
 
 
Figure 29: Comparison of cell cycle phases of GDC-0980 sensitive parent (P) and 
resistant (R) H1975 and A549 adenocarcinoma cells. [-]: resistant cells cultured 
without drug and [+]: resistant cells cultured with drug (1µM and 3.34µM final 
concentration for H1975 and A549 respectively).  
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6.3.3.3. Histone 3 confirmation of cell cycle arrest at G1 phase in A549 
resistant cells 
Shown in figure 30 is a western blot comparing histone 3 abundance in GDC-0980 
sensitive cells compared to resistant A549 lung adenocarcinoma cells in the 
presence (R+) and absence (R-) of the drug. H3 was significantly lowered in both 
treated (B) and non-treated (A) resistant cells compared to the parent cells. The p-
values for the differences were 0.01 and 0.003 in R+ and R- cells, respectively. 
 
 
Figure 30: Immunoblotting comparison of histone 3 (H3) levels in GDC-0980 
sensitive parent (P) and resistant (R) A549 lung adenocarcinoma cells. P1, P2, P3 
and R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: resistant cells 
cultured without drug and [+]: resistant cells cultured in F12 medium containing 
3.34 µM GDC-0980. Shown in this figure is a scatter plot representing the 20 µg 
content of H3 measured by ImageJ and represented as triplicates per phenotype (C 
and D). 
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6.3.3.4. Histone 3 levels confirmation of cell cycle arrest at G2/M in H1975 
resistant cells  
Figure 31 shows a comparative western blot of histone 3 abundance in GDC-0980 
sensitive and GDC-0980 resistant H1975 lung adenocarcinoma cells incubated with 
(R+) or without (R-) the drug. H3 was overexpressed in both treated (B) and non-
treated (A) resistant cells compared to the parent cells (p= 0.08 in both R+ and R- 
cells, respectively). HDAC I and PCNA proteins were used as a loading control 
when (R-) and (R+) were compared to the parent cells, respectively (refer to section 
2.4.6.6). 
      
Figure 31: western blot comparison of histone 3 (H3) protein abundance levels in 
GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, 
P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total protein. [-
]: resistant cells cultured without drug and [+]: resistant cells cultured in RPMI 
medium containing 1µM GDC-0980. Shown also is a scatter plot of the ECL-
chemilescence signal, normalized for the loading control, measured by ImageJ and 
represented as a H3 to loading control ratio (C and D).  
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6.3.3.5. Histone 3 co-localization 
6.3.3.5.1. H1975 parent cells 
 
Figure 32 shows DAPI staining of DNA of H1975 cells (A), histone 3 (B), and cells 
visualised by light transmission (C). Histone 3 is localised in the nucleus (D), where 
the overlap area between DAPI and Alexafluor-488 was 0.89.    
 
                                 
 
Figure 32: Nuclear histone 3 localisation. (P): GDC-0980 parent sensitive cells. 
(A) DAPI DNA visualisation, (B) AlexaFluor-488 coupled anti-H3 monoclonal 
antibody, (C) adherent cells seen under light microscopy, (D) localisation of H3 
using DAPI/Alexa-Fluor signals. 
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6.3.3.5.2. H1975 resistant cells (R-) 
 
Figure 33 shows DAPI staining of H1975 cells’ DNA (A), histone 3 (B), and cells 
visualized using light transmission (C). Histone 3 was localised in the nucleus (D) 
where the overlap area between DAPI and Alexafluor-488 was 0.92.    
 
 
 
 
Figure 33: Nuclear histone 3 localisation. (R-): GDC-0980 resistant H1975 cells 
grown in GDC-0980 free media. (A) DAPI DNA visualisation, (B) AlexaFluor-488 
coupled anti-H3 monoclonal antibody, (C) adherent cells seen under light 
microscopy, (D) localisation of H3 using DAPI/Alexa-Fluor signals. 
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6.3.3.5.3. H1975 resistant cells (R+) 
 
Figure 34 shows DAPI staining of GDC-0980 resistant H1975 (R+) DNA (A), 
nuclear histone 3 (B), and cells visualised by light transmission (C). Histone 3 is 
localised in the nucleus (D), where the overlap area between DAPI and Alexafluor-
488 was 0.94.    
 
 
 
 
 Figure 34: Nuclear histone 3 localisation. (R+): GDC-0980 resistant H1975 cells 
grown inmedia containing 1 µM GDC-0980.  (A) DAPI DNA visualisation, (B) 
AlexaFluor-488 coupled anti-H3 monoclonal antibody, (C) adherent cells seen 
under light microscopy, (D) localisation of H3 using DAPI/Alexa-Fluor signals. 
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6.3.3.6. H1975 Cyclins profile 
6.3.3.6.1. Cyclin D1 
Figure 35 shows a western blot comparing cyclin D1 in GDC-0980 sensitive and 
resistant H1975 lung adenocarcinoma cells with (R+) (B/D) and without (R-) (A/C) 
drug treatment. The abundance of Cyclin D1 was significantly lowered in both 
treated and non-treated resistant cells compared to the parent cells. (p= 0.001 and 
0.0003 in R+ and R- cells, respectively). HDAC I and PCNA proteins were used as 
a loading control when (R-) and (R+) were compared to the parent cells, 
respectively (refer to section 2.4.6.6). 
 
                
 
Figure 35: Comparison of cyclin D1 abundance in GDC-0980 sensitive parent (P) 
cells and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3, and R1, R2, R3 
represent triplicates of 20 µg of total cell protein. [-]: resistant cells cultured without 
drug and [+]: resistant cells cultured in the presence of 1 µM GDC-0980. Shown 
also is a scatter plot of the ECL-chemilescence signal, normalized for the loading 
control, measured by ImageJ and represented as a Cyclin D1 to loading control ratio 
(C and D).  
 
 
193 
6.3.3.6.2. Cyclin D3 
 
Figure 36 shows a western blot comparison of Cyclin D3 abundance in GDC-0980 
sensitive and resistant H1975 lung adenocarcinoma cells with (R+) and without (R-
) drug treatment. The abundance of Cyclin D3 tended to increase in both treated 
(R+) (B) and non-treated cells (R-) (A) compared to the parent cells, but the changes 
were not statistically significant (p= 0.26 and 0.20 in treated and non-treated cells, 
respectively) (C and D). HDAC I and PCNA proteins were used as a loading control 
when (R-) and (R+) were compared to the parent cells, respectively (refer to section 
2.4.6.6). 
                
Figure 36: Comparison of cyclin D3 abundance in GDC-0980 sensitive parent (P) 
and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 
represent triplicates of 20 µg of total cell protein. [-]: resistant cells cultured 
without drug and [+]: resistant cells cultured in the presence of 1 µM GDC-0980. 
Shown also is a scatter plot of the ECL-chemilescence signal, normalized for the 
loading control, measured by ImageJ and represented as a Cyclin D3 to loading 
control ratio (C and D).  
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6.3.3.6.3. Cyclin A2 
 
Shown in figure 37 is a western blot comparison of Cyclin A2 expression levels in 
GDC-0980 sensitive and GDC-0980 resistant H1975 lung adenocarcinoma cells 
with (R+) and without (R-) the drug treatment. Cyclin A2 was significantly 
downregulated in both treated cells (R+) (B) and non-treated resistant cells (R-) (A) 
compared to the parent cells (p= 0.0007 and  0.001 in treated and non-treated cells, 
respectively) (C and D). HDAC I and PCNA proteins were used as a loading control 
when (R-) and (R+) were compared to the parent cells, respectively (refer to section 
2.4.6.6). 
 
 
 
Figure 37: Western blotting comparison of cyclin A2 protein abundance in GDC-
0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, 
P3 and R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: resistant 
cells cultured without drug and [+]: resistant cells cultured in the presence of 1 
µM GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
Cyclin A2 to loading control ratio (C and D).  
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6.3.3.6.4. Cyclin B1 
 
Shown in figure 38 is a western blot comparing Cyclin B1 abundance in GDC-0980 
sensitive and GDC-0980 resistant H1975 lung adenocarcinoma cells with (R+) and 
without (R-) drug treatment. Cyclin B1 was significantly downregulated in both 
treated (R+) (B) and non-treated (R-) resistant cells (A) compared to the parent 
cells. The p-value of the dysregulation was 0.0009 and 0.002 in treated and non-
treated cells, respectively (C and D). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6). 
 
 
Figure 38: Comparison of cyclin B1 abundance in GDC-0980 sensitive parent (P) 
and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent 
triplicates of 20 µg of total cell protein. [-]: resistant cells cultured without drug and 
[+]: resistant cells cultured in the presence of 1 µM GDC-0980. Shown also is a 
scatter plot of the ECL-chemilescence signal, normalized for the loading control, 
measured by ImageJ and represented as a Cyclin B1 to loading control ratio (C and 
D).  
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6.3.3.6.5. Cyclin H 
 
Shown in figure 39 is a western blot of Cyclin H abundance in GDC-0980 sensitive 
and GDC-0980 resistant H1975 lung adenocarcinoma cells treated (R+) or not 
treated (R-) with the drug. Cyclin H was significantly downregulated in both treated 
(R+) (B) and non-treated (R-) (A) resistant cells compared to the parent cells. P 
values were; 0.001 and 0.07 when treated and non-treated resistant cells were 
compared with the parent cells, respectively (C and D). HDAC I and PCNA proteins 
were used as a loading control when (R-) and (R+) were compared to the parent 
cells, respectively (refer to section 2.4.6.6). 
 
 
Figure 39: Comparison of cyclin H abundance in GDC-0980 sensitive parent (P) 
and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 
represent triplicates of 20 µg of total cell protein. [-]: resistant cells cultured 
without drug and [+]: resistant cells cultured in the presence of 1 µM GDC-0980. 
Shown also is a scatter plot of the ECL-chemilescence signal, normalized for the 
loading control, measured by ImageJ and represented as a Cyclin H to loading 
control ratio (C and D).  
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6.3.3.6.6. Cyclin dependent kinase VI 
 
Shown in figure 40 is a western blot comparing cyclin-dependent kinase 6 (CDK6) 
abundance in GDC-0980 sensitive and GDC-0980 resistant H1975 lung 
adenocarcinoma cells with (R+) and without (R-) drug treatment. CDK6 was 
significantly lowered in both treated and non-treated resistant cells compared to the 
parent cells. P values were; 0.005 and 0.0007 for treated and non-treated resistant 
cells, respectively, compared with parent cells (C and D). HDAC I and PCNA 
proteins were used as a loading control when (R-) and (R+) were compared to the 
parent cells, respectively (refer to section 2.4.6.6). 
 
 
 
Figure 40: Comparison of cyclin dependent kinase 6 protein (CDK6) abundance in 
GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, 
P2, P3 and R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: 
resistant cells cultured without drug and [+]: resistant cells cultured in the 
presence of 1 µM GDC-0980. Shown also is a scatter plot of the ECL-
chemilescence signal, normalized for the loading control, measured by ImageJ and 
represented as a CDK6 to loading control ratio (C and D).  
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6.3.4. Proteins that affecting cell cycle progression 
6.3.4.1. P53 tumour suppressant gene 
Figure 41 shows a western blot comparison of P53 abundance in GDC-0980 
sensitive and GDC-0980 resistant H1975 lung adenocarcinoma cells with (R+) (B) 
and without (R-) (A) drug treatment. P53 was significantly overexpressed in both 
treated and non-treated resistant cells compared to the parent cells. P= 0.0004 and 
<0.0001 when treated and non-treated resistant cells were compared with the parent 
cells, respectively (C and D). HDAC I and PCNA proteins were used as a loading 
control when (R-) and (R+) were compared to the parent cells, respectively (refer 
to section 2.4.6.6).  
 
                       
 
Figure 41: Comparison of P53 levels in GDC-0980 sensitive parent (P) and resistant 
H1975 lung adenocarcinoma cells. (A): no drug treatment and (R-)(B) when cells 
were incubated in medium containing 1 µM GDC-0980 (R+). P1, P2, P3 and R1, R2, 
R3 represent triplicates of 20 µg of total cell protein. Shown also is a scatter plot of 
the ECL-chemilescence signal, normalized for the loading control, measured by 
ImageJ and represented as a P53 to loading control ratio (C and D).  
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6.3.4.2. The adapter proteins (14-3-3) 
6.3.4.2.1.  Zeta/delta isoform 
 
Figure 42 shows a western blot comparison of 14.3.3 zeta/delta [ζ/𝛅] abundance in 
GDC-0980 sensitive compared to GDC-0980 resistant H1975 lung adenocarcinoma 
cells with (R+) (B) and without (R-) drug treatment (A). 14.3.3 zeta/delta [ζ/𝛅] was 
significantly overexpressed in R- and downregulated in R+ compared to the parent 
cells. P values were 0.002 and 0.004, respectively (C and D). HDAC I and PCNA 
proteins were used as a loading control when (R-) and (R+) were compared to the 
parent cells, respectively (refer to section 2.4.6.6). 
 
                   
 
Figure 42: Comparison of 14.3.3 zeta/delta (ζ/𝛅) protein abundance in GDC-0980 
sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and 
R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: resistant cells 
cultured without drug and [+]: resistant cells cultured in the presence of 1 µM GDC-
0980. Shown also is a scatter plot of the ECL-chemilescence signal, normalized for 
the loading control, measured by ImageJ and represented as a 14.3.3 zeta/delta to 
loading control ratio (C and D).  
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6.3.4.2.2. Epsilon isoform 
 
Figure 43 shows a western blot comparison of 14.3.3 epsilon (ℇ) abundance in 
GDC-0980 sensitive compared to GDC-0980 resistant H1975 lung adenocarcinoma 
cells with (R+) (B) and without (R-) (A) drug treatment. 14.3.3 ℇ was significantly 
overexpressed in non-treated (R-) cells (p= 0.001) and downregulated in treated 
(R+) cells (p= 0.0001) (C and D). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6). 
 
 
 
Figure 43: Comparison of 14.3.3 epsilon (ℇ) protein abundance in GDC-0980 
sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and 
R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: resistant cells 
cultured without drug and [+]: resistant cells cultured in the presence of 1 µM 
GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
14.3.3 epsilon to loading control ratio (C and D).  
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6.3.4.2.3. 14.33. gamma isoform (ȣ) 
Figure 44 shows a western blot comparison of 14.3.3 gamma (ȣ) abundance in 
GDC-0980 sensitive compared to GDC-0980 resistant H1975 lung adenocarcinoma 
cells with (R+) (B) and without (R-) (A) drug treatment. 14.3.3 ȣ isoform was 
significantly down regulated in both treated (B) and non-treated (A) resistant cells 
compared to the parent cells (p=  0.01 in both comparison) (C and D). HDAC I and 
PCNA proteins were used as a loading control when (R-) and (R+) were compared 
to the parent cells, respectively (refer to section 2.4.6.6). 
 
 
Figure 44: Comparison of 14.3.3 gamma [ȣ] protein abundance in GDC-0980 
sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and 
R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: resistant cells 
cultured without drug and [+]: resistant cells cultured in the presence of 1 µM 
GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
14.3.3 gamma to loading control ratio (C and D).  
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6.3.4.2.4. 14.3.3. alpha/beta isoform (14.3.3α/β) 
Figure 45 shows a western blot comparison of 14.3.3 α/β levels in GDC-0980 
sensitive H1975 lung adenocarcinoma cells when compared with the resistant cells 
with (R+) (B) and without (R-) (A) drug treatment. 14.3.3α/β isoform was 
significantly upregulated in (R-) (p= 0.0006) and downregulated in (R+) (p= 
0.0003) compared with the parent cells (C and D). HDAC I and PCNA proteins 
were used as a loading control when (R-) and (R+) were compared to the parent 
cells, respectively (refer to section 2.4.6.6).  
 
 
 
Figure 45: Comparison of 14.3.3 alpha/beta protein abundance levels in GDC-
0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, 
P3 and R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: resistant 
cells cultured without drug and [+]: resistant cells cultured in the presence of 1 
µM GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
14.3.3 α/β to loading control ratio (C and D).  
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6.3.4.3. P21 regulatory protein 
Figure 46 shows a western blot comparison of p21 abundance in GDC-0980 
sensitive compared to GDC-0980 resistant H1975 lung adenocarcinoma cells with 
(R+) and without (R-) drug treatment. p21 was significantly down regulated in both 
treated (B) and non-treated (A) resistant cells compared to the parent cells. P 
<0.0001 in both treated (R+) and non-treated (R-) cells, respectively (C and D). 
HDAC I and PCNA proteins were used as a loading control when (R-) and (R+) 
were compared to the parent cells, respectively (refer to section 2.4.6.6). 
 
 
 
Figure 46: Comparison of p21 protein abundance in GDC-0980 sensitive parent 
(P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 
represent triplicates of 20 µg of total cell protein. [-]: resistant cells cultured 
without drug and [+]: resistant cells cultured in the presence of 1 µM GDC-0980. 
Shown also is a scatter plot of the ECL-chemilescence signal, normalized for the 
loading control, measured by ImageJ and represented as a p21 to loading control 
ratio (C and D).  
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6.3.4.4. Proliferating cells nuclear antigen [PCNA] 
Figure 47 shows a western blot comparison of PCNA abundance in GDC-0980 
sensitive compared to GDC-0980 resistant H1975 lung adenocarcinoma cells 
grown with (R+) or without (R-) the drug. The abundance of PCNA was 
significantly (p= 0.01) downregulated in the non-treated cells (R-) (A) and 
upregulated (p=>0.99) in the treated cells (R+) (B) compared to the parent cells (C 
and D). HDAC I and PCNA proteins were used as a loading control when (R-) and 
(R+) were compared to the parent cells, respectively (refer to section 2.4.6.6). 
 
 
 
Figure 47: Comparison of Proliferating cells nuclear antigen (PCNA) abundance 
in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. 
P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: 
resistant cells cultured without drug and [+]: resistant cells cultured in the 
presence of 1 µM GDC-0980. Shown also is a scatter plot of the ECL-
chemilescence signal, normalized for the loading control, measured by ImageJ and 
represented as a PCNA to loading control ratio (C and D).  
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6.3.4.5. Ubiquitination levels of PCNA (Ub-PCNA) 
Figure 48 shows a western blot comparison of Ub-PCNA levels in GDC-0980 
sensitive compared to GDC-0980 resistant H1975 lung adenocarcinoma cells with 
(R+) (B) or without (R-) (A) the drug. PCNA ubiquitination was significantly 
downregulated (p= 0.004) in R+. The decrease in the non-treated cells (R-) was not 
significant (p= 0.29) (C and D). HDAC I and PCNA proteins were used as a loading 
control when (R-) and (R+) were compared to the parent cells, respectively (refer 
to section 2.4.6.6). 
 
 
 
Figure 48: Comparison of the ubiquitination level of PCNA (Ub-PCNA) protein 
abundance levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 
adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of 
total cell protein. [-]: resistant cells cultured without drug and [+]: resistant cells 
cultured in the presence of 1 µM GDC-0980. Shown also is a scatter plot of the 
ECL-chemilescence signal, normalized for the loading control, measured by 
ImageJ and represented as a Ub-PCNA to loading control ratio (C and D).  
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6.3.4.6. Bcl-associated X protein [BAX] 
Figure 49 shows a western blot comparison of BAX abundance in GDC-0980 
sensitive and GDC-0980 resistant H1975 lung adenocarcinoma cells with (R+) (B) 
or without (R-) (A) drug treatment. BAX was significantly down regulated in the 
non-treated (R-) cells compared with the parent cells (P= 0.0006) and its expression 
was elevated in the treated cells (R+) (P= 0.5) (C and D). HDAC I and PCNA 
proteins were used as a loading control when (R-) and (R+) were compared to the 
parent cells, respectively (refer to section 2.4.6.6). 
  
 
 
Figure 49: Comparison of Bcl-associated X large protein (BAX) abundance in 
GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, 
P2, P3 and R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: 
resistant cells cultured without drug and [+]: resistant cells cultured in the 
presence of 1 µM GDC-0980. Shown also is a scatter plot of the ECL-
chemilescence signal, normalized for the loading control, measured by ImageJ and 
represented as a BAX to loading control ratio (C and D).  
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6.3.4.7. B-cell lymphoma extra-large [BCL-XL] 
Shown in figure 50 is a western blot of BCL-XL expression levels in GDC-0980 
resistant cells with (R+) or without (R-) drug treatment compared to sensitive cells 
(P). The levels were significantly upregulated in both treated (B) and non-treated 
conditions (A) compared to the parent cells. The p-values were 0.01 and 0.0001 in 
the treated (R+) and non-treated (R-) cells, respectively, compared to the parent 
cells (C and D). HDAC I and PCNA proteins were used as a loading control when 
(R-) and (R+) were compared to the parent cells, respectively (refer to section 
2.4.6.6).    
 
 
Figure 50: Comparison of the levels of BCL-XL abundance in GDC-0980 sensitive 
parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, 
R3 represent triplicates of 20 µg of total cell protein. [-]: resistant cells cultured 
without drug and [+]: resistant cells cultured in the presence of 1 µM GDC-0980. 
Shown also is a scatter plot of the ECL-chemilescence signal, normalized for the 
loading control, measured by ImageJ and represented as a BCL-XL to loading 
control ratio (C and D).  
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6.3.4.8. Nuclear factor kappa B1 [NFKB1]   P105/P50 
Shown in figure 51, the resistant cells treated with the drug (R+), native NFκB1 
(P105) level was not significantly different (p= 0.18) in comparison to parent cells 
(B). In contrast, non-treated (R-) resistant cells (A) exhibited significant up-
regulation of native NFKB1 protein (P105) (p= 0.001). On the other hand, P50 in 
both treatment conditions was significantly up-regulated (p= 0.01 and 0.004, 
respectively). Shown also is a scatter plot representing the ECL-chemilescence 
correspondent signal measured by ImageJ and plotted in triplicates per phenotype 
(C and D). HDAC I and PCNA proteins were used as a loading control when (R-) 
and (R+) were compared to the parent cells, respectively (refer to section 2.4.6.6). 
 
     
 
Figure 51: Comparison of the levels of Nuclear factor kappa B1 (P105/P50) 
abundance and its degradation in GDC-0980 sensitive parent (P) and resistant (R) 
H1975 adenocarcinoma cells. P1, P2, P3 and R1, P2, R3 represent triplicates of 
20 µg of total cell protein. [-]: resistant cells cultured without drug and [+]: 
resistant cells cultured in the presence of 1 µM GDC-0980. Shown also is a scatter 
plot of the ECL-chemilescence signal, normalized for the loading control, measured 
by ImageJ and represented as a P105/P50 to loading control ratio (C and D).  
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6.3.4.9. Transcription factor Rel-A (P65)   
The level of P65 (Rel-A) showed a non-significant elevation in resistant cells, both 
treated (R+) (B) and non-treated (R-) (A). The p-value was 0.1 in both treated and 
non-treated cells, respectively. Shown also is a scatter plot representing the ECL-
chemilescence correspondent signal measured by ImageJand plotted as triplicates 
per phenotype (C and D) (figure 52). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6). 
 
   
 
Figure 52: comparison of the Rel- associated protein [Rel-A] abundance levels in 
GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, 
P2, P3 and R1, R2, R3 represent triplicates of 20 µg of total cell protein. [-]: 
resistant cells cultured without drug and [+]: resistant cells cultured in the 
presence of 1 µM GDC-0980. Shown also is a scatter plot of the ECL-
chemilescence signal, normalized for the loading control, measured by ImageJ and 
represented as a Rel A to loading control ratio (C and D).  
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6.3.4.10.  Transcription factor Rel- B 
The level of Rel-B was significantly down-regulated in the both treated (R+) (B) 
and non-treated (R-) (A) resistant cells compared to their parent cells (p= 0.0008 
and 0.03, respectively). Shown also is a scatter plot representing the ECL-
chemilescence correspondent signal measured by ImageJ and plotted as triplicates 
per phenotype (C and D) (figure 53). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6).  
 
 
 
Figure 53: Comparison of Rel-B protein abundance levels in GDC-0980 sensitive 
parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, 
R3 represent triplicates of 20 µg of total cell protein. (-): resistant cells cultured 
without drug and (+): resistant cells cultured in the presence of 1 µM GDC-0980. 
Shown also is a scatter plot of the ECL-chemilescence signal, normalized for the 
loading control, measured by ImageJ and represented as a Rel B to loading control 
ratio (C and D).  
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6.3.4.11. Transcription factor [c-Rel] 
c- Rel in treated resistant cells was not significantly different from that in parent 
cells (p= 0.1), while in non-treated cells it was significantly lower (p= 0.01). Shown 
also is a scatter plot representing the ECL-chemilescence correspondent signal 
measured by ImageJ and plotted as triplicates per phenotype (C and D) (figure 54). 
HDAC I and PCNA proteins were used as a loading control when (R-) and (R+) 
were compared to the parent cells, respectively (refer to section 2.4.6.6).  
 
 
 
 
Figure 54: Comparison of c-Rel protein abundance levels in GDC-0980 sensitive 
parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, 
R3 represent triplicates of 20 µg of total cell protein. (-): resistant cells cultured 
without drug and (+): resistant cells cultured in the presence of 1 µM GDC-0980. 
Shown also is a scatter plot of the ECL-chemilescence signal, normalized for the 
loading control, measured by ImageJ and represented as a c-Rel to loading control 
ratio (C and D).  
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6.3.4.12. Histone acetyltransferase 
6.3.4.12.1. General control of amino acid synthesis protein [GCN5L2] 
The level of GCN5L2 was significantly down-regulated in treated (R+) cells (B) 
compared to parent cells and was significantly up-regulated in non-treated resistant 
cells (R-) (A) (p= 0.003 and 0.0004, respectively). Shown also is a scatter plot 
representing the ECL-chemilescence correspondent signal measured by ImageJ and 
plotted as triplicates per phenotype (C and D) (figure 55). HDAC I and PCNA 
proteins were used as a loading control when (R-) and (R+) were compared to the 
parent cells, respectively (refer to section 2.4.6.6). 
 
 
Figure 55: Comparison of general control of amino acid synthesis (GCN5L2) 
protein abundance levels in GDC-0980 sensitive parent (P) and resistant (R) 
H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 
20 µg of total cell protein. (-): resistant cells cultured without drug and (+): 
resistant cells cultured in the presence of 1 µM GDC-0980. Shown also is a scatter 
plot of the ECL-chemilescence signal, normalized for the loading control, measured 
by ImageJ and represented as a GCN5L2 to loading control ratio (C and D).  
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6.3.4.12.2. p300/CBP-associated protein [PCAF] 
The level of PCAF was significantly down-regulated in treated (R+) cells (B) 
compared to parent cells and was significantly up-regulated in non-treated resistant 
cells (R-) (A). The p-values were <0.0001 and 0.0007 in treated and non-treated 
resistant cells, respectively. Shown also is a scatter plot representing the ECL-
chemilescence correspondent signal measured by ImageJ and plotted as triplicates 
per phenotype (C and D) (figure 56). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6). 
 
 
Figure 56: Comparison of p300/CBP-associated protein (PCAF) abundance levels 
in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. 
P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total protein. 
(-): resistant cells cultured without drug and (+): resistant cells cultured in 1µM 
GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
PCAF to loading control ratio (C and D).  
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6.3.4.13. Histone deacetylases 
6.3.4.13.1. HDAC I 
In the presence of GDC-0980, HDAC I was significantly up-regulated (R+) (B) 
compared to parent cells (p= 0.0002), but it became down-regulated with p value 
of >0.99 when the drug was cleared from the medium (R-) (A). Shown also is a 
scatter plot representing the ECL-chemilescence correspondent signal measured by 
ImageJ and plotted as triplicates per phenotype (C and D) (figure 57). HDAC I and 
PCNA proteins were used as a loading control when (R-) and (R+) were compared 
to the parent cells, respectively (refer to section 2.4.6.6). 
 
 
Figure 57: comparison of histone deacetylase I (HDAC I) protein abundance levels 
in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. 
P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total protein. 
(-): resistant cells cultured without drug and (+): resistant cells cultured in 1µM 
GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
HDAC I to loading control ratio (C and D).  
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6.3.4.13.2. HDAC II 
HDAC II was significantly upregulated in treated (R+) cells (B) compared to the 
parent cells (p= 0.01), but in non-treated cells (R-) (A) it remained up-regulated 
(p= 0.09). Shown also is a scatter plot representing the ECL-chemilescence 
correspondent signal measured by ImageJ and plotted as triplicates per phenotype 
(C and D) (figure 58). HDAC I and PCNA proteins were used as a loading control 
when (R-) and (R+) were compared to the parent cells, respectively (refer to section 
2.4.6.6). 
 
 
 
Figure 58: Comparison of histone deacetylase II (HDAC II) protein abundance 
levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma 
cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total 
protein. (-): resistant cells cultured without drug and (+): resistant cells cultured 
in 1µM GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
HDAC II to loading control ratio (C and D).  
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6.3.4.13.3. HDAC III 
HDAC III was significantly up-regulated in treated (R+) cells (B) compared to 
parent cells (p= 0.0003) while this increase went back to become down-regulated 
with p value of 0.2 when the inhibitor was cleared from the medium (R-) (A). 
Shown in this figure also is a numeric representation of the ECL-chemilescence 
signal, measured by ImageJ and represented as triplicates per phenotype (C and D)  
(figure 59). HDAC I and PCNA proteins were used as a loading control when (R-) 
and (R+) were compared to the parent cells, respectively (refer to section 2.4.6.6).  
 
 
 
Figure 59: Comparison of histone deacetylase III (HDAC III) protein abundance 
levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma 
cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total 
protein. (-): resistant cells cultured without drug and (+): resistant cells cultured 
in 1µM GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
HDAC III to loading control ratio (C and D).  
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6.3.4.13.4. HDAC IV 
HDAC IV was significantly up-regulated in treated cells (R+) (B) compared to 
parent cells (p= 0.03) and was significantly decreased (p= 0.001) when GDC-0980 
was not contained in the medium (R-) (A). Shown also in this figure is a scatter plot 
representation of the ECL-chemilescence signal, measured by ImageJ and 
represented as triplicates per phenotype (C and D) (figure 60). HDAC I and PCNA 
proteins were used as a loading control when (R-) and (R+) were compared to the 
parent cells, respectively (refer to section 2.4.6.6).  
 
 
 
Figure 60: Comparison of histone deacetylase IV (HDAC IV) protein abundance 
levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma 
cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total 
protein. (-): resistant cells cultured without drug and (+): resistant cells cultured 
in 1µM GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
HDAC IV to loading control ratio (C and D).  
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6.3.4.13.5. HDAC VI 
HDAC VI was significantly up-regulated in the treated cells (R+) (B) compared to 
the parent cells with, p value of  0.0003, and was significantly decreased (p= 0.001) 
when GDC-0980 was not contained in the medium (R-) (A). Shown in this figure 
also is a numeric representation of the ECL-chemilescence  signal, measured by 
ImageJ and represented as triplicates per phenotype (C and D) (figure 61). HDAC 
I and PCNA proteins were used as a loading control when (R-) and (R+) were 
compared to the parent cells, respectively (refer to section 2.4.6.6).  
 
 
Figure 61: Comparison of histone deacetylase VI (HDAC VI) protein abundance 
levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma 
cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total 
protein. (-): resistant cells cultured without drug and (+): resistant cells cultured 
in 1µM GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
HDAC VI to loading control ratio (C and D).  
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6.3.4.13.6. Phospho-HDAC 4,5 
Phosphorylated HDAC 4,5 was significantly lowered in both treated cells (R+) (B) 
and non-treated cells (R-) (A) compared to parent cells. P-values were < 0.0001 
and 0.0003, respectively. Shown also in this figure is a numeric representation of 
the ECL-chemilescence  signal, measured by ImageJ and represented as triplicates 
per phenotype (C and D) (figure 62). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6). 
 
 
 
 
Figure 62: Comparison of phosphorylated HDACs IV and V (P- HDAC IV & V) 
protein abundance in GDC-0980 sensitive parent (P) and resistant (R) H1975 
adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of 
cells lysate total protein. (-): resistant cells cultured without drug and (+): resistant 
cells cultured in 1µM GDC-0980. Shown also is a scatter plot of the ECL-
chemilescence signal, normalized for the loading control, measured by ImageJ and 
represented as a P-HDAC 4,5 to loading control ratio (C and D).  
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 6.3.4.14. Histone acetylation 
6.3.4.14.1. H1975 H3K9 
 
The level of acetylated lysine-9 in Histone 3 (H3K9) was increased in the treated 
cells (R+) (p = 0.18) (B). Upon withdrawal of GDC-0980 from the medium (R-) 
(A), its level went back to below the parent cells, but without significance (p= 0.3). 
Shown in this figure also is a scatter plot representing the ECL-chemilescence  
signal correspondent to acetylation level, measured by ImageJ and represented as 
triplicates per phenotype (C and D) (figure 63). HDAC I and PCNA proteins were 
used as a loading control when (R-) and (R+) were compared to the parent cells, 
respectively (refer to section 2.4.6.6). 
      
 
Figure 63: Comparison of acetylated levels of lysine 9 of histone 3 (H3) protein in 
GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, 
P2, P3 and R1, R2, R3 represent triplicates of 20 µg of cells lysate total protein. (-
): resistant cells cultured without drug and (+): resistant cells cultured in 1µM 
GDC-0980. Shown also is a scatter plot of the ECL-chemilescence signal, 
normalized for the loading control, measured by ImageJ and represented as a 
H3K9 to loading control ratio (C and D).  
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6.3.4.14.2. A549 H3K9 
 
Acetylated lysine-9 in Histone 3 (H3K9) was significantly lowered in both treated 
(R+) (B) and non-treated cells (R-) (A) (both p <0.0001). Shown in this figure also 
is a scatter plot representation of the ECL-chemilescence  signal, measured by 
ImageJ and represented as triplicates per phenotype (C and D) (figure 64).  
 
       
 
Figure 64: Comparison of acetylated lysine 9 of histone 3 (H3K9) protein 
abundance levels in GDC-0980 sensitive parent (P) and resistant (R) A549 
adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of 
cells lysate total protein. (-): resistant cells cultured without drug and (+): resistant 
cells cultured in F12 containing 3.34 µM GDC-0980. Shown in this figure is a 
scatter plot representing the 20 µg content of H3K9 measured by ImageJ and 
represented as triplicates per phenotype (C and D). 
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6.3.4.14.3. H1975 H3K18 
 
Acetylated lysine-18 in Histone 3 (H3K18)  was significantly increased in the 
treated cells (R+) (B) compared with the parent cells (p= 0.002). When GDC-0980 
was withdrawn from the medium (R-) (A), its level went back to below the parent 
cells but without significance (p= 0.5). Shown in this figure also is a scatter plot 
representation of the ECL-chemilescence signal, measured by ImageJ and 
represented as triplicates per phenotype (C and D) (figure 65). HDAC I and PCNA 
proteins were used as a loading control when (R-) and (R+) were compared to the 
parent cells, respectively (refer to section 2.4.6.6). 
 
       
 
Figure 65: Comparison of acetylated lysine 18 of histone 3 (H3K18) protein 
abundance levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 
adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of 
cells lysate total protein. (-): resistant cells cultured without drug and (+): resistant 
cells cultured in RPMI containing 1 µM GDC-0980. Shown also is a scatter plot of 
the ECL-chemilescence signal, normalized for the loading control, measured by 
ImageJ and represented as a H3K18 to loading control ratio (C and D).    
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6.3.4.14.4. A549 H3K18 
 
The level of acetylation of H3K18 was significantly lowered in both treated (R+) 
(B) and non-treated (R-) A549 cells (A) (p< 0.0001 in both cases). Shown also is a 
scatter plot representation of the ECL-chemilescence signal, measured by ImageJ 
and represented as triplicates per phenotype (C and D) (Figure 66). 
 
 
       
 
Figure 66: Comparison of acetylated lysine 18 of histone 3 (H3K18) protein 
abundance levels in GDC-0980 sensitive parent (P) and resistant (R) A549 
adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of 
cells lysate total protein. (-): resistant cells cultured without drug and (+): resistant 
cells cultured in F12 containing 3.34 µM GDC-0980. Shown in this figure is a 
scatter plot representing the 20 µg content of H3K18 measured by ImageJ and 
represented as triplicates per phenotype (C and D). 
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6.3.4.14.5. H1975 H3K27   
 
Acetylated lysine-27 in Histone 3 (H3K27)  was increased in treated cells (R+) (p= 
0.17) (B). Upon withdrawal of GDC-0980 from the medium (R-) (A), its level went 
back to below the parent cells but without significance (p= 0.2). Shown also is a 
scatter representation of the ECL-chemilescence  signal, measured by ImageJ and 
represented as triplicates per phenotype (C and D) (figure 67). HDAC I and PCNA 
proteins were used as a loading control when (R-) and (R+) were compared to the 
parent cells, respectively (refer to section 2.4.6.6). 
 
      
 
Figure 67: Comparison of acetylated lysine 27 of histone 3 (H3K27) protein 
abundance levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 
adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of 
cells lysate total protein. (-): resistant cells cultured without drug and (+): resistant 
cells cultured in RPMI containing 1 µM GDC-0980. Shown also is a scatter plot of 
the ECL-chemilescence signal, normalized for the loading control, measured by 
ImageJ and represented as a H3K27 to loading control ratio (C and D).  
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6.3.4.14.6.  H1975 histone 4 
 
Histone 4 (H4) was significantly upregulated  in GDC-0980 resistant H1975 cells 
in both treated (R+) (B) and non-treated (R-) cells (A) compared to the parent cells 
(both p< 0.0001). Shown also is a scatter plot representation of the ECL 
chemilescence signal, measured by ImageJ and represented as triplicates per 
phenotype (C and D) (figure 68). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6). 
 
       
  
Figure 68: Comparison of histone 4 protein abundance in GDC-0980 sensitive 
parent (P) and resistant (R) H1975 adenocarcinoma cells. P1, P2, P3 and R1, R2, 
R3 represent triplicates of 20 µg of total cell protein. (-): resistant cells cultured 
without drug and (+): resistant cells cultured in RPMI containing 1 µM GDC-0980. 
Shown also is a scatter plot of the ECL-chemilescence signal, normalized for the 
loading control, measured by ImageJ and represented as a H4 to loading control 
ratio (C and D).   
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6.3.4.14.7. H1975 H4K5 
 
The level of histone 4 acetylation at lysine 5 (H4K5) was significantly increased in 
GDC-0980 treated resistant H1975 cells (R+) compared to parent cells (B) (p= 
0.0001). H4K5 levels decreased when the cells passaged in the absence of the drug 
(R-) (A) (p= 0.42). Shown in this figure also is a scatter plot representation of the 
ECL-chemilescence signal, measured by ImageJ and represented as triplicates per 
phenotype (C and D) (figure 69). HDAC I and PCNA proteins were used as a 
loading control when (R-) and (R+) were compared to the parent cells, respectively 
(refer to section 2.4.6.6).       
 
 
Figure 69: Comparison of acetylated lysine 5 of histone 4 (H4K5) protein 
abundance levels in GDC-0980 sensitive parent (P) and resistant (R) H1975 
adenocarcinoma cells. P1, P2, P3 and R1, R2, R3 represent triplicates of 20 µg of 
cells lysate total protein. (-): resistant cells cultured without drug and (+): resistant 
cells cultured in RPMI containing 1 µM GDC-0980. Shown also is a scatter plot of 
the ECL-chemilescence signal, normalized for the loading control, measured by 
ImageJ and represented as a H4K5 to loading control ratio (C and D).   
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6.3.4.15. GDC-0980 dose-response curve for parent and resistant H1975 cells  
Shown in figure 70 are cytotoxicity graph plots shifted to the right in resistant cells 
compared to sensitive cells. The calculated IC50 values were 1.79 and 16.59 nM for 
the parent and resistant H1975 cells, respectively.  
 
Figure 70: Dose-response curve of GDC-0980 for GDC-0980 resistant [R-] and 
parent [P] H1975 lung adenocarcinoma cells.  
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6.3.4.16. SAHA dose-response curve for H1975 parent and resistant cells  
Shown in figure 71 is the cytotoxicity dose-response curve of SAHA HDAC 
inhibitor for the GDC-0980 sensitive parental cells (middle), GDC-0980 resistant 
cells (R-) (right), and GDC-0980 resistant cells pre-incubated with 1 µM GDC-
0980 (left). The calculated IC50s were 5.2, 8.08 and 4.34 nM in the parent, resistant 
(R-) and resistant (R+) cells, respectively.  
 
 
 
 
Figure 71: SAHA dose response curve represented as percent inhibition of growth 
vs the log dose of SAHA. The cells were tested were H1975 GDC-0980 parent, 
H1975 GDC-0980 resistant cells (R-) and GDC-0980 resistant cells in the presence 
of 1µM GDC-0980 (R+).  
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                  Table 51: Western blot assessment of proteins affecting the cell cycle   
 
 
Abundance analysis: S-Up: small increase in the protein abundance,  
S-down: small decrease in the protein abundance. 
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Table 52: Western blot analysis of HAT/HDAC and histone acetylation of GDC-
0980 resistant H1975 ( treated and non-treated) cells compared to the sensitive 
parent cells. 
 
 
Abundance analysis: S-Down: small decrease in the protein abundance,  T- Up: 
tends to rise as it was at low abundance before drug incubation, T-down: tends to 
decrease as it was higher during drug incubation. 
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Figure 72 shows the cell cycle KEGG pathway analysis of the proteins detected  by 
LC-MS/MS significantly upregulated in both treated (R+) and non-treated (R-) 
GDC-0980 resistant H1975 cells compared to parent cells (cut-off value: 1.2-fold 
increase). 
 
 
Figure 72: KEGG pathway analysis of the proteins found upregulated in the GDC-
0980 resistant cells compared to the parent cells in both treated (R+) and non-
treated (R-) cells. Proteins with red letters were significantly upregulated in R+ 
or/and R-, Smc3: structural maintenance of chromosome 1, Stag 1,2: stromal antigen 
1,2, MCM: minichromosome maintenance complex, CDK: cyclin dependent kinase, 
HDAC: histone deacetylase, ORC: origin recognition complex, Bub3: budding 
uninhibited by benzimidazoles 3 (mitotic check point, ATM: ataxia telangiectasia 
mutated (serine/threonine kinase), SCF: stem cell factor, TGFB: tumour growth 
factor, GSK: glycogen synthase kinase, ATR:ataxia telangiectasia and Rad3-related 
protein.     
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Figure 73 shows the  cell cycle KEGG pathway analysis of the proteins detected by 
LC-MS/MS significantly down regulated in both treated (R+) and non-treated (R-) 
GDC-0980 resistant H1975 cells compared to parent cells (cut-off value: 1.2-fold 
decrease). 
 
 
Figure 73: KEGG pathway analysis of cell cycle proteins. Red protein names were 
found downregulated in the GDC-0980 resistant cells compared to the parent cells 
in both treated (R+) and non-treated (R-) cells. Bold R+/R- denote proteins were 
found down-regulated in the resistant cells (treated and non-treated). PCNA: 
proliferating cell nuclear antigen, Smc1: structural maintenance of chromosome 1, 
CDK: cyclin dependent kinase1, MCM: minichromosome maintenance protein 
complex, Orc: origin recognition complex, CycB: cyclin B, 14.3.3: protein kinase C 
inhibitor protein.   
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6.4. Discussion 
The GDC-0980 resistant A549 and H1975 lung adenocarcinoma cells used in this 
experiment were maintained at all times in F12 medium containing 3.34 µM or RPMI 
containing 1 µM GDC-0980, respectively, unless stored frozen. The cell cycle profile 
of GDC-0980-resistant cells in the two cell lines was completely different from their 
parent sensitive cells (Figure 28). The cell cycle profile of GDC-0980 sensitive A549 
was 46.1% in G1, 43.26% in S and 10.6 in G2/M phase (Figure 28: A549P). In 
contrast, the cell cycle profile of the GDC-0980 resistant A549 cells passaged in F12 
medium containing 3.34 µM GDC-0980 (R+) was 74.1% in G1 phase, 23.5% in S 
phase and 2.3% in G2/M phase (Figure 28: A549R+). After five consecutive passages 
of 3 days each in GDC-0980 free medium, the cell cycle profile changed and 
approached that of parent cells, where the percentage of the cells in G1 phase went 
down to 56.8%, in S-phase increased to 36.2%, and in G2/M phase reached 7% 
(Figure 28). GDC-0980 was found to cause the cells to accumulate in G1 phase 
(Figure 29: A549 G1-phase) (p<0.0001), leading to fewer cells entering S (p<0.0001) 
and G2/M phases (p<0.0001) (Figure 29: A549 S-phase). Upon eliminating the drug 
effect, the percentage of cells in S (p<0.0001) and G2/M (p<0.0001) phases improved 
and more cells started to leave G1 phase (p<0.0001) (Figure 29: G2/M phases).  
These findings indicate that GDC-0980 causes cell cycle arrest in G1 phase in GDC-
0980 resistant A549 cells. However, inhibition of the PI3K signalling pathway in 
tumour cells with the small molecule ZSTK474 caused cell cycle arrest in G0/G1 
phase (Dan et al., 2009). GDC-0980, a PI3K-mTOR dual inhibitor, has been reported 
to cause G1 cell cycle arrest in many cell lines, including A549 lung adenocarcinoma 
cells (Wallin et al., 2011). Cell cycle arrest was confirmed by comparing the levels 
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of histone 3 in the parent and resistant cells in (R+) and out (R-) of the drug 
incubation (Figure 30). 
In this research work, mass spectrometry analysis of GDC-0980 resistant H1975 
(growing in RPMI medium containing 1 µM GDC-0980) (R+) compared to the 
sensitive parent cells (P) showed a significant upregulation (Table 47) and 
dysregulation (Table 49) of some proteins known to have a role in cell cycle control, 
such as Cyclin-dependent kinases (CDKs), Histone deacetylases (HDACs), P53, and 
check point controlling proteins (Figures 72 and 73). When non-treated GDC-0980 
resistant cells were compared to the parent cells (P), some proteins were also found 
differentially expressed (Tables 48, 50). LC-MS/MS detected proteins differentially 
expressed between the different conditions in addition to other proteins controlling 
the cell cycle, which were assessed by western blot (Figures 35-69). Some 
comparisons matched the mass spectrometry findings (table 51).  
Using a cell cycle imaging system (Cytell®), GDC-0980 was also found to cause 
cell cycle arrest in G2/M (p<0.0001) phases and prolongation of the lag time of S 
phase (p<0.0001) (Figure 29: H1975 S & G2/M phases). The cell cycle profile 
pattern in GDC-0980 sensitive H1975 cells was 52.5% G1 phase, 36.2% S phase and 
11.3 G2/M phase (Figure 28: H1975P). In the presence of 1 µM GDC-0980, the cell 
cycle profile of GDC-0980 resistant H1975 cells showed only 10.7% in G1 phase. 
In contrast, 66.7% and 22.7% of the cells accumulated in phases S (p<0.0001) and 
G2/M (p<0.0001), respectively (Figure 28: H1975R+). Clearing GDC-0980 from the 
culture media (15 days) had no significant effect on the cell cycle profile of GDC-
0980 resistant cells (Figure 29) [H1975 G0/G1 (p=0.5), S (p=0.19) and G2/M 
(p=0.27) phases]. The increased accumulation of 4N-containing cells (G2/M) was 
confirmed by measurement of histone 3 levels in the parent, resistant [R+] and 
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resistant [R-] cells. The western blot revealed increased levels of histone 3 (Figure 
31). This step was followed by histone co-localization using confocal microscopy, 
which confirmed localization of histone 3 to the nucleus (Figures 32-34).  
Moreover, the increased proliferation rate in cancer results from the increased 
cellular signalling and cross talk caused by gain of function or gene amplification 
mutations, accompanied by impairment of the balance between oncogenes and 
tumour suppressant genes. The overall downstream signalling events result in 
increased phosphorylation rates, which require abundance of adenosine triphosphate 
(ATP). Therefore, cell cycle controlling pathways have become a hot research area 
for the development of  cancer treatment (Schafer, 1998).   
It is well known that the cell cycle is controlled by enzymes called cyclin-dependent 
kinases (CDKs), activation of which involves their binding to cyclins, whereby the 
ATP-binding domains become unmasked and are subsequently phosphorylated by 
CDK-activating kinases (CAK) (Lolli and Johnson, 2005) (figure 74).  
Cyclins are cell cycle specific proteins. Cyclins D1, 2, 3 and cyclin E are involved at 
early stages (G1 and transition from G1/S phase). Cyclins A and B are required at 
the G2/M transition phase (Viallard et al., 2001). Cyclin- D1 binds and activates 
CDK4/6, which in turn phosphorylates and inhibits retinoblastoma protein (pRb), 
which binds and represses EF2 transcription factor, needed for transcription of other 
cyclins and progression of the cell cycle (Ravitz and Wenner, 1997). Inhibition of 
AKT/PKB phosphorylation by GDC-0980 interferes with CAK activation and 
progression of the cell cycle.  
Cyclin D1 is a proto-oncogene cell cycle protein (Bates and Peters, 1995), and its 
increased expression has been observed in many cancers (Alao, 2007). Cyclin D1 
abundance was found reduced in advanced cancers such as colorectal, breast and 
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lung squamous cell carcinoma (Li et al., 2010a). Such down regulation was found 
associated with poor prognosis and increased metastasis and invasion (Lehn et al., 
2010). On the other hand, overexpression of cyclin D1 had a proliferation effect and 
was associated with resistance to chemotherapy (Biliran et al., 2005). Tyrosine 
kinase inhibitors (TKI) were found to decrease the expression of cyclin D1, D3 and 
E2 (Petty et al., 2004, Phuchareon et al., 2015). In this study, cyclin D1 was found 
significantly downregulated in both GDC-0980-treated [R+] H1975 cells (p= 0.001) 
and non-treated [R-] cells (p= 0.0003) (Figure 35). Cyclin D3 was found slightly 
upregulated in both treated [R+] (p= 0.26) and non-treaed (p= 0.2) H1975 cells 
(Figure 36). Cyclin D3 is also a proto-oncogene, and increases in its levels denote 
increased tumour aggression and metastasis (Wang et al., 2017a). Overexpression of 
cyclin D3 was found to indicate erlotinib resistance in aerodigestive tract cancer 
(Petty et al., 2011).  
Cyclin-dependent kinase 6 (CDK6) functions at stage G1 of the cell cycle (Figure 
74). Low levels of CDK6 were found to slow the rate of cell proliferation in cancer  
(Laurenti et al., 2015). In this study, the level of CDK6 was significantly low in the 
GDC-0980 resistant H1975 cells compared to the sensitive cells in both treated (p= 
0.005) and non-treated conditions (p= 0.0007) (Figure 40). The growth curve 
showed that GDC-0980 treated cells tended to grow very slowly compared to the 
parent cells. On the other hand, when the cells were grown in GDC-0980 free 
medium, they started to proliferate at higher rates and became more aggressive than 
the parent cells (Figure 27). GDC-0980 inhibits PI3K/mTOR downstream signalling 
controlling a broad range of transcription factors responsible for cell growth and 
proliferation. So, diminished phosphorylation by GDC-0980 might be the main 
reason of slow proliferation in the treated cells rather than the abundance of the 
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cyclins; cyclin D3 is more important than cyclin D1 for cell progression from G1 to 
S phase in H1975 lung adenocarcinoma cells (Figure 74).  
 
Figure 74: Summary of experimental findings of cell cycle control proteins in H1975 
cells. Cell cycle progression (geen arrows), proteins favouring the effect of other 
proteins (red interrupted arrows), proteins interfering with the function of other 
proteins (black interrupted arrows), consequence of findings (red arrows).   
 
Cyclin E is an oncogenic cell cycle modulating protein required for G1/S transition. 
Its expression starts to increase at late G1 phase and starts to decline at late S-phase, 
which explains its role in G1/S-phase (DNA synthesis) transition (Mazumder et al., 
2004). Cyclin A is also an oncogenic cell cycle protein functioning to bind, 
phosphorylate and activate CDK1/2, leading to downstream activation of DNA 
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synthesis. Cyclin A was found overexpressed in cancer, and such an increase was 
found associated with increased cancer progression, metastasis and poor prognosis 
in breast cancer (Baldini et al., 2006, Gray-Bablin et al., 1996) and colorectal cancer 
(Li et al., 2002). Cyclin A elevation was also used as a marker associated with poor 
prognosis and low survival rates in non-small cell lung cancer (Mishina et al., 2000). 
In the GDC-0980 resistant cells, both treated (p= 0.0007) and non-treated (p= 0.001) 
resistant cells showed a significant decrease in the level of cyclin A2 (Figure 37). 
This might explain their prolonged S phase lag time compared to the parent cells. 
Cyclin B1 and CDK1 together are known as the M phase-promoting factor, which 
regulates cell entry into M phase (Hunt, 1989). Overexpression of cyclin B1 has been 
demonstrated in many cancers, including colorectal and non-small cell lung cancer, 
and they too were found associated with poor prognosis (Wang et al., 1997, Suzuki 
et al., 2007, Soria et al., 2000). In the current study, cyclin B1 was significantly 
down-regulated in both treated (R+) and non-treated (R-) GDC-0980 resistant cells 
compared to the parent cells (p= 0.009 and 0.002, respectively) (Figure 38). Cyclin 
H is required for cell proliferation, and its overexpression was found elevated in 
breast cancer (Patel et al., 2016). In this study, Cyclin H was also found decreased in 
both conditions of the resistant H1975 cells, whether treated (p= 0.001) or non-
treated (p= 0.07) (Figure 39). Cycline D1, A, B1 and H were all found significantly 
decreased in the treated and non-treated GDC-0980 resistant H1975 cells. Therefore, 
these cyclins might be good biomarkers for immunohistochemical monitoring of 
potential development of tumour resistance to GDC-0980 in lung cancer.  
However, after completion of DNA synthesis in S phase, the tumour suppressor gene 
P53 and its inhibitor the murine double minute 2 (MDM2) play a crucial role in DNA 
repair and cell cycle progression. MDM2 is negatively regulated by a series of 
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proteins, such as P21 and 14-3-3 (Reynisdóttir et al., 1995, Viallard et al., 2001, 
Levkau et al., 1998).    
The P53 family, including P53, P63 and P73 isoforms, is composed of pro-apoptotic 
tumour suppressor transcription factors localised mainly in the cytoplasm and 
accounting for the main operator responsible for activation of DNA repair and cell 
cycle arrest (Uramoto et al., 2006).  In P53 wild-type cells, any abnormalities 
(damage) to DNA discovered at the G2/M cell cycle checkpoint leads to cell cycle 
arrest and activation of the DNA repair machinery by activation of the P53-dependent 
pathway: failure to do so favours the induction of cell death (Ozaki and Nakagawara, 
2011, Sionov and Haupt, 1999).  P53 in healthy cells is inactivated by binding to 
MDM2, an ubiquitin ligase oncogenic enzyme, which keeps its abundance low (Nag 
et al., 2013). Upon DNA damage, phosphorylation and dissociation of P53 from its 
partner suppressor (MDM2) leads to increased transcription of cell cycle arrest 
proteins as well as proteins involved in DNA repair (Piette et al., 1997). The tumour 
suppressor activity of P53 is favoured when it interacts with some regulatory 
proteins, such as 14-3-3 sigma, which competes with and inhibits MDM2 binding 
(Yang et al., 2003). 14-3-3 directly binds and stabilises P53, leading to additive 
tumour suppressant activities and counteracting the tumorigenic effect of BCL-XL 
by increasing the P53 mediated increase in BAX expression (Samuels-Lev et al., 
2001). P53 activation is inhibited when P53 binds to another regulatory protein called 
the mediator of DNA damage check point 1 protein (MDC1). When MDC1 binds to 
P53, it protects it from being phosphorylated by ATM kinase, thus protecting the cell 
from apoptosis giving DNA repair a chance. Later, when the machinery fails to do 
so, the complex dissociates, leading to phosphorylation of P53 and induction of 
apoptosis (Nakanishi et al., 2007). P53 also binds to  RUNX3, improving its 
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transcription performance (Yamada et al., 2010) and increasing P53- mediated P21 
transcription (Ozaki and Nakagawara, 2011).  
In clinical proteomics, P53 was found overexpressed in cancers of liver (Gillet et al., 
2000), head and neck (Watling et al., 1992, Field et al., 1992, Edström et al., 2001), 
and breast (Davidoff et al., 1991). In lung cancer, P53 abundance was found 
significantly increased in more than 50% of squamous cell carcinoma and more than 
25% in adenocarcinoma (n = 132) (Uramoto et al., 2006). If these findings are 
normalised for the approximate percentage of mutated P53 in cancer (50%) 
(Higashitsuji et al., 2007), that would support and confirm P53  loss-of-function as a 
positive driving force to increase its expression (Blagosklonny, 1997, Higashitsuji et 
al., 2007). P53 abundance was found significantly overexpressed in both treated (R+) 
(p= 0.0004) and non-treated (R-) (p <0.0001) resistant cells (Figure 41). In H1975 
cells used in this study, P53 gene is mutated and its abundance is expected to be 
elevated. The use of GDC-0980 to interfere with P53 function by upstream inhibition 
of ATM phosphorylation would lead to induction of P53 expression. The increased 
level of P53 in GDC-0980 resistant cells in both experimental conditions (R+, R-) 
might be used as a marker for immunohistochemical detection of tumour resistance 
to GDC-0980 and to tyrosine kinase inhibitors that target the PI3K/AKT pathway.  
The 14-3-3 Protein family consists of phosphoserine/threonine binding proteins that 
do not possess catalytic subunits that can modify other proteins but can bind and 
regulate more than 100 phosphorylated proteins (Dougherty and Morrison, 2004) 
controlling several cellular signalling pathways, including DNA replication, cell 
cycle, cell growth, apoptosis, proliferation and migration. 14-3-3, sometimes called 
adaptor proteins, has seven isoforms, including alpha, beta, gamma, sigma, epsilon, 
zeta and theta. They exist in the cytosol and are exported to play roles in the 
 
 
241 
extracellular regulation of other proteins involved in several cell communication 
processes (Kaplan et al., 2017). Theta, sigma and zeta were found to differ in 
abundance from one tissue to another, meaning that each single isoform has distinct 
tissue-specific functions (Qi et al., 2005). Studies based on immunohistochemistry 
and western blot analysis have revealed that all 14-3-3 isoforms, except epsilon and 
zeta, are found 11 ± 3 times more abundant in lung cancer than in normal lung tissues, 
and this elevation was confirmed by RT-PCR (Qi et al., 2005). 
In all studies, 14-3-3 was claimed to be involved in tumorigenesis and therefore can 
be used as a marker to diagnose and monitor lung cancer (Marx et al., 2016). 14-3-3 
zeta/delta overexpression was found involved in resistance to cisplatin, as its lowered 
expression was found associated with improved cisplatin-induced inhibition of cell 
proliferation in A549 lung adenocarcinoma cells (Fan et al., 2007). 14-3-3 zeta/delta 
was found significantly (p= 0.004) down-regulated in GDC-0980 resistant H1975 
cells when cultured in the presence of 1µM GDC-0980 (R+) and significantly 
elevated (p= 0.002) in the non-treated cells (R-) (Figure 42).  
14-3-3 sigma is an epithelial cell-specific isoform found down-regulated in most 
human carcinomas, including primary bladder, gastric, head and neck tumours 
(Dellambra et al., 2000, Vellucci et al., 1995, Ostergaard et al., 1997, Suzuki et al., 
2000) and was undetectable in most breast, stomach and liver carcinomas (Ferguson 
et al., 2000, Suzuki et al., 2000, Iwata et al., 2000). 14-3-3 sigma has tumour 
suppressant activity through its positive regulation of P53-mediated apoptosis 
(Figure 73) (Yang et al., 2003). It can also bind and inactivate CDK 2 and 4 and 
compromise the cell cycle (Laronga et al., 2000).  
14-3-3 theta exerts oncogenic activity by interfering with binding of P21 to CDKs, 
preventing cell cycle arrest and enhancing proteasomal degradation of P21 (Wang et 
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al., 2010). 14-3-3 theta has been found overexpressed in female breast cancer and is 
responsible for tumour migration and metastasis (Xiao et al., 2014). Overexpression 
of 14-3-3 theta was also found involved in tamoxifen resistance in breast cancer 
(Wang et al., 2010). 14-3-3 epsilon has tumour suppressant activity and was found 
down-regulated in many carcinomas including gastric carcinoma (GC) (Leal et al., 
2012) and larynx squamous cell carcinoma (LSCC) (Che et al., 2010). Increased 
levels of 14-3-3 epsilon was associated with epithelial-mesenchymal transition 
(EMT) and low survival rates in hepatocellular carcinoma (Liu et al., 2013). In this 
study, 14.3.3 epsilon was detected significantly overexpressed in the GDC-0980 non-
treated resistant cells (R-) (p= 0.001) and was significantly (p= 0.0001) down 
regulated in the treated cells (R+) (Figure 43). 
Among 14-3-3 isoforms that have oncogenic function is the 14.3.3 gamma. It acts by 
stabilising DNA and facilitating mitotic check-point bypass at G2/M cell cycle 
phase. 14.3.3 gamma was found to cause polyploidy in the H322 lung cancer cell 
line (Qi et al., 2007). Clinically, 14-3-3 gamma was detected overexpressed in lung 
(Qi et al., 2007) and breast tumours (Song et al., 2012). In this study, the 14-3-3 
gamma profile in GDC-0980 resistant H1975 cells was significantly down-regulated 
compared to sensitive cells in both treated (R+) and non-treated (R-) (p= 0.01 both) 
resistant cells (Figure 44). 14-3-3 beta/alpha was found by western blot to be 
upregulated in many lung adeno and squamous carcinoma cell lines, but it was 
undetectable in normal cell lines (Qi et al., 2005). The abundance of this isoform was 
significantly downregulated (p< 0.0001) in treated GDC-0980 resistant H1975 cells 
and was significantly upregulated (p= 0.001) in resistant cells grown without GDC-
0980 compared to sensitive cells (Figure 45).  
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P21, also called p21WAF1/Cip1, which has several anti-tumour activities (Figure 73), 
functions mainly to bind and inhibit cyclin-dependent kinases (Deng et al., 1995, 
Abukhdeir and Park, 2008). It also binds and antagonises the proliferating-cell 
nuclear antigen (PCNA) responsible for activation of DNA synthesis and cell 
proliferation, as well as DNA repair. P21 positively regulates P53-dependent 
apoptosis, leading to cell cycle arrest at G1 phase (Luo et al., 1995, Abbas and Dutta, 
2009). P21 binds to CDK 1,2, thereby interfering with cell cycle progression at S and 
G2/M phases (Deng et al., 1995, Abbas and Dutta, 2009). P21 was also found to bind 
and interfere with E2FI, STAT3 and MYC transcription factors at their promoter 
sites (Abbas and Dutta, 2009).  
Cancer cells counteract the anti-proliferating effect of p21 by two methods. First, it 
phosphorylates and interferes with its nuclear translocation, which is offered 
naturally by the higher rates of phosphorylation in cancer (López Villar et al., 2015) 
via AKT1 (Abbas and Dutta, 2009). The second is to increase p21 degradation by 
ubiquitin-mediated proteolysis during S-phase upon binding to PCNA (Nishitani et 
al., 2008). P21 ubiquitination and degradation is also mediated at G2/M cell cycle 
transition phase by a sensor complex called anaphase-promoting complex-cell 
division complex 20-E3 ubiquitin ligase complex (APC-CCDC20-E3 ligase 
complex). This sensor recognises the p21-bound cyclin A or B and prevents 
immature cell division (Amador et al., 2007). P21 was evaluated as a cancer 
biomarker in 18 studies reviewed in (Chen et al., 2013). Significant but 
heterogeneous expression of p21 was observed in nine studies and in the other 9 it 
was unchanged by immunohistochemistry (IHC). In 2000, a study examined the 
clinical utility of p21 as a marker of early occupational lung cancer, but it was not 
detected in any of the serum samples from patients with asbestos-induced lung 
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cancer (Schneider et al., 2000). However, down-regulation of p21 or loss of its 
function was found involved in the tumorigenesis of many cancers as well as in 
development of drug resistance in cancer (Abukhdeir and Park, 2008).  
In this study, P21 was down-regulated in GDC-0980 resistant H1975 cells in the 
presence of the 1µM GDC-0980 and in its absence (both p< 0.0001) compared to the 
parent sensitive cells. These findings might be attributed to the elevated P53 levels 
(Figure 41) (Elbendary et al., 1996). However, GDC-0980 had no effect on the 
expression of P21. Therefore, dysregulation of P21 can be validated and used to 
monitor the development of GDC-0980 resistance by immunohistochemistry using 
normal tissues surrounding the tumour as a control (Figure 46).  
Proliferating-cell nuclear antigen (PCNA) is a nuclear proto-oncogene homo-trimer 
DNA polymerase delta cofactor protein functioning to increase the speed of DNA 
replication and to prevent the polymerase from falling off the leading strand during 
DNA replication (Kelman and O'Donnell, 1995). The active form of this protein is 
the ubiquitylated PCNA (Schurtenberger et al., 1998, Stoimenov and Helleday, 
2009).  PCNA-mediated activation of DNA polymerase delta is negatively regulated 
by P21, leading to cell cycle arrest and termination of DNA synthesis (Figure 74) 
(Waga et al., 1994). Two PCNA isoforms have been detected in breast cancer, PCNA 
and ca-PCNA (Cancer-associated PCNA). Ca-PCNA overexpression was claimed as 
a biomarker for detecting breast malignancy by immunohistochemistry (Malkas et 
al., 2006). Phosphorylation of PCNA at threonine 211 was found crucial for its 
proliferation promoting activity. Interfering with this phosphorylation site by Y211F 
(peptide) was found to cause cell cycle arrest at S phase and inhibition of DNA 
synthesis in prostate cancer cell lines (Zhao et al., 2011).  
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In breast cancer, Ca-PCNA was found, by IHC, overexpressed six-fold higher than 
in normal tissues with no differences in post-translation modifications (Naryzhny 
and Lee, 2007). PCNA is still used as a cell proliferation marker to exclude negative 
axillary lymph nodes in breast cancer, and its overexpression was found to denote 
disease relapse and short survival in breast cancer patients (Aaltomaa et al., 1993). 
Immunohistochemical examiation revealed the overexpression of PCNA along with 
esophagin in 177 pharyngeal neoplasia tumours, including all types of pharyngeal 
cancers, and was claimed as a promising biomarker in early diagnosis of oesophageal 
neoplasia (Kimos et al., 2004). PCNA was also found heterogeneously expressed in 
94 lung cancer specimens using IHC assays and higher levels of expression were 
found directly correlated with poor patient outcome (Caputi et al., 1998).  
As increased levels of PCNA are indicative of cell proliferation, its decreased levels 
would be helpful in predicting treatment success and good prognosis. In H1975 
resistant cells (R+) treated with GDC-0980, the level of PCNA was elevated (p> 
0.99) (Figure 47) and the ubiquitylation levels were significantly decreased (p= 0.01) 
(Figure 48). Inhibition of PCNA phosphorylation was found to decrease its 
proteasome-mediated degradation (Wang et al., 2006). GDC-0980 might interfere 
with PCNA phosphorylation by inhibiting the upstream phosphorylation of the 
PI3K/AKT signalling pathway, which might explain the elevated levels of PCNA in 
GDC-0980 treated cells (R+). The slow rate of proliferation of GDC-0980 resistant 
H1975 cells might be attributed to dysregulation of the active PCNA form (Ub-
PCNA) (Figures 27, 47 and 48) (Wang et al., 2006). In contrast, no change (p= 0.29) 
in the ubiquitination rates of PCNA in the non-treated resistant cells (R-) (which 
interpret the higher proliferation rates seen in figure 27 with a significant (p= 0.004) 
decreased levels of the native protein due to increase degradation of PCNA by 
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restoration of PCNA phosphorylation upon withdrawal of the inhibitor (GDC-0980) 
from the media (Figures 27, 47 and 48). 
BAX and BCL-XL control the release of cytochrome c from mitochondria. Bcl2-
associated X protein (BAX), a tumour suppressor gene also called apoptosis 
regulator, releases cytochrome c, leading to initiation of P53-mediated apoptosis via 
activation of the caspase cascade, whereas BCL-XL inhibits its release and so it is 
categorized as an oncogene (Kimos et al., 2004). BAX expression was found 
significantly low in many tumours, including 62 breast cancers by flow cytometry 
and 50 colorectal cancers by IHC (Pluta et al., 2011). BAX was also correlated with 
advanced stages of cancer; it was found significantly elevated in lymph nodes and in 
vascular infiltration cells in colorectal cancer (Pryczynicz et al., 2014, Pöhland et al., 
2006). However, BAX levels were elevated in breast cancer patients responding to 
chemotherapy (Gibson et al., 1999). In lung cancer, BAX was found significantly 
overexpressed in 20% (n = 60) of NSCLC (> 80% of the BAX-positive cancers were 
adenocarcinoma), but it was overexpressed only in 10% of squamous cell carcinoma 
(Porebska et al., 2006). In the non-treated GDC-0980 resistant H1975 cells (R-), the 
levels of BAX were significantly downregulated (p= 0.0006), and its abundance 
tended to exceed the parent levels in the treated cells (R+) (p= 0.51) (Figure 49).  It 
can be concluded that downregulation of BAX can be used as a marker for IHC 
evaluation of tumour resistance to GDC-0980 if a control tissue biopsy is taken as a 
control before the inhibitor is withdrawn.  
B-cell lymphoma extra-large (BCL-XL), a mitochondrial transmembrane anti-
apoptosis protein encoded by the BCL2-like 1 gene, functions to prevent BAX-
mediated release of cytochrome c from the mitochondria and induction of P53-
mediated apoptosis (Korsmeyer, 1995). BCL-XL also plays a role in the endoplasmic 
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reticulum-induction of cell proliferation by modulating the calcium signalling 
pathway (Akl et al., 2014). In non-small cell lung cancer, BCL-XL was found 
overexpressed in 59% of squamous cell carcinoma (n = 27), 28% of adenocarcinoma 
(n = 25) and 38% of large cell carcinoma (n = 13). In colorectal cancer, BCL-XL 
was found to function as a driver for tumorigenesis and was found involved in tumour 
resistance to treatment  (Scherr et al., 2016). Therefore, targeting BCL-XL to 
improve treatment response and avoid the development of resistance has recruited 
many scientists, as reviewed in (Cory et al., 2016). BXI-72 is a small-molecule 
inhibitor that binds to BCL-XL and interferes with its inhibition of cytochrome-c 
release, leading to cytochrome c release and induction of P53-mediated apoptosis via 
activation of caspase-3 (Park et al., 2013).  
In this study, significant overexpression of BCL-XL was exhibited by both treated 
(R+) (p= 0.01) and non-treated (R-) (p= 0.0001) GDC-0980 resistant H1975 lung 
adenocarcinoma cells (Figure 50). However, BCL-XL can be used as an IHC marker 
to detect resistance of tumours to GDC-0980. 
Nuclear factor kappa B (NFKB) is a transcription factor belonging to the Rel motif-
containing protein family. The five known Rel-containing proteins are Rel-A, Rel-
B, c-Rel, P50 and P52. The later two are formed from the proteasomal degradation 
of their precursors NFκB1 and NFκB 2, respectively. The Rel motif (about 300 
amino acids) is located at the amino terminus of members of the NFκB family and is 
responsible for their dimerisation, nuclear translocation, and binding to their DNA 
promotors (Hayden and Ghosh, 2004). Rel-A and B have a transactivating domain 
opposite to the Rel motive, i.e., at the carboxyl terminus. This transactivating domain 
activates the formation of P50 and P52 heterodimers with other Rels (A, B, C) and 
acts as a transcription repressor when P50 and P52 form homodimers (Chen, 2005, 
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Thoms et al., 2010). Two main signalling pathways are involved in the activation of 
NFκB. The canonical pathway involves hetero-dimerisation of Rel A or c-Rel with 
P50, and the non-canonical pathway involves dimerisation of P52 with Rel-B. In 
both cases, the result is nuclear translocation and activation of target genes (Lin et 
al., 2010). In clinical proteomics, NFKB was found to play a role in many cancers, 
including lung cancer (Chen et al., 2011, Lin et al., 2010), colorectal cancer 
(Sakamoto and Maeda, 2010), and breast cancer (Sarkar et al., 2013). Its 
overexpression was found more correlated with P53-mutated tumours and to play a 
role in resistance to chemotherapy and radiotherapy (Park et al., 2007, Vaughan et 
al., 2012). Overexpression of Rel-A and B in NSCLC favours tumour invasion and 
resistance to chemotherapy and radiotherapy by opposing P53-mediated apoptosis 
(Tang et al., 2006, Bailey et al., 2014). Therefore, Rel family proteins were scanned 
by western blot in this research work.  
The results revealed a significant increase in the levels of P50 in both the treated 
(R+) (p= 0.01) and non-treated (R-) (p= 0.004) GDC-0980 resistant H1975 cells. 
This was due to activation of proteasomal degradation of the precursor NFKB1 
(P105) protein (Figure 51).  
Rel A was found elevated in the treated resistant cells (R+) (p= 0.15) but no 
significant change was observed in the non-treated cells (R-) (p= 0.14) (Figure 52). 
Rel-B and Rel-C were both significantly (except  C Rel in R+) down regulated in the 
GDC-0980 resistant cells in both treated (R+) and non-treated (R-) compared to the 
parent cells (Figures 53, 54). The p values were (0.0008 and 0.03) and (0.1 and 0.01) 
for Rel B and C-Rel, respectively. In histopathology, P50 and Rel-B might indicate 
tumour resistance to GDC-0980 as they are not affected by drug. 
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Histone acetyltransferases (HATs) and histone deacetylase enzymes (HDACs) are 
among the most important enzymatic machineries regulating the cell cycle and gene 
expression. Imbalance in regulation of these two enzyme families was found 
associated with the development of many types of tumours (Timmermann et al., 
2001). Histones have lysine residues that can be acetylated by a histone-specific 
acetyltransferases (HATs), which is mostly part of transcription factors' associated 
regulatory protein complex (Legube and Trouche, 2003).  
In normal cells, HDACs was found to bind and repress retinoblastoma protein (pRB) 
and to interfere with the transcription of cyclins A and E, which are needed in the 
cell cycle S-phase. Class I HDACs, including HDAC 1,2 and 3, are recruited to the 
EF2 responsive elements of DNA by retinoblastoma protein (pRb), leading to 
repression of transcription of the encoded genes (Lai et al., 2001). In cancer, 
increased kinases activity interferes with such binding, where phosphorylation of 
HDACs by these kinases deactivates them and leads to cell cycle progression (Wang 
et al., 2001). Phosphorylation of pRb by CDK4 leads to its dissociation and 
proteasomal degradation. The liberated EF2 is then phosphorylated by CDK2/cyclin 
E. The phosphorylated EF2 then recruits HATs to acetylate histones in order to 
facilitate its access to its responsive promoters (Chan and La Thangue, 2001).  
The levels of HDACs were found downregulated in colorectal and lung cancer, and 
the dysregulation was associated with poor prognosis (Osada et al., 2004). HDAC 
inhibitors were also found to induce P21 expression, leading to an additive cell cycle 
arrest effect at G1 phase (Kim et al., 2000). Drug resistance to tyrosine kinase 
inhibitors (TKIs) was found accompanied by diminished levels of many histone 
acetyltransferases (HATs) (Bixby and Talpaz, 2009).  
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In this study, HATs were significantly down-regulated [PCAF (p< 0.0001) and 
GCN5L2 (p= 0.0007)] in the treated GDC-0980 resistant H1975 cells (R+) 
compared to the parent cells (figures 55, 56). Similar findings have been reported for 
other tyrosine kinase inhibitors (TKI) in (Bixby and Talpaz, 2009). GDC-0980 was 
observed to cause H1975 cells to accumulate pyruvate (next chapter), the natural 
inhibitor of HDACs. GDC-0980 also found to induce HDACs expression [HDAC I 
(p= 0.0002), HDAC II (p= 0.01), HDAC III (p= 0.0003), HDAC IV (p= 0.03), 
HDAC VI (p= 0.0003)] (Figures 57-61) with a significant decrease in their 
phosphorylation [eg: hypo-phosphorylation of HDAC IV and V (p< 0.0001)] (Figure 
62). The net result of the inactivated HDACs in H1975 resistant cells was hyper-
acetylation of histone 3 [lysine 9 (p= 0.18), lysine 18 (p= 0.002) and lysine 27 (p= 
0.17)] (Figures 63, 65 and 67) and histone 4 lysine 5 (p=0.0001) (Figure: 69) when 
the signal (western blot) was normalized for the abundance of the native histone 
proteins 3 and 4 (Figures: 30 and 68). A549 was used as a control to support this 
interpretation (Figures 29, 64, 66).  
In non-treated GDC-0980 H1975 (R-), the HATs were significantly overexpressed 
[PCAF (p= 0.0007) and GCN5L2 (p= 0.0004)] (Figures 56 and 55). All evaluated 
HDACs [HDAC I (p>0.99), HDAC III (p= 0.21), IV (p= 0.001) and VI (p= 0.001)] 
were down-regulated (Figures 57, 59, 60, 61) except HDAC II was overexpressed 
(p= 0.09) when compared with the parent sensitive H1975 cells (Figure 58). The 
phosphorylation levels and activities of HDAC IV and V (p= 0.0003) started to 
recover, leading to the hypo-acetylation profile of the evaluated histone lysines 
(Figures 63, 65, 67 and 69). Again, A549 also was used as a control (Figures 29, 64, 
66). 
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The decreased phosphorylation of HDACS and increased acetylation of histones in 
the treated (R+) GDC-0980 resistant H1975 cells and the hypoacetylation of the 
histones upon clearing the drug from the media (restoration of HDACs 
phosphorylation) would suggest GDC-0980 and phosphorylation of HDACs to play 
a role in acetylation of histones.  
Interestingly, GDC-0980 resistant H1975 cells (R-) tolerated higher doses of HDACi 
(SAHA) than H1975 GDC-0980 sensitive parent cells (Figure 71). This might 
suggest that HDACs play a role in multiple drug resistance. GDC-0980 at 
concentrations of 1 µM (equivalent to about IC10) was found to re-sensitize the 
GDC-0980/Vorinostat resistant cells to Vorinostat (Figure 71) which support the 
notion that GDC-0980 mediates deactivation of HDACs by interfering with their 
phosphorylation and accumulation of pruvate, the endogenous inhibitor of HDACs.   
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7. GDC-0980 resistant H1975 lung adenocarcinoma cells energy  
7.1. Introduction 
Normal proliferating cells obtain their energy from complete oxidation of glucose in 
the mitochondria. Under anaerobic conditions, cells convert pyruvate to lactate with 
a net energy production of two ATP molecules per glucose molecule. Cancer 
cells can convert pyruvate to lactate even in the presence of oxygen, the 
phenomenon called Warburg effect (Vander Heiden et al., 2009). Due to their 
increased demand for nucleic acids production, cancer cells utilize glucose-6-
phosphate in the pentose phosphate pathway (PPP), the main pathway for purine and 
pyrimidine production. Fermentation of pyruvate to lactate is inefficient for ATP 
production, but the rate of ATP production is 100 times faster than in aerobic 
glycolysis (Devic, 2016). Downstream signalling of the PI3K pathway stimulates the 
uptake and utilization of glucose by increasing glucose uptake by its transporters 
(GLUT-transporters), and increases glucose trapping by the enzyme hexokinase 
(Ben-Haim and Ell, 2009, DeBerardinis et al., 2008, Engelman et al., 2008). PI3K 
also stimulates through m-TOR signalling pathway the utilization of amino acids for 
protein synthesis (Vander Heiden et al., 2009). Inhibition of the PI3K signalling 
pathway was shown by positron emission tomography to decrease the 
uptake and utilization of glucose (Ben-Haim and Ell, 2009). PI3K inhibitors are in 
clinical use and cancer cells resistance to this category of treatment is well 
documented. Here, energy phenotyping of H1975 lung adenocarcinoma cells that are 
resistant to GDC-0980 (dual inhibitor of PI3K and m-TOR) was compared to their 
sensitive parent cells, both in the presence (R+) or the absence (R-) of the drug.  
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7.2. Experimental design  
GDC-0980-sensitive parent (P) and resistant H1975 lung adenocarcinoma cells were 
used. The parent cells were used as control to assess the differences in the metabolic 
phenotypes of the resistant cells in the presence (R+) and inthe absence of the drug 
(R-). Parent and resistant cells in the presence or absence of the drug were compared 
by mass-spectrometry, and western blot was used to assess mitochondrial membrane 
markers involved in oxidative phosphorylation. The mitochondrial membrane 
voltage potential was assessed by flow- cytometry using TMRE and the extent of 
active mitochondria in all GDC-0980 phenotypes was performed using mito-
Tracker® and confocal microscopy. Seahorse (principle see figure 75) energy 
phenotyping was conducted to validate the interpretation of the findings.   
 
 
 
Figure 75: Seahorse basic principle. (a) shows the principle of oxidative 
phosphorylation consumption of oxygen for production of ATP and the rate of acid 
production (mainly lactate) through glycolysis, (b) shows how their concentrations 
utilized by seahorse basic metabolic phenotyping [modified from agilent 
www.agilent.com/en/products/cell-analysis-(seahorse)/seahorse-analyzers 
/seahorse -xfp-analyzer].   
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7.3. Results 
7.3.1. Glycolysis in the GDC-0980 resistant H1975 cells (GDC-0980 R-). 
Figure 76 showed a KEGG pathway analysis of the proteins  detected by LC-MS/MS 
significantly up-regulated in the GDC-0980 resistant H1975 (non-treated) compared 
to the parent cells focusing on glycolysis/gluconeogenesis pathways, enzymes in red 
numbers found elevated.  
 
Figure 76: KEGG pathway analysis of up-regulated glycolysis enzymes in GDC-
0980 non-treated resistant cells H1975 (R-). Enzyme codes in red numbers were 
upregulated in the resistant cells (R-) compared to the parent cells (P), [3.1.3.9]: 
glucose-6-phosphatase, [5.4.2.2.]:phosphoglucomutase, [5.3.1.9]: glucose-6-
phosphate isomerase, [2.7.1.11]: 6-phosphofructokinase 1, [5.3.1.1.]: 
triosephosphate isomerase, [1.2.1.12]: glyceride 3-phosphate dehydrogenase 
(GAPDH), [2.7.1.40]: pyruvate kinase.  
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7.3.2. Glycolysis in the GDC-0980 resistant H1975 cells (GDC-0980 R+). 
Figure 77 showed a KEGG pathway analysis of the proteins  detected by LC-MS/MS 
significantly up-regulated in the GDC-0980 resistant H1975 (treated) compared to 
the parent cells focusing on glycolysis/gluconeogenesis pathways, enzymes in red 
numbers found elevated.  
 
Figure 77: KEGG pathway analysis of up-regulated glycolysis enzymes in GDC-
0980 non-treated resistant cells H1975 (R+). Enzyme codes in red numbers were 
upregulated in the resistant cells (R+) compared to the parent cells (P). [3.1.3.9]: 
glucose-6-phosphatase, [5.4.2.2]: phosphoglucomutase, [2.7.1.11]: 6-
phosphofructokinase 1, [1.2.1.12]: glyceride 3-phosphate dehydrogenase (GAPDH), 
[2.7.1.40]: pyruvate kinase.   
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7.3.3. Mitochondrial cytoplasmic distribution 
Shown in figure 78, Mito-Tracker®-red mitochondrial labelling-based confocal 
imaging of GDC-0980 parent (P) and resistant (R) H1975 lung adenocarcinoma 
cells. Mitochondrial activity has increased in both treated and non-treated GDC-
0980 resistant cells compared to the parent cells. 
 
 
 
Figure 78: Mito-Tracker®-red mitochondrial labelling-based confocal imaging of 
GDC-0980 parent (P) and resistant (R) H1975 lung adenocarcinoma cells. [-]: in 
GDC-0980 free medium and [+]: cells maintained in the presence of 1µM GDC-
0980 final concentration. Blue: DAPI staining of nuclei, red: Mito-Tracker staining 
of mitochondria.  
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7.3.4. Cell cycle-based mitochondrial activity  
Figure 79 shows flow cytometry of GDC-0980 parent and resistant H1975 eiher 
treated (R+) or non-treated (R-) using TMRE active mitochondrial staining. TMRE: 
Tetra-methyl-rhodamine-methyl ester (TMRM) staining was strong in late cell cycle 
phases (G2/M) or 4N cells in all conditions. Using TMRE, the cells representing 
G2/M phase cells were shifted from the upper left quadrant to the right upper 
quadrant, while the G1 remained at the same position (the lower left quadrant). The 
mitochondrial membrane negative charge of the resistant cells was higher than in 
parent cells, as indicated by pre-treatment of the cells with FCCP, which abolishes 
the negativity of the mitochondrial membrane.    
          
               
 
Figure 79: TMRE labelling of mitochondrial activity of GDC-0980 sensitive (P) 
and resistant (R) H1975 lung adenocarcinoma cells in the presence [+] or 
absence of the drug incubation [-]. FCCP: carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone was used as negative control and mito-
Tracker® (MT) was used to label mitochondria of all cells, including G1-
attendant cells, nil: only cells, both: cells were pre-treated by FCCP 20 min prior 
TMRE staining.  
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7.3.5. Pyruvate dehydrogenase 
Figure 80 shows a quantitative western blot  comparison of pyruvate dehydrogenase 
(PDH) abundance between H1975 GDC-0980 sensitive (parent) and resistant cells 
(R) in the presence [+] or absence [-] of the drug. PDH was significantly down-
regulated in the treated (B/D) resistant cells (p= 0.01) and significantly up-regulated 
in non-treated (A/C)  resistant cells compared to the parent cells (p= 0.002). HDAC 
I and PCNA proteins were used as a loading control when (R-) and (R+) were 
compared to the parent cells (P), respectively (refer to section 2.4.6.6).     
       
 
Figure 80: Comparison of pyruvate dehydrogenase abundance in GDC-0980 
sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1-3 and R1-3 
represents triplicates of 20 µg of total cell protein. [-]: resistant cells cultured in 
drug-free medium and [+] resistant cells cultured in medium containing 1µM GDC-
0980 . C and D are scatter plots representing the ratio of ECL chemilescence signal 
of PDH from 20µg total protein to the signal of HDAC I or PCNA (loading controls) 
measured by image J and plotted as triplicates.  
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7.3.6. Superoxide dismutase  
Figure 81 a quantitative western blot  comparison between superoxide dimutase 
abundance in H1975 GDC-0980 sensitive (parent) and resistant cells in the presence 
or absence of the drug. Protein abundance was significantly up-regulated in the 
treated (B/D) resistant cells (p= 0.04), but significantly down-regulated in non-
treated (A/C)  resistant cells compared to the parent cells (p < 0.0001). HDAC I and 
PCNA proteins were used as a loading control when (R-) and (R+) were compared 
to the parent cells (P), respectively (refer to section 2.4.6.6).     
       
             
 
Figure 81: Comparison of superoxide dismutase (SOD1) abundance between GDC-
0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1-3 and 
R1-3 represents triplicates of 20 µg of total cell protein. [-]: resistant cells cultured 
in drug-free medium and [+] resistant cells cultured in medium containing 1µM 
GDC-0980 . C and D are scatter plots representing the ratio of ECL chemilescence 
signal of PDH from 20µg total protein to the signal of HDAC I or PCNA (loading 
controls) measured by image J and plotted as triplicates. 
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7.3.7. Succinate dehydrogenase  complex flavoprotein subunit A  
Figure 82 shows a quantitative western blot comparing the abundance of succinate 
dehydrogenase  complex flavoprotein subunit A between H1975 GDC-0980 
sensitive (parent) and resistant cells in the presence or absence of the drug. There 
was  no change in the abundance of the protein in the treated (B/D) resistant cells 
(p= 0.7), but it was significantly up-regulated in non-treated (A/C)  resistant cells 
compared to the parent cells (p < 0.0001). HDAC I and PCNA proteins were used as 
a loading control when (R-) and (R+) were compared to the parent cells (P), 
respectively (refer to section 2.4.6.6).     
       
     
 
Figure 82: Comparison of succinate dehydrogenase  complex flavoprotein subunit 
A (SDHA) abundance between GDC-0980 sensitive parent (P) and resistant (R) 
H1975 adenocarcinoma cells. P1-3 and R1-3 represents triplicates of 20 µg of total 
cell protein. [-]: resistant cells cultured in drug-free medium and [+] resistant cells 
cultured in medium containing 1 µM GDC-0980 . C and D are scatter plots 
representing the ratio of ECL chemilescence signal of PDH from 20µg total protein 
to the signal of HDAC I or PCNA (loading controls) measured by image J and plotted 
as triplicates. 
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7.3.8. Prohibitin B  
Figure 83 is a quantitative western blot  comparing prohibitin B (PHB1) abundance 
between H1975 GDC-0980 sensitive (parent) and resistant cells in the presence or 
absence of the drug. The protein was significantly up-regulated in both treated (B/D) 
resistant cells (p= 0.07) and non-treated (A/C)  resistant cells (p= 0.0007) compared 
to the parent cells. HDAC I and PCNA proteins were used as a loading control when 
(R-) and (R+) were compared to the parent cells (P), respectively (refer to section 
2.4.6.6).    
              
 
Figure 83: Comparison of  prohibitin B abundance between GDC-0980 sensitive 
parent (P) and resistant (R) H1975 adenocarcinoma cells. P1-3 and R1-3 represents 
triplicates of 20 µg of cells lysate total protein. [-]: resistant cells cultured in drug-
free medium and [+] resistant cells cultured in 1µM GDC-0980 containing medium. 
C and D are scatter plots representing the ratio of ECL chemilescence signal of PDH 
from 20µg total protein to the signal of HDAC I or PCNA (loading controls) 
measured by image J and plotted as triplicates. 
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7.3.9. Voltage-dependent anionic channels  
Figure 84 shows a quantitative western blot  comparison of voltage-dependent 
anionic channel protein (VDAC) abundance between H1975 GDC-0980 sensitive 
(parent) and resistant cells in the presence or absence of the drug. There was  no 
change in protein expression levels in the treated (B/D) resistant cells (p= 0.7), but it 
was significantly up-regulated in non-treated (A/C)  resistant cells compared to the 
parent cells (p= 0.0006). HDAC I and PCNA proteins were used as a loading control 
when (R-) and (R+) were compared to the parent cells (P), respectively (refer to 
section 2.4.6.6).     
                  
Figure 84: Comparison of the abundance of voltage-dependent anionic channels 
(VDAC) between GDC-0980 sensitive parent (P) and resistant (R) H1975 
adenocarcinoma cells. P1-3 and R1-3 represents triplicates of 20 µg of total cell 
proteins. [-]: resistant cells cultured in drug-free medium and [+] resistant cells 
cultured in medium containing 1µM GDC-0980. C and D are scatter plots 
representing the ratio of ECL chemilescence signal of PDH from 20µg total protein 
to the signal of HDAC I or PCNA (loading controls) measured by image J and plotted 
as triplicates. 
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7.3.10. Heat shock protein 60 
Figure 85 is a quantitative western blot  comparison of heat shock protein-60 
(HSP60) abundance between H1975 GDC-0980 sensitive (parent) and resistant 
cells in the presence or absence of the drug. The abundance of HSP60 was  
significantly down-regulated in the treated (B/D) resistant cells (p= 0.007) but 
significantly up-regulated in the non-treated (A/C) resistant cells compared to the 
parent cells (p < 0.0001). HDAC I and PCNA proteins were used as a loading 
control when (R-) and (R+) were compared to the parent cells (P), respectively 
(refer to section 2.4.6.6).     
           
Figure 85: Comparison of heat shock protein 60 (HSP60) abundance between 
GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. P1-
3 and R1-3 represent triplicates of 20 µg of total cell protein. [-]: resistant cells 
cultured in drug-free medium and [+]: resistant cells cultured in medium 
containing 1µM GDC-0980. C and D are scatter plots representing the ratio of 
ECL chemilescence signal of PDH from 20µg total protein to the signal of HDAC 
I or PCNA (loading controls) measured by image J and plotted as triplicates. 
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7.3.11. Cytochrome C Oxidase IV  
Figure 86 is a quantitative western blot  comparison of cytochrome c oxidase (COX 
IV) abundance between H1975 GDC-0980 sensitive (P) and resistant cells in and out 
of the drug incubation. Protein abundance was significantly up-regulated in both 
treated (B/D) and non-treated (A/C) resistant cells compared to the parent cells. The 
p values were 0.01 and 0.009 in the treated and non-treated conditions, respectively. 
HDAC I and PCNA proteins were used as a loading control when (R-) and (R+) were 
compared to the parent cells (P), respectively (refer to section 2.4.6.6).     
      
             
 
Figure 86: Comparison of cytochrome oxidase (COX IV) protein abundance levels 
in GDC-0980 sensitive parent (P) and resistant (R) H1975 adenocarcinoma cells. 
P1-3 and R1-3 represents triplicates of 20 µg of cells lysate total protein. [-]: 
resistant cells cultured in drug-free medium and [+] resistant cells cultured in 1µM 
GDC-0980 containing medium. C and D are scatter plots representing the ratio of 
ECL chemilescence signal of PDH from 20µg total protein to the signal of HDAC I 
or PCNA (loading controls) measured by image J and plotted as triplicates. 
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7.3.12. Cytochrome c  
Figure 87 represents a quantitative western blot comparison of cytochrome c (Cyt.c) 
abundance between H1975 GDC-0980 sensitive (P) and resistant (R) cells in the 
presence [+] or absence [-] of the drug. Cytochrome c abundance was significantly 
down-regulated in both treated (B/D) and non-treated (A/C) resistant cells compared 
to the parent cells. The p-values were 0.01 and 0.006 in the treated and non-treated 
conditions, respectively. HDAC I and PCNA proteins were used as a loading control 
when (R-) and (R+) were compared to the parent cells (P), respectively (refer to 
section 2.4.6.6).     
                        
 
Figure 87: Comparison of cytochrome c protein abundance in GDC-0980 sensitive 
parent (P) and resistant (R) H1975 adenocarcinoma cells. P1-3 and R1-3 represent 
triplicates of 20 µg of total cell protein. [-]: resistant cells cultured in drug-free 
medium and [+] resistant cells cultured in medium containing 1 µM GDC-0980. C 
and D are scatter plots representing the ratio of ECL chemilescence signal of PDH 
from 20µg total protein to the signal of HDAC I or PCNA (loading controls) 
measured by image J and plotted as triplicates. 
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7.3.13. Acetyl co-A precursors 
Figure 88 depicts a colorimetric assay of the levels of the main molecules involved 
in the synthesis and fate of acetyl Co-A. The level of pyruvate was shown to be 
significantly up-regulated in the treated (R+) resistant cells (p= 0.001) but down-
regulated (p= 0.01) in the non-treated resistant cells (R-) compared with the parent 
cells. Free fatty acids were down-regulated in both treated and non-treated resistant 
cells (p= 0.16) but down-regulation was significant only in the treated condition (p= 
0.001). Acetoacetic acid levels were significantly up-regulated in the treated resistant 
(R+) cells (p < 0.0001) and were little a bit lower than the parent cells in the non-
treated (R-) condition (p= 0.02). The changes in b-hydroxyl butyrate abundance 
compared to the parent cells (P) were significant in both conditions. Its abundance 
was increased in the treated (R+) compared to the parent cells (p= 0.02) while it was 
significantly down-regulated in non-treated resistant cells (p= 0.002). Acetyl Co-A 
was downregulated in the treated resistant cells (R+) compared to the parent cells 
(p= 0.07), but no difference was observed between the non-treated resistant cells (R-
) and the parent cells (p= 0.4).   
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Figure 88: Comparison of acetyl Co-A and its main precursors, pyruvate, free fatty 
acids, acetoacetic acid and b-hydroxy butyrate, in GDC-0980 sensitive parent (P) 
and resistant (R) H1975 adenocarcinoma cells. [-]: resistant cells cultured in drug-
free medium and [+] resistant cells cultured in medium containing 1 µM GDC-
0980.  
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7.3.14. Seahorse cell energy phenotyping 
Shown in figure 89 is a comparison of oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) between the GDC-0980 resistant H1975 
cells (R-) compared to the parent sensitive cells (P). The figure shows the effect of 
a final concentration of 1 µM GDC-0980 (+) on the energy of the resistant cells. 
The resistant cells in the absence of drug incubation (R-) were very energetic 
compared to the parent cells; the former tended to depend on the mitochondria 
rather than on glycolysis. In the presence of 1 µM GDC-0980, the resistant cells 
(R+) were quiescent, hypo-energetic, and fully dependent on the aerobic energy 
production with a profound shut down of glycolysis.   
 
 
 
Figure 89: Seahorse energy phenotyping of GDC-0980 resistant H1975 cells in the 
presence of 1 µM final concentration GDC-0980 or absence of the drug compared 
to GDC-0980 native H1975 lung adenocarcinoma cells.  
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7.3.15. Mitochondrial respiration- oxygen consumption rate (OCR). 
Shown in figure 90, a comparison of mitochondrial OCR between GDC-0980 parent 
sensitive (P) and resistant H1975 lung adenocarcinoma cells either GDC-0980 
treated (R+) or non-treated (R-) using seahorse XF24 extracellular Flux AnalyZer. 
The aerobic respiration was significantly increased in the non-treated GDC-0980 
cells (p= 0.02) as indicated by their increased rate of oxygen consumption. 
Mitochondrial respiration in the treated resistant cells (R+) was lower than in parent 
cells, but the difference was not significant (p= 0.06). 1µM GDC-0980 incubation 
(R+) reverses the increased mitochondrial respiration in the resistant cells (p= 0.01).  
 
 
Figure 90: Mitochondrial respiration activity (aerobic respiration) of GDC-0980 
resistant H1975 cells compared to GDC-0980 sensitive H1975 lung 
adenocarcinoma cells (P). R+: effect of 1µM GDC-0980 incubation on the drug 
resistant H1975 cells. 
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7.3.16. Extracellular acidification rate (ECAR) 
Figure 91 shows a comparison of ECAR between GDC-0980 sensitive (P) and 
resistant H1975 lung adenocarcinoma cells either GDC-0980 treated (R+) or non-
treated (R-) using seahorse XF24 extracellular Flux AnalyZer . The ECAR was 
significantly decreased in the non-treated (R-) GDC-0980 resistant cells (p< 0.0001). 
1µM GDC-0980 incubation (R+) had an additive lowering effect on the rate of lactate 
production compared with the parent cells (p < 0.0001).  
 
 
 
 
Figure 91: Extracellular acidification rates (Glycolysis) of GDC-0980 resistant 
H1975 cells compared to GDC-0980 sensitive (P) H1975 lung adenocarcinoma 
cells. R+: effect of 1µM GDC-0980 incubation on the ECAR of the drug resistant 
H1975 cells. 
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Table 53: Summary of western blot and biochemical assays findings  
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7.4. Discussion  
Summary of the overall results obtained in this research work with a proposed story 
approach to connect and interpret these results are summerized in figure 92. Seahorse 
was used for energy phenotyping of treated (R+) and non-treated (R-) GDC-0980- 
resistant H1975 lung adenocarcinoma cells and to compare them with the GDC-0980 
parent (P) cells (Figure 89). This analysis was very informative when interpreted in 
parallel with their corresponding rate of proliferation (Figure 27), their mitochondrial 
membrane potential as measured by TMRE labelling (Figure 79), their mitochondrial 
mito-Tracker labelling (Figure 78), and their levels of pyruvate and ketone bodies 
(Figure 88), along with the LC-MS/MS analysis (Appendices: 47-50).  
The cytoplasmic conversion of pyruvate into lactate is favoured in cancer cells even 
in the presence of excess oxygen demand (Vander Heiden et al., 2009). In GDC-
0980 resistance, mass spectrometry revealed increased glycolytic activity and 
increased abundance of pyruvate kinase in both non-treated (R-) and treated (R+) 
H1975 cells compared to the parent cells (Appendices 87 and 89). The difference in 
the availability of pyruvate was most likely due to the effect of GDC-0980 (Figure 
88).  
GDC-0980 was shown to compromise both mitochondrial oxidative phosphorylation 
and utilization of glucose via its conversion into lactate, keeping the resistant cells 
(R+) at very slow metabolic rates (Figure 88). The rates of lactic acid production 
(ECAR) (Figure 91) and oxygen consumption (OCR) decreased (p= 0.06, 
p < 0.0001, respectively) (Figure 90). In addition, there was a significant decrease in 
the levels of pyruvate dehydrogenase (p= 0.01) (Figure 80). Combined, these results 
indicate that energy production was at very low levels, and this was reflected on their 
proliferation rate (Figure 27). The significant decrease in pyruvate dehydrogenase 
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(PDH) (p= 0.01) (Figure 80) and lactate dehydrogenase A (p= 0.01) (Appendix 50) 
might explain the accumulation of pyruvate (p= 0.001) and low levels of acetyl Co-
A (p = 0.07) in the (R+) cells (Figure 88).  
Upon withdrawl of GDC-0980, the resistant cells exhibited an aggressive rate of 
proliferation (Figure 27). Resistant cells (R-) started to utilise oxygen at a higher rate 
than the parent cells (Figure 90). This indicates that the mitochondria started to utilise 
glucose and the Warburg effect became less effective. This assumption can be 
concluded from the increased utilization of pyruvate (p= 0.01) and its conversion 
into acetyl Co-A (Figure 88) by pyruvate dehydrogenase, which was significantly 
elevated (p= 0.002) compared to the parent cells (Figure 80). Their high energetic 
status (Figure 89) in addition to the significant increase in the oxygen consumption 
rate (p= 0.02) (Figure 90) and their decreased lactic acid production (p < 0.0001) 
compared to the parent cells (P) (Figure 91) is indicative the recovery of 
mitochondrial utilisation of glucose.  
The increased mitochondrial activity is expected to be accompanied by increased 
levels of reactive oxygen species (ROS), which are cytotoxic (Auten and Davis, 
2009). However, cells with normal mitochondrial function would utilise such free 
radicals through the oxidative phosphorylation (OP) complexes, which are of two 
categories of ROS consuming complexes: superoxide dismutase (SOD), the main 
cellular ROS scavenger, and cytochrome c oxidase (COX). The other type of 
mitochondrial OP complex is the ROS producing succinate dehydrogenase (SDH), 
which catalyses the transport of electron radicals from succinate to the mitochondrial 
membrane, thereby connecting OP to the citric acid cycle. 
Superoxide dismutase 1 and 2 have been reported as down-regulated in many cell 
lines representing primary and metastatic colorectal cancer, and their levels were 
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found directly correlated with the increased ROS concentration (Skrzycki et al., 
2015). Tyrosine kinase inhibitors (TKIs) compromises mitochondria and cause 
increased reactive oxygen species (ROS) (Okon et al., 2015). Therefore the 
abundance of cytoplasmic superoxide dismutase (SOD1) (Fukai and Ushio-Fukai, 
2011) in the treated resistant cells was significantly elevated  (p= 0.02) (Figure 80). 
This overexpression might have been due to SOD1 dysfunction (Robbins and Zhao, 
2014, Oberley and Buettner, 1979) and increased ROS (Yankovskaya et al., 2003, 
Horsefield et al., 2004) caused by GDC-0980.  
The level of cytochrome c oxidase (COX-IV) (R-) was also upregulated (p= 0.01) 
(Figure 86) compared to the parent cells, and the level of succinate dehydrogenase 
(SDH) showed no change (Figure 82). These findings support that GDC-0980 
compromises the mitochondrial oxidative phosphorylation and increases the levels 
of ROS scavenger SOD1 protein as a consequence of accumulation of ROS in the 
absence of mitochondrial membrane function which can be seen clearly in figure 91 
(Xu et al., 2014).  
The significant accumulation of pyruvate (p= 0.001) (Figure 88) and decreased 
pyruvate dehydrogenase (PDH) (p= 0.01) (Figure 80) in the treated resistant cells 
might serve as a protective mechanism for the cells in order to prevent production of 
more acetyl co-A (Figure 88), the main source of toxic reactive oxygen species 
(ROS) which found to induce several cell death mechanisms (Valencia and Morán, 
2001).  
In contrast, when the resistant cells grow in GDC-0980 free media (R-) they exhibit 
a low level of superoxide dimutase (SOD) compared to the parent cells (p<0.0001) 
(Figure 81), cytochrome c oxidase was upregulated (p= 0.009) (Figure 86) and the 
level of succinate dehydrogenase was also overexpressed (p<0.0001) (Figure 82). 
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The decreased SOD1 levels can be attributed to the improved levels of 
phosphorylation and restoration of mitochondorial function as it can be concluded 
from the increased levels of oxygen consumption (Figure 90). The elevated succinate 
dehydrogenase enzyme might reflect the increased utilization of amino acids to 
compensate for the increased energy demand (Figures 27, 82). The lowered pyruvate 
and ketone bodies (Figure 88) levels also indicate increased mitochondrial function.  
 
Prohibitin B (PHB1) is a mitochondrial inner membrane-bound protein regulating 
cell morphogenesis and proliferation, and is involved in the integrity of the 
mitochondrial membrane (Merkwirth and Langer, 2009). PHB1 was evaluated in 
non-small cell lung cancer by RT-PCR, western blot and IHC and its overexpression 
was found associated with the clinically aggressive types of the tumours (Jiang et al., 
2013). Overexpression of PHB1 was also found associated with poor prognosis and 
increased tumour invasion in gallbladder cancer (Cao et al., 2016). 
PHB1 and Heat shock protein 60 (HSP60), which are known to protect the cells 
against various types of stress (Pace et al., 2013, Coates et al., 2001) were 
significantly overexpressed (p= 0.0007 and < 0.0001) in the non-treated resistant 
cells  (R-) (Figure 83 and 85, respectively). This might explain the higher 
proliferation rate of the GDC-0980 resistant cells when grown in drug-free media 
(Figure 27), while the treated cells (R+) exhibited a slow proliferation factor (Figure 
27) despite the elevated PHB1 level (p= 0.07) (Figure  82). GDC-0980 interferes 
with prohibitin phosphorylation, which is required for its function, by upstream 
blockage of AKT/PB phosphorylation (Jiang et al., 2015), resulting in growth rate 
depression (Figure 27).  
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Figure 92: Summary  of chapter findings. PI3K: phosphatidyl inositol 3-kinase, AKT/PKB: 
protein kinase B, ATP: adenosine triphosphate, ADP: adenosine diphosphate, LDH: 
lactate dehydrogenase, PDH: pyruvate dehydrogenase, ROS: reactive oxygen species, 
TCA: tricarboxylic acid cycle, OP: oxidative phosphorylation, SDH: succinate 
dehydrogenase, SOD: superoxide dismutase, COX IV: cytochrome c oxidase 4, ketone 
bodies: (acetoacetic acid, b-hydroxy butyrate), red R+ or R-: found significantly elevated, 
green R+ or R-: found significantly lowered, dotted black arrows: status in R+ (inhibited), 
black arrows: status in R- ( activated), numbering (1-9): increased PI3K-AKT/PKB axis 
activity and increased ATP production from pyruvate, steps (10-17): indicate interrupted 
ATP production and increased utilization of free fatty acids.     
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HSP60 is a mitochondrial chaperon that is elevated in early stages of adeno and 
squamous carcinoma without a significant difference in advanced stages 
(Ağababaoğlu et al., 2017). HSP60 has two main function, to keep unfolded proteins 
protected and facilitate their transport through the inner mitochondrial membrane, 
and to protect the mtDNA during mitochondrial fission (Kaufman et al., 2003). 
HSP60 is significantly downregulated in the treated cells (R+) compared to the parent 
cells (P) (p= 0.007) (Figure 85). This, along with the decreased levels of  Cytochrome 
c (p= 0.02) (Figure 87) and overexpression of BAX (p = 0.51) (Figure 49, Chapter 
6) when compared to the highly down regulated BAX in (R-), also indicate that 
apoptosis was increased in (R+). The mitochondrial activity in (R-) (Figures 78 and 
79) is also explained by the significant upregulation of the mitochondrial voltage-
dependent anionic channel protein (VDAC) (p= 0.001) (Figure 84). VDAC is a 
mitochondrial outer membrane channel protein, when bound to BAX, forms a 
heterodimer leading to the release of mitochondrial cytochrome c and activation of 
the caspase cascade and apoptosis; this occurred in (R+).  In (R-), the overexpression 
of VDAC in (R-) was not sufficient to release the folded cytochrome c (Shoshan-
Barmatz et al., 2006), as the level of  BAX was extremely downregulated (p= 0.0006) 
(Figure 49, Chapter 6). This also demonstrates the increased proliferation rate in (R-
) (Figure 27).    
In summary, GDC-0980 was shown to cause the resistant cells (R+) to live at very 
low levels of energy leading to a dramatic decline in their proliferation rate (Figure 
27). This might have been due to an increased rate of apoptosis compared to the 
newly divided cells. GDC-0980 was also found to compromise mitochondrial 
function and drive the cells to utilise less ROS-producing energy substrates. The 
overall increased production of ketone bodies and accumulation of pyruvate in (R+) 
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(Figure 88) supports the mitochondrial dysfunction caused by GDC-0980. 
Interestingly, the current data showed that mitochondrial activity was restricted to 
cells that contained 4N ploidy (Figure 79). 
Finally, the clinical utility of protein biomarkers found differentially expressed in 
GDC-0980 resistant H1975 in the presence (R+) or absence (R-) of the drug 
(Summarized in table 53) should be assessed in experimental animals models of lung 
cancer (e.g., rodents) (Wang et al., 2012) to monitor their levels before and after 
starting GDC-0980 treatment, and also before and after development of tumour 
resistance. Monitoring could be done by IHC staining as an initial validation. This 
would be the future extension of this piece of research work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
 
 
 
General discussion, conclusion and future work 
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8.1. Discussion  
Per the most recent estimates held by the International Agency for Research on 
Cancer, 1.82 million new cases were estimated for lung cancer in 2012 (Ferlay et al., 
2015). With an overall ratio of mortality to incidence of 0.87, lung cancer is one of 
the deadliest cancers worldwide. By region, the highest estimated lung cancer 
mortality rates (per 100,000) in 2012 were in Northern America (23.5), Northern 
Europe (19.1), Eastern Asia (16.2), Western Europe (14.8), Oceania (14.1), and 
Caribbean (12.2). 
More-reliable biomarkers are needed to identify the development of lung cancer at 
the earliest stage and to predict which patients are likely to respond to treatment. 
Validating a candidate biomarker is a demanding process requiring large numbers of 
patient samples from multiple sites. Progress has been made over previous years in 
the early detection and treatment of lung cancer, but more progress is needed so all 
patients can benefit from new screening approaches and molecularly targeted 
therapies with associated companion biomarkers. 
Blood is the most frequently sampled biofluid, obtaining it is minimally invasive, 
and it is readily available. Moreover, because blood circulates throughout the body, 
it contains proteins secreted, shed or released from all cells and tissues. However, 
using blood as a biofluid in biomarker discovery is especially challenging. The huge 
dynamic range and the fact that the proteome is represented mainly by a few high 
abundance proteins (22 most abundant proteins represent approximately 99% of the 
total protein mass) makes the identification and quantification of lowly abundant 
proteins extremely difficult. It is very likely that any proteins produced by or 
associated with the tumour will be of low abundance, so their detection will often be 
hindered by the masking effect of highly abundant proteins such as albumin, which 
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can be present at a billion-fold higher level than some of the proteins that are of 
interest from a biomarker discovery perspective. 
Biological material assayed for discovery phase analysis can also originate from 
proximal fluids, i.e., biofluids in close or direct contact with the site of disease. The 
protein concentration of potential biomarkers is enriched in these biofluids because 
masking proteins such as albumin are present at greatly reduced levels, and the 
proteins secreted or shed by tumours should be present at elevated levels. Therefore, 
such liquids, which include cerebrospinal fluid, bronchoalveolar lavage fluid, saliva, 
urine, tears and various gastrointestinal secretions, are valuable resources for initial 
biomarker discovery.  
Lung cancer protein biomarkers currently include carcinoembryoinc antigen (CEA), 
neuron-specific enolase (NSE) and cytokeratin 19 fragment (CYFRA21-1), but 
more-accurate biomarkers are needed. The number of investigations examining 
bronchoalveolar lavage fluid (BALF) for protein biomarkers is increasing. BALF 
samples are used for cytological, hematologic, biochemical, and microbiological 
examination. 
BALF is a mixture of different cell types and a wide variety of soluble components, 
such as phospholipids, nucleic acids, peptides and proteins. The utility of BALF has 
been exploited for many years in clinical research, with recent technological 
advances permitting detailed proteomic profiling of protein/peptide signatures in 
particular lung diseases. This approach provides a rich source of candidate 
biomarkers, in addition to providing insight into the complex pathological mediators 
associated with lung diseases at the molecular level. 
The data presented in this study demonstrate that the abundance of proteins involved 
in cellular and metabolic processes is markedly increased in BALF from patients 
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with lung cancer compared to controls. Following selection of four candidate 
proteins for verification in plasma, TIMP-1, Lipocalin-2 and Cystatin-C were all 
found to be significantly elevated in NSCLC compared to control. This demonstrates 
that BALF represents a mirror biofluid for blood (serum/plasma), and that many of 
the signatures discovered in proximal biofluids such as BALF will be identifiable 
with similar abundance patterns in blood. This opens up the possibility of identifying 
panels of protein biomarkers in BALF, validating their abundance in blood, and 
developing unique biomarker panels associated with different types of lung cancer, 
as well as different stages/grades and signatures associated with response to 
treatment. A critical finding of this investigation was that the abundance of a 
substantial number of proteins in BALF was significantly different in lung 
adenocarcinoma and squamous cell carcinoma of the lung. Some chemotherapeutic 
regimens are more effective for squamous cell carcinoma, so it is necessary to 
differentiate the two major types of NSCLCs because treatments options become 
more extensive and sub-type associated.  
Fine needle aspiration (FNA) cytology performed by transthoracic and/or 
transbronchial procedures are important approaches to obtain tumour tissue for 
histological diagnosis and molecular characterisation of tumours. In some cases, 
distinguishing between adenocarcinoma and squamous cell carcinoma by analysis of 
FNA specimens can be challenging, such as in poorly differentiated NSCLCs and 
adenosquamous carcinomas. Therefore, an assay of protein abundance in BALF 
could be useful in cases of poorly differentiated NSCLCs and adenosquamous 
carcinomas.  
Another finding of particular interest is that folate receptor alpha was increased 13.9-
fold in adenocarcinoma compared to squamous cell carcinoma (3.8 fold). Previous 
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work has shown that immunohistochemical analysis of folate receptor alpha 
expression can effectively discriminate between lung adenocarcinoma and squamous 
cell carcinoma, a good validation of this current approach. 
Drug resistance is a major obstacle facing successful development of anti-cancer 
therapies. Many cancers initially respond well to therapy but eventually develop drug 
resistance. Anti-cancer therapies exert an additional selective pressure on cancer cell 
populations, further affecting the clonal evolution processes resulting in the 
acquisition of drug resistance (Greaves and Maley, 2012). These processes are 
extremely difficult to investigate using tumour tissue because the invasive sampling 
procedures are sometimes impossible to perform. Furthermore, the biopsies might 
not be representative due to intra-tumour heterogeneity. Therefore, model systems 
are needed to investigate the mechanisms underlying the acquisition of drug 
resistance in cancer cells in order to develop hypotheses that can be tested on clinical 
material and to identify resistance pathways/biomarker signatures that can be 
associated with specific therapeutics.  
The huge wealth of clinical research data clearly shows tumour heterogeneity at both 
the individual and intratumoural levels. In cancer, nonrecurring mutations and large 
genomic alterations generate immense heterogeneity, producing tumours populated 
by cells with particular characteristics. Factors such as clonal evolution and positive 
selective pressure from anticancer therapies also contribute significantly to tumour 
heterogeneity. This phenomenon has been a significant obstacle for the development 
of an accurate biomarker profile and associated targeted anticancer treatments. The 
literature clearly shows a lack of information on tumour heterogeneity at the protein 
level, which significantly compromises our knowledge about how protein changes 
contribute to subpopulation phenotypes. Over the coming years, more-reliable 
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biomarker signatures of tumour presence and development, together with new 
therapeutic strategies, will inevitably depend on the ability to further characterise 
tumour heterogeneity and take it into account. Interrogating proteins in the context 
of tumour heterogeneity using state-of-the-art omics platforms will unquestionably 
prove extremely useful in the clinic. 
Tumour tissue samples are difficult to analyse cleanly (when compared to cell line 
models for example) as different cell types are present, including tumour cells, 
normal epithelial and stromal, and inflammatory cells, as well as vascular cells, 
which can contribute plasma proteins into the mixture (Schor and Schor, 2001). 
Many investigations have been done on complete tissue sample homogenates, so the 
associated proteome reflected a mixture of proteomes from different cell types. Thus, 
the heterogeneous characteristics of these tissue samples were missed. This is a 
significant problem with solid tumours, as enrichment techniques employed in 
studies on blood cancers (plasma cells can be enriched by targeting the marker 
CD138+ that is uniquely expressed on these cells) are difficult to apply to solid 
tumours.  
We contribute to this effort by characterising the proteomic heterogeneity of human 
lung cancer biopsy samples, by investigating different regions of the tumour and 
comparing their proteomes to each other and to associated matched control tissue. 
From the data, many differences in protein abundance exist between matched control 
and tumour tissue samples. When comparing the quadrants of the tumour, distinct 
differences are apparent, and while some proteins do show a consistent abundance 
pattern when comparing the individual quadrant to control and identifying 
commonality, significant differences exist.  
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When trying to identify new potential biomarkers or therapeutic targets, these data 
emphasize the need to include many biopsy samples from the same tumour and 
matched control tissue in order to identify the most robust protein signatures. In the 
context of identifying biomarkers associated with subtypes of lung cancer that are 
common for most or all patients, a comprehensive analysis of many patient samples 
and many biopsies from these patient is required to identify strong candidate 
proteins. From an individualised protein signature perspective, multiple tumour 
biopsies and indeed multiple matched control tissue samples are needed. In tissue 
proteomics, tissue heterogeneity and inadequate sampling may result in low 
reproducibility of proteomic data, as the ratio of cells will depend on the tissue area 
examined. 
An example of multiple biopsy testing is HER2 amplification in gastroesophageal 
adenocarcinoma (GEA). Given the issue of intratumoural heterogeneity in GEA 
specimens, it is preferable to test multiple biopsy fragments (from a primary or 
metastatic site) or from the resected primary tumour. The National Comprehensive 
Cancer Network (NCCN) Guidelines (Jouret-Mourin et al., 2012, Bartley et al., 
2016) recommends a minimum of five biopsy specimens, and optimally six to eight, 
to account for intratumoural heterogeneity and to provide adequate tumour 
specimens for diagnosis and biomarker testing. 
Immunohistochemical analysis of protein expression in a large number of tumour 
tissue samples is expensive and time consuming. Tissue microarray (TMA) 
technology can facilitate the sampling of hundreds of tumour and/or control tissue 
samples on a single slide, which can then be analysed by immunohistochemistry. In 
this study, TMAs were used to evaluate the abundance of some candidate proteins 
that were differentially expressed in tumour and control tissues. This approach was 
 
 
287 
very useful for identifying the strongest candidate biomarkers to include in more 
intensive investigations, but it also demonstrated the effect of tumour heterogeneity 
and the difficulty of finding robust biomarkers across multiple patient samples. In 
the future, when constructing our own TMAs, an important consideration will be to 
include multiple tissue samples from individual patients, representing heterogeneity 
at the intratumoural level, and helping refine the process of selecting strong candidate 
tissue biomarkers. 
Laser capture microdissection (LCM), a state-of-the-art technology for isolating pure 
cell populations from a heterogeneous tissue specimen, may help address some of 
the limitations of using whole or parts of tissue homogenates. However, LCM is 
extremely expensive and the quality of microdissected tissues may not meet the 
standard quality for further analysis due to its exposure to fixatives and staining 
reagents (Chung and Shen, 2015). This work clearly identifies the need for multiple 
biopsy samples when performing proteomics analysis and confirms the importance 
of multiple biopsy sampling for clinical diagnosis and prognosis.  
The application of metabolomics to cancer research has led to increasing interest in 
applying it to the identification and characterisation of metabolites associated with 
cancer development and progression. Although cancer has factually been regarded 
as an abnormality associated with uncontrolled proliferation, recent evidence has 
suggested that it should also be considered a metabolic disease. Growing tumours 
revamp their metabolic platforms to meet and even exceed the bioenergetic and 
biosynthetic demands of continuous cell growth and proliferation. The cancer 
glycolytic phenotype described decades ago by Otto Warburg, commonly known as 
the Warburg effect, has been found in nearly every type of cancer investigated. 
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Interest in and publications associated with metabolic abnormalities in cancer 
dramatically disappeared in the 1960s and 70s as other areas in cancer research came 
to the fore. Only in the last 10-15 years has interest in metabolomics been revitalised, 
mostly due to the increased accessibility of metabolomics and the identification of 
useful cancer metabolite biomarkers or “oncometabolites.” The fact that 
metabolomics can be performed on a range of different sample types, including 
tissues, cells, and bio-fluids such as serum, plasma, urine and saliva, makes this 
platform attractive for mining the oncometabolome. 
The most investigated feature of cancer metabolism is central carbon metabolism 
and the relationship between glycolysis, the tricarboxylic acid (TCA) cycle, and 
oxidative phosphorylation. Additionally, significant differences exist in the reported 
levels of amino acids detected in blood samples from cancer patients. Cancer cells 
require certain amino acids, for example, glutamine (Gln), for DNA synthesis, 
angiogenesis and ultimately proteins synthesis.  
Recently, Kim and co-workers showed that in the early stages of lung cancer (I and 
II), the relative levels of threonine, citrulline, histidine and tryptophan decrease 
significantly, whereas proline and isoleucine increase (Kim et al., 2015). However, 
significant increase in phenylalanine and ornithine during the late stages (III and IV) 
were discovered. In this study, a significant increase in the serum concentration of 
many amino acids was observed in advanced lung cancer patients. Determination of 
the precise mechanism underlying changes in the amino acid profiles has great 
potential for cancer diagnosis and treatment. 
Glutamate, a nonessential amino acid, is a major bioenergetic substrate for 
proliferating normal and neoplastic cells. Validation studies showed a significant 
decrease in the level of in serum glutamate in lung cancer patients. However, the 
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overall profile of this cohort was from more early stage lung cancer. This contrasts 
with our discovery phase analysis, where a significant increase in serum glutamate 
was found by mass spectrometry, possibly because these samples were from 
advanced lung cancer patients.  
Research is needed to identify amino acid profiles that discriminate individual cancer 
types at different stages from healthy controls. Strategies to exploit such ‘metabolic 
addictions’ in cancer management include depleting amino acids in blood, blocking 
uptake by transporters, inhibiting biosynthetic and/or catabolic enzymes, and 
measuring levels of specific amino acids as biomarkers. 
Metabolomics and proteomics are promising complementary strategies for the 
effective understanding the associations between metabolites and proteins on the one 
hand and disease on the other, and for the development of more accurate diagnostic 
and monitoring tools and effective therapies. Both omics approaches help researchers 
to make sense of their research data, with extra layers of information available to 
understand tumour biology, ultimately leading to the discovery of stronger candidate 
biomarkers and potential therapeutic targets.  
Metabolic reprogramming is a hallmark of cancer (Hanahan and Weinberg, 2011). 
Increased cells proliferation in cancer is common among tumours. To cope with the 
increased demand for energy, cancer cells must utilize all possible energy substrates. 
The candidate energy substrate in cancer cells is very selective. Selection of substrate 
utilisation is driven by some tumour driving mutations. Most cells with loss of 
function mutations in the P53 gene are addicted to glutamine as a source of carbon 
and nitrogen for synthesis of lipids and nucleotides (Xing et al., 2015). Lipid and 
cholesterol metabolism is also described in tumours with overall increased uptake 
and synthesis of lipid was observed. The accumulation of lipid droplets in cancer 
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cells was found associated with the aggressive type of tumours (Bozza and Viola, 
2010).  Adaptive glucose utilisation was the first known adaptive response of cancer 
cells to the stresses of nutrient scarcity and poor oxygenation within the tumour.  
The mechanistic target of rapamycin (mTOR1), a serine-threonine kinase, plays a 
master role in regulation of cell growth, proliferation and metabolism. This pathway 
promotes glycolysis, lipogenesis and nucleotide synthesis and serves as a sensor for 
amino acids and growth factors (Chantranupong et al., 2015). Signalling of growth 
factor, also mediated by the PI3K/Akt pathway, promotes glucose uptake and 
utilisation in lipogenesis as well as regulating the supplement of Kreb’s cycle with 
intermediate metabolites of glucose (Ward and Thompson, 2012). 
Interference with tyrosine kinases using GDC-0980, a PI3K/mTOR dual inhibitor, 
was promising in the treatment of tumours associated with increased expression of 
growth factor receptors and/or gain of function mutations in the tyrosine kinases 
(Wallin et al., 2011). Development of tumour cell resistance to tyrosine kinase 
inhibitors is well documented (Camidge et al., 2014). The GDC-0980 inhibitor, 
meant to improve the outcome of treatment with tyrosine kinase inhibitors, is still in 
phase I clinical trial (Dolly et al., 2016). Cell lines provide a good model for studying 
the mechanisms by which tumours acquire resistance to chemotherapy or targeted 
therapy, including small-molecule inhibitors.  
Drug resistance in cancer can be due to genetic factors and/or acquired through 
adaptive post-translational modifications to combat the molecular effects of drugs 
(McGranahan and Swanton, 2017). Dominant sub-clonal cancer cell populations 
with natural or acquired resistance to treatment are common in cancer. These cell 
populations become dominant when the drug-sensitive populations are 
eliminated and became responsible for tumour relapse, drug resistance and the 
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overall treatment outcome (McGranahan and Swanton, 2017, Greaves, 2015). 
Tumour resistance to treatment interferes with the clinical utility of markers that can 
be used for multiple reaction monitoring (MRM) of patients. Therefore, validating a 
panel of biomarkers for monitoring the development of drug resistance would be of 
great value.  
In the last two chapters, GDC-0980 resistant and GDC-0980 sensitive lung 
adenocarcinoma H1975 and A549 cell lines (mainly H1975) were used to study and 
validate biomarkers that could indicate the development of resistance to GDC-0980. 
In A549 intrinsically resistant cells, GDC-0980 treated cells were arrested at the G1 
phase, but this was reversible upon drug withdrawal. This effect was also seen in the 
parent A549 cells (Wallin et al., 2011). Interestingly, GDC-0980 caused irreversible 
cell cycle arrest at G2/M with prolonged S- cell cycle phase lag time (Figures 27, 
28).  
The proteins involved in cell cycle progression, including cyclins D1, D3, A2, B1, 
H and CDK6, were evaluated in parent H1975 (P) and resistant cells in the presence 
of GDC-0980 (R+) and in its absence (R-). All tested cyclins and CDK6 were 
significantly downregulated in resistant H1975 cells in the presence of (R+) and 
absence of (R-) GDC-0980 compared to the sensitive cells, but the down regulation 
was stronger in treated resistant cells (Figures 35- 40) (Table 51). Other cell cycle 
controlling proteins that showed the same expression profile include p53, p21, p50, 
p65 (Rel-A), Rel-B, Bcl-XL and 14.3.3 gamma. These proteins could serve as 
biomarkers of tumour resistance to GDC-0980 in matched mutational profile lung 
adenocarcinoma. Other evaluated cell cycle controlling proteins showed the opposite 
profiles in (R+) and (R-) cells when compared to the parent cells. These proteins 
include PCNA (both native and ubiquitinated), 14.3.3 α/β, 14.3.3 ζ/δ, and 14.3.3 ε. 
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Regardless of their expression profiles, these proteins are still valuable for detecting 
tumour resistance to GDC-0980 of same matching genetic abnormalities.   
Acetylation is a post-translational modification controlling the level of gene 
expression by changing the overall net charge on the histones to relatively negative 
by adding acetyl groups to the lysine residues on the histones. This modification 
facilitates accessibility of transcription factors to their promotors, thus favouring 
gene transcription. The machinery governing the acetylation of histones consists of 
two set of enzymes, histone acetyl transferases (HATs) (GCN5L2 and PCAF were 
evaluated) and histone deacetylases (HDAC 1, 2, 3, 4, 6 and phosphorylated HDAC 
4, 5 were tested). The levels of histone 3 and 4 acetylation at certain acetylation sites 
were evaluated in this study as well (Table 52). The results showed decreased HAT 
levels and elevated HDAC levels in treated H1975 cells compared to the parent cells, 
despite the overall increased histone acetylation. The phosphorylation of HDACs 
was found crucial for HDAC activity, and this was validated using SAHA (class I 
HDACs inhibitor) (Pflum et al., 2001). The GDC-0980 resistant H1975 cells were 
found to tolerate higher doses of SAHA compared to the parent cells, which indicates 
that HDACs play a role in the development of multiple drug resistance (Figure 70). 
When GDC-0980 was included in the culture media, the resistant cells became more 
sensitive to SAHA than the GDC-0980 parent cells, indicating that GDC-0980 
affects the phosphorylation of HDACs required for their activities (Pflum et al., 
2001, Steliou et al., 2012). Histone acetylation levels, when normalised for the 
abundance of the native histone proteins, also indicated decreased acetylation in the 
non-treated cells due to restoration of HDACs phosphorylation (Figure 62). 
Therefore, a combination of the two drugs would be better than using them as a 
monotherapy (Figure 71). 
 
 
293 
Whether the protein was overexpressed or down regulated (GCN5L2, PCAF, HDAC 
II, HDAC IV, HDAC VI, H3, H4, H3 and pyruvate levels), these findings might also 
be applied to immunohistochemically identify resistance to GDC-0980 in solid 
tumours of the same genetic abnormalities, whenever a control sample was taken 
before the start of treatment.  
Growth curves of GDC-0980 sensitive and GDC-0980 resistant H1975 cells treated 
(R+) or not treated with GDC-0980 (R-) showed a depressed rate of proliferation in 
the GDC-0980 treated resistant cells (Figure 27). This indicates that the energy 
production machinery was affected by GDC-0980 as an adaptive response to 
maintain cell survival in the stressful environment. Seahorse is an instrument that 
can assess the overall activity of mitochondrial and non-mitochondrial pathways for 
production of ATP.  
Seahorse energy phenotyping of cells relies on measuring increased acidity of the 
medium (ECAR), which reflects the rate of lactic acid production and the decline of 
oxygen concentration in the medium (OCR), which in turn reflects increased 
mitochondrial activity (Figure 89). Both GDC-0980 treated (R+) and non-treated (R-
) GDC-0980 resistant H1975 cells showed a significant decrease in the production 
of lactic acid production (Figure 91), which was greater in the treated cells. GDC-
0980 compromised the mitochondrial oxidative phosphorylation of resistant H1975 
cells. Mitochondrial oxidative phosphorylation activity increased in GDC-0980 
resistant H1975 cells (R-) compared to parent cells, as indicated by their increased 
oxygen consumption rate (Figure 90) and decreased production of lactate indicated 
by their decreased ECAR upon consumption of the glucose in the medium. A 
concentration of 1 µM of GDC-0980 compromised mitochondrial oxidative 
phosphorylation and further depressed ECAR (Figure 91).    
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In the search for biomarkers to detect tumour resistance to GDC-0980, the 
mitochondrial membrane oxidative phosphorylation complexes were evaluated by 
western blot. The results summary is in table 53, and the findings are summarised in 
figure 92 and discussed in detail in chapter 7. The energy profiling of GDC-0980 
sensitive and GDC-0980 resistant H1975 cells revealed several proteins and 
metabolites that might help in detecting the development of GDC-0980 resistance in 
solid tumours because their abundance in drug resistant tumour cells differed from 
that in drug-naive tumour cells. These molecules are pyruvate, acetyl coA, ketone 
bodies, free fatty acids as well as pyruvate dehydrogenase, lactate dehydrogenase, 
superoxide dismutase, succinate dehydrogenase, HSP60, Cytochrome c, cytochrome 
c oxidase, and voltage dependent anionic channel proteins. 
 
 
 
 
8.2. Conclusion  
The aims of this research were to identify abnormalities in the abundance of proteins 
and/or metabolites associated with lung cancer and development of drug resistance. 
Several strong candidate biomarkers were found in BALF for differentiating between 
controls and lung cancer as well as for distinguishing adenocarcinoma from 
squamous cell carcinoma. These potential biomarkers might be used to screen 
biofluids from high risk individuals (e.g., those with benign lung nodules) and also 
to examine the BALF proteome when a definitive diagnosis of adenocarcinoma or 
squamous cell carcinoma is difficult to determine histologically. Many of the 
proteins the abundance of which was altered in BALF exhibited similar trends in 
tumour tissue from lung cancer patients compared to matched control. This 
highlights the strong relationship between tissue protein and biofluid protein levels. 
However, many proteins did not share such similarity in blood and BALF, results 
that are confirmed by the obvious tumour heterogeneity discovered by mass 
spectrometry of different parts of the tumour compared to matched tissue. These 
results highlight the need for comprehensive experimental designs when screening 
for new candidate biomarkers or therapeutic targets, as well as the need for multiple 
biopsies when diagnosing, staging and grading malignancies. The strong metabolic 
signature found when examining BALF and tissue was also confirmed when 
applying metabolomics to investigate blood samples from lung cancer patients. 
Proteomics and metabolomics are complementary techniques and provide additional 
pieces of information to help unravel the proteome or metabolome respectively. The 
metabolome is a stable environment, and it is likely that future biomarker panels will 
contain elements from both the proteome and metabolome.  
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Biomarker signatures relating to altered cellular pathways were also identified using 
a cell line model of resistance to Apitolisib (GDC-0980), a dual phosphatidylinositol-
3-kinase and mammalian target of rapamycin kinase inhibitor. To that end, A549 and 
H1975 lung adenocarcinoma cell line models were analysed by mass spectrometry. 
The analysis of tumour samples from lung cancer patients developing resistance to 
specific anti-cancer treatments is difficult, mostly due to the difficulty of obtaining 
clinical material. Cell line models offer an alternative platform to understand changes 
at the protein level associated with the development of resistance, and to identify 
biomarker signatures associated with resistance in order to understand the 
development of resistance pathways and how to avoid or overcome them. The levels 
of cell cycle specific and mitochondrial associated proteins are perturbed in the 
resistant phenotype. This valuable information can be used to form the foundation 
for hypothesis-driven research on clinical material from patients treated with 
Apitolisib. 
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8.3. Future Plans 
The lists of proteins that were found significantly dysregulated (upregulated and 
downregulated) in non-small cell lung carcinomas lavages compared to the normal 
lungs control lavage fluids “especially those distinguishing adenocarcinoma from 
squamous cell carcinoma and confirmed in the FFPE lung adenocarcinoma tissue 
specimens” will be studied and validated more. The validation will involve using 
tissues and bio-fluid samples from patients diagnosed with lung adenocarcinoma, 
lung squamous cell carcinoma and poorly differentiating non-small cell lung cancer. 
The future study will also involve training the neural network thinking software to 
help distinguishing the poorly differentiated and mixed types of lung cancer using 
the lists of proteins came off this research work in parallel with the currently used 
tissue- based biomarkers.  
My future work would also involve immunohistochemically validation of the 
proteins that were found significantly changing upon development of tumour 
resistance to the PI3K-Akt/PKB, m-TOR dual inhibitor (GDC-0980). Some proteins 
such as HDACs will be tested in other forms of drug resistance in solid tumours to 
elucidate their possible role in multiple drug resistance. Successful candidate 
protein(s) that can detect early development of drug resistance in tumour tissue 
would be utilized to detect the resistance invivo in experimental animal model of 
drug resistance in tumour using positron emission tomography (PETscan) or single 
photon emission computed tomography (SPECT).  
The future plan would also involve radio-labelling of some metabolites such as 
glutamine and aspartate and studying their pharmacokinetics in solid tumours after 
intra-venous administration using PETscan as an approach to increase the clinical 
utility of such biomarkers and improve diagnosis of lung cancer.       
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